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Abstract 
 
The clonal producer cell lines are inherently variable and hardly predictable, despite the various 
advances in the field of biopharmaceutical production. These features are inherent to the process and 
are difficult to control. The number of strategies available to salvage a batch culture with undesired 
behaviour is limited, and this causes uncertainty in the production process. 
During the present study, chemicals which had favourable traits and were previously described in 
unrelated fields of literature, were selected and screened, in order to identify possible improvements 
in the final and specific productivity. Of those selected, catechins and resveratrol were further 
investigated in order to check their effect on the cell cycle, to optimize their addition in scale-up cultures 
and to check their effect on the quality of the monoclonal antibody. 
Resveratrol and the compounds from the catechin group, were able to increase the specific productivity 
by approximately 2.5 and 2-fold respectively. This was achieved by cytostaticity. Studies of resveratrol 
and catechins on cell cycle, showed that these chemicals stopped the cell cycle in the S and G2/M 
phase. This was probably due to their effect on topoisomerases. Furthermore, when added at late 
stages of the culture during the optimization experiments, resveratrol and catechin improved the final 
titre by 1.37- and 1.43-fold increase respectively, without causing any negative effects. Finally, the 
quality assessment of the monoclonal antibody did not show any changes in aggregation or 
fragmentation. Resveratrol and catechin caused a decrease of the acidic species by 6.75 ± 3.91% and 
3.58 ± 0.28 respectively. The mass spectrometry analysis showed that the treated samples were less 
likely to suffer reduction in the variable region, indicating that these chemicals could preserve the 
antigen recognition site. 
The present study suggests that resveratrol and catechin are promising additives that could improve 
the recombinant monoclonal antibody production and preserve the product from undesired 
degradation and modifications with potential improvements of the shelf-life and potency.  
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1.1 Biopharmaceutical industry 
The development and production of drug molecules take place in the biopharmaceutical 
sector of the pharmaceutical industry. These drugs need to be produced in living systems due 
to their complexity. The traditional chemical engineering approach used to develop these 
drugs, known as biomanufacturing or bioproduction, is limited, due to technological and 
economic reasons.  
During the last decades, this sector has increased drastically and continues to grow. The 
economic investment from companies has been substantial. According to the Research and 
Development investment scheme of 2013, almost 100 billion euros were spent in 2013, 
making it the top investment in their list (IFPMA, 2014). 
The need for new biopharmaceuticals is fundamental, in order to improve the treatments for 
many diseases. However, their development is complex, long and expensive.  The first stage 
of the process involves drug discovery; in this phase, the proof of concept is elaborated and 
tested. Then, safety and clinical efficiency are addressed in preclinical studies with animals. 
After that, clinical trials are implemented in humans and finally, the regulatory agency 
approves the biomanufacturing production. The average time to commercialise a drug 
molecule is approximately 15 years (IFPMA, 2012)(Figure 1). 
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Figure 1 The investment in industry sectors in 2013 
 Modified from (IFPMA, 2014). 
 
Successful products are incredibly expensive, as they need to counterbalance not only the 
economical income needed for the successful drug production, but also to recover the 
investment on other candidates that are not successful. 
The first mass-produced biopharmaceutical drug, penicillin, was developed by Pfizer. It was 
directly obtained from the organism Penicillium chrysogenum (Ginsberg, 2008), which is a 
natural producer of penicillin. Decades later, biotechnological research led to DNA 
manipulation and its insertion into organisms, opening the possibility of using cells as 
production factories for non-native (recombinant) proteins. 
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Figure 2 Approved products in the biopharmaceutical industry 
Expressed as a percentage of total approvals. The red bars represent the period from 2010-2014, while 
the blue bars are the cumulative figures for the period 1982–2014. Image from (Walsh 2014) 
 
Nowadays, the biopharmaceutical industry produces molecules of nucleic and amino acidic 
nature. The most characteristic representatives are proteins, and more specifically 
monoclonal antibodies (mAbs) and their derivatives (Walsh, 2014) (Figure 2). 
1.1.1 Production system requirements 
In order to have a production system that is suitable for biopharmaceutical purposes, cell 
lines need to hold specific characteristics that would allow them to perform efficiently at 
certain standards. Some of these requirements are: 
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Suspension culture: cell lines need to be able to grow in suspension. This is fundamental in 
order to maximize and standardize the production in reactors. Unicellular organisms are easy 
to adapt to suspension. On the other hand, mammalian cells are difficult to adapt due to their 
original conformation in tissues and their sensitivity to share stress because of their big 
dimensions and membrane thickness. 
Cell growth: cell lines need to have a short doubling time, as this will shorten all the stages of 
the process. As an example, Escherichia coli has a doubling time of over half an hour (Prasad, 
Khadatare and Roy, 2011), while the Chinese hamster ovary (CHO) cell, one of the fastest 
mammalian organisms, doubles its population between 1 and 2 times a day, depending on 
the cell line (Percell Biologyca AB, 2000).  
 
Figure 3 Comparison of different parameters of CHO culture in 1986 and 2004. 
(A) Cell concentration (green-2004; orange bottom-1986) and viability (purple-2004; orange top-1986) 
of the cultures along time (hours). (B) Antibody production (purple-2004; orange small chart–1986) 
along time (hours). Image from (Wurm, 2004) 
 
A B 
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Final cell concentration is the maximum concentration to which producer cells can be 
cultured; it is considered a fundamental factor in order to obtain high recombinant protein 
titres, as these two parameters are often proportional. Cells can be stressed when cultured 
in high concentrations, limiting the production phase in fermenters. As an example, in 1986, 
the CHO final cell concentration was maintained over 1 million and cell viability preserved up 
to 180 hours. Following that time, cell viability and concentration were successfully 
engineered, with data from 2004 showing that a 100-fold increase in the antibody production 
(Wurm, 2004)(Figure 3). 
Stable transfectants: cell lines transfected with a vector need to be stable, which means that 
the integration of the foreign DNA has to be inside the genome of the targeted system. When 
a subpopulation of the cell culture is not stable and no longer produces the desired protein, 
it gathers an energetic advantage, growing faster than the producer population. Therefore, 
the stability of transfectants is fundamental, as instability could lead to an overtake of these 
producers causing an economic loss. To avoid this phenomenon, selective chemicals are kept 
in the culture during the process.  
Transient transfectants: in this case, the migration of DNA occurs within the cell without 
necessarily integrating into the genome. This is a fast, simple and efficient process to produce 
recombinant proteins and is mainly used for clinical trials. 
Safety: producer cells have the potential to be infected by a disease or act as vectors of it. 
Consequently, it is important to identify and assess the level of jeopardy associated with this 
organism in order to meet regulatory agency standards for biopharmaceutical production. 
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1.1.2 Main host systems for recombinant production 
There are different organisms used for biomanufacturing such as the prokaryote Escherichia 
coli. This was first used to generate recombinant insulin and currently, it is used to produce 
hormones and other biologics (Baeshen et al., 2015). Another example is yeast Pichia pastoris, 
which, since its approval in 2009,  has been mainly used to produce transmembrane proteins 
(Gonçalves et al., 2013) (Walsh, 2010). These microorganisms are industrially attractive 
because their manufacture is cheap, it can be fastly implemented and is able to achieve high 
yields. At the same time, these systems have limitations due to their lower degree of 
complexity when maturing polypeptides. 
Proteins that require an elaborated process of folding, assembling and posttranslational 
modifications are fabricated in mammalian cells.  
Human cell lines such as human embryonic kidney cells (HEK), human retina derived cell line 
(PER C6) and human cells derived from amniocytes (CAP-T) are mildly used for industrial 
processes. Their ability to grow in suspension up to high concentrations under free serum 
conditions (Garnier et al., 1994; Jones et al., 2003)  and to generate human posttranslational 
modifications, make them a promising future production platform (Fliedl, Grillari and Grillari-
Voglauer, 2014). However, their drawback is their potential to carry human diseases, a fact 
that compromises safety. Recently, in 2014, HEK293 was approved for recombinant protein 
production of blood factors (Walsh, 2014). 
Murine cells, on the other hand, are able to resemble many features of human 
posttranslational modifications (Walsh and Jefferis, 2006) and have a low risk of hosting 
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human diseases, making them the main organisms used in biomanufacturing at present. 
Some employed cell lines are: mouse myeloma NS0, baby hamster kidney cells (BHK) and 
Chinese hamster ovary cells (CHO). CHO cells are the most common mammalian expression 
system for large-scale commercial production of therapeutic proteins (Jayapal et al., 2007).  
1.2 Chinese hamster ovary (CHO) cells 
Although many cell lines have been proved suitable for the production of recombinant 
proteins, the CHO cell line is the most common platform system used (Walsh, 2014). It is used 
in 66% of the total recombinant protein production and in 60% of the clinical trials (Wurm, 
2013). In 2014, the FDA approved 11 new biopharmaceuticals, 8 of which were produced in 
CHO cells (Food and Drug Administration, 2015). The predominance of this murine cell line is 
due to different characteristics that make it more suitable for biomanufacturing.  
To begin with, these cells have been proved safe, as their risk to host main human pathogens 
is low (Wiebe et al., 1989). Secondly, their growth characteristics are suitable, as they grow 
fast in suspension and serum-free media, supporting high share stress conditions. 
Furthermore, they are able to fold, assemble and modify proteins at high titres, in a similar 
fashion to human cells (De Jesus and Wurm, 2011). Also, biotechnological tools that can 
genetically engineer CHO cells, are available. Finally, this cell line was the first mammalian cell 
line approved by the regulatory agencies for recombinant protein production, thus it now has 
a long, robust record of regulatory acceptance (J. Zhu, 2012). 
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1.2.1 History and cell lines 
Chinese hamster ovary cells were isolated from a mammalian rodent (Cricetulus griseus) 
located at dry ecosystems such as the Gobi Desert in central Asia. This hamster was 
introduced as a model organism for laboratory experimentation in 1919, but it was not until 
1957, that an ovary cell was isolated and used to start a cell line (CHO-ori) (Puck, Cieciura and 
Robinson, 1958). 
Since then (1957-1970), this cell line was widely distributed among different laboratories. This 
was due to their fast growth rate, their low number of chromosomes and their big size and 
the fact that the cells can be easily mutated. The original cell line was used in monoculture 
studies with different purposes such as the study of gene function by the induction of 
spontaneous mutations. This situation created divergence across laboratory cell lines at a very 
fast pace and at the same time new desired features of culture behaviour were selected.  
Puck and Kao studied and cultured CHO-ori for more than ten years and created a new cell 
line called “CHO-K1” with a considerably lower amount of DNA. This cell line became very 
popular and intensively distributed along many research laboratories. Afterwards, the CHO-
DXB11 was originated by Urlaub and Chasin in 1980 (Urlaub and Chasin, 1980). This cell line 
is Dihydrofolate reductase (DHFR) negative, with one DHFR locus deleted and a missense 
mutation existing on the second one. This cell line became the first one to be used for the 
production of recombinant proteins in 1983.  
Fintoff in 1976, characterized the CHO-Pro3- cell line as unable to produce proline (Flintoff, 
Davidson and Siminovitch, 1976). After exposing it to ethyl methane sulfonate (EMS), one of 
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the DHFR copies was deleted (CHO-MTXRIII) and further experimentation under gamma 
radiation by Urlaub and Chasin, caused a deletion of the second locus in 1983, giving birth to 
one of the most used cell lines, CHO-DG44 (Urlaub et al., 1983). 
Another CHO-ori cell line was sent to Tobey’s lab and a variant was created after several years 
of study. In 1973, Thompson isolated a suspension-adapted culture from Tobey’s variant, 
known as suspension CHO line (CHO-S) (Thompson and Baker, 1973). However, the lack of a 
gene amplification system was a major drawback for its later development into industry. 
Instead, lines like CHO-DG44 or CHO-DXB11 with amplification systems available, were 
preferred as producing lines and then adapted individually to suspension. 
Along the years, different cell lines have been stored in different cell banks such as the 
American Type Culture Collection (ATCC) or the European Collection of Cell Culture (ECACC).  
This has been done in order to cryopreserve original cell lines from evolutionary changes and 
to distribute them for research purposes.  
Currently, there are three main streams used for research and product development, the 
stream CHO-K1, which uses a GS amplification system and the DG44 and CHO-DXB-11 lines, 
which have a DHFR amplification system (Lewis et al., 2013). When cells are transfected, a 
cell population with different numbers of exogenous DNA copies is created. The ones having 
more copies, are those with the potential for higher recombinant protein production. 
Therefore, during the first years of mammalian biotechnology, the focus was to develop 
systems that could select better producers (amplification systems) (Figure 4).  
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Figure 4 Chronologic diagram of the different CHO cell lines  
Showing the main isolated CHO cell lines and their amplification systems 
 
1.2.2 Genomic variability 
During the last 50 years, CHO cells have been cultured and distributed creating high genome 
variation. In nature, hamsters possess eleven pairs of chromosomes. In cell cultures, this 
number can vary between cell lines and within the same population, due to the lack of 
constraints that a cell from the organism would have. Chromosomal structure and integrity 
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are also very unstable. As a result, over the years, chromosomes have changed drastically and 
at least one from each couple has been heavily affected (Figure 5). 
 
 
Figure 5 Chromosome structure and integrity  
The figure shows a normal Chinese hamster genome (left) and a CHO-K1 cell line, which has eight 
normal chromosomes and thirteen considerably modified (right). Image from (Wurm, 2013) and 
adapted from (Wurm and Hacker, 2011). 
 
In 2011, the first CHO cell genome was published (CHO-K1) (Xu et al., 2011) and in 2013 the 
genome differences between the main cell culture lines (CHO-S, DG44, and CHO-K1) were 
studied (Lewis et al., 2013). The comparison is limited as there is no CHO-ori genome to be 
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compared with. Therefore, until an outside CHO cell line that does not share the same history 
as the current culture lines is found, the amount of information is restricted. Finally, in 2015 
the genome of the cell line CHO-DXBB11 was sequenced (Kaas et al., 2015). 
1.3 Production of recombinant proteins and challenges 
CHO cells are widely used to make recombinant proteins. Many of these proteins are 
successfully produced at high titres, but this was not always the case. During the first days of 
recombinant CHO production, cultures were limited in the amount of heterologous protein 
that they could output.   
The first strategies trying to overcome the low production, were focused on the expression 
phase. The aim was to increase and stabilize the gene expression through the increase of DNA 
intake, the use of a new vector system and the improvement in culture techniques and media 
development (Almo and Love, 2014). 
Nowadays, the bottleneck is related to the maturation process (Le Fourn et al., 2014). This 
could be due to the lack of common evolutionary history between the folding mechanism and 
the recombinant protein. This is also extenuated due to a constant culture pressure towards 
maximum production.  As a result, recombinant proteins can be misfolded, poorly 
transported or undesirably targeted by molecular chaperones. This results in their retention 
and promotes aggregation. This in result causes agglomeration inside the cell, leading to ER 
stress, unfolded protein response (UPR) triggering and ends in apoptosis. These phenomena 
are not predetermined by genetic features (Sato et al., 2004), leading to the unpredictable 
variability between batches (Pilbrough, Munro and Gray, 2009). 
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Although monoclonal antibodies have been produced for decades and improvement of the 
production pathway has been achieved, some limitations inherent to the process still remain. 
The production rate of the chains is not proportional, eventually accumulating the exceeding 
one and causing difficulties for the producer cell (Schlatter et al., 2005; Ho et al., 2013; 
Reinhart et al., 2014).   
1.3.1 Protein folding and stability 
The protein function is linked to their 3D-structure (final conformation). The process of an 
amino acid chain or “primary structure”, to reach its final folded or native state is very 
complex. The main principle of protein folding is that the information needed for the correct 
folding lies within its amino acid sequence. This principle, called thermodynamic hypothesis, 
states that under a specific set of conditions, the final structure of the folding protein (native 
state) is the one which causes the lowest Gibbs free energy of the system (Anfinsen, 1973).  
This principle is true for most small globular proteins, which have a more direct process and 
can be easily studied in isolation to an atomic level, with techniques such as Nuclear Magnetic 
Resonance. Complex proteins, such as the ones produced in recombinant mammalian cells, 
are formed by multiple domains and are post-translationally modified. This affects the folding 
process, making it unpredictable.  Cell-free studies cannot reproduce the folding process 
along the ER, and cell studies are only able to analyse slow or big changes in this process. 
Techniques for assessing protein conformation in intact cells are currently being developed 
to overcome these technical limitations (Sakakibara et al., 2009). 
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Figure 6 Diagram of the funnel protein folding 
The vertical axis represents the Gibbs free energy of the system and how it decreases along the folding 
process until it reaches its native conformation. The width of the well represents the conformational 
entropy of the system giving a visual appreciation of the free movement of the chain and how it is 
restricted as it folded. Figure modified from (Mendoza-Espinosa et al., 2009) 
 
Independently of the protein type, the amino acid sequence resulting from years of evolution 
is based on the robustness of the folding process which is a broad concept influenced by many 
parameters (Onuchic and Wolynes, 2004).  The funnelling theory supports the principle of 
robustness; it states that random alterations do not affect the capacity of the protein to fold. 
Generally, proteins tend to achieve their functional form by energetic drive; this process can 
be interpreted as a funnel of energy where polypeptides tend to approach their native state 
while energy is lost along the process (Figure 6). 
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Amino acid chains do not arrange themselves in structures, such as domains; that could be a 
conflict when considering the assembling process. Instead, successful proteins tend to have 
folding events that are cooperative and supportive. Thus, mild mutations could make proteins 
shift between different paths of the same route If the folding route is truncated, in the case 
of severe mutations, then another route can undertake the folding process, as long as the 
final structure stability is not compromised (Onuchic and Wolynes, 2004).  
When the final protein conformation is compromised, proteins tend to expose hydrophobic 
residues to the media as their concentration increases, interacting with each other and giving 
form to aggregates (Dobson, 2003). This is sometimes the result of a domain swapping effect 
(Liu et al., 2001). The nucleation phase, where proteins start to aggregate, is a slow stage, 
where the system’s Gibbs free energy increases. Aggregation, on the other hand, becomes 
faster along the growth phase, because of a free energy decrease in the system. The length 
and transition between the stages are specific for each process (Eisele et al., 2015). 
Recombinant mammalian proteins are in most cases mAbs, which are large multidomain 
complexes with many post-translational modifications; their high production by cell factories 
(CHO cells) at the ER, often causes aggregation problems, making the industrial process less 
effective. The most studied case of aggregation nowadays is amyloid β peptides, intensively 
researched because of its relation to Alzheimer’s and Huntington’s disease  (Eisele et al., 
2015); in this case the aggregation event is well understood and transferring knowledge to 
recombinant protein studies could be useful (Hartl and Hayer-Hartl, 2009). 
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1.3.2 Protein maturation and molecular chaperones  
The process by which an amino acid chain achieves a fully functional protein structure is 
known as the maturation process. This mechanism can vary depending on the organism type 
or the final destination of the polypeptide. In eukaryotic cells, proteins with cytosolic function 
are directly produced in the cytoplasm, while proteins that need to be secreted or located in 
the membrane are produced and processed along the ER and Golgi; this is the case with 
mammalian recombinant proteins (Braakman and Bulleid, 2011). 
During the maturation process, the protein is folded and additional modifications are 
implemented to form a fully functional polypeptide. These changes are known as post-
translational modifications. Some examples are enzymatic changes or covalent adjustments 
which add specific features to proteins, such as recognition, half-life increase or quality 
control amongst others. One of the most important post-translational modification features 
is glycosylation, which can affect protein stability and track the protein folding process (Wang, 
Groenendyk and Michalak, 2015). This modification is fundamental in most recombinant 
proteins. 
Protein maturation also involves molecular chaperones. These enzymes interact with newly 
synthesized proteins through their hydrophobic exposed areas. They then prevent 
aggregation and they assist the proteins to undergo through the correct folding pathways, 
although they do not assemble them. Their action also makes them capable of checking 
different points in transportation, by differentiating between properly and improperly folded 
polypeptides. This pool of proteins is also responsible for regulating the level of Ca2+ (Hayashi 
and Su, 2007), a signaling molecule that affects the ER function  (Sambrook, 1990). 
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In the case of correctly folded proteins, the interaction with molecular chaperones along the 
maturation process is transient; they are then quickly released to continue with the next 
stages until they reach their final destination. On the contrary, misfolded proteins have a 
longer interaction with the enzymes and that prevents them from being transported into the 
Golgi system (Schuler et al., 2010; Hartl, Bracher and Hayer-Hartl, 2011). If the proteins 
cannot be recovered, the chaperones will guide them to a translocon in the ER membrane, 
that will export them into the cytoplasm, where they will be targeted by proteasomes. This 
mechanism is known as the endoplasmic reticulum associated degradation path (ERAD) 
(Buchberger, Bukau and Sommer, 2010). 
When the level of misfolded proteins is high, the degradation system cannot cope with it. As 
a result, accumulation and aggregation are induced at the endoplasmic reticulum, causing ER 
stress and triggering the UPR. 
1.3.3 Unfolded protein response (UPR) 
The endoplasmic reticulum is highly regulated as it supports and possesses many cell 
functions that are fundamental for cell survivability. This organelle processes secreted 
proteins, and when folding problems occur, a complex signal pathway is activated to resolve 
the issue or terminate the cell, called the UPR (Bertolotti et al., 2000). 
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Figure 7 Unfolded protein response (UPR) 
The mechanism is triggered by misfolding events. It can inhibit the translation and regulation at the 
transcriptional level to improve ER folding and restore homeostasis. The UPR also promotes the 
membrane expansion through phospholipid synthesis and degradation pathways (ERAD and 
Autophagy). Furthermore, UPR can be activated by reactive oxygen species (ROS) formed during the 
protein folding process. Image from (Hussain, Maldonado-Agurto and Dickson, 2014). 
 
The UPR is normally activated to recover and preserve the integrity and functionality of the 
ER. In order to do so, the UPR works through a cascade of signalling pathways that cause 
different outcomes. 
Some pathways are able to inhibit the translation and promote mRNA degradation, while 
others act at the transcriptional level, by affecting molecular chaperones and by regulating 
the expression of secretory proteins. Another route works through the expansion of the ER 
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through lipid synthesis. This route aims to make more room and facilitate the formation of 
autophagosomes, which can then isolate protein aggregates, in order to degrade them (Figure 
7).  
If the combination of responses fails to balance the ER homeostasis and functionality, the UPR 
takes a terminal path triggering apoptosis. Under some circumstances, when protein 
production is intense in the ER, considerable amounts of reactive oxygen species (ROS) are 
produced, which could activate the UPR apoptotic pathway directly (Eletto et al., 2014). 
Although a lot is understood about each path involved in the UPR system, there is still a lack 
of knowledge around the set process behaviour, making predictions uncertain (Hussain, 
Maldonado-Agurto and Dickson, 2014).  
1.4 Optimization of recombinant protein production 
The biopharmaceutical industry has been trying to reduce costs associated with the 
production of recombinant proteins. Different approaches have been tested in order to 
achieve improvements in recombinant protein production. These strategies include the use 
of better expression systems, enhancement of media composition and implementation of 
favourable culture conditions. The final scope is to extend the lifespan of the culture (Sunley 
and Butler, 2010) or reach higher cell densities (Sheikholeslami, Jolicoeur and Henry, 2013; 
Kishishita et al., 2015) which would lead into an increase of the therapeutic protein produced.  
Other strategies relay in the control of non-desirable metabolite production such as lactate 
or ammonia or the control of media depletion such as glucose (Lao and Toth, 1997; Tsao et 
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al., 2005; Freund and Croughan, 2018; Noh, Shin and Lee, 2018; Pereira et al., 2018). One of 
the most reliable ways to accomplish this, is through the induction of cytostatic culture 
conditions.  
1.4.1 Cytostatic culture conditions 
Cell culture characteristics that could help the protein production, involve a delay of the cell 
growth and an increase of specific protein production during key moments, while maintaining 
viability. Cellular metabolic features result in a shift towards reducing nutrient consumption, 
low toxic compound formations and reactive oxygen species. This is done by increasing the 
protein half-life, by reducing the degradation pathways and by delaying their progress 
through the cell cycle and apoptosis. A combination of these features often accomplishes an 
increase in qp (Avello et al., 2017). 
The addition of cytostatic components that are able to decrease the cell growth rate is one of 
the main strategies to achieve these conditions. The method by which cell growth is stopped 
in order to increase protein production, is likely to do with triggering secondary metabolism 
in the cells as differences in regulatory pathways between a cell fully growing and the one 
that is arrested is considerable (Pereira, Kildegaard and Andersen, 2018). 
Growing cells are mainly committed to biomass production destined to increase their size and 
divide.  Stationary cells are likely to be more prone to product synthesis. These cells do not 
need to spend the energy and molecules to grow and divide; they use the resources available 
for recombinant protein synthesis (Vergara et al., 2014; Pereira, Kildegaard and Andersen, 
2018). This principle is the base of many methods that help protein production, such as low-
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temperature shifts, hyperosmolarity and chemical additives. The mechanism by which the 
different strategies accomplish the improvement of specific protein production is by cell cycle 
arrest (Sunley and Butler, 2010). 
All these methods accomplish final titre increase through what is described as a cell culture 
biphasic strategy. The culture is initially kept under optimal conditions for cell growth, with 
the aim to accomplish fast cell concentration and biomass accumulation. The second stage 
focuses on implementing conditions to achieve the highest specific protein production while 
maintaining good quality (Kaisermayer et al., 2016). 
1.4.1.1 Role of the cell cycle phase in static cultures 
Many parameters are of importance when maximising heterologous protein expression, such 
as media composition, gas diffusion, cell culture stage, cell size (Lloyd et al., 1999, 2000). The 
effect of the cell cycle phase arrest is another variable studied.  There is a correlation between 
the number of cells in G1 and the increase of recombinant protein expression (Hendrick et al., 
1999; Dutton, Scharer and Moo-Young, 2006). The possible mechanism behind this is the fact 
that G1 cells tend to be larger in size and have a more active metabolism (Carvalhal, Marcelino 
and Carrondo, 2003; Bi, Shuttleworth and Al-Rubeai, 2004). The proportion of G1 cells can 
therefore be used as a marker of the improvement of production. 
1.4.1.2 Strategies to improve recombinant protein production 
Previous studies have used mild hypothermia, hyperosmotic pressure and the addition of 
small molecules with no direct nutritional value to improve the cell specific productivity (qp). 
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These strategies have also been used to reduce problems in the production phase such as 
aggregation (Johari et al., 2015a).  
1.4.1.2.1 Temperature shift 
Temperature is a variable that impacts both the cell growth rate and the protein expression 
rate. By modulating temperature conditions, we can initially favour cell growth to then allow 
shifting into conditions that increase protein synthesis. This optimises fed-batch cultures. 
Mild hypothermia (reduced temperature) has been used to slow down cellular growth while 
allowing protein synthesis to continue, improving qp values (Chen, Wu and Liu, 2004; 
Trummer et al., 2006; Kou et al., 2011; Gomez et al., 2012). Temperature reduction can also 
reduce protein aggregation in a cell culture reactor (Johari et al., 2015a).  
1.4.1.2.2 Osmotic pressure 
Another method for modulating cell growth rates is by altering the osmotic pressure of the 
media. The negative effects caused by the hyperosmotic pressure conditions can be 
counteracted by the addition of the osmolyte glycine betaine. This can achieve slower cellular 
growth and, in some circumstances, can improve the qp value (Ryu et al., 2000; Tae Kyung et 
al., 2000; Kim and Lee, 2002). It was believed that the presence of low concentrations of 
glycine betaine does not interfere with cell growth or protein synthesis and that its effect was 
just targeted on helping the cell to cope with the described conditions. However, more recent 
work has found glycine betaine to be capable of reducing aggregation (Mortazavi et al., 2018). 
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1.4.1.2.3 Chemical additives 
The addition of low-molecular weight molecules with no nutritional value is another strategy 
to improve recombinant protein production.  These chemicals have the potential to improve 
product yields by either modulating cell growth, stabilising the product or reducing chemical 
modification. Butyric acid, valeric acid, valproic acid, 4-phenylbutyric acid and zinc have been 
used in recombinant CHO cell culture media (Yam et al., 2007; Jiang and Sharfstein, 2008; 
Yang, Lu and Nguyen, 2014; Coronel et al., 2016; Avello et al., 2017; Paul et al., 2018; Prabhu, 
Gadre and Gadgil, 2018). Valeric acid (pentanoic acid) produced higher product titres and 
increased qp for an unnamed recombinant protein in CHO cells (Liu, Chu and Hwang, 2001; 
Coronel et al., 2016). Valproic acid (2-propylpentanoic acid) addition to cell culture media has 
also been reported to improve antibody expression (Yang, Lu and Nguyen, 2014; Paul et al., 
2018). 4-phenylbutyrate has also been used to minimise aggregation in proteins expressed in 
CHO cells (Yam et al., 2007).  
The number of chemical additives developed and the understanding of their mechanism is 
limited. These chemicals are often very specific and can rarely be used across different cell 
lines or recombinant molecules reliably. With all this, the identification of further potential 
additives is desirable in order to increase the flexibility of engineering options during 
production processes. 
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1.5 Recombinant monoclonal antibodies  
Monoclonal antibodies are the main proteins produced by recombinant CHO cells. These are 
highly complex proteins formed by four polypeptide chains, whose maturation process 
involves assembling while folding.  
1.5.1 Heterogeneity of monoclonal antibodies 
The improvement in the quantity of the heterologous protein produced is one of the main 
aims when trying to optimise the biopharmaceutical production process. However, the 
quantity produced should be constrained by the quality of the product (Hadavand, Valadkhani 
and Zarbakhsh, 2011).  
The main factors that affect the quality are the monoclonal cell line, the process conditions 
and the culture media. The cell production process is affected by the surrounding 
environment creating different metabolic profiles in different conditions; this leads to a 
product with variable attributes. Therefore, media composition and culture conditions are 
fundamental in defining the quality of the product (Torkashvand and Vaziri, 2017).  
Monoclonal antibodies are intrinsically heterogeneous. The variants can be classified to those 
having a negative impact on the quality of the product (product-related impurities) and to 
those that do not have any negative effect on the efficiency of the biologic or its safety 
(product-related substances). As many product-related molecules as possible are supposed 
to be removed during the production process in order to optimise the procedure. 
Nevertheless, there has to be a compromise between product purity, process complexity and 
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expenditure, leading to only partial purification. Subsequently, the initial heterogeneity of the 
product previous to processing, is the key to the final product quality (Liu et al., 2016).  
The heterogeneity of the recombinant monoclonal antibody, is a result of post-translational 
modifications and degradation reactions. These changes cause differences in molecular 
weight, charge, etc. Most of these modifications occur between the cell culture stage and the 
purification step with protein A columns. Modifications can occur due to enzymatic or non-
enzymatic reactions inside or outside the cell (Liu et al., 2008) 
It is commonly assumed that antibodies are inherently variable in charge and that this profile 
is a representation of the modification state of the product. As a result, charge-based 
analytical techniques are commonly used to assess the quality and heterogeneity of the 
product. Compromised functionality is also linked to the structure of the compound. 
Understanding the integrity and behaviour of the drug produced is essential when identifying 
the quality of the heterologous protein. As a result, techniques that are able to assess the 
folding and assembling quality, as well as the product’s behaviour when interacting within 
itself (eg. whether it causes aggregating patterns), are fundamental to ensure safety (Fekete 
et al., 2013). 
1.5.2 Monoclonal antibody modifications  
The heterogeneity of the product, although sometimes intrinsic to the process, is often the 
result of specific modifications taking place. It is fundamental to understand the modifications 
that are causing these changes, as this could indicate the source of the change or the 
implications in the structure and functionality of the biopharmaceutical.   
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1.5.2.1 Disulphide bonds 
The disulphide bond is a fundamental modification of the cysteine residues in order to form 
and maintain the structure of the monoclonal antibody. Although these modifications are 
highly consistent (Zhang and Czupryn, 2002), changes in the pattern of the disulphide bonds 
can be observed. Incomplete disulphide bonds are sometimes present in the culture, thus 
leaving behind two very reactive sulfhydryl groups which lead to free thiols (Lacy, Baker and 
Brigham-burke, 2008). The lack of a disulphide bond can be a result of either incomplete 
formation or posterior reduction of the already existing bond. In either case, this causes 
decreased stability to the monoclonal antibody and leads to an increase in aggregation (Huh 
et al., 2013). These modifications are mainly found in the variable domains. The sulfhydryl 
group is not charged under neutral conditions and does not affect the charge heterogeneity. 
However, the lack of disulphide bonds could cause structural disturbances that could lead to 
changes in charge or size (Buren et al., 2009).  
1.5.2.2 Glycosylation 
Glycosylation is a post-translation modification of the primary structure of the peptide and 
one of the most important ones in the cells. Glycosylation is an enzymatic reaction where 
monosaccharides are added, cleaved and modified as the antibody matures. Heterogeneity 
of the glycan structure is common and it is mainly a result of the synthesis and processing 
inside the cell. Studies with late culture conditions have shown that glycoside activity can also 
occur outside the cell (Gramer and Goochee, 1993; Gramer et al., 1995).  The glycosylation 
profile is influenced by many factors such as the cell line, the nutrient levels, the age of the 
culture and the accumulation of metabolic products. These different parameters can interfere 
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with the enzymatic activity of the glycosylation process or they can shift the availability of the 
nucleotide sugar precursor. One feature of the glycosylation pattern that can affect the 
quality of the product considerably, is the sialic acid addition, which triggers the human 
immune response. Sialic acid possesses a negative charge and can shift the isoelectric point 
of the molecule; CHO cell lines tend to have low quantities of this molecule (Maeda et al., 
2012). Another feature that can affect the quality is the high content of mannose, which is 
related to low immune system recruitment (Kanda et al., 2006) and a shorter half-life (Goetze 
et al., 2011; Alessandri et al., 2012). 
1.5.2.3 Peptide ends modifications 
The N-terminal glutamine present in the heavy and light chains of the monoclonal antibody, 
is converted to pyroglutamate. This cyclisation is mainly a result of fermentation and is more 
prevalent in extended cultures. However, cyclisation can also occur as a result of purification 
steps (Dick et al., 2007). A loss of the N-terminal primary amine can occur; this process would 
lead to a drop of the isoelectric point.  Nevertheless, this modification does not seem to cause 
any change in potency (Lyubarskaya et al., 2006). 
The lysine can also be removed from the C-terminal of the heavy chain thus reducing the 
positive charge and causing an increase of the isoelectric point. Both modifications can appear 
fully or partially in IgG molecules, creating a diversity which can affect the charge 
heterogeneity considerably (Dick et al., 2008). It has been shown that modifications such as 
lysine clipping to those regions do not cause structural changes (Tang et al., 2013). However, 
a recent study showed that the removal or presence of complete terminal lysine residues, 
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lowers the complement-dependent cytotoxicity (CDC) response, by inhibiting the formation 
of hexametric rings (van den Bremer et al., 2015). 
1.5.2.4 Deamidation 
Deamidation is a common non-enzymatic process which occurs mainly in asparagine residues 
in monoclonal antibodies (Wright and Urry, 2008).  This modification is linked to ageing 
degradation pathways and it causes important shifts of the charge heterogeneity profile 
(Ponniah et al., 2017). Long periods of culture, high temperature or high pH can increase the 
levels of deamidation (Pace et al., 2013). This modification can occur at any given time, from 
the maturation of the antibody inside the cell to its storage.  Deamidation causes the 
asparagine to be modified into aspartic acid, thus adding a negative charge and increasing the 
number of acidic species (L. Huang et al., 2005).  
1.5.2.5 Oxidation 
Oxidation of methionine is one of the major degradation pathways in protein 
pharmaceuticals. Oxidation occurs in many amino acids, making the side chain more polar 
and increasing the isoelectric point of the recombinant protein. Although methionine is the 
most susceptible amino acid for this modification, other residues such as tryptophan, 
histidine and proline can go through this modification at a lower rate. Cysteine is also a 
plausible site, but due to the fact that these residues are often forming disulphide bonds, the 
chance of oxidation is limited. When oxidation occurs in methionine residues located in the 
conserved Fc region,  this results to a loss of the neonatal Fc receptor binding and a decrease 
of the complement-dependent cytotoxicity (CDC) activity (Mo et al., 2016).  
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1.5.3 Rituximab 
Rituximab was the first monoclonal antibody approved for treating cancer in patients with 
leukaemia, in 1997. It was further approved for use in autoimmune related diseases. This 
chimeric Immunoglobulin G (IgG), is a subtype 1 and has the capacity to target the B 
lymphocyte surface receptor CD-20. The global sales for Rituximab were 7.78 billion dollars 
during the 2017 fiscal year and 29.1 billion dollars over the period 2014-2017. Due to its 
success and the fact that the patent would expire in 2018, a second wave of 6 drugs derived 
from Rituximab has been approved in 2017 (Walsh 2018). 
1.5.3.1 Structure 
Rituximab is an IgG type 1, which is the most abundant form in serum. This type of IgG is 
characterized by four peptide chains; two heavy chains and two light chains.  
The light chain is composed of 213 amino acids and has two domains formed by interchain-
disulphide bonds. The first domain is the variable light chain region (VL), with a disulphide 
bond between amino acids 23 and 87. The second domain is a constant region of the light 
chain (CL) and has a disulphide bond between 133 and 193.  
The heavy chain is formed by 451 amino acids and is composed of 4 main domains. The first 
domain is the variable region of the heavy chain (VH), formed by a disulphide bond between 
amino acid 22 and 96. The other three domains are the constant regions CH1, CH2 and CH3 with 
sulphide bonds between 148-204, 265-325 and 371-429 respectively. The hinge is a region of 
16 amino acids (220 to 235), located between CH1 and CH2; this is where all the disulphide 
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bonds between the different peptide chains exist. Each heavy chain links to the light chain at 
residues Cys220 and  Cys213 respectively. Cysteines in positions 230 and 233 form two sulphide 
bonds between the two heavy chains (Figure 8).  
The structure also suffers post-translational modifications along the maturation and secretion 
processes. One of the main modifications is the addition of a glycan chain at Asn301, in both 
CH2 of the heavy chains.  This modification is fundamental to determine the structure of the 
fragment crystallisable (Fc) region, composed of the two CH3-CH2 domains. Furthermore, the 
N-terminal glutamines of the peptides are cyclised to pyroglutamic-acid for both heavy and 
light chains. On the other end, C-terminal lysines from the heavy chain are often cut.  
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Figure 8 Rituximab structure 
Rituximab as a “collier de perles” format with variable regions in green for the light (VL) and heavy (VH) 
chains and constant regions in blue for the light (CL) and heavy (CH1, CH2 and CH3) chains. The hinge 
region is represented in orange. The disulphide bonds are represented as red lines between the cysteine 
residues. Glycosylation of the CH2 region is represented as a yellow sequence. 
 
VH 
VL 
CL 
CH1 
CH2 
CH3 
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1.6 Database search and chemical selection 
Web of science was the search engine used in this study in order to identify potential 
chemicals to test. The search terms used were: endoplasmic reticulum stress, unfolded 
protein response, protein aggregation, maturation, folding, stability. 
Most of the information during the search was coming from biomedical studies. In order to 
assess this phenomenon, a study of different areas of research like biotechnology and 
microbiology and biochemistry and molecular biology was performed.  
As expected, areas like biochemistry and molecular biology were found to be quite 
overlapping with biotechnology and microbiology (Table 1).  
Table 1 Overlap (%) of biotechnology with other different areas of research  
 
On the other hand, life sciences and biomedicine were found to have a very small overlap. 
The number of hits from this area was equal or in most cases higher to the one from 
biotechnology and microbiology.  This indicates that both fields of research are quite 
independent of each other, although they have the same degree of interest for the topics 
selected.  
Hits Life Scn & BM BC & MB Cell Bio Pharma Scn Tch
ER stress 1327 17.6 74.2 50.0 42.6 15.5
UPR 779 13.2 78.4 70.5 34.3 18.0
Port. Maturation 7973 9.2 74.0 54.8 32.7 20.9
Prot. Aggregation 6476 6.0 62.4 24.2 46.9 24.7
Prot. Folding 34889 10.9 84.5 29.2 28.8 25.9
Prot. Stability 38942 6.3 63.2 13.6 35.8 22.2
Unfolded protein response (UPR), protein (Prot.), lifescience and  biomedicine (LScn & BM), biochemistry 
and molecular biology (BC & MB), Cell biology (Cell Bio),  Pharmacology pharmacy (Pharma),  Science 
technology and other topics (Scn Tch)
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The reason that many of the hits came from biomedical studies, was the fact that events like 
aggregation are involved in human diseases. The most studied case of aggregation, is the one 
of amyloid β peptides, intensively researched because of their relation to Alzheimer’s or 
Huntington’s disease  (Eisele et al., 2015). In these cases, the aggregation event is well 
understood, therefore, transferring this utility to the recombinant proteins studies could be 
useful (Hartl and Hayer-Hartl, 2009). 
As a result of this literature study, the selection process was focused on molecules with some, 
if not all characteristics (seen below) which could be beneficial for media culture addition in 
order to improve recombinant protein production. All the selected chemicals were heavily 
studied in other fields of research. 
• The natural origin of the chemical and its presence in the diet. This would facilitate 
toxicological studies and it would positively affect their acceptance in the 
biopharmaceutical production process 
• Ability to be easily produced, obtained and store. This would avoid shortage during 
process runs and find standard batches that will reduce variation of the chemical to a 
minimum.  
• Previously described in the literature, with mechanistic understanding behaviour on their 
positive traits 
- Antioxidant 
- Antiaggregating  
- Anti-inflammatory or antiapoptotic 
- Cytostatic 
- Chaperone activity 
• Affordable price 
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One family of chemicals that has received extensive research due to potential benefits to 
human health are the phenolic compounds, but research in their use as potential additives in 
cell culture media is limited (Hossler et al., 2015; Tian, 2016; Chung et al., 2019). Phenolic 
compounds are common in nature and play a range of roles, especially in vascular plants 
where they have been associated with antimicrobial activity, UV protection, antioxidant 
activity, antiaggregation and allelopathy (Jovanovic et al., 1994; Pietta, 2000; Thorpe et al., 
2009). In some cases, plant-derived phenolic compounds have been credited with a diverse 
range of benefits for animal cells. Polyphenols have had diverse medical attributes allocated 
to them, including the treatment and prevention of cancer and cardiovascular disease. They 
have also been suggested to be antiulcer, antithrombotic, anti-inflammatory, antiallergenic, 
anticoagulant, immune modulating, antimicrobial, vasodilatory, and analgesic (Ozdal, 
Capanoglu and Altay, 2013). These group of chemicals heavily researched in the biomedical 
field possess traits that could be beneficial for recombinant protein production in CHO cell 
host systems.  
A final group of fifteen molecules was selected, many of them were part of the phenol family, 
while others were previously researched in the biopharmaceutical industry. The next section 
of this thesis describes in more detail the structure and the characteristics of these molecules. 
 Chapter 1 57 
1.7 Chemical candidates 
1.7.1 Sodium 4-phenylbutyrate (4-PBA) 
This is an aromatic fatty acid that has been 
extensively studied in the last two decades 
due to its potential chaperone activity as a 
hydrophobic soluble compound (Figure 9). Furthermore, cell-free studies demonstrated its 
capability to prevent aggregation (Kubota et al., 2006).  
Research on this component is mainly focused in the area of misfolding and ER-stress-related 
diseases (Kubota et al., 2006; Kuryatov, Mukherjee and Lindstrom, 2013; Cho et al., 2014). 
Although no specific mechanism of action is described, it was reported that sodium 4-
phenylbutyrate is able to protect human cells from DNA damage and to reduce the ER stress 
(Lenin et al., 2012) and the UPR (De Almeida et al., 2007). Research done in CHO cells did not 
show any increase in the specific recombinant protein production(Roth et al., 2012) nor any 
inhibition of aggregates (Hwang et al., 2011). 
1.7.2 Caffeine 
Caffeine is a chemical compound composed by trimethyl 
xanthine and is produced in plants (Figure 10). This chemical 
is found in foods such as coffee and tea. The compound is 
highly studied as it is a stimulant of the central nervous 
Figure 9 The chemical structure of sodium 4-
phenylbutyrate  
Figure 10 The chemical structure 
of caffeine 
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system. This chemical was found to act by reducing ER stress (Hosoi et al., 2014) and 
protective properties (Painter, 1980). 
1.7.3 Caffeic acid phenethyl ester (CAPE) 
CAPE is a molecule found in 
propolis, which is made by bees. 
It is used extensively in traditional 
medicine in Asia. This molecule is 
a phenethyl alcohol ester of 
caffeic acid and is highly bioactive. This compound was found to be protective against ER 
stress by some authors (Armagan et al., 2008; Kavakli et al., 2010). However, other recent 
studies show that this compound is highly toxic to the cell, causing apoptosis due to its 
pernicious effect over the mitochondrial dysregulation, through  ER stress pathways (Jin et 
al., 2008; Ozturk et al., 2012).  Cell resistance has been proven to be acquired (El-Khattouti et 
al., 2015). Furthermore, CAPE is able to prevent the aggregation of platelets. This is due to 
the inhibition of platelet activation, by mobilisation of the calcium ion (Hsiao et al., 2007).  
Therefore, this compound has been heavily researched in food industry and medicine. 
However, the characteristics of the chemical are in principle undesirable for the production 
of recombinant proteins. There are no studies published on the effect of this chemical on 
recombinant producer cell lines and it was included in the present study. 
Figure 11 The chemical structure of caffeic acid phenethyl ester 
 Chapter 1 59 
1.7.4 Curcumin 
This is a diarylheptanoid, grouped 
in the turmeric compounds (Figure 
12). It has low solubility in water 
and it is used as a colouring agent in food industry (Yan, Geusz and Jamasbi, 2012). 
Curcumin folding activity was studied in a cell-free system and it was found that it can inhibit 
the nucleation of amyloid β aggregates. However, it was not able to inhibit or reverse the 
expansion phase (Borana et al., 2014). Other studies showed destabilizing effects in the fibril 
formation of amyloid β aggregates, caused by this compound (Ono et al., 2004). A study using 
different curcumin analogues, showed that the chaperone activity was different amongst 
them, highlighting how small changes in the chemical structure could lead to considerable 
changes in the chaperone behaviour (Endo et al., 2014). 
In vitro cell study experimentations, showed that this molecule has the capability to rescue 
the maturation of a mutated protein unable to properly fold which seemed to be linked to a  
drop in calcium levels at the ER (Robben et al., 2006). Finally, studies done in CHO cells to 
assess whether the molecule would enhance the protein production titre, did not show any 
positive effects. On the other hand, there was a tendency to increase productivity when used 
in combination with glycine betaine  (Roth et al., 2012).  
Figure 12 The chemical structure of curcumin  
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1.7.5 Catechin compounds 
These are a group of antioxidants that belong to the flavan-3-ols (flavanols)(Figure 13). They 
are naturally produced from plants by secondary metabolism. They can be found in tea and 
wine as well as other food products derived from plants. In general, this group of chemicals 
seemed to have properties that would be of interest to this study.  
Epigallocatechin gallate (EGCG) is the most studied compound of this group, as it is the most 
predominant in green tea. Medical research showed that this compound is able to help 
against aggregation problems (Ehrnhoefer et al., 2008; Bieschke et al., 2010; Bleiholder et al., 
2013). Furthermore, it can reduce the levels of ER stress, protein oxidation and apoptosis 
(Ferreira, Saraiva and Almeida, 2012).  
Unlike other chemical components from the same group, the catechin chaperone activity has 
not been thoroughly studied. Medical studies showed that this molecule was able to protect 
cells against amyloid β peptides aggregation (Conte, Pellegrini and Tagliazucchi, 2003) and 
against ER stress (Lee, Kim and Heo, 2011), although this is probably connected to a 
mechanism not involving its antioxidant potential (Auger et al., 2005). 
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Epicatechin is an epimer of catechin and has not been extensively studied. Bastianetto 
published data indicating that this chemical did not prevent induced amyloid β aggregates in 
cell cultures. Furthermore, the combination of EGCG, ECG and Gallic acid inhibited apoptosis 
mediated by the accumulation of Aβ-aggregation (Bastianetto et al., 2006). 
 
Figure 13 The chemical structure of catechins 
 
1.7.6 Glycine betaine 
Betaine (glycine betaine) is a natural amino acid 
derivate, produced by plants which use it as an 
osmolyte (Figure 14). It is abundant in foods like 
wheat, quinoa or spinach. Due to its osmo-
protective properties, this chemical has already 
Catechin Epicatechin 
Epigallocatechin gallate Gallocatechin gallate 
(Cat) (EC) 
(GCG) (EGCG) 
Figure 14 The chemical structure of betaine 
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been applied to biopharmaceutical industry under hyperosmotic pressure conditions, leading 
to an improvement of the specific protein production (DeZengotita et al., 2002) and cell 
growth (Ahn et al., 1999). This effect has been shown to vary, depending on the cell line (Tae 
Kyung et al., 2000). The increase in production is mainly due to the elongation of the cell 
viability culture (Yoon and Ahn, 2007). This compound although heavily researched within 
recombinant IgG production process was studied as a positive control.  
1.7.7 Kaempferol 
This is a flavanol (Figure 15) found in plants and 
it can prevent amyloid β aggregates by 
inhibiting nucleation in cell-free studies (Nisha 
et al., 2014) (Borana et al., 2014). 
The mechanism of action on the aggregation of proteins by kaempferol is not clear. Some 
studies indicate that the mechanism of action does not seem to be related to its antioxidant 
activity (Roth, Schaffner and Hertel, 1999). On the other hand,  it is not clear whether its 
performance is due to a direct interaction with the protein, an indirect effect by interacting 
with estrogen receptors (Kim et al., 2010) or a combination of both.  
Figure 15 The chemical structure of 
kaempferol 
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1.7.8 Luteolin 
Luteolin or luteolol, is a naturally occurring 
chemical produced by plants. This type of 
polyphenol (Figure 16) is found in fresh 
vegetables such as green peppers or celery. As 
with most polyphenols, luteolin has been 
proven to be a very bioactive compound, able to 
interact with cells at different parts of the regulatory pathway, such as dopamine activation 
(J. J. Zhang et al., 2010). Furthermore, this compound has been found to help against cell 
cellular stress (J. J. Zhang et al., 2010) and more specifically induced mitochondrial stress  
(Murugesan and Manju, 2013). Luteolin was initially found capable of inducing ER stress and 
triggering apoptosis (Choi et al., 2011; Park et al., 2013). However, recent experimentations 
contradict this idea (Tai et al., 2015; Wu et al., 2015). Finally, this molecule is able to interact 
with molecules at the molecular level and prevent aggregation (Lee et al., 2010; Churches et 
al., 2014). 
1.7.9 Piceid 
Piceid or polydatin, is a 
stilbenoid glucoside produced 
by plants and found in great 
quantities in the skin of grapes. 
It is a derivate of resveratrol and 
is substituted with a glucosyl residue at position 3 (Figure 17). Recent studies show that this 
Figure 16 The chemical structure of luteolin 
Figure 17 The chemical structure of piceid 
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compound is able to increase stress resistance, by creating a mitochondrial response in cells 
(Robb and Stuart, 2014). Furthermore, it seems that this chemical is a strong antioxidant, a 
characteristic that does not seem to relate to the release of a resveratrol molecule (Storniolo 
et al., 2014). This is especially true when affecting lipids (Fabris et al., 2008). Piceid is probably 
less studied due to its lower bioactivity when compared to resveratrol; this seems to be a 
result of the compound being more difficult to be assimilated by cells (Su et al., 2013). 
1.7.10 Resveratrol 
It is a natural phenol from the group of the 
phenylpropanoids (Figure 18). Less toxic 
aggregates were formed during cell-free system 
studies using this molecule. However, the 
molecule could not shift or reverse more noxious 
conformations already aggregated  (Ladiwala et 
al., 2010). Cell assays displayed two different behaviours depending on the molecule’s 
concentration; concentrations above 50µM were toxic and arrested cell growth. 
Concentrations below 50 µM, prevented amyelation (Conte, Pellegrini and Tagliazucchi, 
2003). Resveratrol’ s mechanism of action, seems to be linked to an enhancement in the 
degradation path through the proteasome (Marambaud, Zhao and Davies, 2005), and it is 
proven not to be related to its antioxidant activity (Auger et al., 2005). 
Figure 18 The chemical structure of 
resveratrol 
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1.7.11 Tocopherols 
Tocopherols are a group of 
organic, soluble, lipid 
compounds, that can be found 
in vegetable oils and fats. They are formed of four main types; alfa, beta, delta and gamma. 
All of them are compounds of vitamin E. They consist of a 2H-1-benzopyran-6-ol nucleus with 
a long hydrocarbon chain of 13 carbons, decorated with isoprenoid units; this gives these 
molecules antioxidant properties (Figure 19). Research in CHO cells found that the alpha and 
beta forms can alter the gene expression, by inhibiting the protein kinase C (Fazzio, Marilley 
and Azzi, 1997). Furthermore, tocopherol was found to be helpful against induced oxidative 
stress (Li et al., 2008). 
1.8 Aims of the study 
The process and variability of recombinant protein production in CHO cell lines are still not 
fully understood. Clonal producer cell lines are inherently variable and difficult to predict. This 
is due to the fact that the process is related to many different features such as epigenetic 
traits, culture conditions and cell growth behaviour. These features cannot be fully controlled 
during the manufacturing production process. Nevertheless, control over the process is 
fundamental as it affects the quantity and quality of the biopharmaceutical.  Uncontrolled 
batch cultures can pose problems such as aggregation, misfolding, degradation of the product 
leading to ER-stress, UPR response and apoptosis. This uncertainty in the production process 
can lead to economic losses and a potential shortage of needed drugs in the market.  
Figure 19 The chemical structure of alpha-tocopherol 
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A biphasic culture is one of the most common strategies to help the production and to control 
behaviour in the cell culture batch. The general mechanism involves stopping the cell growth 
in the final phase through cytostatic conditions. Strategies used include temperature shift, 
osmotic pressure and addition of low-molecular weight molecules. The development of 
chemical additives for recombinant protein production improvement in running CHO cells 
batch cultures is limited. Moreover, their use is very specific, with low transferability of the 
effect to other cell lines or recombinant products. 
A number of studies on the use of natural chemical molecules is included in the biomedical 
research literature. These studies report the effect of these chemicals on mammalian cell 
cultures and describe their mechanism. Many parameters such as antiaggregation, antitumor 
and chaperone activity, associated with molecules studied in medical research, could be 
transferable to biopharmaceutical production processes in CHO cells. Therefore, one of the 
first steps of this study, was to select natural chemical compounds studied in biomedical 
literature. The selection would be based on traits that could favour recombinant protein 
production in CHO cells. Only chemicals not yet developed for biopharmaceutical process as 
chemical additives at the time of this study would be selected. 
The overall aim of the project was to study and develop new chemicals as additives in order 
to improve protein production for recombinant IgG produced in CHO cells. 
The objectives of this project were to: 
- Identify the concentrations at which selected chemicals are capable of increasing qp 
without jeopardising the viability of the culture 
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- Study the effects of successful treatment over time with screened chemical candidates 
on cell culture growth, cell morphology and cell cycle phase arrest 
- Determine whether chemical treatments found to have an increase in qp during 
screening, have the same effect in scale-up cultures and whether they cause an 
increase in the final titre production through optimization of feeding strategies 
- Determine whether the increase in the final titre of IgG by the chemical additives has 
an effect on the quality of the product 
 The results of this dissertation are divided into four chapters.  
• Chapter 3 focuses on developing a reliable method in order to assess the effect of 
chemical candidates on cell culture growth and specific productivity 
• Chapter 4 studies the effect over time on cell culture conditions and cell cycle phase 
arrest 
• Chapter 5 optimises feeding strategies of the chemical additives in scale-up cultures 
to assess the increase of the final recombinant IgG titre 
• Chapter 6 examines the effect of the optimised feeding conditions on the quality of 
the product 
Chapter 7 summarizes all the results and compares the findings to the available literature, 
suggesting areas of further work. 
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2.1 Cell culture 
2.1.1 Maintenance of CHO cells  
The cell line used in the experimentation was an IgG recombinant CHO-DG44 producer cell 
line, kindly provided by Fujifilm Diosynth Biotechnologies UK (FDBK). This cell line was 
maintained for the entirety of the project. The recombinant protein produced was a 
monoclonal antibody (mAb) called Rituximab; this targets a B-cell lymphocyte membrane 
protein called CD20. Cells were grown in 125 mL Erlenmeyer flacks, with 30 mL of culture 
media in a shaking incubator at 130 rpm and a 5% CO2 modified atmosphere. The culture 
media used to grow the cells was an already prepared CD Opti-CHOTM (Life technologies TM) 
with L-Gln added to 8 mM and Hygromycin b to 100 µg/mL.  Subcultures were done every 3-
4 days alternatively, with an initial seeding density of 0.2 x 106 viable cells/mL.  
 
2.1.2 Generation of CHO cell cultures in well plates 
96-well and 24-well plates were set up with an initial volume of 200 µL and 1000µL 
respectively at a concentration of 0.2 x 106 viable cells/mL. Plates were incubated for 3 days 
in a static humidified incubator. 
 
2.1.3 Generation of CHO cell cultures in Erlenmeyer flask 
Cells were seeded to an initial concentration of 0.2 x 106 viable cells/mL, from a previous 
exponential phase culture. An initial volume of 33 mL of culture was seeded to a 125mL 
 Chapter 2 72 
Erlenmeyer culti-flask (Corning, Tewksbury, MA, US). The cultures were run under shaking 
humid conditions as specified in section 2.1.1 for a period of 10 days. 
 
2.1.4 Detection of cell density, viability, diameter and circularity 
A volume of 500 µL of each sample was used to measure the density, viability and morphology 
of the cell with a trypan blue exclusion method carried out by a Vi-cellTM XR (Beckman-Coulter, 
Brea, CA, USA). For 96-well plates, 150 µL from each sample was collected, mixed with 
Phosphate-buffered saline (PBS) buffer up to 500 µL previous to taking the measurement.  
 
2.1.4.1 Measurement of LC50 and GI50 
Data from the Vi-cell was used to further calculate the lethal concentration at 50% LC50. To 
do so, the number of alive and dead cells for each sample were analyzed by an R function 
developed by Pacheco and Revelo in 2013; this was based on Probit statistical test. 
Furthermore, the growth inhibition at 50% (GI50) was calculated by analyzing the viable 
concentration and the viable cells’ data coming from the Vi-cell reading. The R program tool 
requires the data to be positive integers. The two variables were determined as follows: 
• Cell growth: number of cells that duplicated over this period of incubation 
• Cell inhibition: cells that were not able to grow with respect to the control 
“Cell growth” was calculated as the net VCD of the sample (subtracting the VCD at time 0) 
divided by the average of the Net VCD of the control samples, and multiplied by the number 
of viable cells in the sample (Error! Reference source not found.). 
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!"##	%&'()ℎ = ,!-. − ,!-0123(,!-5 − ,!-0) × 	8')9#	!"##: 
Equation 1 
 
“Cells inhibition” was calculated as the difference between the total cells of the sample and 
the previously calculated cells grew (Error! Reference source not found.). 
!"##	;<ℎ=>=)='< = 8')9#	!"##: − !"##	%&'()ℎ 
Equation 2 
 
When using the average to compare values at the end and beginning of the concentration 
range may lead to negative values of cells for cell growth or inhibition. The code used in these 
calculations is unable to process negative values, as it lays information as cells alive and dead. 
As a result of this, the negative values were corrected as specified in the following equations 
for cell growth (Error! Reference source not found.) and cell inhibition (Error! Reference 
source not found.).  
!'&&"?)"@	!"##	%&'()ℎ = 	AB| D':=)=2"	29#E"F"39)=2"	29#E" |G × 	D':=)=2"	29#E"H + !"##	%&'()ℎB| D':=)=2"	29#E"F"39)=2"	29#E" |G  
Equation 3 
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Equation 4 
 
Finally, the data was entered into the R coding system previously used for LC50 (Appendix 1).  
This method is only used as a way to indicate toxicity and cytostaticity and does not pretend 
to generate accurate values. Complete and more define curves would have to be investigated 
and this was not the present work. 
 
 
2.1.5 Direct protein quantification 
Samples were centrifuged for 10 minutes at 400 g.  Then, 200 µL of the supernatant is 
transferred (for 96-well plates, 100 µL of supernatant from each well was collected and mixed 
with 100 µL of PBS buffer) into a solid black 96-well plate (Greiner-bio-one, Kremsmünster, 
Austria).  Finally, the plate was put in storage overnight at -80oC, and later used to analyze 
protein concentration with an Octet® QKe (Pall FortéBio, Fremont, California, USA). 
 
For specific protein production (qp) traked over 10 day cultures, qpwas determined by dividing the 
total protein produced after ten days incubation by the integral of the VCD curve over the same 
duration (Renard et al., 1988). 
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2.1.6 Chemicals 
The chemicals tested to validate the screening methods were selected based on previous 
studies (Table 1). 
All the chemicals, due to their hydrophobic character, were dissolved into Dimethyl sulfoxide 
(DMSO) to its highest possible concentration and put into storage at -80oC. Then, different 
dilutions from the stock concentration were pipetted into DMSO, in order to study their 
impact on the Cho cell cultures and their capacity to produce recombinant protein. 
2.2 Flow cytometry 
2.2.1 Propidium iodide staining protocol 
This protocol is an optimized version adapted from Krishan (1975), the process of 
optimization s described below (section 4.2.1) 
First, cells were collected from 24-well plate cultures and transferred into a 1.5 mL Eppendorf 
to be centrifuged at 300 g for 5 minutes. The pellet was then discarded. CHO cells are very 
robust and can endure high centrifugation speeds. This centrifugal force was selected based 
on empirical data from previous work done with this cell type in the laboratory. More extreme 
centrifugation at 400 g, had the same results in terms of pellet formation and cells were able 
to maintain integrity. These conditions can be adapted when cells are more difficult to collect 
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in the early stages, but if not needed it is better to use 300g as a conservative measurement 
to preserve the cell’s integrity until fixation. Later, the cell pellet was resuspended gently into 
30 µL of ice-cold PBS buffer. This step was performed in order to avoid clumps of cells and 
facilitate the fixation of cells that would follow. If the pellet was to be very abundant at this 
step, then 60 µL of PBS buffer could be used instead of the 30 µL one. However, this would 
also mean that the amount of ethanol in the subsequent steps should be doubled.  
Next, cells were fixated with ice cold ethanol at 70% which was added drop by drop to the 
cell suspension, while vortexing the Eppendorf at medium intensity.  Vortexing allows for the 
fast dissolution of the ethanol in the media. It also allows the ethanol to act on the cells 
homogenously, thus avoiding the formation of clumps and aggregates. Fixation was allowed 
for 30 minutes at 4oC but this was flexible ranging from 20 minutes to overnight. Following 
fixation, cells were centrifugated at 400 g for 5 minutes followed by removal of the ethanol 
supernatant.  At this stage centrifugation should not be a problem; cells come out from the 
solution easily and form a very compact pellet. In order to avoid future PBS passages without 
compromising the removal of ethanol, the maximum amount of supernatant possible, has to 
be removed at this stage. As ethanol is removed, the pellet would be exposed and rapidly 
dried due to the fast evaporation of the ethanol remaining in the pellet. That is why, the 
immediate subsequent addition of PBS buffer to the pellet in order to avoid the formation of 
aggregates and lumps, is crucial. 
The pellet was then resuspended gently in 1 mL. Cells were left to rehydrate for at least 15 
minutes. The volume of the PBS buffer wash needed to be maximized in order to counteract 
the lack of future washes and reduce the amount of ethanol left in the vial. Then, cells were 
centrifuged at 400 g for 5 minutes. At this stage cells tended to rehydrate and lose density, 
thus forming very fussy pellets. Therefore, this could result in considerable cell loss. For that 
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reason, it is recommended to use high speed when centrifuging in order to obtain the best 
pellet possible. Next, a supernatant removal and addition of 30 µL of RNAase (100µg/mL) and 
200 µL of propidium iodide (50 µg/mL) were performed. Finally the sample was left to 
incubate for 5 to 10 minutes. 
 
2.2.2 Flow cytometry and data analysis 
Samples were analyzed with an AttuneTM NxT Flow Cytometer & autosampler (Thermo Fisher 
scientific), The acquisition volume for each well was 200 µL the device was set to a high 
sensitivity with a flow speed of 100 µL per minute and 50.000 events per well. 
Finally, the data collected was analyzed with FlowJoTM v10 (San Carlos, California, USA).  In 
order to obtain reliable histograms, the information coming out of the flow cytometer needed 
to be gated. First, the cells were graphed in forward Scatter vs side scatter   FCS-A vs SSC-A 
(Figure 20A). This graph shows the distribution of the cell population; it distinguishes different 
cell types and is used in this instance to identify that there is no more than one cell type in 
the sample. Secondly, the cell population is graphed by the height of the intensity vs the area 
(Figure 20B), this is in order to discriminate signals associated with two cells passing at the 
same time (doublets) they are characterized by having the same high but an increased area. 
As a result, only signals inside the diagonal between blue laser fluorescence area (BL2-A) and 
blue laser fluorescence height (BL2-H) are gaited for further reading. Finally, singlets are then 
studied by gating the area vs the width (Figure 20C), this graph shows two hot spots that 
indicate the G1/G0 and the G2/M phases linked by the S phase in between. This graph allows 
for further discrimination of duplicates and aggregates as well as debris. For the gating draw 
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a square in this area, then this gating is saved to be used for all the samples. All histograms 
were displayed as the number of cells vs the width of the signal (Figure 20D). The assignment 
of the cell cycle phases was done automatically by the FlowJo software. The graphs were 
displayed in number of cells vs the height of the signal.  
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Figure 20 Gating workflow of flow cytometry data 
(A) forward scatter area (FSC-A) by side scatter area (SSC-A) graph to visualize the cell types of the 
sample. (B) distribution of signal events graphing area (BL2-A) versus height (BL2-H) to identify singlets 
by a gate (yellow delimited area). (C) distribution of area (BL2-A) over width (BL2-H) with a density plot 
to identify and gate cells in the cell cycle. (D) Histogram of the distribution of cells (Count) by the area 
(BL2-A) of the signal. CHO cell culture cells were fixed and stained with propidium iodide. BL2 is the 
scattering signal of the second channel of blue light. 
 
A 
B 
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2.3 Antibody purification 
2.3.1 ÄKTA 
To analyze the characteristics of the recombinant protein of interest, the media was 
processed in order to isolate the product through affinity chromatography. The cell culture 
was centrifuged at 800g for 10 minutes. The supernatant was filtered with a hydrophilic PVDF 
membrane with a 0.22 µm pore size (Starlab, Milton Keynes, UK) and mixed up to 50 mL with 
a binding buffer for adaptation. 20 mM of sodium phosphate and  0.15 M  of NaCl, (pH 7.2) 
were used as binding and equilibration buffers respectively. The flow rate was set at 5 mL/min 
for 100 mL, after injecting the sample during the binding phase. The elution of the IgG was 
obtained by a sudden swap of the buffer to 0.1 M of citric acid (pH 3). The elution phase was 
prolonged for 50 mL to ensure the detachment of the IgG. The peak sample was collected 
manually. After the citric acid wash, the column was equilibrated again for 25 mL, previous to 
the next sample run.  Purification was carried with an ÄKTATM pure (GE Healthcare) with the 
use of a 1x5mL HiTrapTM MabSelect SureTM protein A column (GE Healthcare) and then stored 
at -80oC until further analysis. 
Note: resveratrol was found to have a specific binding affinity for the protein A column, even 
stronger than that one of the IgG. Most of the resveratrol was eluted after washing with 
sodium hydroxide. 
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2.3.2 SDS-PAGE 
To further corroborate the purity of the product after the ÄKTA purification step and the 
behaviour of the column, the first and last samples run for purification each set were run in 
an SDS-PAGE gel. One µL of control samples were diluted with 4 µL of eluent buffer from the 
purification step and mixed with 5 µL of Laemmli buffer while 5 µL of the treatment at 500 
µM resveratrol was mixed directly with 5 µM of Laemmli buffer. The mixture was incubated 
for five minutes at 95oC.  
SDS gel electrophoresis was performed under reducing conditions with 1.0 M Tris-HCl buffer 
(pH 6.8) for the stacking gel (4% acrylamide) and 1.5 M Tris-HCl buffer (pH 8.8) for the 
separating gel (10% acrylamide). Migration was performed at 120V for one hour. The gel was 
stained with Page Blue Protein Staining Solution, left shaking overnight (8 hours) and then it 
was distained with 4 washes of milliQ water every 2 hours for 8 hours. The molecular weight 
ladder was P7706S (Appendix 3). 
2.4 High-performance liquid chromatography (HPLC) 
2.4.1 Size exclusion chromatography (SEC) 
The Thermo UltiMate 3000 Rapid Separation HPLC System (Thermo Fisher Scientific, 
Waltham, MA, United States) was used to study how the addition of resveratrol and catechin 
to a recombinant CHO culture media, affects the final aggregation or fragmentation of the 
recombinant antibody produced. A MabPac SEC-1 4x300 mm column with 10 µm particles 
(Thermo Fisher Scientific) was used in an isocratic regime with a buffer of 20mM MES+0.3M 
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NaCl at a pH of 6.1. Samples were run for cycles of 30 minutes each at 0.2 mL/min at 25oC. In 
order to eliminate the noise of the chromatogram, only peaks above 0.1% were considered 
significant.  
The identification and relative quantification of the peaks was performed automatically by 
Chromeleon software. Bovine serum albumin (BSA) was used to condition the column. 
Furthermore, BSA was used along the process of chromatography, to ensure that there would 
not be any changes in the behaviour of the experiment over time. Finally, the BSA conditioned 
spectrum was used to create a correlation curve between the time of elution and the 
molecular weight. 
2.4.2 Cation exchange chromatography (CEX) 
The samples were first treated with carboxypeptidase-B from porcine pancreas (Merk, 
Kenilworth, NJ , United States) at a temperature of 37oC for a period of two hours with an 
enzyme to protein ratio of 1:25, as previously described (Flores-Ortiz et al., 2014). The Thermo 
UltiMate 3000 Rapid Separation HPLC System (Thermo Fisher Scientific, Waltham, MA, United 
States) was used to perform high-performance liquid chromatography to discriminate 
different recombinant IgG species based on their charge. A MAbPac SCX-10 4x250 mm 
(Thermo Fisher Scientific) column with 10  µm diameter particles was used under a 1 mL/min 
flow regime, at a temperature of 50oC. A gradient system, ranging from 15% to 36.4% of 
buffer B (20 mM + 300mM NaCl at pH 5.6) in buffer A (20 mM + 60mM NaCl at pH 5.6) was 
used for 25 minutes, followed by two minutes of cleaning with buffer C (20 mM + 1M NaCl at 
pH 5.6) and 15 minutes of reconditioning at 15% buffer B in buffer A. 
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After the chromatograms were run, the files were exported in CDF format from the 
Chromeleon software and they were processed and analyzed by R software. First, the 
chromatograms were delimited between sample injection and cleaning, as those parts 
contain no relevant information related to the study. Then the files were compiled and colour-
coded by treatment type (Figure 21A). To further process the data, the spectra were aligned 
by their maximum peak (Figure 21B). Antibody ion-exchange chromatograms were 
characterized with a high peak, when fully cleaved from C-terminal lysine; the peak 
corresponded to the mean charge variation of the molecule. This peak was used as a landmark 
in the chromatogram profile, in order to align all the different chromatograms. The shift 
between the spectra observed in this data could be a result of small changes in the pH when 
preparing the buffers. The alignment process causes the spectra to shift and some data could 
be missing at one end or another. As a result, the next step in formatting the data, was to 
crop both sides of the spectrum, in order to remove these regions without relevant parts 
(Figure 21C). Furthermore, the baseline spectrum was assessed with a linear model and then 
corrected (Figure 21D). The data were then corrected for negative values (Figure 21E). This 
was done because negative values could create problems during normalization, as they are 
subtracted from the final area under the curve. Each spectrum was corrected by adjusting the 
most negative value to zero. The data was normalized (Figure 21F), the extension of the mean 
peak was stated and the regions were defined. Finally, the acidic species, the mean variant 
and basic species of the IgG were measured. Results were evaluated for statistical significance 
by one-way ANOVA, p-values were considered significant bellow 0.05. Further information of 
the process is displayed in Appendix 4. 
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Figure 21 Data analysis of the ion-exchange chromatography spectra with the R software 
(A) Compilation of the data by the program and assignment of the treatment groups (colours). (B) 
Alignment of the data by the maximum peak intensity. (C) Cropping excess of the chromatogram from 
both sides to standardize the distance in chromatographic time to the maximum intensity peak. (D) 
Baseline correction for each individual chromatogram with a linear model. (E) Correction of negative 
values. (F) Normalization of the area under the curve. 
 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
 Chapter 2 85 
2.5 Mass spectrometry 
2.5.1 IgG digestion 
In order to study the modifications of the recombinant IgG, previously purified samples were 
used to measure the concentration of IgG after purification, using NanodropTM 2000c 
(Thermo Fisher Scientifics). 40 µg were retrieved in a final volume of 200 µL by addition of pH 
7.5 denaturation buffer (7.5M GdnHCl and 0.25 M Tris). Reduction was performed by the 
addition of 1 µL of TCEP at 50 mM and incubation for 10 minutes at 70oC. After cooling the 
samples in ice for 5 minutes, 2 µL of 0.5 M IAA were added and the samples were left in the 
dark for 30 min at room temperature, in order to achieve carboxy-methylation. Finally, 100 
mM ammonium-bicarbonate (AB) was added to a final volume of 500 µL.  IgG samples were 
buffer-exchanged into a pH 7.5 digestion buffer (100 mM AB) using a NAP-5 column (GE 
Healthcare, Piscata-way, NJ, USA).  
Lyophilized trypsin was dissolved in 100 mM AB to a final concentration of 0.1 µg/µL and 
added to the samples in a 1:25 ratio. Digestion was performed in an oven at 37oC in a period 
of 30 minutes. The reaction was then stopped by lowering the pH to 3.0, by adding 5.5 µL of 
100% formic acid. Samples that were not used immediately, were stored at -20oC. The 
protocol was adapted from (Ren et al., 2009). 
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2.5.2 Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
Samples were run through a Dionex Ultimate 3000 uHPLC with a PepMapTM RSLC C18 2 µm 
100 Å 50 µm x 15 cm coupled to an Orbitrap Elite MS (Thermo Fisher Scientific, Waltham, MA, 
United States) with an EASY-SprayTM Ion Source.  
A volume of 18 µL of each digested IgG sample was used for LC-MS/MS analysis. Peptides 
were separated in a Dionex Ultimate 3000 uHPLC (Thermo Fisher Scientific, Waltham, MA, 
United States) with an Acclaim™ PepMap™ 100 C18 trap column (3 µm particle size, 75 µm x 
150 mm) and an EASY-Spray™ C18 column (2 µm particle size, 50 µm x 150 mm) using a 35 
min method at 0.25 µL/min with 0.1% formic acid in water (mobile phase A) and 0.1% formic 
acid in 80% acetonitrile (mobile phase B) as follows: 0-3 min, hold at 3% B; 3-21 min, from 3% 
B to 40% B; 21-21.1 min, from 40% B to 90% B; 21.1-26 min, hold at 90% B; 26-26.1 min, from 
90% B to 3% B; 26.1-35 min, re-equilibrate at 3% B. MS analysis was performed on a LTQ 
Orbitrap Elite (Thermo Scientific) hybrid ion trap-orbitrap mass spectrometer equipped with 
an EASY-SprayTM Ion Source. MS survey scans in positive ion mode were acquired in the FT-
orbitrap analyzer using an m/z window from 375 to 1600, a resolution of 60,000, and an 
automatic gain control target setting of 1 × 106. The 20 most intense precursor ions were 
selected for the acquisition of MS/MS spectra in the ion trap (Normal Scan Rate) using 
collision-induced dissociation (CID) with normalized collision energy of 35%, activation time 
of 10 ms, isolation width of 2 Th, and automatic gain control target value of 1 × 103. The 
charge states 1+ were excluded from precursor selection. Monoisotopic precursor selection 
was activated. Dynamic exclusion for precursor ions was applied for 45 s after 1 fragmentation 
count and a repeat duration of 30 s. 
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2.5.3  Data processing 
Processed raw data files were then used for dependent peptide search. This was performed 
with the MaxQuant (v 1.6.2.6) software (Max Planck Institute for Biochemistry, Munich, 
Germany), and then the data was processed with an R software code previously published 
(Acosta-martin et al., 2016). The data for mass shift differences from each sample were 
gathered together into a single file. The treatment files were then compared versus the 
control individually. Firstly, the mass shift spectrum was broken into discrete pockets (0.05 
Da); the number of mass shift events in each pocket was compared between the control and 
the treated sample. Then a Z-score was calculated to identify outliers (>3.5) within the 
comparison test (Figure 22A) (Appendix 6). Unusual mass shift differences were characterized 
as significant differences and were plot in a histogram to visually assess the reliability of the 
mass shift difference (Appendix 7). Peaks that were high and had a consistent shape (Figure 
22B) were taken forward to identify the modification. Histograms that did not show reliable 
peaks were discarded (Figure 22C). This process for the light and the heavy chain were done 
independently.  
Modifications that were predominant and those of interest for the functionality of the IgG 
(Table 2), were studied with a direct modification search using the label-free quantification 
method in the MaxQuant (v 1.6.2.6) software (Max Planck Institute for Biochemistry, Munich, 
Germany). 
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Table 2 Mass spectrometry searched modifications 
 
The obtained files were then processed by a code (Appendix 8) in the R software and the files 
were integrated into one data set. Modifications were only considered significant if they 
appeared consistently (in 3 out 4 replicates) for every treatment. Finally, they were compared 
based on their ratio of modified peptides per non-modified ones.  
Obtained peptide files were also used to study the sequence coverage of the analysis, with 
the use of the R software. Files with all the peptides combined, were loaded to the software, 
and accumulative intensity was calculated for each amino acid under specific treatment 
conditions by applying R coding (Appendix 5), to then be displayed as a heatmap. 
 
 
Modification Composition Monomeric peak
Oxidation O 15.994915
Trioxidation O (3) 47.984744
Acetylation H(2) C(2) O 42.010565
Reduction O (-1) -15.994915
Deamidation H(-1) N(-1) O 0.984016
Carbamidomethylation H(3) C(2) N O 57.021464
Hydroxykynurenine C(-1) O(2) 19.989829
Kynurenine C(-1) O 3.994915
loss of ammonia H(-3) N(-1) -17.026549
Pyroglutamate H(-2) O 13.979265
Gln->Ala H(-3) C(-2) N(-1) O(-1) -57.021464
Asn->Gly H(-3) C(-2) N(-1) O(-1) -57.021464
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Figure 22 Identification process of the mass shift differences between sample treatments 
Graphical representation of the selection of mass shift differences between the control and the 25 µM-
treatment with resveratrol for the light chain (LC) of rituximab by a non-specific search for 
modifications. (A) The spectrum of molecular weight studied and the differences between the samples 
are graphed as z-scores; the molecular weight of significantly different signals is displayed. (B & C) 
histograms of the frequency of differences for the specific section of the molecular weight spectrum. 
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2.6 Statistical methods 
Experimental results were expressed as mean ± 1 standard deviation (SD). Standard deviation 
was selected over standard error of the mean in order to emphasis the deviation of the 
replicates in the sample (Altman and Bland, 2005). Relevant differnces between means was 
addressed thorugh statistical test. The t-tests analysis or ANOVA were run with 	α	= 0.05.  
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3.1 Initial remarks 
The development of chemical additives for improving the recombinant protein production in 
running CHO cells batch cultures is limited. Their use is very specific with low transferability 
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of the effect on other cell lines or recombinant products. This chapter focuses on the 
development of a robust screening process to assess naturally occurring low-molecular 
weight molecules in a broad range of concentrations, in order to study their effect on cell 
growth and viability as well as recombinant IgG expression levels.  
In order to assess the different chemicals identified as potential tools for recombinant IgG 
production in previous literature (Chapter 1), the feasibility of a 96-well plate-system was 
studied and compared to a 24-well plate-platform. Further, the chemical candidates were 
screened to identify possible candidates for future stages of research.  
3.2 96-well plates 
96-well plate cultures were set-up according to section 2.1.2 and eight wells were treated for 
each chemical concentration (Table 3). From each treatment, four wells were used to measure 
cell concentration and viability as specified in section 2.1.4. The remaining four wells of each 
column were used to measure protein production following section 2.1.5.  
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Table 3 The study range of the chemicals screened 
 
To screen through a high number of components in a fast and reliable way it is fundamental 
to scale down the process in order to make it more affordable. To do so, well plates were 
used as the main platforms to grow cells in different conditions. 96-well plates were used 
(Greiner-bio-one, Kremsmünster, Austria).  
The use of shallow 96-well plates constrained conditions of the experiment to static 
conditions and the use of small volumes; therefore, the behaviour of the cell growth was first 
studied. 
3.2.1.1 Vi-cell vs CSI cell density measurement 
The Vi-cell is the gold standard system to study cell concentration and viability in cell cultures. 
This device can directly study the culture growth and viability under the presence of the 
chemical candidates. However, this instrument is not adapted to perform analysis in 96-well 
plate platforms. This would entail transferring each sample to a tube and then be analyzed, 
making it a long and very expensive process.  
Chemicals Acronym Study Range (µM)
4-phenylbutyric acid 4-PBA 500 103 2·103 4·103 8·103
Caffeine Cff 13 31 63 94 125
Caffeic acid phenethyl ester CAPE 2 10 20 30 40
Curcumin Cur 5 10 20 40 80
Catechin hydrate Cat 10 25 50 75 100
Epicatechin EC 1 5 10 15 20
Epicatechin gallate ECG 10 25 50 75 100
Epigallocatechin gallate EGCG 5 25 50 75 100
Gallocatechin gallate GCG 5 25 50 75 100
Glycine Bettaine Bet 10 25 50 75 100
Kaempferol Kmp 10 50 100 150 200
Luteolin Ltl 2 5 10 15 20
Piceid Pcd 10 25 50 75 100
Resveratrol Resv 10 25 50 75 100
Tocopherol Tcp 35 175 350 525 700
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As an alternative, and to facilitate a high throughput system of screening, the Cloner Imager 
Select (CSI) was used.  The CSI is a device able to measure cell growth in a 96-well plate format 
by assessing the confluence of each well after focusing and capturing images from bellow. 
This method allows fast scanning of the entire plate. It also preserves the samples, allowing 
multiple analyses over time and making it possible to track the growth. Due to the advantages 
that CSI brings for high throughput experimentation, this system was studied in relation to 
the Vi-cell system in order to validate its reliability for the screening process. 
96-well plates were seeded and grown under the conditions specified before, then alternative 
wells were selected every day. The cultures were analyzed using the CSI and then using the 
Vi-cell. Finally, the relationships between the confluence of the well and the exact value of 
total cell concentration, the viable cell contrition and the viability were studied. 
3.2.2 Results 
3.2.2.1 Cell growth curve and the edge effect 
To create a robust system able to produce reliable data it is fundamental to understand how 
reliable the different components of the system are and how the cell line behaves within 
itself. In order to do this, plates were tested in order to analyze their intrinsic variability and 
to identify specific features such as the edge effect. Furthermore, the assessment of the cell 
line growth behaviour within the conditions of the system was needed in order to obtain 
incubation times and to decide when to apply the treatment. 
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Figure 23 Study of cell growth in 96-well plates 
(A) Graph of total (red) viable (orange) cell concentration across time (days). (B) Graph of cell viability 
(%) across time (days). This data was gathered from CHO cell incubation under static conditions in 
shallow 96-well plates. 
 
The cell growth curve was studied for six days. Cell population grew exponentially until day 3 
with a maximum concentration of 1 million cells per mL at 94% viability. Rapidly after, viability 
was compromised and dropped to 80% by day four, although the total number of viable cells 
remained constant (Figure 23).  
 
Figure 24 Study of the edge effect in 96-well plates 
(A) Graphs of cell concentration (blue) and viability (yellow) for the different sections in a 96-well plate. 
Cultures were incubated for 3 days under static humid conditions. (B) Representation of the different 
sections selected from a 96 and a 24-well plate respectively. 
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The cell concentration and viability measurements in 96-well plates after three days 
incubation in a static humid incubator, did not show significant differences between the ones 
taken from the edge and the ones from the rest of the plate sections (Figure 24). 
3.2.2.2 Vi-cell vs CSI cell density measurement 
Figure 25 Comparison of Vi-cell vs CSI 
The relation between Vi-cell cell concentration readings and confluence readings from a CSI device as 
the CSI reaches saturation at 0.6 million cells. 
 
 
There was a linear correlation between the cell growth measured with Vi-Cell and the one 
measured with the CSI. However, the saturation of the wells was very fast with values close 
to 95% at concentrations of 0.6×106cells/mL. As a result, in order to measure growth in a semi-
reliable way, concentrations up to 0.6×106cells/mL have to be used. The correlation between 
total cell concentration and confluence stills had an r2 of 0.57. As expected, this was the best 
match for correlation as viability and viable cell density gave worst results (Figure 25). 
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3.2.2.3 Screening system 
Different chemicals with potential chaperone activities were used in a range of 
concentrations to treat low-density CHO cell cultures for three days in a static humid 
incubator. These experiments were undertaken in 96 and 24 shallow well plates.  From this 
set of experiments data of total cell concentration, viability and total recombinant IgG 
production were collected. Later, total recombinant IgG production was divided by its 
respective cell density to obtain the amount of recombinant protein produced per cell (or 
relative protein production). 
3.2.2.3.1 Viability and cell concentration by CSI 
The results from the CSI showed that components such as catechin, epicatechin or 
epicatechin gallate, were not affecting growth significantly during the first three days of 
treatment under static conditions. On the other hand, 4-PBA, resveratrol and curcumin 
inhibited growth at high concentrations while growth at lower concentrations was not 
affected. 
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Figure 26 Cell density measurements with CSI I 
Display of cell density measurements of confluence by a CSI device for samples grew during 3 days in 
a static humidified incubator in 96-well plates (section 2.1.2) and treated with (A) 4-PBA, (B) Catechin 
(Cat), (C) Curcumin (Curc), (D) Epicatechin (EC). The error bars represent ±SD of quadruplicates. 
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Figure 27 Cell density measurements with CSI II 
Display of cell density measurements of confluence by a CSI device for samples grew during 3 days in 
a static humidified incubator in 96-well plates (section 2.1.2) and treated with (A) Epicatechin gallate 
(ECG), (B) Kaempferol (Kamp), (C) Resveratrol (Resv). The error bars represent ±SD of quadruplicates. 
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Kaempferol increased cell concentration at time zero in a concentration-dependent manner. 
As the time of treatment progressed, the cells treated at high concentrations did not grow, 
whereas the less concentrated samples were able to grow parallel to the control. 
Kaempferol caused the initial cell concentration (confluence) to immediately peak at time 
zero, whereas the cell concentration in all the wells was the same, further study was done to 
understand the nature of these results. Images at time zero from the CSI were taken to have 
an insight into the problem (Figure 28). 
 
 
 
Figure 28 CSI images of kaempferol treatment on cell cultures 
Images taken from samples by the CSI at time zero for (A) cells without treatment, (B) cells treated at 
100 µM and (C) cells treated at 200 µM of kaempferol. 
 
The images show how the cells treated with kaempferol reacted in a concentration-
dependent manner. At 100 µM of kaempferol, the cell surface was not as regular as in the 
control. Some of the cells started to lose their integrity, bursting open and creating clumps 
that aggregated.  At 200 µM, this reaction was more acute; cells were smaller or broken and 
the amount of debris was high due to the large number of cells that released their content to 
the media.  
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As shown in the graph (Figure 28), there was a correlation between the measurements done 
by the CSI and the actual concentration obtained by the vi-cell. However, the correlation was 
weak as stated by the r2 value. Therefore, the measurements with the CSI could give an 
approximation of the population dynamics (growing, stationary or decreasing) but could not 
indicate accurate values. 
3.2.2.3.2 Viability and cell concentration by Vi-Cell 
Data on cell concentration and viability in 96-well plates showed cell growth inhibition and 
low viability by 4-PBA and curcumin at high chemical concentrations. In the case of catechin 
and epicatechin growth was repressed at high concentrations but viability was never 
compromised. Finally, resveratrol and kaempferol restrained cell growth and viability in a 
gradient dependent response, causing less effect as chemical concentrations were lower. 
Results from Vi-cellTM XR (Beckman-Coulter, Brea, CA, USA) readings in 96-well plates Figure 
29) were analogous to those further obtained in the 24-well plates analyses. A more detailed 
description of the chemical influence on cell concentration and viability can be found in the 
next section. 
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Figure 29 Cell density measurements with Vi-cell 
Display of cell density measurements of cell concentration (blue) and viability (yellow) by a Vi-cell 
device (section 2.1.4) for samples grew during 3 days in a static humidified incubator in 96-well plates 
(section 2.1.2) and treated with (A)4-PBA, (B) Curcumin (ECG), (C) Catechin, (D) Epicatechin (EC), (E) 
Kaempferol, (F) Resveratrol. The error bars represent ±SD of quadruplicates. 
 
3.2.2.3.3 Protein production 
Protein production was displayed as binding rate and it was directly related to its 
concentration. Results exhibited a high degree of inconsistency in signal intensity and showed 
different trends (Figure 29). A clear example of this was epicatechin (Figure 29C) that had 
different results for each one of the three experimental replicates. 
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Figure 30 IgG concentration of samples grown in 96-well plates 
Graph of total recombinant IgG production measurement (section 2.1.5) in three independent 
experiments for samples cultured in 96-well plates during 3 days in a static humidified incubator 
(section 2.1.2) and treated at different concentrations with 4-PBA (A), curcumin (B) catechin (C), 
epicatechin (D), kaempferol (E) and resveratrol (F). The protein quantity is expressed as binding rate 
and the error bar is the ±SD of quadruplicates. 
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3.2.3 Discussion 
The growth curve study indicated that the viability in the 96-well started to decrease after the 
first 48 hours, but the levels were maintained above 90% during the first 3 days. The samples 
were cultured for 3 days in order to extend the period of effect of the chemical for as long as 
possible. That had to be done without compromising the level of viability, which is a key 
feature of the initial toxicological tests. Furthermore, if the cultured was maintained longer, 
this would allow for a higher concentration of cells and IgG production.  
The edge effect was proven to be of no significant impact on cell growth or viability under 
these conditions. Since edge effect was reported in the literature, well plate companies have 
started to develop methods and features to minimize this phenomenon. This effect is mainly 
caused by liquid loss, which originates an increase of cell concentration in the well and 
variation in the behaviour of cells. It has been described that this effect could lead to a loss of 
up to 15% of the volume in the corner wells depending on conditions such as the lid used, the 
time of incubation and the humidity percentage. Our experiments in 96-well plates were 
performed at 200 µL per well, in plates with lid edge ribs and rings. These were incubated for 
three days at 95% humidity. Results showed no significant differences in growth across the 
plate rings. These results are similar to the ones from previous studies using the same 
conditions; the study showed a difference of evaporation lower than 1% between the edges 
and the rest of the plate (Esser, P and Weitzmann, 2011). 
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CSI is easier to adapt to a high throughput system of screening for cell density measurements 
compared to a Vi-Cell system. The accuracy of the readings was not as good as the ones from 
the Vi-cell; there was a loss of accuracy as this device uses an indirect method of measuring. 
When comparing the measurements, it was shown that when cell cultures reached 0.5x106 
cells/mL, readings of confluence were often close to 100%. From the growth curve study, it 
was identified that this concentration was reached after 48 hours. This means that if the cell 
culture was to be grown under proper conditions, the CSI after the second day would not be 
able to show any differences. After the first two days, the CSI device became unreliable in 
measuring the growth, as the culture could overshoot the working range of the apparatus. 
The addition of chemicals could have an artifact effect on cell concentration readings. 
Kaempferol at time zero caused an increase of confluence due to its effect on cells. Finally, 
CSI was unable to give any information on the viability of the cells in the culture. This limited 
its usage for the toxicological studies where, both cell growth arrest and the effect over 
viability are relevant and important features in order to understand the impact on the cell 
culture.  
CSI is a less reliable device to measure the toxic effect of chemicals in CHO cell cultures and 
could constrain the study considerably as it was not designed to be used for this purpose. This 
apparatus was built to screen producer desirable cells in a well plate after gene transfection. 
This method is used in identifying single transformed cells and track their growth. As a result, 
when the well gets densely populated, the device struggles to give accurate readings, as it 
was never intended to be used under such circumstances. Newer devices used for the same 
reason, but with more advanced systems to measure cell density, could be a future possibility 
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in order to reduce the costs and time of measuring in Vi-cells. The NyONE device has worked 
around the problems of these devices, such as the loss of focussed images when moving along 
the well plate.  
IgG concentration was very fluctuating and unreliable among the three independent 
triplicates. There are different reasons why this could be happening. The samples that were 
obtained from the well plates had low concentrations of the IgG, due to the low cell density 
and time of culture under these conditions. Furthermore, Octet needs 200 µL volume for 
reliable readings. The culture volume of 96-well plates is very close to this value, which means 
that only 100 µL of the final culture had to be taken to ensure that after centrifugation there 
was only supernatant. This accentuated the low concentration of the culture even further as 
100 μL of fresh media had to be added. The samples were taken from different wells and that 
could cause a small impact when relating to the other measurements.  
This system is very dependent on low volumes which increases the uncertainty of the results 
and small changes in the collection could lead to big changes in the data. As a result, a new 
system with 24-well plates with 1 mL cultures per well was proposed in order to make the 
readings more reliable. At the same time, the change of the platform would not result in big 
differences in the volume of the cell cultures nor time nor resources. That would mean that 
the experiment could run in a more robust way with almost no increment in cost. 
3.3 24-well plates 
The previous experiments showed that taking measurements of cell concentration with CSI, 
has its limitations at high cell densities and that the additions of chemicals could cause 
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artifacts on the readings. Furthermore, the use of 96-well plates was not found to provide 
ideal conditions for the experimentation processes. In answer to these findings, a 24-well 
plate experimentation platform, using a Vi-cell to measure growth and viability, was studied 
and implemented for the screening of the chemical candidates. 
24-well plate cultures were set-up according to section (2.1.2) and wells were treated for each 
chemical concentration (Table 3). By the end of the culture each treatment was measured for 
cell concentration viability and morphology (section 2.1.4) and recombinant IgG production 
(section 2.1.5). The experiment had four biological replicates and was repeated twice 
independently.  
3.3.1 Results and discussion 
3.3.1.1 Cell growth curve and the edge effect 
To create a robust system able to produce reliable data it is fundamental to understand how 
reliable the different components of the system are and how the cell line behaves within 
itself. In order to do this, plates were tested in order to analyze their intrinsic variability and 
to identify specific features such as the edge effect. Furthermore, the assessment of the cell 
line growth behaviour within the conditions of the system was needed, in order to obtain 
incubation times and to decide when to apply the treatment. 
A 
 
B 
 
A) B) 
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Figure 31 Study of cell growth in 24-well plates 
(A) Graph of total (red) viable (orange) cell concentration across time (days). (B) Graph of cell viability 
(%) across time (days). This data was gathered (section 2.1.4) from CHO cell incubation under static 
conditions in a 24-well plate (section 2.1.2). 
 
The cell growth curve was studied for 10 days. Cells grew to a cell concentration of 0.9 million 
cells per mL on day 3 with viability close to 100%. Afterward, the viability dropped by 10% 
over the following 24 hours and declined constantly for the rest of the experiment. The total 
cell concentration increased along the entire experiment, while the viable cell concentration 
reached its peak on day five (Figure 31). 
Figure 32 Study of the edge effect in 24-well plates 
Graphs of cell concentration (blue) and viability (yellow) (section 2.1.4) for the different sections in 24-
well plates respectively. Cultures were incubated for three days under static humid conditions (section 
2.1.2). The error bars represent ±SD of quadruplicates. 
 
The cell concentration and viability measurements in 24-well plates after 3 days incubation in 
a static humid incubator, did not show significant differences between the ones taken from 
the edge and the ones from the rest of the plate section (Figure 32). 
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3.3.1.2 Chemical screening results 
3.3.1.2.1 4-PBA 
4-PBA caused a decrease in cell viable concentration indirectly proportional to the increase 
of the concentration treatment; this was also observed in other studies (Hwang et al., 2011). 
As a result, there was a decrease from 1.13 106 Viable cells/ mL of 22%, 29% and 52% of viable 
cells for 0.5, 1 and 2 mM. Higher concentrations of 4 and 8 mM caused complete growth 
arrest. The GI50 was close to 2 mM (Figure 33A). 
Viability was preserved at 95% for concentrations of up to 2 mM, while concentrations of 4 
mM and 8 mM caused a decrease to 29% viability (Figure 33A). This resulted in an LC50 of 4.7 
mM, the lethality curve of the component was only comprehended for the drop in viability 
between the 2 and 4 mM treatments, the lack of data between these two values reduced the 
confidence of the LC50 value obtain.  
The difference between the concentrations of GI50 (»2 mM) and LC50 (4.7 mM) and the fact 
that total growth inhibition was reached at 8mM or earlier, indicates that there was a partial 
separation between the lethal curve and the inhibition curve. The inhibition curve started at 
0.5 mM and carried all the way to 4 mM with complete cell arrest. Lethality was a sudden 
event and happened almost completely between 2 mM and 4 mM. Based on these values, 
the 2 mM concentration was the limit to where 4-PBA was acting exclusively as a cytostatic, 
while higher concentrations involved toxic effects on the cells. Nevertheless, CHO cell lines 
have been shown to have different ranges of tolerance to this chemical (Allen et al., 2008; 
Hwang et al., 2011). 
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 There seems to be a relationship between the effect of the chemical in culture Cell 
morphology features and viable cell concentration. Cell size followed the same trend as VCD, 
with a gradient decrease in cell diameter from control (15.2±0.36 µm) to 2 mM (13.5±0.8 
µm); concentrations beyond 2 mM showed a steep drop at around 11.75±0.06 µm (Figure 
33C). On the other hand, the circularity of the cell culture had an inverse relationship to VCD, 
increasing progressively from the control (0.78 ± 0.1) to 4 mM (0.86 ± 0.1) and mainly 
maintained at 8 mM (Figure 33D).  
The IgG total titre showed a direct relationship with the viable cell density; it decreased as 
the number of cells diminished, dropping from 6.74±0.76 at the control to 0.78± 0.12 µg/mL 
at 4 mM treatment. The concentration of IgG at 8 mM was so low, that a measurement could 
not be obtained. The relationship between the decrease in viable cell density and the total 
IgG produced was proportional, giving no significant differences in the specific protein 
produced for treatments up to 2 mM. Four mM treatment, on the other hand, had a four-fold 
increase in qp when counted for viable cells. This increase in protein in qp, is likely to be a 
result of the low viability of the culture (29%) (Figure 33B).  The abundant dead cells lose their 
wall integrity and unfinished IgG products are released to the media increasing the reading 
on the Octet. The non-mature products in the media, could cause aggregation problems, 
causing an even bigger loss of the product during purification as 4-PBA does not help to avoid 
it (Hwang et al., 2011). At the same time, the addition of impurities could lead to 
overcomplicated downstream processing (Liu et al., 2010). 
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4-PBA caused cell inhibition and reduction of the cell size at low concentrations, but 
maintained qp. This indicates, that although cells were smaller and fewer, they were able to 
produce more in relation to their biomass. 
Allen et al in 2008 and Su-Jeong Hwang et al in 2011, found that 4-PBA at 0.5 and 1 mM 
respectively, acted over the recombinant CHO cell line flask cultures by:  reducing the growth 
of the viable cell curve, increasing the viability of the culture over the time of incubation and 
by increasing qp. However, this qp increase was always observed after three days of 
incubation. No improvement in protein production was found during the first 72h of 
treatment. It is possible that the ineffectiveness of this chemical on the culture was due to 
the short period of incubation. Other variables that could be involved are the conditions of 
the culture (volume, agitation), the cell line or the recombinant protein studied. 
Other studies found 4-PBA successful at increasing specific protein production and final titre, 
making it a well-established chemical chaperone. Its main mechanism of action is assisting 
the folding process at different stages (Chollet et al., 2015; Ma, Goldberg and Goldberg, 
2017). Furthermore, a study with a transient difficult to express protein showed an increase 
of specific productivity while reducing viable cell density (Johari et al., 2015a). However, the 
present study did not give promising results for further study aligning with other studies in 
CHO cell recombinant protein (Roth et al., 2012). A possible explanation could be that the cell 
line did not struggle significantly in the folding and assembly processes and there was not 
much that 4-PBA could do to increase qp or total titre. Another explanation could be that the 
 Chapter 3 115 
production was limited by other steps such as insufficient mRNA, etc. Furthermore, the 
reduction in size by the treatment, is not a desirable feature.  
 
Figure 33 The effect of 4-PBA on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with 4-PBA (0.5-8 mM) during 3 days in a static 
humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.2 Caffeine 
Caffeine was able to lower the final viable cell concentration mildly (1.26±0.08 Viable cells/mL 
at the control level to around 1.0±0.1 106 Viable cells/mL at concentrations 13 to 125 µM). 
Viability was mildly affected with a 3 % drop from control (94.2±0.5 % to 91.3±0.6 % for most 
of the treatments) (Figure 34A). 
Cell size was not affected, while the shape showed an increase in circularity that although not 
significant indicated a tendency of the cells to be more rounded (Figure 34D). This could be 
the result of an increase in osmolarity.  
Finally, the total IgG produced was reduced slowly as the concentration of caffeine increased. 
(from 10.88±0.44 µg/mL to a final titre of 7.62±0.69 µg/mL when treated at 125 µM). The 
difference between the control and the treated samples was significant, but no distinction 
could be made across them, showing that no main differences could be found between the 
13µM and 125 µM treatments (Figure 34B). 
Caffeine has been of interest to the scientific community due to its capacity to interact with 
the cell replication step, by increasing the DNA growing points (Lehmann and Kirk-Bell, 1972; 
Tatsumi and Strauss, 1979). This capacity was associated with possible changes in the 
chromatin structure, which also allowed for making the cell less sensitive to DNA damage 
(Painter, 1980). As a result, caffeine was studied in order to prevent induced toxic conditions 
with mitoxantrone and was found to revert cell growth inhibition (Traganos, Kaminska-Eddy 
and Darzynkiewicz, 1991). It was also shown that, the effect over the cell line at 5 mM 
concentrations caused only a 5-10% decrease in cell growth. A through study of the toxicity 
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of this component in CHO cells, indicated that concentrations bellow 5 mM were not able to 
cause any significant inhibition of cell growth aligning with the findings from Traganos et al. 
Furthermore, this study reported how concentrations higher than 5mM (10 and 16mM) 
caused DNA fragmentation and increased levels of caspase 8, creating apoptosis (Fernandez 
2003). On the other hand, lower concentrations between 1-2.5 mM, were able to induce 
positive antioxidant effects in stress CHO cells.  
A patent with caffeine used in order to enhance recombinant production was created in 2005. 
The research indicated that caffeine in concentrations between 0.5 mM and 1.4 mM was able 
to increase the recombinant polypeptide production in CHO cells for different cell lines. 
Nevertheless, the optimized concentration of the treatment was specific to the cell line and 
it could only be implemented based on empirical data. This method gave up to a 1.3-fold 
increase in some cases. The patent study reported that the lowest concentration of caffeine 
(0.5 mM) resulted in the best production titre. Furthermore, 1.4mM concentrations had titre 
values close to the control but the viability was compromised. Nevertheless, the relation 
between cell growth inhibition and an increase in specific productivity was apparent. 2.5mM 
concentrations on the other hand, were completely toxic for the cultures. Finally, it was 
pointed out that lower concentrations than 0.5 mM could theoretically cause even better 
improvements, however they were not studied (Van Ness et al., 2005).  
Another study performed with CHO cells using 1 mM of caffeine, showed that the final titre 
and specific productivity were improved while the viable cell density and viability were kept 
stable. It was shown that the specific cell line was able to produce more by increasing the 
mRNA levels that correlated with productivity (Fomina-Yadlin et al., 2015). Although this 
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could be one of the mechanisms by which caffeine could work in improving production, not 
all the cells are limited at the transcription level. Therefore, it is likely that more mechanisms 
are involved.  
In the current project, caffeine was studied at lower concentrations than the ones reported 
in the literature as being active. Our study showed that lower concentrations to those 
previously studied did not cause any relevant changes, other than a mild inhibition of the cell 
growth. That was the reason for not including caffeine in the next stages of this study. 
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 Figure 34 The effect of caffeine on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with caffeine (Cff) (13-125 µM) during 3 days in a static 
humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.3 Caffeic acid phenethyl ester 
CAPE was studied in the concentration range of 2 to 40 µM. This chemical had severe effects 
on viable cell growth arrest, with complete inhibition observed at the lowest concentration 
studied (0.20±0.04 106 viable cells/mL). Higher treatment concentrations had even more 
severe effects, lowering the final viable cell density bellow the initial value (0.04±0.01 106 
viable cells/mL) (Figure 35A). 
Viability was affected for all treatments when compared to the control (91.76±0.85 %). The 
lowest concentration used (2 µM), resulted in a value of 61.94±5.14 %. 10 µM treatment 
caused an even further decrease reaching a value of 24.37±2.77 %. Subsequent increases in 
chemical concentration, resulted in a partial recovery of viability to around 40% for 
treatments of 30 and 40 µM (Figure 35A). 
The cell diameter was reduced for all concentrations. The diameter at the control level was 
14.99±0.10 µm; that was reduced initially to 13.83±0.17 µm at 2 µM, while further increases 
of the concentration reduced the cell size to 11.79±0.20 µm (Figure 35C). Cell circularity, was 
only increased at 2µM and 4 µM treatments, from 0.81±0.00 at control level to 0.85±0.01. 
The rest of the concentrations did not have any significant changes in the circularity of the 
cells (Figure 35D). 
The total recombinant IgG production was also reduced following the same pattern as the 
viable cell density. Productivity halved from 8.44±0.31 µg/mL at control level to 4.43±0.31 
µg/mL at 2 µM, and subsequently decreased to values around 2 µg/mL for further 
concentrations. Nevertheless, the rate of inhibition of the cell culture by the chemical was 
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more effective than the one observed in the final titre. This resulted in an increase of the 
specific productivity for all treatment samples. The average qp for the control was 3.14 
pg/cell·day; treatment with 2 µM doubled the specific productivity to 7.44±0.50 pg/cell·day. 
Further increments in concentration increased the specific productivity to 17.12±0.70 
pg/cell·day (5.45-fold increase) (Figure 35B). This production is associated with very high 
levels of toxicity; the increase in protein in the media per cell could be an artifact and just 
being a result of cells losing their cell membrane integrity. 
There are no available studies on the effect of CAPE on CHO cells. However, this molecule has 
been used in medical studies and it has been reported that it interacts with various important 
regulatory pathways like  NF-Kappa B (Wang et al., 2016),  nitric oxygen synthetase and has 
enzyme activity (Song et al., 2002). Overall, the study of this molecule indicates that it has a 
very strong antiproliferative effect and apoptotic capacity (Ozturk et al., 2012). All this relates 
to the high levels of toxicity found in this project. 
It is unlikely that this chemical could be used for the production process in recombinant CHO 
cell lines, as the levels of toxicity associated are very high. On the other hand, lower 
concentration treatments, that could affect the cell without compromising the viability of the 
culture, might be possible.  
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Figure 35 The effect of CAPE on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with caffeic acid phenethyl ester (CAPE) (2-40 µM) during 
3 days in a static humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell 
viability (yellow) (section 2.1.4); (B) total protein production (grey) and relative protein production 
(orange) (section 2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars 
represent ±SD of quadruplicates. Statistical t-test was perform to compare treatments with control at 
p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.4 Curcumin 
Curcumin inhibited viable cell growth in a concentration-dependent manner. Concentrations 
of 5, 10 and 20 µM caused growth inhibition of the viable cells of 26%, 32% and 56% 
respectively. Concentrations of 40 and 80 µM resulted in complete inhibition (Figure 36A). 
The GI50 was estimated at 17.2 µM. 
Viability was maintained constant, at about 95%, in up to 20 µM treatments. However, 
treatments of 40 and 80 µM caused the viability to drop drastically down to 31 and 16% 
respectively (Figure 36A).  The LC50 was calculated at 47.4 µM. 
Only concentrations between 5 and 20 µM seemed to have exclusively cytostatic effects, 
while increasing the concentration beyond this range caused severe losses of viability and 
complete arrest. Therefore, the capacity to use this chemical without toxic effects is very 
narrow. 
Cell size was mildly affected when comparing control and treatment at 20 µM, with only a 
small drop in cell diameter observed (from 15.9±0.20 to 15.3±0.14 µm). On the other hand, 
the size was considerably reduced to 12.2±0.37 µm for treatments at 40 and 80 µM (Figure 
36C). Shape followed a different trend with small changes in circularity from 0.80±0.012 
during the control treatment to 0.83±0.012 at 20 µM. This value stabilized as the 
concentration of the treatment increased (Figure 36D). 
The total IgG produced followed the same trend as VCD. There was a reduction in the protein 
produced from the control (12.1±0.43) compared to the one produced with the 40 µM 
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treatment (1.15±0.69 µg/mL). The 80 µM treatment caused a mild increase, reaching 
2.11±0.29 µg/mL of total IgG (Figure 36B). qp remained constant (5.80±0.23 pg/cell·day), 
although for 40 and 80 µM treatments there was an increment of almost two-fold (9.78±2.57 
pg/cell·day) and 10-fold (37.3±3.69 pg/cell·day) respectively (Figure 36B). It is very likely that 
the increase observed in qp values for higher concentrations, is directly linked to the loss of 
integrity of the dead cells, causing a release of unwanted unfinished products in the media. 
Octet measures concentration based on the amount of protein linked to protein A of the 
measurement tip. It is unable to differentiate between properly folded proteins, partially 
assembled proteins or mature cases that still link to protein A. This could also explain why 
there was also an increase in total IgG when doubling the treatment from 40 to 80 µM. 
Another conclusion could be that although the viability was very low at 40 µM, cells were 
more likely to preserve the membrane integrity to some extent, as total cell density was very 
similar between the two (0.12±0.03 for 40 and 0.11±0.02 106 total cells/mL for 80µM); the 
total number of dead cells does not explain the increase in qp. 
Originally, curcumin was identified as a cytotoxic agent because of its capability to cause 
chromosomal aberrations in CHO cells. Nevertheless, it was found that this effect could be 
mitigated when in the presence of Fe ions(Antunes et al., 2005). This has driven scientists to 
think that the toxic behaviour is related to its pro-oxidant nature, which generates free 
radicals.  Media composition in CHO cell cultures is often heavily enriched with ions. A 
different reaction would be expected under these conditions, as curcumin was also identified 
to bind with orotein kinase C affecting its assembly and the signaling pathways (Pany, You and 
Das, 2016).  
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Park et al studied the effect of curcumin treatment in shaking flasks at a 20 µM concentration 
(cultured for a period of 16 days). The effect on recombinant CHO cells producing rituximab 
was similar to the ones observed in the current study. The viable curve was partially inhibited, 
while the viability was maintained. The protein production was very similar to that of the 
control (Park et al., 2016).  
Curcumin is a very toxic compound whose lethal curve overlapped significantly with the 
growth inhibition one. This reduces the range of available working concentrations. 
Furthermore, there was no improvement in the final titre or the specific protein production 
without a considerable drop in viability. Taking all this data into consideration, it was 
concluded that curcumin would not be a successful candidate for further research. 
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Figure 36 The effect of curcumin on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with curcumin (Crc) (5-80 µM) during 3 days in a static 
humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.5 Catechin 
Catechin inhibited viable cell growth in a concentration-dependent manner. Concentrations 
of 10 and 25 µM caused viable cell growth inhibition of 28% and 51% respectively. Higher 
concentrations did not increase the inhibition; this remained close to 50% (Figure 37A). The 
GI50 was estimated to be around 55.12 µM. 
GI50 was only estimated and could not be reliably measured here, as the curve was not 
complete. In order to produce accurate values with the probit method, the curve needs to be 
delimited by two completely saturated values before and after, as well as more than one point 
in the middle. The values were the same for concentrations between 25 and 100 µM. 
Viability was stable across the entire range of treatments (Figure 37A). LC50 could not be 
estimated nor calculated. Catechin had exclusively cytostatic effects on the cell culture and 
could be used for experimentations in a relatively wide range of concentrations without 
mayor concerns for toxic effects. 
During the study of cell morphology, there were no significant changes in the cell diameter 
(Figure 37C); there was only a small tendency to an increase of circularity. This could be a 
result of the increase in osmolarity by the addition of the chemical to the media. 
The total IgG produced followed the same trend as VCD. There was a reduction of the protein 
produced from the control (8.18±0.61µg/mL) compared to the one produced with the 25 µM 
treatment (5.25±0.47 µg/mL). Higher concentration treatments had the same reduced level 
of production. qp was constant (2.12±0.11 pg/cell·day), only for the 10 µM treatment, while 
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the rest of treatments caused a significant increase (13%, 45%, 41% and 17% increase in the 
qp for 25, 50, 75 and 100 µM respectively) (Figure 37B). 
Previous studies have shown that catechin has the capacity to protect the DNA. It can also 
inhibit the cell from forming micronucleated toxic components that suppress the cell cycle 
(Lee Ching et al., 1996). However, not much else is known about the effect of this chemical in 
CHO cells. 
Catechin was further studied recently and was patented along with other potential 
antioxidants that could be added to the media to improve recombinant protein production 
(Tian, 2016). This patent studied catechin at 62.5 µM, 250 µM and 1mM concentrations; 
viability was preserved above 90% for all cases and the final titre was improved to 17%. 
Furthermore, it was reported that the addition of this chemical to the media, results in a 
decrease in ammonia and lactate levels. Finally, this experiment showed that this chemical 
was capable of working in high volumes up to 20 L and the improvement of productivity was 
maintained (Tian, 2016). Our results look more promising than the patent study data, due to 
higher increases in final qp. Scale down studies in this area tend to show big improvements in 
recombinant protein production, but when scaling up, the gain observed is reduced or 
insignificant.  
Viable cell growth on the other hand, was clearly inhibited in our study at lower 
concentrations than the ones stated in the patent. This could be the result of the use of 
different cell lines (aCD137 vs DG44) or different growth conditions (static well plates vs 
shaker flask fed-batch culture). These parameters could have had an inherent effect on the 
 Chapter 3 129 
sensitivity to the chemical which resulted in the different outcomes. In order to further study 
this, we would have to create experiments similar to the ones described in the patent, to 
analyze how the difference in cell line changes the effect of the chemical (Tian, 2016). 
 
Figure 37 The effect of catechin on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with catechin (10-100 µM) during 3 days in a static 
humidified (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) (section 2.1.4); 
(B) total protein production (grey) and relative protein production (orange) (section 2.1.5); (C) cell 
diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD of 
quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
0 10 25 50 75 100
0.0
0.5
1.0
1.5
2.0
0
50
100
VC
D
 (1
06
ce
lls
/m
l)
ViabilityVCD
Vi
ab
ilit
y 
(%
)
**
*
*
* *
*
0 10 25 50 75 100
0
2
4
6
8
10
0
1
2
3
4
[Ig
G
] (
µg
/m
l)
qP
 (p
g/
ce
ll·
da
y)
[IgG] qP
** **
*
*
*
0 10 25 50 75 100
11
13
15
17
0.7
0.8
0.9
Concentration treatment (µM)
C
el
l d
ia
m
et
re
 (µ
m
)
Av
er
ag
e 
ci
rc
ul
ar
ity
Diametre Circularity
*
A
B
C
 Chapter 3 130 
3.3.1.2.6 Epicatechin 
Epicatechin inhibited viable cell growth in a concentration-dependent manner. There was no 
effect at lower treatments with 1 and 5 µM (approximately 0.8 106 Viable Cells/mL). 
Concentrations of 10 and 15 µM caused viable cell growth inhibition of 70% and 53% 
respectively. The highest treatment with 20 µM maintained the same level of inhibition that 
was found at 15 µM (Figure 38A). The GI50 was estimated to be around 15.26 µM. 
GI50 was only estimated and could not be reliably measured here, as the curve was not 
complete. In order to produce accurate values with the probit method, the curve needs to be 
delimited by two completely saturated values before and after, as well as more than one point 
in the middle. The values were the same for concentrations between 5 and 20 µM. 
Viability was stable across the entire range of treatments. LC50 could not be estimated nor 
calculated. Epicatechin has exclusively cytostatic effects on the cell culture and could be used 
for experimentations in a relatively wide range of concentrations without mayor concerns for 
toxic effects (Figure 38A). 
During the study of cell morphology, there were no differences in shape; circularity was 
constant across the treatments. On the other hand, there was an increase in cell size when 
comparing the control treatment (15.75±0.065 µm) to higher concentrations (16.83±0.15 
µm) (Figure 38C). 
The total IgG produced was constant across the range of concentrations studied and was 
around 12 µg/mL. This, combined with the reduction of VCD in higher treatments, resulted in 
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an increase in the qp. That was true for treatments with 10 µM and above. Maximum 
production of 8.40±0.32 pg/cell·day was observed at 15 µM (versus 5.22±0.10 pg/cell·day for 
control). There was an increase in specific protein production by 37%, 61% and 39% for 10, 
15 and 20 µM respectively (Figure 38B). 
The relationship observed between the increase in cell size and the increase in specific protein 
production, indicates that the reason for the increase in productivity could the bigger size of 
the cells. The volume of the cell at control was 205 µm3 and the volume at 15 µM treatment 
was 250 µm3; only a 20% increase in biomass resulted in a 60% increase in production. 
Therefore, although cells are bigger, they are also more efficient in producing more IgG. 
The literature on this chemical and its effect in CHO cells, is to our knowledge inexistent. Most 
studies looked at other more common or famous chemicals of the same family, such as EGCG 
or catechin or studied the full range of catechins together by adding extracts of green tea. 
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Figure 38 The effect of EC on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with epicatechin (EC) (1-20 µM) during 3 days in a static 
humidified incubator (2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) (2.1.4); (B) 
total protein production (grey) and relative protein production (orange) (2.1.5); (C) cell diameter 
(green) and cell circularity (red) (2.1.4). The error bars represent ±SD of quadruplicates. Statistical t-
test was perform to compare treatments with control at p-values: (*)< 0.05, (**) < 0.01 and  (***) < 
0.001 
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3.3.1.2.7 ECG 
Epicatechin-gallate was able to inhibit viable cell growth at all the treatment concentrations 
studied (10-100 µM). The viable cell growth at the control level was preserved at 0.98±0.05 
106 Viable cells/mL, while treated samples did not grow beyond 0.65±0.02 106 Viable 
cells/mL. Treatment with 100 µM resulted in almost complete inhibition (0.36±0.12 106 Viable 
cells/mL) (Figure 39A). 
Concentrations between 25 and 100 µM showed an effect on viable cell density inhibition in 
a concentration-dependent manner. Treatment at 10 µM seemed to be consistently more 
effective at inhibiting cell growth than 25 µM, and as inhibiting as the 50 µM treatment. Due 
to this unusual effect and to the lack of a complete growth inhibition curve we could only 
estimate the GI50 at about 55.7 µM. 
Viability was preserved at treatments with concentrations of up to 50 µM. There was a 
significant 5 % decrease with respect to the control (88.8±0.9 %). Larger concentrations of 
ECG resulted in a drop in viability (74.4±1.8 and 75.3±6.11 % for 75 and 100 µM respectively) 
Figure 39A). Although there were only indications of a viability drop at the highest 
concentrations and the curve of toxicity was not complete, the LC50 estimation stood at about 
200 µM. This value is just an approximation and a full study of the curve should be done to 
get precise data. 
Nevertheless, it was apparent that there was an overlap between the inhibition curve and the 
toxicity curve after 50 µM. Concentrations below this limit seemed to have mainly cytostatic 
effects in the cell culture. 
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Cell size was increased when comparing the control (14.7±0.12 to 15.4±0.1.8 µm in diameter) 
with the non-toxic concentrations of 25-50 µM; concentrations above or below this range did 
not show significant differences (Figure 39C). On the other hand, cell circularity did not show 
significant differences at low concentrations; there was an increase for treatments of 50 µM 
and above with respect to the control (0.85±0.01 % vs 0.81±0.02 % respectively) (Figure 39D). 
The total IgG produced showed consistent levels of production across all the concentration 
treatments, which were close to the control value (11.1±0.40 µg/mL). This linked to the 
capacity of ECG to inhibit growth, causing a considerable increase in the specific productivity 
of the cell cultures, which was significantly higher for all treatments compared to the control. 
As a result, while the control had a qp of 3.75±0.08 pg/cell·day, treated samples increased 
proportionally to cell inhibition; the specific productivity was close to 10 pg/cell·day for 75 
and 100 µM treatments (2.6-fold increase).  Non-toxic concentrations on the other hand, 
resulted in 2-fold increases, with a final specific productivity of 7.42±0.43 pg/cell·day (Figure 
39B).The inverse relationship between growth and specific productivity was once again 
apparent with this chemical. 
To our knowledge, epicatechin-gallate is a component for which there is no information on 
the effect that it could have on CHO cell cultures, as most studies focus on epigallocatechin-
gallate.  
Overall, ECG looks like a promising candidate for use in recombinant IgG production.  While 
concentrations above 50 µM are toxic and should be avoided, concentrations below this 
threshold are promising. The most ideal concentration would be 10 µM, as it causes the same 
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effects as 25 or 50 but there is less risk of toxicity in the long run. The use of 10 µM would 
also make the process cheaper if it was to be scaled up, as this chemical is very expensive.  
Figure 39 Thd effect of ECG on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with epicatechin-gallate (ECG) (10-100 mM) during 3 
days in a static humidified (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.8 EGCG 
Epigallocatechin-gallate was studied at a range of concentrations from 5 to 100 µM. The effect 
of this chemical on the viable cell density was consistent across all concentrations after three 
days of incubation and resulted in a 42% inhibition when compared to control (0.55±0.06 106 
vs 0.94±0.03 106 viable cells/mL) (Figure 40A). 
On the other hand, viability remained stable for all samples and there were no significant 
differences with respect to the control (92.6±1.4%) (Figure 40A). 
Cell size remained stable with no significant differences with respect to the control 
(16.05±0.32 µm) (Figure 40C). There was a concentration-dependent-increase in cell shape 
(0.76±0.02 at control level to 0.80±0.02 at 50µM) (Figure 40D). The value was maintained at 
this level for increasing concentrations. 
 The total IgG produced was kept constant for all treatments up to 50 µM, while higher 
concentrations resulted in a small decrease of the produced recombinant protein (9.02±0.63 
and 7.7±0.27 µg/mL at 75 and 100 µM respectively vs 8.23±0.7 µg/mL at control level). The 
final titre was reduced by 6% at 100µM. There was more than 40% inhibition of the cell 
density and an increase of the specific productivity observed at all the tested concentrations. 
While treatment at the control level produced protein at a qp of 3.63±0.09 pg/cell·day, 
treatment at 50 µM caused the biggest increase with 6.90±0.42 pg/cell·day produced (1.9-
fold increase) (Figure 40B). 
 Chapter 3 137 
EGCG has the capacity to reduce the toxicity in cultured cells due to aggregation (Bieschke et 
al., 2010) and the capacity to improve the viability of immortal cell lines at low concentrations  
(Lu, Ou and Lu, 2013). Nevertheless, this chemical can also cause DNA damage and trigger 
apoptosis (Lu, Ou and Lu, 2013). The level of toxicity for each cell line is dependent on factors 
such as the interaction of EGCG with the media (Long et al., 2007) or the permeability of each 
cell line to the chemical (Zhang et al., 2013). 
Parallel studies in recombinant protein production in CHO cells, showed that EGCG can be 
implemented in growth cell media composition from 44 µM to 1.1 mM concentrations. The 
chemical had the potential to enhance protein production by 20%. Furthermore, this addition 
was able to reduce the acidic and basic species of the recombinant IgG, reducing the relative 
charge heterogeneity of the product consistently across the time of the culture. Finally, this 
study showed that the half-life of EGCG in the media after the addition was of about six hours 
(Hossler et al., 2015). 
EGCG has been well-researched and has been recently proven to help IgG production (Hossler 
et al., 2015). This correlates with our observations, since it can improve specific productivity 
if added under proper conditions. Its capacity to stop the growth and enhance specific 
recombinant protein production is likely due to the suppression of cell growth and the 
increase of specific recombinant production associates with it (Vergara et al., 2014). The lack 
of toxicity also allows for the usage at a wide range of concentrations to promote changes in 
the metabolic dynamics in cell cultures.  
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Figure 40 The effect of EGCG on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with Epigallocatechin-gallate (EGCG) (5-100 µM) during 
3 days in a static humidified incubator(section 2.1.2): (A) viable cell concentration (blue) and cell 
viability (yellow) (section 2.1.4); (B) total protein production (grey) and relative protein production 
(orange) (section 2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars 
represent ±SD of quadruplicates. Statistical t-test was perform to compare treatments with control at 
p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.9 GCG 
Gallocatechin gallate was studied in the range of 5 to 100 µM. The effect of this flavonoid on 
viable cell density was very similar to the one already observed for EGC; all concentrations 
caused a decrease in the viable cell density after three days of incubation. There was a 16% 
inhibition with treatment at 25 µM compared to control (0.67±0.06 106 vs 0.80±0.06 106 
viable cells/mL). At 100 µM concentration, the respective value was 0.44±0.09 106 viable 
cells/mL; this was the most severe inhibition, equivalent to 45%  (Figure 41A).  Although the 
viable cell density was affected in a concentration-dependent manner, the first treatment 
with 5 µM caused a more severe inhibition than expected. This was similar to the behaviour 
observed when adding structural chemicals of the same family such as EGCG or EGC. As a 
result of this, GI50 was estimated as 41.13 µM. 
Viability was affected in a concentration-dependent manner with a small reduction from the 
control level (91.8.4±1.0 % to 84.3±0.6 % at 100 µM treatment) (Figure 41A).  Overall, only 
concentrations of 50 µM and higher had significantly lower viabilities with respect to control. 
Nevertheless, viability was not affected by big drops. The lack of severe toxicity in this range 
of concentrations made it impossible to estimate the LC50. 
Cell size was affected by GCG treatments, by significantly increasing the cell diameter at 5 µM 
(15.9±0.1 µm) in comparison to the control (15.5±0.2 µm). The further increase in 
concentration, reduced the cell size to a lower, non-significant average (15.2±0.1 µm) at 100 
µM treatment (Figure 41C). Cell shape was increased in a concentration-dependent manner 
with respect to the control (0.75±0.01), with 50 µM treatments and above ranging at the same 
level of circularity (0.83±0.01) (Figure 41D). 
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The total IgG production under all conditions was maintained constant with respect to control 
(7.92±0.63 µg/mL). This together with the inhibitory effect of the chemical, increased the 
specific productivity of all treated samples in comparison to the control. In more detail, at 25 
µM treatment the value was 3.93±0.14 pg/cell·day while at control level the respective value 
was 3.29±0.12 pg/cell·day (1.2-fold increase). The maximum value observed was 5.66±0.39 
pg/cell·day (1.72-fold increase) (Figure 41B). 
Gallocatechin-gallate has not been studied much before. Most studies focus on 
epigallocatechin-gallate which is a more abundant chemical in green tea and other products. 
Nevertheless, GCG showed an important inhibition capacity with very low toxicity levels, 
which would allow studies in recombinant production. Furthermore, this chemical was able 
to enhance specific productivity. Like many other chemicals of the same family, such as ECG 
or EGCG, GCG was able to shift primary metabolism into secondary metabolism, without 
compromising cell viability. This characteristic could be useful in recombinant IgG production. 
Finally, it is important to point out that this chemical acted almost identically as EGCG, and it 
is likely that the mechanism of action behind is very similar. 
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Figure 41 The effect of GCG on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with gallocatechin-gallate (GCG) (5-100 µM) during 3 
days in a static humidified incubator(section 2.1.2): (A) viable cell concentration (blue) and cell viability 
(yellow) (section 2.1.4); (B) total protein production (grey) and relative protein production (orange) 
(section 2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars 
represent ±SD of quadruplicates. Statistical t-test was perform to compare treatments with control at 
p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.10 Glycine betaine 
Glycine betaine caused an increase in the viable cell density growth in a concentration-
dependent manner. The final viable cell density was 40% higher at 100 µM (1.13±0.16 106 
Viable cells/mL) with respect to the control (0.81±0.03 106 Viable cells/mL) (Figure 42A).  
Parallel to this, viability was not affected in this range of treatments and it was preserved at 
a range of 90 to 92% in all cases (Figure 42A). 
The cell morphology study did not show any differences; cell size was maintained constant at 
14.77±0.14 μm (Figure 42C). On the other hand, circularity showed an increase on average 
from 0.81±0.02 at the control level to 0.83±0.004 at 100 µM, although this was not significant 
(Figure 42D). 
The total IgG produced was mildly reduced across the study range; at the control level, the 
IgG was 9.05±0.53 µg/mL, decreasing down to values around 7.5-8.0±1 µg/mL. The reduction 
of production was not always significant. This was linked to an increase of viable cells, 
resulting in a decrease in the specific protein production in a concentration-dependent 
manner (3.75±0.08 at control to 2.24±0.14 pg/cell·day at 100 µM, a 60% decrease) (Figure 
42B). 
Betaine was able to increase cell proliferation and maintain the viability of the cells, without 
affecting cell morphology.  Unfortunately, this did not result in a direct immediate increase 
of the total IgG production or an increase in qp. This could be the result of this chemical 
fomenting cell growth, which in turn diminishes the number of resources that the cell would 
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put into IgG production. It is well established that when cells lower their primary metabolism 
(growth metabolism) they shift into secondary metabolism, which among other things 
comprises recombinant IgG production. As a result, the relationship between cell growth and 
specific productivity is often inverse as shown here. 
Glycine betaine could be used in the early stages of the culture to promote cell growth, but 
this would need to be measured carefully. The investigations on CHO cell cultures showed 
that the faster the culture grows, the faster it enters into late-stage and the stationary phase 
is shortened. This could lead to premature low viability and a lower quality of the product. 
Glycine betaine has been heavily researched before as an osmoprotective agent. When used 
in combination with sodium chloride it improves recombinant protein production. However, 
this modification of culture conditions caused simultaneous suppression of cell growth. As a 
result, this osmoprotective chemical was studied in order to negatively mitigate the effects 
of high osmolarity conditions. Research showed that the chemical was able to mitigate 
hyperosmotic stress by increasing cell growth and specific productivity (Ahn et al., 1999). The 
method used to implement this technology consisted of a two-step culture. During the first 
step, cells were allowed to grow; during the second one,  glycine betaine and sodium chloride 
were added simultaneously to increase the production of erythropoietin up to 3-fold. 
Erythropoietin is difficult to express protein (Ahn et al., 1999). Nevertheless, the effects of 
glycine betaine are not easily transferable, and there are different responses depending on 
the cell line used (Tae Kyung et al., 2000) or the clone of the same cell line (Ryu et al., 2000).  
Further studies indicate that, the use of this chemical in combination with cold temperature 
shifts, is able to enhance productivity by elongating viability on the culture when added at 
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15mM (Yoon and Ahn, 2007). Although, current experiments in a transient cell line with a 
difficult to express biologic indicate no positive significant changes in specific productivity nor 
final titre (Johari et al., 2015a). 
The mechanism by which glycine betaine could help protein production is not well 
understood. Studies have suggested that the effect of the chemical may have to do with 
translation, as mRNA levels correlate to the productivity of the different cell lines (Tae Kyung 
et al., 2000). Nevertheless, the mechanism is very complex and difficult to predict, as it 
involves upregulations of proteins that are part of cellular metabolism, mRNA profiling, 
protein folding and secretion as well as cellular structure (Kim, Kim and Lee, 2012). 
The present results encounter a different context for glycine betaine as, cells were not treated 
at high osmolarities, shifted to low temperatures or cultivated for long periods of time. This 
could be the main reason why glycine betaine in the present study did not show 
improvements in recombinant protein production. Other factors that could have had an 
impact are the cell line, the recombinant protein or the media used. 
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Figure 42 The effect of  glycine betaine on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with  glycine betaine (Btn) (10-100 µM) during 3 days in 
a static humidified incubator(section 2.1.2): (A) viable cell concentration (blue) and cell viability 
(yellow) (section 2.1.4); (B) total protein production (grey) and relative protein production (orange) 
(section 2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars 
represent ±SD of quadruplicates. Statistical t-test was perform to compare treatments with control at 
p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001 
 
0 10 25 50 75 100
0.0
0.5
1.0
1.5
0
50
100
VC
D
 (1
06
ce
lls
/m
l)
ViabilityVCD
Vi
ab
ilit
y 
(%
)
0 10 25 50 75 100
0
2
4
6
8
10
0
1
2
3
4
5
[Ig
G
] (
µg
/m
l)
qP
 (p
g/
ce
ll·
da
y)
[IgG] qP
***
***
*
0 10 25 50 75 100
11
13
15
17
0.7
0.8
0.9
Concentration treatment (µM)
C
el
l d
ia
m
et
re
 (µ
m
)
Av
er
ag
e 
ci
rc
ul
ar
ity
Diametre Circularity
A
B
C
 Chapter 3 146 
3.3.1.2.11 Kaempferol  
Viable cell density dropped consistently and reached full viable growth arrest at 100 µM 
(0.18±0.1 106 Viable cells/mL). Higher concentrations of kaempferol reverted this and a small 
increase of the viable cell density was seen with subsequent treatments at 150 and 200 µM 
(0.31±0.02 and 0.44 ±0.08 106 Viable cells/mL respectively) (Figure 43A). This recovery effect 
could be a result of drop out of solution of kaempferol at higher treatment conditions. 
Kaempferol is a flavonoid. It is soluble in organic solvents and has low solubility in aqueous 
solutions. The estimated GI50 was 56 µM. This value is just a general reference. It might not 
be accurate as viability came back up as explained previously. 
Toxicity was not observed in treatments of 50 µM or bellow. Concentrations above those (100 
to 200 µM) caused a decrease in viability to about 67±3.46 % (Figure 43A). The LC50 could not 
be properly calculated nor estimated due to the lack of the complete toxicity curve. Another 
reason could be the fact that the chemical likely dropped out of solution in the higher 
concentration treatments. Nevertheless, the overlap between the inhibition curve and the 
toxic curve was considerable and the range of concentrations that could be effective but not 
toxic is narrow. 
The study of the morphology showed that there was no significant change in size for 
concentrations that were not affecting viability. In more detail, treatment with the control 
and treatments with concentrations up to 50 µM, had an average size of 15.8±0.26 µm, while 
treatments with concentrations above 50 µM, caused a big decrease in cell diameter 
(12.8±0.29, 10.8±0.26 and 10.4±0.32 µm for 100, 150 and 200 µM respectively) (Figure 43C).  
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There was a tendency for an increase in cell circularity as concentrations increased from 0 
(control) to 50 µM. On the other hand, there was a big drop in circularity at 50 (0.81±0.01) 
and 100 µM (0.74±0.01). Higher successive concentrations only resulted in small increases in 
circularity (Figure 43D).  
The total IgG concentration decreased slowly and in a proportional way to viable cell density 
in 10 and 50 µM treatments, resulting in a specific protein production of 3.85±0.15 
pg/cell·day. The total protein production for the 100 µM treatment, had a big drop to 
3.24±0.19 µg/mL. This reduction in the IgG produced was not as significant as the reduction 
of the viable cell density. Specific protein production was increased by 60% (5.91±0.16 µg/mL) 
with respect to the original control value. Higher concentrations of the treatment resulted in 
a decrease of qp with respect to the control, but the total production was maintained to the 
levels observed at 100 µM treatment (Figure 43B). The viable cell density observed was 
recovered as explained before. 
In summary, kaempferol treatment did not cause toxic effects in concentrations up to 50 µM; 
it reduced the viable cell concentrations, it did not change cell size, but it increased circularity, 
probably due to an increase in osmolarity. There were no changes in the relative production 
and the total IgG was reduced. Overall, it was not apparent how kaempferol could be used 
for protein production in this range of concentrations and within this set of conditions. 
The 100 µM treatment showed complete cell growth arrest; viability was compromised.  Cell 
shape and size changed drastically. Although there were signs of an increase in the specific 
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productivity, this is linked to low viability; the increase could be a result of cell death and loss 
of cell membrane integrity causing non-mature IgG leakage into the media.   
Overall, kaempferol seems to be a very cytotoxic component that does not improve specific 
protein production without compromising viability. It causes radical changes in cell 
morphology (eg. diameter). It is unlikely that kaempferol could be used in this set of 
conditions for the improvement of recombinant protein production. 
Kaempferol was found to affect CHO cells by causing chromosomic aberrations for 
concentrations between 87 to 157 mM (Carver, Carrano and Macgregor, 1983). Little else has 
been studied about the effects of this chemical in CHO cells. 
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Figure 43 The effect of kaempferol on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with kaempferol (Kmp) (10-200 µM) during 3 days in a 
static humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.12 Luteolin 
Luteolin was studied in a range of concentrations from 2 to 20 µM. Treatment for three days 
resulted in a concentration-dependent decrease in viable cell density from 0.93±0.13 106 
viable cells/mL at control level to 0.52±0.06 106 viable cells/mL at 20 µM (equivalent to a 45% 
decrease) (Figure 44A). The estimated GI50 was 13.15 µM although the curve was not 
completely studied. 
Viability was preserved above 90% for all cases, with no significant differences with respect 
to the control (94.87±1.07%). The only exception was the 20 µM treatment, which is 
significant with viability of 91.1±0.58% (Figure 44A). 
Cell size followed the same trend as viability and was maintained constant (14.78±0.15 mµ) 
regardless of the treatment (Figure 44C). At the same time, cell shape was maintained (Figure 
44D). 
The total recombinant protein produced remained stable at all treatments on levels close to 
the control (11.75±0.46 µg/mL). This resulted in a steady increase in specific protein 
production in a concentration-dependent manner, with a final qp of 7.13±0.27 pg/cell·day for 
the highest concentration of luteolin treatment (20 µM). This was equal to a 1.72-fold 
increase with respect to the control (3.29±0.12 pg/cell·day) (Figure 44B). 
There is limited information about the effect of luteolin in CHO cells. Most studies performed 
used this cell line as a recombinant factory in order to study the medical effects of the 
chemical in functional pathways, such as the ones of dopamine transporter interaction with 
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this flavonoid (J. Zhang et al., 2010; Zhao et al., 2010). This indicates bioactivity of the 
component, but does not relate to the study circumstances described here. 
Other studies carried out, used a plant extract including luteolin and not the isolated 
chemical. As a result, it is difficult to correlate any of the effects described (Gemelli et al., 
2015; Jaramillo-García et al., 2018). 
To our knowledge there is no study available on the effect of luteolin on non-producer or 
recombinant CHO cell lines. Our hypothesis is that luteolin could be a good candidate for 
further research in recombinant production, as this molecule is able to shift primary 
metabolism into secondary, without having main toxic effects. Moreover, it can increase the 
specific productivity without main alterations in the cell morphology. 
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Figure 44 The effect of luteolin on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with luteolin (Ltl) (2-20 µM) during 3 days in a static 
humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.13 Piceid 
Piceid was studied in the concentration range from 10 to 100 µM. The chemical was found 
not to affect the viable cell concentration (0.85±0.05 106 Viable cells/mL) nor the viability 
(93.0±1.2 %) (Figure 45A). Furthermore, the morphology of the cells was kept constant with 
no significant changes in cell size (diameter 15.03±0.09 µm, circularity around 0.82±0.01) 
(Figure 45C&D). 
The total IgG produced decreased from 14.55±0.26 µg/mL to about 11.3±0.55 µg/mL (32% 
reduction). The specific productivity also decreased from 5.7±0.1 pg/cell·day at the control 
level to 4.04±0.12 pg/cell·day at 100 µM (Figure 45B). 
Piceid is the major precursor of resveratrol, which is a well-studied bioactive compound. Most 
of the studies performed were carried out using the final form. A study performed on cancer 
cells showed that it had a higher scavenging capacity than resveratrol, but caused less 
biological activity (Su et al., 2013). Finally, the only study available on the effect of this 
component on CHO cells reported that piceid was not able to bind to CHO cells at the same 
concentrations as resveratrol (Xue, Dong and Liang, 2016). This correlates with the lack of 
bioactivity observed in our study when investigating the same concentrations of resveratrol 
and piceid. This difference in bioactivity could be linked to the difficulty of the cell to uptake 
the molecule (Xue, Dong and Liang, 2016). 
Piceid is unlikely to be considered as a potential chemical additive as it caused no apparent 
benefits to the producing cell line in the current examination. Further research into higher 
concentrations may be needed in order to properly assess the capabilities of this molecule. 
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 Figure 45 The effect of piceid on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with piceid (Pcd) (10-100 µM) during 3 days in a static 
humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.14 Resveratrol 
The effect of resveratrol treatment at 10 μM resulted in a marginal reduction of VCD while 
the rest of the parameters were not significantly different. Total protein production showed 
some tendency to drop from 12.05 ±0.5 at the control level, but that was not significant. The 
small drop was consistent with the drop of viable cells. As a result, the specific protein 
production qp, remained constant as did the morphology of the cells (both the circularity and 
the diameter were constant). 
VCD diminished as treatment concentration increased. 25 and 50 μM treatments caused 42% 
and 78% decrease of viable cells respectively, while higher concentrations resulted in 
complete viable cell growth arrest (Figure 46A). GI50 for these conditions was calculated at 28 
μM. 
Resveratrol started to affect viability at concentrations of 50 μM. While resveratrol had a mild 
effect at 50 µM, concentrations of 75 µM and 100 µM resulted in drops of up to 70% (Figure 
46A). The estimated LC50 for resveratrol was 163 μM, but this is out of the range of 
treatments, it can only be used as an indication. 
The GI50 (28 μM) and the LC50 (eligibly 163 μM) estimations were considerably distanced, 
which indicates that the overlap between the cell inhibition and cell toxicity is minimal and 
resveratrol could be used under the concentrations where it has cytostatic properties. We 
considered that 50 μM concentrations of resveratrol should be the study upper limit as values 
above it could geoparticle cell integrity. 
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The effect of resveratrol on the morphology of the cells showed that there are two main 
responses from the cell population depending on the concentration.  
Cell size: Concentrations between 10 and 50µM caused an increase in cell diameter in a 
concentration-dependent manner. At the control level, the size was 15.7±0.1 μm whereas at 
50 μM the average diameter was 16.3±0.3 μm. That was the only significant increase 
observed. On the other hand, concentrations above 50µM caused a significant drop of the 
diameter (more than 1 μm), reaching 14.4±0.8 μm at 100 μM (Figure 46C).  
Cell shape: There was an increase in the circularity as the concentration increased. There was 
a peak at 25 and 50 μM. Concentrations of 75 and 100 μM did not cause any changes (Figure 
46D).    
There was an inverse relationship between IgG total titre and resveratrol concentration, 
causing approximately a 3-fold decrease at 100 μM. The cell growth was inhibited more 
heavily than IgG production. This resulted in an increase of qp from 3.3 pg/cell·day at the 
control level, to almost 4 times increase at 75 and 100 μM concentrations (12.3 pg/cell·day) 
(Figure 46B). 
The impact of resveratrol treatment on cells, indicated that the cultures react in two main 
ways depending on the concentration of the treatment. 
For concentrations up to 50 μM, the viable cell concentration decreased but viability was 
mainly preserved. This caused an increase in both the cell size and the average circularity of 
the cells, which is likely to be the cause of the increase in the specific protein production. 
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Estimation of the average size of the cells was done considering circularity insignificant; at the 
control level the volume was 2.03 mm3, while at 50 μM the volume was 18.1 mm3. The nine-
times increase of the cell volume only gave a 3.17 increase in qp, which showed that cells were 
producing 3 times less per biomass volume. 
On the other hand, at 75 µM and 100 μM concentrations, cells behaved in a completely 
different manner. Cell growth was completely arrested, viability was reduced by up to 20% 
and cells were diminished in size although they preserved their cell shape. It is likely that the 
increase of the specific protein production at these concentrations was due to a very different 
mechanism that is likely to do with the chemical’s toxic effect. If this was the case, a change 
in the characteristics of the IgG produced would be expected.  
Recent work done on the effect of resveratrol in recombinant CHO cell lines indicates that 
concentrations of 10 µM were not able to affect the viability, cell density or final recombinant 
protein titre (Baek et al. 2016). These results correlate with the findings of this 
experimentation which showed that there were no significant differences in these 
parameters when comparing the control with the 10 µM treatment. 
Resveratrol has been recently studied and included in a patent in order to be used as an 
additive for recombinant protein production in CHO cells. The chemical was studied at 62.5 
µM, 250 µM and 1 mM. It was found to increase the viable cell density in some circumstances, 
although it was not clear that this phenomenon was significant on a regular basis. 
Furthermore, resveratrol was able to cause up to a 1.44-fold increase in production when 
added at 1mM concentration (Tian, 2016).  
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The disparity in the effects of the chemical in the different experimentations has to be 
addressed and checked whether it is significant. Resveratrol in the current study was found 
to be toxic at concentrations above 50 µM and was estimated to cause considerable toxic 
effects at concentrations around 163 µM. On the other hand, concentrations around 1000 
µM were not reported as very toxic in the patent study. Furthermore, other studies done with 
different CHO cell lines, identified toxic effects at concentrations as low as 80 µM (Basso et 
al., 2013). This discrepancy can only be possible if the cell line has been adapted to withstand 
such high concentrations of the chemical or if the cell line is inherently resistant.  
In order to further clarify the real differences across the studies, a scale-up method where 
comparable methods could be assessed needs to be implemented (static well plates vs shaker 
flask fed-batch culture) (Tian, 2016). 
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Figure 46 The effect of resveratrol on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with resveratrol (Rsv) (10-100 µM) during 3 days in a 
static humidified (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) (section 
2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 2.1.5); (C) 
cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD of 
quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.1.2.15 Tocopherol 
Tocopherol was studied in a wide range of concentrations from 35 to 700 µM, and the 
experiments showed that the concentration had no effect on the results. 
Tocopherol affected the viable cell density by decreasing it from 0.58±0.004 106 Viable 
cells/mL at control, to values around 0.36±0.04 106 Viable cells/mL for all treated samples 
(Figure 47A). This represents a 38% inhibition after three days of incubation. Due to the fact 
that tocopherol was not studied in concentrations before inhibiting or after complete 
inhibition, plus all the concentrations studied showed the same level of inhibition, there was 
no way of assessing GI50 not even by approximation. 
Viability was not significantly changed when compared with the control and all values were 
found to be between 92 to 88 % (Figure 47A). LC50 was not considered. 
Cell size was maintained constant across the range of study, with no significant differences 
with respect to the control (average cell diameter of 14.88±0.13 µm) (Figure 47C). 
Furthermore, the cell shape was also unaltered significantly, with an average circularity of 
0.84±0.02 (Figure 47D). 
The total IgG was reduced for all treated samples and was found to be around 11.9±0.2 
mg/mL; the respective control value was 13.85±0.35 µg/mL. This 14% decrease in IgG 
produced is lower than the general 38% decrease in viable cell density. As a result, all treated 
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samples had increased specific productivities of approximately 1.6-fold 
(13.32±0.71pg/cell·day) compared to the control (8.06±0.08 pg/cell·day) (Figure 47B).  
Tocopherol was found to affect growth without causing any toxic effects at any of the 
concentrations studied. Furthermore, it was able to enhance specific protein production. This 
chemical is likely to be a good candidate for supplementation strategies. However, this 
chemical is very difficult to manipulate due to its high viscosity and it is difficult to preserve 
in proper conditions as it undergoes oxidation at a very high rate. 
Fazzio and colleagues found tocopherol to a cause slight inhibition of the cell growth and 
linked this to gene expression activation of Kinase C (Fazzio, Marilley and Azzi, 1997). Vitamin 
E has been researched heavily for its capacity to help mitigate stress and toxic conditions in 
CHO cells (Soloneski, Reigosa and Larramendy, 2003; Kmetič et al., 2009).  
This chemical was found to be useful in assisting CHO cell lines to adapt to short-term 
hypothermic preservation (Byoun and Park, 2006). It is also present in well-described media 
compositions for biopharmaceutical production (Krishnan, Rendeiro and San-Dadi, 2010). 
However, its effect as an additive to the media has not been studied.  
The results of our investigation indicate that tocopherol affects growth at all the studied 
concentrations, without causing any toxic effects. Furthermore, it is able to enhance specific 
protein production. This chemical is likely to be a good candidate for supplementation 
strategies. 
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Figure 47 The effect of tocopherol on the cell culture and IgG production in 24-well plates 
Display of measurements for samples treated with tocopherol (Tcp) (35-700 µM) during 3 days in a 
static humidified incubator (section 2.1.2): (A) viable cell concentration (blue) and cell viability (yellow) 
(section 2.1.4); (B) total protein production (grey) and relative protein production (orange) (section 
2.1.5); (C) cell diameter (green) and cell circularity (red) (section 2.1.4). The error bars represent ±SD 
of quadruplicates. Statistical t-test was perform to compare treatments with control at p-values: (*)< 
0.05, (**) < 0.01 and  (***) < 0.001 
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3.3.2 Conclusions 
The 24-well plate screening method was found to be reliable and had high reproducibility. 
There was no edge effect. However, the process was limited to three days of incubation, to 
preserve the viability of the cell culture across the experiment.  This platform was very 
efficient in identifying chemicals able to shift cell growth into specific IgG production, but was 
limited in identifying other mechanisms of action. Furthermore, the data obtained, although 
indicative, are not directly transferable to scale up conditions, as cells were incubated for a 
short period of time and under static conditions. 
From all the chemicals studied, 4-PBA,  glycine betaine, caffeine and piceid did not cause any 
improvements in the production process. Other compounds such as curcumin, kaempferol 
and CAPE, showed drastic toxic effects and an increase of qp was only linked to low levels of 
viability. Based on this investigation, these compounds will not be considered for further 
research, as it seems unlikely that they could help the protein production. 
Finally, catechin, epicatechin, resveratrol, EGC, tocopherol, EGCG and GCG, showed positive 
effects on the recombinant IgG production. Some of these chemicals were also patented and 
data from those studies correlate with our findings. However, little information on the 
mechanism of action of the chemicals was identified. The present study showed that most of 
the chemicals with positive features are able to improve the specific protein production by 
inhibiting cell growth without lowering viability. 
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Table 4 Effect of chemical treatments in CHO cell culture growth and IgG production 
 Chemical 
candidates VCD [IgG] Viability qP Score 
Catechin - - - = + + 
Epicatechin - - - = + + 
ECG - - = = + + 
EGCG - - - = + + 
GCG - = = + + 
Kaempferol - - - - = = - 
Luteolin - = = + + 
Piceid = = = - - 
Resveratrol - - - = +++ +++ 
CAPE - - - - - - - - - - - -  - - - 
Curcumin - - = = - 
Tocopherol - = = ++ ++ 
Btn + = = - - 
4-PBA - - - = = - 
Caffeine - - = = - 
Effect of cytostatic conditions of chemical candidates on viable cell density (VCD) IgG 
recombinant titre (IgG) viability and specific IgG production (qp) for producing CHO cell 
cultures. (ECG) Epicatechin gallate, (EGCG) Epigallocatechin gallate, (GCG) Gallocatechin 
gallate, (CAPE) Caffeic acid phenethyl ester, (Btn) glycine betaine,  (4-PBA) 4-
phenylbutyrate. Minus symbol (-) represent the a decrease in the variable, an equal (=) 
indicates that the variable stais the same and a plus symbol (+) indicates a increase on the 
variable. The over all score represent an arvitrari measurement to assess the capacity of the 
chemicals to increase productivity in the recombinant cell line.  
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4.1 Initial remarks 
The results from the previous chapter (Chapter 3) showed that some of the initial chemical 
candidates screened (resveratrol and the catechin family compounds) were able to increase 
qp by slowing cell growth without lowering cell viability. This indicated that their capacity to 
improve recombinant IgG production is probably linked to their cytostatic nature. In order to 
better understand the effect of those conditions, cell cultures were followed over time to 
study their viability, cell growth, cell morphology and cell cycle composition. 
24-well plate cultures were set-up as specified in section 2.1.2. Measurements of viability, cell 
concentration (section 2.1.4) and cell cycle phase analysis (section 2.2) were performed every 
24 hours for catechin group treatments and every eight hours for resveratrol treatments. All 
the measurements were done in quadruplicates and were repeated twice independently. 
4.2 Results and discussion  
4.2.1 Protocol optimization for fixation and propidium iodide staining 
The resveratrol cultures had to be studied after eight hours of incubation, as described in the 
previous section. The problem with this, is the fact that the cell density would be limited. 
Flowcytometry requires large numbers of cells to produce reliable data and this could 
jeopardize the quality of the readings. The fixing protocol of cell cultures is a very long process 
that requires many intermediate steps; each step can reduce the number of cells. The present 
study intended to analyze the buffer exchange steps, which are critical for the loss of cells and 
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to minimize this loss without compromising the results by studying the changes in 
concentration of the sample across the protocol  
The experiment was carried out in six different chemicals for three concentration treatments, 
at three different time points and in triplicates. The protocol needed to be adapted to 
minimize the waste of chemicals and the time to run it. 
The cell fixation and propidium iodide stain protocol, is a robust method that has been 
implemented in the flow cytometry cell cycle study, since its very early stages of development 
(Krishan, 1975). Due to the advantages of this technique, a standard method optimizing the 
process followed shortly after (Fried, Perez and Clarkson, 1976).  Since then, the protocols 
have diversified and been adapted to new technologies and needs, in order to reduce the 
time and money put into the process (Pozarowski and Darzynkiewicz, 2004; Kumar et al., 
2014). The first implementations of this method were performed in the field of medicine. In 
these cases, the amount of sample was the limiting factor.  
In the present set up, the process is not limited by a reduced number of samples. On the 
contrary, the samples were many and required a very long process of fixation and staining, 
making the high throughput capability the main concern. Furthermore, some samples had 
limited low cell concentration. This was critical, as the protocol requires many steps and 
samples could be lost in the process. 
The standard conservative protocols tend to wash the sample several times in order to 
preserve them and ensure that they have correct fixation and stain (Table 5). This is a problem 
in terms of time and reagents used. Moreover, it could cause problems with the final cell 
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density measured, especially when having to deal with a big number of samples, some of 
them with very low cell concentrations. 
In order to optimize time reagents and deal with low cell concentration samples, a study of 
the protocol with a smaller number of washes was looked into. PBS buffer washes in steps 3 
and 4 were reconsidered, as previously described (Yeh et al., 2009; Kumar et al., 2014). At the 
same time, step 7 was reduced to two washes (steps 12 and 13), as some manufacturer 
protocols indicate two or even one wash (Molecular Probes, 1999; Abcam, 2012; H. Zhu, 
2012). The study protocol was assessed at four main checkpoints in order to track the loss of 
cells (steps 2, 8, 9 and 10). 
The experiments showed, as was expected, that the steps which included buffer exchange or 
supernatant removal were associated with a considerable loss of cells. The study protocol 
resulted in a loss of 94% of the cells. The disposal of the supernatant media in step 3, resulted 
in an initial cell loss of 29.4%. Step 8 was less critical and only resulted in a 19.4% loss of the 
cells when discarding ethanol. Subsequent washes with PBS buffer at steps 9 and 10, were 
identified as the most critical ones, with a loss of 56.3 and 76.1 % respectively (Table 6).  
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Table 5 Propidium iodide fixation and stain protocol adaptation 
 
Initial protocol Study protocol Final protocol
1 Collection of sample in vial Collection of sample in vial Collection of sample in vial
2 Cell centrifugation and disposal of 
media supernatant
*Cell centrifugation and disposal 
of media supernatant
*Cell centrifugation and disposal 
of media supernatant
3 1st PBS wash centrifugation and 
supernatant disposal
--- ---
4 2nd PBS wash centrifugation and 
supernatant disposal
--- ---
5 PBS resuspension to minimal 
volume
PBS resuspension to minimal 
volume
PBS resuspension to minimal 
volume
6 Fixation with 70% ethanol Fixation with 70% ethanol Fixation with 70% ethanol
7 Incubation for 30 minutes Incubation for 30 minutes Incubation for 30 minutes
8 Centrifugation and disposal of the  
ETOH supernatant
*Centrifugation and disposal of 
the ETOH supernatant
*Centrifugation and disposal of 
the ETOH supernatant
9 1st PBS wash centrifugation and 
supernatant disposal
*1st PBS wash centrifugation and 
supernatant disposal
*1st PBS wash centrifugation and 
supernatant disposal
10 2nd PBS wash centrifugation and 
supernatant disposal
* 2nd PBS wash centrifugation and 
supernatant disposal
---
12 3rd PBS wash centrifugation and 
supernatant disposal
--- ---
13 4th PBS wash centrifugation and 
supernatant disposal
--- ---
14 Addition of RNAase Addition of RNAase Addition of RNAase
15 Addition of  propidium iodide Addition of propidium iodide Addition of propidium iodide
16 Incubation in dark for 5-10 
minutes
Incubation in dark for 5-10 
minutes
Incubation in dark for 5-10 
minutes
* Steps after which cell concentration was studied 
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Table 6 Cell loss along the steps of propidium iodide fixation and stain protocol 
 
Pellet formation and integrity are key components when removing the supernatant. Two 
main factors that affect the pellet formation are the nature of the liquid phase and the state 
of the cells. If pellet formation is compact and maintains integrity, the supernatant collection 
can be done easily without perturbing the sediments, thus reducing cell loss to a minimum. 
On the other hand, loose pellet formation hinders the collection of the liquid phase, without 
perturbating the pellet and often results in a considerable cell loss or an incomplete removal 
of the supernatant. 
When cells are fixed with ethanol, they lose their membrane integrity and a decrease of both 
the cytoplasmic content as well as the cell diameter can be observed (Gusnard and Kirschner, 
1977; Hobro and Smith, 2017). These physiological changes make the cells more buoyant and 
more difficult to centrifuge, thus making the pellet less consistent. 
The liquid phase also plays an important role. Non-fixed cells were easy to centrifuge out of 
the solution. Fixed cells were also easily spin out of solution when in ethanol, thus resulting 
in a very compact pellet. On the other hand, fixed cells formed very loosed pellets in PBS 
Step
Cell concentration            
(Cells 106/mL)
Cell loss 
(%) Supernatant Cell state
Mean SD by step accumulative
Initial 1.9 ± 0.12 -- -- -- --
Step 3 1.34 ± 0.13 29.4 29.4 Media Non-fixated
Step 8 1.08 ± 0.09 19.4 43.1 70% ethanol Fixated
Step 9 0.47 ± 0.06 56.3 75.1 PBS Fixated
Step 10 0.11 ± 0.02 76.1 94 PBS Fixated
The steps of the protocol contemplated in this study were only the ones of buffer exchange and supernatant removal
 Chapter 4 174 
buffer and this resulted in a big loss of cells when exchanging buffers. This condition is to be 
avoided when there is concern about samples with a low number of cells. As a result, the 
protocol was further adjusted by dropping the wash at step 10.  
All the previous experimentations resulted in the formation of the final protocol:  
1. Cells to be collected from 24-well plate cultures and transferred into a 1.5 mL 
Eppendorf 
2. Cells to be centrifuged at 300 g for 5 minutes and then pellet to be discarded  
Note: CHO cells are very robust and stand high centrifugation speeds. This centrifugal 
force was selected based on empirical data from previous work done with this cell 
type in the laboratory. More extreme centrifugation at 400 g, had the same results in 
terms of pellet formation and cells were able to maintain integrity. These conditions 
can be adapted when cells are more difficult to collect in the early stages, but if not 
needed it is better to use 300g as a conservative measurement to preserve the cell’s 
integrity until fixation 
5. Cell pellet to be resuspended gently into 30 µL of ice-cold PBS buffer 
Note: This step was performed in order to avoid clumps of cells and facilitate the 
fixation of cells that would follow. If the pellet was to be very abundant at this step, 
then 60 µL of PBS buffer instead of 30 µL could be used. However, this would also 
mean that the amount of ethanol in the subsequent steps should also be doubled 
6. Cell fixation: Ice cold ethanol at 70% to be added drop by drop to the cell suspension, 
while vortexing the Eppendorf at medium intensity 
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Note: Vortexing allows for the fast dissolution of the ethanol in the media. It also 
allows the ethanol to act on the cells homogenously, thus avoiding the formation of 
clumps and aggregates 
7. Incubation to be performed for at least 30 minutes at 4oC 
Note: The time of incubation could be adjusted starting from 20 minutes and up to 
overnight, depending on the protocol 
8. Centrifugation to be performed at 400 g for 5 minutes followed by removal of the 
ethanol supernatant 
Note: At this stage centrifugation should not be a problem; cells come out from the 
solution easily and form a very compact pellet. In order to avoid future PSB passages 
without compromising the removal of ethanol, the maximum amount of supernatant 
possible, has to be removed at this stage 
As ethanol is removed, the pellet would be exposed and rapidly dried due to the fast 
evaporation of the ethanol remaining in the pellet. That is why, the immediate 
subsequent addition of PBS buffer to the pellet in order to avoid the formation of 
aggregates and lumps, is crucial 
9. A. 1000 µL of PBS buffer to be added and the pellet to be resuspended gently in the 
new buffer. Cells should be left to rehydrated for at least 15 minutes. The volume of 
the PBS buffer wash is to be maximized in order to counteract the lack of future 
washes and reduce the amount of ethanol left in the vial 
B. Centrifuging should be performed at 400 g for 5 minutes 
Note: At this stage cells tend to rehydrate and lose density, thus forming very fussy 
pellets. Therefore, this could result in considerable cell loss. For that reason, it is 
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recommended to use high speed when centrifuging in order to obtain the best pellet 
possible 
C. Supernatant to be removed 
Note: If there was a doubt regarding the amount needed to be removed, then leaving 
a small quantity of the supernatant behind would be allowed; the opposite could 
easily lead to loss of the sample 
      14.  Addition of 30 µL of RNAase (100µg/mL) 
      15.  Addition of 200 µL of propidium iodide (50 µg/mL) 
      16.  Incubation of the sample for 5 - 10 minutes 
This protocol is able to minimize the cell sample loss over the fixation and stain process, and 
reduces the time of performance. The subsequent experiments of this chapter were 
performed following this protocol with no loss of sample quality at the flow cytometry 
readings. As a result, we believe that this strategy is robust and could be useful for future 
studies. 
 
4.2.2 Resveratrol time course study and cell cycle  
The time course study undertaken in 24-well plates, showed that resveratrol treatment 
delayed the exponential phase of the cell culture in a concentration-dependent manner 
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(Figure 48A).  Control and 10 μM treatments showed a stationary phase, that lasted less than 
16 hours before the CHO cells started to grow with a steady increase in VCD for 72 hours. 25 
μM treatment lengthened the stationary phase by approximately 32 hours. However, the 
growth after that point was of the same rate as the control, indicating that after the cells had 
adapted to the media, the presence of resveratrol did not affect growth. Treatment with 50 
μM resveratrol lengthened the stationary phase by approximately 32 hours, but the growth 
after that point and up to the end of the experiment (72 hours) was sluggish. The effects on 
viability (Figure 48B).   in the untreated control and the 10 μM resveratrol, both remained 
high around 97-98%, dropping to 95% after 72 hours in culture. The 25 μM resveratrol 
treatment showed a temporary dip in viability, to around 93±0.95% between 24 and 40 hours, 
but recovered to mirror the control after 40 hours in culture. The 50 μM resveratrol treatment 
showed a temporary dip in viability after 40 hours in culture, down to around 90.24±0.83%, 
but then showed signs of recovery after 48 hours. Resveratrol treatment caused a temporary 
increase in cell diameter from around 14.5 μm to 16.5 μm (Figure 48C).  This peaked at 32 
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hours for the 25 μM (16.62±0.17 µm) treatment and at 48 hours for the 50 μM treatment 
(16.43±0.12 µm). The cell diameter then dropped to match the control values. 
 
Figure 48 Time course study effect of resveratrol over cultures in 24-well plates 
Effect of resveratrol (Resv) on viable cell density (VCD) (A), viability (B) and cell diameter (C) (section 
2.1.4) at 10 µM (yellow), 25 µM (green) and 50 µM (blue) treatments for CHO cells grown in 24-well 
plates (section 2.1.2). Each data point represents the average from a triplicate, and the error bars 
correspond to ±SD. These experiments were repeated independently. 
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The cell cycle analysis of the samples from the time course study (Figure 49 and Table 7), 
showed that the presence of resveratrol had an impact on the population of the cells at 
different parts of the cell cycle. The untreated control showed a rise in the G1/G0 phase cells 
at 8 hours and S phase cells at 16 hours after inoculation. The control then returned to a 
stable population with around 40% of the cells at G1/G0 phase, 40% at S phase and 15 to 20% 
at G2/M phase. The cells with 10 μM resveratrol treatment behaved very similarly to the 
control. The cells with 25 μM resveratrol treatment displayed some perturbation to the cell 
cycle with elevated levels of cells in the S phase at 8, 16, 32 and 40 hours after inoculation; at 
48 and 72 hours the cell population returned to levels similar to the untreated control. The 
cells with 50 μM resveratrol treatment showed no marked changes in their population for the 
first 24 hours after inoculation, but by 32 hours there was a peak in the S-phase cells and a 
corresponding collapse in the G1/G0 phase cells. The cells in this treatment group did not 
return to a normal population as seen in the untreated control over the 72 hours of the 
experiment, but had elevated levels of G2/M phase cells at 40 and 48 hours and elevated S 
phase cells at 72 hours. 
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Figure 49 Cell cycle distribution under resveratrol treatment 
Cell cycle distribution for G1/G0 (grey), S (orange), and G2/M (black) phases under resveratrol 
treatments at 0 µM (A), 10 µM (B), 25 µM (C) and 50 µM (D) for CHO cells grown in 24-well plates for 
three days (section 2.1.2). Each data point represents the average from a triplicate, and the error bars 
correspond to ±SD. These experiments were repeated independently. 
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Table 7 Cell cycle distribution at different time points under resveratrol treatment  
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Resveratrol acted by lengthening the stationary culture phase trough, causing cell growth 
arrest and a small slope of decreasing viability. This stationary stage was more apparent and 
lengthened as resveratrol concentration increased. This was characterized by a peak of cells 
in the S phase at the end of this stage, which aligned with a drop in viability and an increase 
in the diameter. Then, cell growth was restored and parameters tended to normalize towards 
the control values. This suggests that a significant part of the big drop in viability, is associated 
with the end of this stage and synchronized with the accumulation of cells in the S phase. This 
process can be related to the capacity of resveratrol to interfere with DNA duplication, repair 
and segregation (Basso et al., 2013; Traversi et al., 2016) accumulating cells in the S phase 
through direct (N’soukpoé-Kossi et al., 2015) and indirect (Leone et al., 2010)  mechanisms 
late in the culture (Subramanian, Soundar and Mangoli, 2016). Previous studies report that 
DNA damage occurs at high concentrations with a subsequent possibility of apoptotic events 
(Basso et al., 2013; Uchiumi et al., 2016). However, not all studies reported the same results 
(Sainz et al., 2003). One of the mechanisms of the toxicity of resveratrol on CHO cell dividing 
cultures, could be its interaction with topoisomerases during the S phase (Leone et al., 2012; 
Basso et al., 2013). 
Regardless of all this, the connection between the arrest at S phase from the viability drop 
and the growth inhibition should not be assumed. During treatment with the highest 
concentration of resveratrol (50 µM), not many cells were found in the S phase during the 
culture; the peak was observed at 48h. On the other hand, the growth arrest and the drop in 
viability took place consistently for the first 48 hours of the culture. This disparity between 
the three effects suggests that the previous mechanism of S phase arrest cannot fully explain 
the growth arrest or the drop of viability that took place previous to 48 hours. Therefore, it is 
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likely that another mechanism is also involved. This is in line with other findings (Della Ragione 
et al., 1998). Furthermore, other studies have shown that the cell growth stops in other 
phases (Rubiolo et al., 2012; Gokbulut et al., 2013) or stops in a non-specific way (Pozo-
Guisado et al., 2002). 
We hypothesize that the results observed by resveratrol treatment in CHO cell cultures under 
these conditions are due to complex effects, giving different outcomes depending on the 
concentration of the treatment or the moment of it. Due to its bioactive characteristics, 
resveratrol is more likely to be causing a pleiotropic effect on CHO cells by interfering with 
signaling and metabolic pathways in many different ways. This could lead to different effects 
by introducing small changes in concentration (Hahnvajanawong et al., 2011; Rubiolo et al., 
2012; Bosutti and Degens, 2015).  
Overall, resveratrol caused cell growth arrest in a concentration-dependent-manner. The 
effect was observed in the stationary phase of the cell culture, with a small drop in viability 
and a sudden increase of cells in the S phase. The toxic behaviour seen in this study is related 
partially to resveratrol’s interference with DNA replication, repair and segregation 
mechanisms, indicating that highly dividing cells could be more affected. This hypothesis 
correlates with cancer studies where resveratrol was identified to have anti-tumour effects 
due to its capacity to selectively cause higher toxic effects in highly dividing tissues (Zhou et 
al., 2011; Trung et al., 2015).  
Based on this investigation, we suggest that resveratrol should be considered and further 
studied for the use in recombinant IgG production. In order to improve protein production 
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under scale-up conditions, the effect of toxicity and cell division should be investigated as well 
as the capacity of this chemical to stop growth.  
4.2.3 Catechins time-course study and cell cycle  
4.2.3.1 Catechin 
The time-course study of cell cultures in 24-well plates under static conditions indicated that 
cells adapted and started to grow before 24 hours (from 0.2 at time zero to 0.3 106 cells/mL 
after 24 hours for all concentrations).  Control reached specific cell growth (µ) of 
approximately 1 days-1 for the next 48h to up to 0.97±0.06 106 cells/mL. Treatment with 
catechin at 10 µM caused no changes in the growth curve. Higher concentrations of 25 and 
50 µM caused inhibition of the specific growth rate to half (0.53 days-1) but did not elongate 
the cells in the stationary phase as all readings after 24 hours were similar for all conditions 
(approximately 0.3±0.02 106 cells/mL) (Figure 50A).  
Cell viability was not really affected at any point during the culture or under any given 
treatment concentration. The measurements ranged from 95 to 99%. There was a small trend 
of higher viability of the treated samples with respect to control, at any given concentration 
after the initial 24 hours. Treatment at 50 µM resulted in an increase in viability of 
approximately 2% over the control after the first 24 hours.  This increase could be related to 
a delay in the cell concentration of the well plate. As well plates become more densely 
populated, cell cultures become less hospitable. as there is a fast consumption of the 
nutrients and accumulation of toxic components.  Nevertheless, the cells treated with control 
were growing at the fastest doubling time until day three, so it is unlikely that the conditions 
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in the culture cause stress at that. Catechin was able to cause conditions in the culture which 
increase viability minimally, although the mechanism by which this happens is unclear (Figure 
50B). 
Cell diameter was increased by the addition of catechin in the culture. Cell size in the control 
samples was initially 15.16±0.30 µm, with no significant differences observed at the treated 
samples. By day 3, non-treated cells increased slightly in size up to 15.52±0.16 µm. On the 
other hand, catechin was able to increase the cell size to 16.70±0.29 µm for treatments at 25 
and 50 µM concentrations, after three days of incubation.  Treatment with 10 µM caused a 
less severe increase with a final diameter of 16.23±0.11 µm (Figure 50C). The increase in size 
during the first 24 hours indicates that this parameter does not have to be strictly linked to 
cell growth arrest, since the 10 µM treatment caused considerable cell size increment with 
no apparent cell growth arrest. Another possible reason for cell size increase could be an 
increase in homeostasis when adding this chemical to the media.  
Overall, the cell cycle study showed significant differences between the non-treated samples 
and the treated samples. Nevertheless, all concentrations of the treatment seemed to have 
a very similar effect on the cell cycle. Catechin reduced the relative population of cells in G1/G0 
phase and in return increased the number of cells in the S and G2/M phases. Furthermore, 
the G2/M increase was more evident after 72 hours. It is difficult to elucidate the reason by 
which catechin is able to elongate the cell cycle at these two stages (Figure 51).  
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Figure 50 Time course study effect of catechin over cultures in 24-well plates 
Effect of catechin (Cat) on viable cell density (VCD) (A), viability (B) and cell diameter (C) (section 2.1.4) 
at 10 µM (yellow), 25 µM (green) and 50 µM (blue) treatments for CHO cells grown in 24-well plates 
(section 2.1.2). Each data point represents the average from a triplicate, and the error bars correspond 
to ±SD. These experiments were repeated independently. 
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Figure 51 Relative cell cycle distribution under catechin treatment 
Relative change in cell cycle distribution compared to the control for G1/G0 (A), S (B), and G2/M (C) 
phases under catechin (Cat) treatments at 10, 25 and 50 µM for CHO cells grown in 24-well plates for 
three days (section 2.1.2). Each data point represents the average from a triplicate, and the error bars 
correspond to ±SD. These experiments were repeated independently. Statistical two-way ANOVA test 
was perform to compare treatments with control at p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
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4.2.3.2 Epicatechin 
The time-course study of cell cultures in 24-well plates under static conditions, indicated that 
cells adapted and started to grow before 24 hours (from 0.14±0.01 at time zero to 0.33±0.01 
106 cells/mL after 24 hours for all concentrations).  Control reached specific cell growth (µ) of 
approximately 1 days-1 for the next 48h (up to 0.97±0.04 106 cells/mL). Treatment with 5 µM 
did not cause any change in the growth curve. 10 µM concentration treatment caused decay 
in growth rate after 48 hours and the 15 µM treatment caused a continuous steady increase, 
equal to the one observed during the first 24 hours. Epicatechin was able to arrest cell growth 
in a concentration-dependent manner (Figure 52A), as described in previous results 
mentioned in Chapter 2. 
Viability was maintained along the three days of incubation, with values ranging between 92 
and 99%. Addition of the chemical seemed to cause toxicity in the culture at time zero since 
the average values dropped to 93.49±0.14% for 10 µM and 92±1.50% for 20 µM treatments 
with respect to the control (95.90±0.76%). During the first 24 hours, viability increased to 
then steadily decrease during the next 48 hours of culture. This trend was consistent across 
all samples, both treated and untreated (Figure 52B). 
Cell diameter was equal for all samples at time zero and increased over time under all 
conditions. Samples treated with control, increased their cell diameter from 14.82±0.20 µm 
at time zero, to 15.62±0.04 µm after three days of incubation. Treated samples increased 
their cell size more, up to 16.73±0.20 µm for 20 µM, 16.26±0.10 µm for 10 µM and 16.31±0.09 
µm for 5 µM treatments. That was observed after three days of incubation. Epicatechin’s 
effect on cell size, is not linked to its growth inhibition, as treatment at 5 µM caused an 
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increase in cell size, with no cell growth inhibition associated. Furthermore, the trends of 
growth arrest and cell diameter increase did not much at all data points (Figure 52C). 
Figure 52 Time course study effect of EC over cultures in 24-well plates 
Effect of epicatechin (EC) on viable cell density (VCD) (A), viability (B) and cell diameter (C) (section 
2.1.4) at 10 µM (yellow), 25 µM (green) and 50 µM (blue) treatments for CHO cells grown in 24-well 
plates (section 2.1.2). Each data point represents the average from a triplicate, and the error bars 
correspond to ±SD. These experiments were repeated independently. 
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Overall, the cell cycle study showed significant differences between the non-treated samples 
and the treated samples. Nevertheless, all concentrations of the treatment seemed to have 
a very similar effect in the cell cycle. Epicatechin reduced the relative population of cells in 
G1/G0 phase and in return increased the number of cells in the S and G2/M phases. 
Furthermore, G2/M increase was more evident after 72 hours. It is difficult to elucidate the 
reason by which epicatechin is able to elongate the cell cycle at these two stages (Figure 53).  
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Figure 53 Relative cell cycle distribution under epicatechin treatment  
Relative change in cell cycle distribution compared to the control for G1/G0 (A), S (B), and G2/M (C) 
phases under epicatechin (EC) treatments at 5, 10 and 20 µM for CHO cells grown in 24-well plates for 
three days (section 2.1.2). Each data point represents the average from a triplicate, and the error bars 
correspond to ±SD. These experiments were repeated independently. Statistical two-way ANOVA test 
was perform to compare treatments with control at p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
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4.2.3.3 Epicatechin-gallate 
The time-course study of cell cultures in 24-well plates under static conditions indicated that 
cells adapt and start to grow way before 24 hours. With growth from 0.150±02 at time zero 
to 0.30±0.04 106 cells/mL after 24 hours for all concentrations.  Control reached specific cell 
growth (µ) of approximately 1 days-1 for the last 48h of the culture reaching 1.01± 106 cells/mL 
after 72h of culture. All the treatments of epicatechin-gallate (5, 25 and 50 µM) caused very 
similar responses on the cell culture (Figure 54A). Under these conditions cell growth is 
partially repressed with an overall cell growth rate of 0.78 days-1.  
Cell viability was maintained between 94 and 97% for all samples at all times, this indicates 
that regardless the inhibitory effect of the chemical over the population, these concentrations 
do not cause severe toxic effects in the cultures under these conditions (Figure 54B).  
Epicatechin-gallate caused no significant changes in cell size under these conditions with 
values close to the control (15.2-15.3 µm). Cell diameter is maintained very similar to the 
control although after 72h there is a consistent increase in size to 16.06±0.23 µm for all 
treatments with respect to the control at 15.62±0.12± µm (Figure 54C). 
 
 
 
 Chapter 4 193 
Figure 54 Time course study effect of ECG over cultures in 24-well plates 
Effect of epicatechin gallate (ECG) on viable cell density (VCD) (A), viability (B) and cell diameter (C) 
(section 2.1.4) at 10 µM (yellow), 25 µM (green) and 50 µM (blue) treatments for CHO cells grown in 
24-well plates (section 2.1.2). Each data point represents the average from a triplicate, and the error 
bars correspond to ±SD. These experiments were repeated independently. 
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The concentration of 5 µM epicatechin-gallate causes no main changes in cell cycle 
composition after 24 hours. Accumulation of cells in the G2/M phase appears after 48 and 72 
hours of treatment in detriment of mainly G1/G0.  
Concentrations of 50 µM have a very different effect with a consistent significant increase in 
S phase. While at the beginning this cell increase in the S phase accounts mainly from loss of 
cell in the G2/M phase, as time passes by the cells missing in the G1/G0 phase are more 
numerous. After 72 hours the accumulation of cells in the S phase accounts exclusively from 
cells in the G1/G0 phase and there is also a consistent increase in G2/M. It is likely that the 
missing cells under different phases of the cell cycle are due to partial synchronization taking 
place as cells are immediately partially arrested in S phase as early as 24 hours after 
treatment. This could explain the depletion of cells in G2/M phase as cells cannot move 
further from the S phase. As the culture elongates in time, cells pass to G2/M phase but they 
don’t reach G1/G0. 
The concentration of 25 µM is a mix in between. This indicates that the chemical is likely able 
to elongate both phases of the cell culture S and G2/M. Furthermore, the face that is more 
affected shifts as the concentration increases (Figure 55).  
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Figure 55 Relative cell cycle distribution under epicatechin gallate treatment 
Relative change in cell cycle distribution compared to the control for G1/G0 (A), S (B), and G2/M (C) 
phases under epicatechin gallate (ECG) treatments at 5, 25 and 50 µM for CHO cells grown in 24-well 
plates for three days (section 2.1.2). Each data point represents the average from a triplicate, and the 
error bars correspond to ±SD. These experiments were repeated independently. Statistical two-way 
ANOVA test was perform to compare treatments with control at p-values: (*)< 0.05, (**) < 0.01 and  
(***) < 0.001. 
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4.2.3.4 Epigallocatechin-gallate 
The time-course study of cell cultures in 24-well plates under static conditions indicated that 
cells adapted and started to grow before 24 hours (from 0.16 at time zero to 0.35 106 cells/mL 
after 24 hours for all concentrations).  Control reached specific cell growth (µ) of 
approximately 1 days-1 for the last 24h of the culture (up to 0.98±0.03 106 cells/mL). 
Treatment with epicatechin-gallate at 5 µM caused severe inhibition of the cell growth, 
although this was taking place at a lower rate, with a specific growth rate close to 0.64 day-1.  
Higher concentration treatment at 25 µM, caused a considerable inhibition of cell growth at 
the first 48 hours of the culture, close to the one observed during the 5 µM treatment. The 
last 24 hours however, caused complete cell growth arrest, with a final total cell density of 
0.37±0.06 106 cells/mL. Treatment with 50 µM, caused the complete arrest of the cell culture 
over the entire period of cultivation, with a final density of 0.23±0.03 106 cells/mL. These 
results, are not identical to the ones obtained during the initial screening of the chemicals. 
During this investigation, EGCG seems to have a stronger inhibition effect (Figure 56A). 
Cell viability was maintained between 92 and 96% for all samples at all times. This indicates 
that, regardless of the sudden inhibitory effect of the chemical over the population, these 
concentrations do not cause severe toxic effects in the cultures under these conditions. There 
were no main differences in the initial viability values. However, this does not ensure that this 
chemical does not have minimal cytotoxic effect when added to the culture, since the 
variation at time zero was considerable. This effect can be observed at time zero, since the 
Vi-cell readings take place at very low concentrations, close to the limit of resolution of the 
device. This is further confirmed as the error bars diminished as the cell culture grew (Figure 
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56B). The final viability numbers, indicated that this chemical caused a small drop in viability 
(3.3-1.5±0.54%) in the last 24 hours, with significant differences from the control 
(95.57±0.24%). This may indicate that epigallocatechin-gallate could have adverse effects on 
the culture if recorded for longer.  
Epigallocatechin-gallate caused no significant changes in cell size under these conditions with 
values close to the control (15.1-15.5 µm) (Figure 56C). 
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Figure 56 Time course study effect of EGCG over cultures in 24-well plates 
Effect of epigallocatechin gallate (EGCG) on viable cell density (VCD) (A), viability (B) and cell diameter 
(C) (section 2.1.4) at 10 µM (yellow), 25 µM (green) and 50 µM (blue) treatments for CHO cells grown 
in 24-well plates (section 2.1.2). Each data point represents the average from a triplicate, and the error 
bars correspond to ±SD. These experiments were repeated independently. 
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The cell cycle experiment did not show a clear pattern. The 5 µM concentration of 
epigallocatechin-gallate, caused accumulation of cells in the G2/M phase after 72 hours of 
treatment, in detriment of G1/G0. Concentrations above (25 and 50 µM) had a very different 
effect, with a consistent significant increase in S phase. In the beginning, this cell increases in 
the S phase accounted mainly from the loss of cells from the G1/G0 phase. However, as time 
passed by, the cells missing from the G1/G0 phase were more numerous. After 72 hours, the 
accumulation of cells in the S phase accounted exclusively from cells in the G1/G0 phase and 
there was also a consistent increase in G2/M. It is likely that the missing cells under different 
phases of the cell cycle, are due to partial synchronization taking place, as cells were partially 
arrested in S phase as early as 24 hours. This could explain the depletion of cells in G2/M phase 
as cells cannot move further from the S phase (Figure 57). As the culture elongated in time, 
cells passed to G2/M phase, but they did not reach G1/G0. 
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Figure 57 Relative cell cycle distribution under epigallocatechin gallate treatment 
Relative change in cell cycle distribution compared to the control for G1/G0 (A), S (B), and G2/M (C) 
phases under epigallocatechin gallate (EGCG) treatments at 5, 25 and 50 µM for CHO cells grown in 
24-well plates for three days (section 2.1.2). Each data point represents the average from a triplicate, 
and the error bars correspond to ±SD. These experiments were repeated independently. Statistical two-
way ANOVA test was perform to compare treatments with control at p-values: (*)< 0.05, (**) < 0.01 
and  (***) < 0.001. 
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4.2.3.5 Gallocatechin-gallate 
The time-course study of cell cultures in 24-well plates under static conditions indicated that 
cells adapt and start to grow way before 24 hours. With growth from 0.16±0.01 at time zero 
to 0.29±0.03 106 cells/mL after 24 hours for all concentrations.  Control reached specific cell 
growth (µ) of approximately 1 days-1 for the last 48h of the culture reaching 1.02±0.04 106 
cells/mL after 72h of culture (Figure 58A). All the treatments of gallocatechin-gallate (5, 25 
and 50 µM) cause very similar responses on the cell culture. Under these conditions, cell 
growth is partially repressed with an overall cell growth rate of 0.79 days-1.  
Cell viability was maintained between 93 and 97% for all samples at all times, this indicates 
that regardless of the inhibitory effect of the chemical over the population, these 
concentrations do not cause severe toxic effects in the cultures under these conditions. The 
increase in the average viability of the samples in a concentration-dependent manner is 
consistent. Treatments at 5 µM concentrations have overall viabilities (94.3-95.1 %) lower 
than 25 µM (95.1-96.7 %), and this one lower than 50 µM (96.5-97.1 %)(Figure 58B). 
Regardless of the consistent trend, there are no significant differences and these treatments 
do not seem to cause any effect in viability under these conditions.  
Gallocatechin-gallate caused no significant changes in cell size under these conditions with 
values close to the control (15.1-15.5 µm). Cell diameter is maintained very similar to the 
control except for 25 µM (16.05±0.15 µm) and 50 µM (15.97±0.11 µm) at 72h which have a 
significant increase in size with respect to the control at 15.5 µm (Figure 58C). 
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Figure 58 Time course study effect of GCG over cultures in 24-well plates 
Effect of gallocatechin gallate (GCG) on viable cell density (VCD) (A), viability (B) and cell diameter (C) 
(section 2.1.4) at 10 µM (yellow), 25 µM (green) and 50 µM (blue) treatments for CHO cells grown in 
24-well plates (section 2.1.2). Each data point represents the average from a triplicate, and the error 
bars correspond to ±SD. These experiments were repeated independently. 
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The cell cycle experiment does not show a clear pattern. The concentration of 5 µM 
epigallocatechin-gallate causes accumulation of cells in the G2/M phase after 72 hours of 
treatment in detriment of G1/G0 (+7.24%). Concentrations above (25 and 50 µM) have a very 
different effect with a consistent significant increase in S phase. While at the beginning this 
cell increase in the S phase accounts mainly from loss of cell in the G2/M phase, as time passes 
by the cells missing in the G1/G0 phase are more numerous. After 72 hours the accumulation 
of cells in the S phase accounts exclusively from cells in the G1/G0 phase and there is also a 
consistent increase in G2/M (Figure 59). It is likely that the missing cells under different phases 
of the cell cycle are due to partial synchronization taking place as cells are immediately 
partially arrested in S phase as early as 24 hours after treatment. This could explain the 
depletion of cells in G2/M phase as cells cannot move further from the S phase. As the culture 
elongates in time, cells pass to G2/M phase, but they don’t reach G1/G0. 
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Figure 59 Relative cell cycle distribution under gallocatechin gallate treatment 
Relative change in cell cycle distribution compared to the control for G1/G0 (A), S (B), and G2/M (C) 
phases under gallocatechin gallate (GCG) treatments at 5, 25 and 50 µM for CHO cells grown in 24-
well plates for three days (section 2.1.2). Each data point represents the average from a triplicate, and 
the error bars correspond to ±SD. These experiments were repeated independently. Statistical two-way 
ANOVA test was perform to compare treatments with control at p-values: (*)< 0.05, (**) < 0.01 and  
(***) < 0.001. 
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4.2.3.6 Discussion 
Catechins cause an inhibitory effect on cell cultures in a concentration-dependent manner. 
The degree of cell arrest seems to be linked to the structure. Catechin is the less effective in 
reducing cell growth, while epigallocatechin-gallate is the one that affects more severely, ECG 
and GCG have very similar trends that are in between both extremes. EC is difficult to 
compare as the concentration range is different, it is less toxic than EGCG or GCG and ECG 
and seems to cause a slightly more severe effect on cell inhibition than catechin. 
 The structure of the compounds seems to be key in the different effects over cell growth 
inhibition as the chemicals with the galloyl group (EGCG, GCG and ECG) seem to have an 
overall more severe effect. Furthermore. The epimerization disposition of the molecule also 
seems to be important as epimeric compounds such as EC or EGCG are prone to inhibit growth 
more effectively than their counterparts catechin and GCG.  
No main changes in viability were observed under all conditions, overall catechin compounds 
are non-toxic regardless of their cell inhibition capacity. 
Cell shape is affected differently depending on the structure of the chemical, while Catechin 
and epicatechin are able to cause severe increases in cell diameter, bigger compounds fail to 
do so and only a small increase after three days can be observed. The addition of the galloyl 
group to the compound again causes a very different effect. In this case the epimeric 
disposition of the molecule does not seem to cause a big difference in the change of size as 
GCG, EGCG and ECG all have a very similar trend, at the same time catechin and epicatechin 
 Chapter 4 206 
seem to be doing very similar changes as both treatments with 10 µM cause very similar 
changes in size. 
Catechins affect cell cycle in a different way depending on the presence of the galloyl group, 
Catechin and epigallocatechin mainly cause increases in the G2/M phase after 3 days 
incubation. For compounds with the galloyl group there is a difference between the lowest 
treatment, and the high concentrated treatment. While treatments at 5-10 µM cause an 
increase to G2/M phase very similar to the one observed in catechin and epigallocatechin, 
higher concentrations tend to cause a bigger accumulation in the S phase after three days of 
incubation.  
EGCG is the most studied compound of the catechin family. Research indicates that this 
compound is able to inhibit the cell cycle in the S phase (Shabana et al., 2014; Shen et al., 
2014). The chemical affects the regulation of many different cell cycle proteins up-regulating 
p21, p27 and inhibiting Nf-κB (Shabana et al., 2014; Shen et al., 2014) among many others. It 
is likely that the effect of the chemical is very complex and that although looking into one 
mode of action there might be pleiotropic mechanisms linked to the high bioactive capability 
of the compound (Ye et al., 2017).  
Although most of the research done has been in EGCG as the main compound, an exception 
to this was the study by Huang et al. 2005 that researched the effect of catechin in murine 
microglial cells.  Catechin causes cell cycle arrest in S phase under induced toxic conditions 
when treated with catechin at 500 µM (Q. Huang et al., 2005). This is similar to the effect seen 
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in compounds with galloyl group, it is possible that the effect of catechin at very high 
concentrations could be similar to those of the compounds with galloyl group.  
Comparative studies of the effect of different catechin compounds on the cell cycle were 
consistent in identifying different behaviours depending on the presence of the galloyl group. 
The studies indicate that. While EGCG (500 µM) and ECG (1 mM) cause increases in G1/G0 
with the respective decreases in S and G2/M phases, EC (1 and 2 mM) causes S phase arrest 
(Tan et al., 2000). Although the arrest happens in a different phase of the cell cycle when 
compared to the present study, the indication of a different behaviour linked to the structure 
is reinforcing in our previous observations. 
A further comparative study of compounds with galloyl groups indicated that ECG, 
gallocatechin (GC) and EGCG cause very similar responses in cell cycle arrest. All the chemicals 
inhibit cell growth in a concentration-dependent manner and cause inhibition of Nf-κB and 
also an increase in S phase while decreasing in G1/G0. 
Showed that different chemicals form the catechin family show different effects in human 
pancreatic ductal adenocarcinoma cell lines. All the chemicals inhibit cell growth in a 
concentration-dependent manner (20-80 µM) and also elongated the S phase of the cell cycle 
in detriment of the G1/G0 phase. Furthermore, all the chemicals caused inhibition of Nf-κB. 
Nevertheless, other markers were not even for all the chemical treatments. GC and ECG 
increase p21 and p27 while EGCG increases p21 but decreases p27 (Kürbitz et al., 2011). This 
reinforces the idea that the galloyl group is relevant and causes changes in the way the 
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chemicals act over the cells, but that small changes in the structure of the catechin even with 
the presence of the galloyl group can account for changes at different levels. 
The mechanism by which catechins may be acting on the cell cycle could include their 
inhibitory effect over the topoisomerase enzymes. EGCG the most studied molecule of the 
family was found to inhibit topoisomerase I and II (Bandele 2008) by sequestrating the 
enzyme in a complex that seems to be mediated by hydrogen peroxide (Lopez-Lazaro 2011). 
Topoisomerases are enzymes that cut one or two strands of DNA to unwind it and access it 
for replication and segregation. This inhibition of topoisomerases leads to G2/M and S phases 
arrest (Cliby 2002). This extends to catechins in general with all indicating certain 
topoisomerase inhibition capability depending in their structure with EGCG being the most 
effecting in inhibiting topoisomerases followed by ECG while compounds such as EC show 
very low inhibitory capacity (Suzuki 2001). This could explain the differences between 
catechin and epicatechin when compared with the compounds with a galloyl group. It is 
possible that EC and Catechin act in a completely different way to the other compounds and 
that most likely the differences in cell size, cell growth inhibition or cell cycle arrest between 
them and the catechins with galloyl groups is due to the capacity of the last ones to interact 
with topoisomerases.  
Two main parameters that seem indicative of the activity of the catechins' effect on cells are 
the galloyl group mainly and the epimeric disposition to a lesser degree.  In order to further 
validate if this group of chemicals can be used as chemical tools for biopharmaceutical 
production improvement as additives, catechin, epicatechin, gallocatechin-gallate and 
epigallocatechin were selected for scale-up studies. 
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Overall, all catechins compounds caused a significant decrease of the relative quantity of cells 
in the G1/G0 phase, refuting the initial hypothesis that this chemicals were able to assist in 
increase in the specific IgG production by specific cell cycle arrest described in previous 
literature (Hendrick et al., 1999; Carvalhal, Marcelino and Carrondo, 2003; Bi, Shuttleworth 
and Al-Rubeai, 2004; Dutton, Scharer and Moo-Young, 2006). It is likely that the method of 
action of these chemicals over the CHO cell culture and specific recombinant antibody 
production is different and could be of use as a tool in industry as an alternative method to 
increase the final titre. 
4.3 Conclusions 
During the present investigation, a protocol for fixation and propidium iodide stain of CHO 
cells with only three washes was developed. This protocol was able to reliably treat cells for 
further flow cytometry studies. Moreover, cell cycle flowcytometry data, indicated that 
resveratrol was able to stop the cell cycle in an aphasic way and elongate the stationary stage. 
Furthermore, resveratrol caused cell growth arrest during S phase in the first cell divisions; 
this phenomenon seems to be linked is to resveratrol’s toxic effect on CHO cells, suggesting 
that the toxic effect over dividing cells may be partially linked to an effect on the 
topoisomerases. All the present results provide a better understanding of how this chemical 
interacts with CHO cell cultures and could help to develop strategies for further scale-up and 
recombinant protein optimization experiments. 
The experiments with components from the catechin family, showed that the galloyl group is 
fundamental in determining the effect of the chemical over the CHO cell culture. Catechin 
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compounds with the galloyl group inhibited cell growth more and the cell arrest was more 
prominent in the S phase. The different levels of cell growth arrest caused by the catechin 
compounds seemed to correlate with their capacity to inhibit the topoisomerase activity. 
Based on the current information, catechins are good candidates for further scale-up and 
recombinant protein optimization experiments. 
In the light of the results of these experiments, resveratrol, catechin, epicatechin, 
gallocatechin-gallate and epigallocatechin-gallate will be taken forward for scaling up and 
optimization. 
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5.1 Initial remarks 
Previous results indicated that resveratrol and catechins are able to improve qp while causing 
cytostatic conditions (Chapter 3). Further experimentation revealed that these chemicals stop 
the cell growth by specific cell phase arrest of the G1/G0 in the case of the catechins (Chapter 
4). Resveratrol, on the other hand, had a a more complex effect on cell growth arrest with an 
aphasic cell cycle arrest (Chapter 4).  The increases in qp studied so far did not translate into 
a final increase in titre. In the current chapter we aimed to investigate the effect of 
resveratrol, catechin, epicatechin, gallocatechin-gallate and epigallocatechin-gallate over the 
cell culture in scale-up conditions, with 33 mL cultures under different feeding regimes. 
To optimize the process of chemical addition to the culture and study the effect that this could 
have in the cell population and the protein production, feed batch Erlenmeyer flask cultures 
were run as specified in section 2.1.3.  Cultures were treated at days 0, 3 and 6 with 25 and 
50 µM concentrations of resveratrol, catechin, epicatechin, gallocatechin-gallate and 
epigallocatechin-gallate. Everyday measurements of viability and concentration (section 
2.1.4) and IgG recombinant IgG production (section 2.1.5) were collected for a period of ten 
days. The experiment was run in triplicates and was repeated twice independently. 
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5.2 Results and discussion  
5.2.1 Resveratrol feeding optimization strategy and effect on cell culture 
5.2.1.1 Viable cell curve and growth rate 
The viable cell density curve of the control indicated that the cells were able to grow 
immediately after inoculation. Twenty four hours of incubation resulted in an increase of 
0.34±0.02 106 viable cells/mL which almost doubled the initial seeding concentration of 
0.18±0.00 106 viable cells/mL. The fast adaptation of the cells to the culture is expected as 
the cells are seeded into the same conditions, and the only change is the fresh media. Cells 
under control conditions grew in cell concentration until day seven, reaching a maximum 
concertation of 12.34±0.20 106 viable cells/mL. After this, the number of viable cells 
decreased drastically to 3.52±011 106 viable cells/mL.  
Treatments with 25 µM concentrations caused a reduction of growth at any given time, and 
did not reach the high concentrations seen for the control at day seven. In contrast, the peaks 
were milder and more elongated in time, creating a stationary phase. When adding 
resveratrol at time zero, the viable cell curve was delayed by one day and the stationary phase 
was between days seven and nine, with a maximum viable cell density observed at day eight 
(9.10±0.61 106 viable cells/mL). Addition of 25 µM of resveratrol at day three, caused a very 
similar delay in the cell curve, but less severe, with maximum viable cell concentration at day 
eight (10.13±0.76). Furthermore, a shorter stationary phase was observed (days seven and 
eight). 25µM of resveratrol at day six, caused an immediate arrest of the cell growth and there 
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was a stationary stage for the next 48 hours. The pattern of the cell culture was the same and 
the viable cell density decayed after incubating for eight days (Figure 60A).  
The effects with 50 µM treatments were more dramatic and the different time of addition 
resulted in clearer differences in the viable cell curve. The addition of 50 µM of resveratrol at 
time zero, caused a severe arrest of the cell culture. This resulted in a delay in the maximum 
viable cell density of three days at 7.55±1.08 106 viable cells/mL by day nine. This curve did 
not show signs of decay for the ten days of incubation studied. A few samples were studied 
under these conditions at days eleven and twelve, and the viable cell density was heavily 
compromised. The 50 µM treatment at day three caused an immediate stop of the viable cell 
growth for 24 hours at 1.65±0.06 106 viable cells/mL. Although cell growth was restored, the 
culture grew slower for the rest of the incubation time, with a delay in respect to the control. 
This treatment resulted in a stationary phase of the viable cell curve during days seven and 
nine (6.86±0.57 106 viable cells/mL). The addition of resveratrol at 50 µM on the sixth day, 
caused cell growth arrest, with a 48 hours stationary phase at 8.95±0.16 106 viable cells/mL. 
Nevertheless, the behaviour of the cell curve was preserved and after day eight, there was a 
decay in viable concentration (Figure 60B).  
The culture under control conditions seemed to grow during the first seven days of the culture 
at an average rate of 0.87±0.09 days-1. The addition of 25 µM of resveratrol did not seem to 
cause a delay in the growth phase nor a change in length maintaining the seven-day period.  
The average of the growth during this period was not significantly compromised, but there 
was a tendency to lose overall growth rate the sooner the chemical was added. The treatment 
with the most inhibitory effect was the one where the chemical was added at time zero 
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(0.75±0.06 days-1). Treatment at day six was the less repressive (0.81±0.17). On the other 
hand, the addition of 50 µM to the media had a very significant effect on the growth phase 
length. The addition of the chemical at day six immediately inhibited the growth, but there 
was no significant difference in the growth rate (0.91±0.19 days-1). Addition on day three had 
a similar effect, with the treatment truncating the growth of the culture for the rest of the 
incubation time. This caused a significant increase in the average growth rate (1.09±0.10 days-
1) as the decay phase was avoided. If 50 µM of resveratrol were added at the initial time of 
the cell culture, the growth phase was longer elongated, up to the ninth day. This is probably 
because the growth rate of the culture significantly decreased with an average of 0.54±0.11 
days-1. Under these conditions cells divided at a slower rate and this extended the growing 
phase mainly because the rate of media consumption was lower (Table 8). 
Table 8 Growth rate of feed-batch cultures treated with resveratrol 
 
5.2.1.2 Viability 
Control samples kept very high levels of viability (above 94%) until day seven.  Viability was 
highly compromised as the cell culture reached the death phase and then dropped to 
 µ  (days⁻¹)  
 Growth phase 
(days) 
Treatment Mean     SD   Start Finish 
Control 0.87 ± 0.09  1 7 
Resv Day0 25 µM 0.75 ± 0.06  1 7 
Resv Day3 25 µM 0.78 ± 0.05  1 7 
Resv Day6 25 µM 0.81 ± 0.17  1 7 
Resv Day0 50 µM 0.54 ± 0.11  1 9 
Resv Day3 50 µM 1.09 ± 0.10  1 3 
Resv Day6 50 µM 0.91 ± 0.19   1 6 
(Resv) resveratrol, (SD) standard deviation 
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78.06±0.78%. After 48 hours, most of the cells in the culture were dead, with a viability of 
33.90±0.75% by day nine. Treatment with 25 µM of resveratrol at time zero resulted in a delay 
of the decay by day one. Viability was preserved at day eight (90.08±0.57%) and day nine, 
having more cells alive than dead (72.78±1.87%). The cell culture was mostly dead again by 
day ten, with a viability of 41.97±2.78%.  The viability behaviour of the cell culture did not 
change under these conditions and was mainly delayed. This aligns with the viable cell density 
curve results. Treatment with 25 µM of resveratrol at day three, caused a less sudden drop 
of viability after day seven, reaching 30.08±0.58 % by day ten. There were no meaningful 
differences between adding 25 µM of the chemical at day three or six (Figure 60C). 
50 µM concentration treatments caused more distinguishable effects on the viability of the 
culture, in a time-dependent manner. Adding the chemical at time zero resulted in an initial, 
steady drop in viability until day four (86.71±1.54%). After that, viability recovered until day 
eight (95.06±0.52%). Finally, viability dropped at the end of the culture (88.05±1.95%), 
although it did not drop as drastically as the control; measurements two days beyond the ten 
days of incubation showed fast drop and viability values below 50%. Addition of 50 µM of 
resveratrol at day three, caused a less severe effect on viability over time; It originated an 
immediate drop in viability at 24 hours (from 97.39±0.30% to 92.44±0.67%) and this level was 
maintained until the decay phase at day eight, which was not delayed. The drop in viability at 
the end of the culture was less severe. Adding resveratrol at the highest concentration (50 
µM) at day six, did not cause any main changes in the behaviour of the culture viability and 
only made the decay curve milder (Figure 60D).  
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Figure 60 Effect of resveratrol over growth and IgG production in flask cultures 
Effect of resveratrol (Resv) treatments in viable cell density (A,B), viability (C,D) and IgG concentration 
(E,F) when added at days 0 (squares), 3 (diamonds) and 6 (circles) for 25 µM (green) and 50 µM (blue) 
concentrations. Cells were incubated in 125mL Erlenmeyer flasks with an initial 33 mL volume for 10 
days under shaking conditions (section 2.1.3). The error bars represent the standard deviation of 
triplicates and the experiment was carried twice independently.  
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5.2.1.3 IgG final titre and specific productivity 
The cell line under control conditions was able to produce at a constant rate that reached a 
final titre of 158.6±11.2 µg/mL. The addition of 25 µM of resveratrol at time zero, did not 
cause any main changes in the production profile of the cell culture over the ten days of 
incubation. The IgG produced reached a non-significant increase in the average final titre 
(186.8±17.5 µg/mL). The addition of 25 µM at day three showed the same response, with a 
non-significant increase (187.4±16.7 µg/mL). Finally, the addition of 25 µM of resveratrol at 
day six, resulted in a significant, 1.28-fold increase of the final titre (203.1±12.0 µg/mL). 
Overall, the chemical seemed to be increasing IgG production in a steady manner (Figure 60E).  
The addition of a 50 µM concentration to the culture at different time points, caused 
important changes to the production process in the cell culture.  Resveratrol in this 
concentration at time zero, caused a delay in the production during the first six days. After 
that, the prolonged static period production of the recombinant protein accelerated, until it 
reached a final titre close to that of the control, but significantly lower (131.9±6.7 µg/mL). 
The addition of 50 µM of resveratrol at day three, did not cause any changes in the pattern 
of the production and slightly increased the productivity over the last two days, reaching 
187.5±6.1 µg/mL (1.18-fold increase). Addition at day six, caused the cell culture to increase 
its productivity with a fast increase observed during the last four days (final titre 216.8±6.29 
µg/mL, equivalent to 1.37-fold increase) (Figure 60F). 
Cell specific productivity was increased for all the treatments of resveratrol compared to 
control (2.21±0.17 pg/cell·day). The addition of 25 µM of resveratrol at different time points 
did not cause any significant changes in the increase of qp, with averages between 3-3.5 
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pg/cell·day. All treatments with 25 µM caused lower qp increases when compared to those 
using 50 µM. This is due to the concentration-dependent effect of cell growth inhibition of 
the chemical. This condition was not paired with a reduction in the productivity of the cells. 
On the contrary, the opposite was often observed. The time of addition of higher treatment 
concentrations of resveratrol, was associated with the increase in qp. Late addition on day six, 
showed the lowest increase (3.88±0.21 pg/cell·day). Addition at time zero (50 µM) caused the 
highest increase in specific productivity (4.74±0.59 pg/cell·day), doubling the effect seen by 
the control. This 2-fold increase, was possibly related to the fast recovery of IgG production 
during the last section of the culture, while cell concentrations never peaked under this 
treatment (Figure 61). 
 
Figure 61 Effect of Resv on relative protein production in flask cultures 
Relative protein production (qp) of 33 ml batch recombinant CHO cell cultures in 125 ml Erlenmeyer 
flasks after a period of 10 days (section 2.1.3) and treated with resveratrol (Resv) at 25 and 50 µM on 
days 0, 3 or 6. qp was calculated by dividing final protein production by the integral of the VCD curve. 
Each data point represents the average from a triplicate, and the error bars correspond to ±SD. These 
experiments were repeated independently. One way ANOVA statistical test was perform for the 
treatment compared to the control for p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
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5.2.1.4 Discussion 
Resveratrol added at time zero, was associated with non-desirable traits of the chemical, 
under the conditions studied. As a result, the cell culture lost its viability and cell growth was 
inhibited considerably. All this elongated the adaption phase of the feed-batch culture. This 
was associated with low specific cell productivity. Moreover, it resulted in levels of final IgG 
concentration equal to control in the best-case scenario. A reasonable hypothesis is that by 
elongating the culture for more days, the stationary phase would extend beyond day ten and 
productivity would increase. Samples analyzed at days eleven and twelve showed a fast decay 
of viability under 50% and indicated that the culture cannot be extended in time. Extension 
of the culture is not a desired feature, because it does not elongate the production phase of 
the culture, which is often found in the deceleration and stationary phase. The extension of 
the culture also requires more time and energy. Finally, the drop in viability of the culture 
could jeopardize the quality of the product, as dead cells lose the integrity of their cell 
membrane; the longer they are in the media, the more likely this is to happen.   
When adding resveratrol at day six, the properties of the chemical were more desirable. 
Under these conditions, cell culture growth was maximized in time, and cells were healthy 
with high viability. Furthermore, at the end of the growth phase, the addition of the chemical, 
stopped uncontrolled cell growth and enhanced the specific protein production. This resulted 
in a considerable increase of the final titre. The chemical is a potent agent for the 
development of biphasic feed-batch strategies in recombinant CHO cell lines. It possesses 
many traits that are associated with successful process engineering strategies (Du et al., 
2015).  
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Intermediate addition of the chemical at day three, caused an intermediate effect compared 
to the ones observed at days zero and six. Furthermore, the higher concertation of the 
chemical caused a more pronounced effect. 
Parallel studies done with resveratrol in recombinant CHO cells, indicated that treatment with  
10 µM had no significant effects (Baek et al., 2016). The screening process of the current 
project identified the same phenomenon and this concentration was discarded. Some feeding 
strategies described in this protocol, using the 25 µM concentration, did not results in any 
main changes in the cell culture or protein production, thus supporting the findings by Baek 
and colleagues. 
Other data available, show how resveratrol can be used as an initial media additive at a very 
high concentration (1 mM), with no negative effects (Tian 2016). Our study showed that 
resveratrol, in concentrations as low as 50 µM, causes a considerable delay on the cell curve 
when added at the beginning of the culture. This is accompanied with a significant, but not 
drastic drop in viability and a decay in the final titre. These differences in the effects of 
resveratrol are difficult to reconcile. Other studies performed with CHO cells (Basso et al., 
2013; Mallebrera et al., 2015) and different mammalian host systems (Lu, Ou and Lu, 2013; 
Quoc Trung et al., 2013) identified a much lower tolerance of the compounds than what 
claimed by Tian and colleagues. This indicates that it is likely that the results from this study 
are an exception, and that most likely, the range of sensitivity of most mammalian cells and 
more specifically CHO cells, is lower than claimed.    
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Resveratrol caused drops in viability when added at time zero; addition at the end of the 
growth phase did not result in any toxic effect. This indicates, as stated in the previous chapter 
on the cell cycle, that the toxic effect of the chemical and the drop in viability, is strongly 
related to the division of cells. 
These results also highlight the capacity to extrapolate general mechanisms of action of 
resveratrol, from the initial screening set-up to the flask scale-up conditions. The same effects 
described in previous chapters were also found in this chapter; these are the inhibition of the 
cell culture combined with the improvement of the IgG specific productivity. Changing from 
a static 3-day incubation system of 1 mL volume, to a shaking ten-day incubation system of 
33 mL was a success. There is still a long way to go to reach a full scale-up 2000L reactor used 
in industry. However, the conditions are closer to the final intended conditions and there are 
many parameters that are relevant when scaling up further. Shear stress, pH and dissociation 
of relevant gases such as CO2 or O2, are some of the principal variables that could affect the 
cell population and the quality of the product when changing the cell culture conditions 
(Brunner et al., 2017). Therefore, these experimentations should be taken as promising 
indicators. Further scaling up should be done to ratify that the compound is adaptable for 
production scale-up processes.  
The effect of the addition of resveratrol at the end of the exponential phase proves that this 
chemical is best used as a late growth phase inhibitor, in order to modulate growth and 
improve final titre during the stationary phase. This ratifies the initial hypothesis that the 
optimal use of the chemical is when cell growth has already been completed.   
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Nevertheless, in order to further consider resveratrol as a possible tool for the production of 
recombinant protein in CHO cells, the quality of the product needs to be assessed, in order to 
ensure that it is not compromised. 
Resveratrol was selected for further studies regarding the quality of the product. This was 
due to the fact that it resulted in the fewest adverse events amongst all the studied chemicals 
and yielded in a considerable increase in the final IgG production.  
5.2.2  Catechins feeding optimization strategy and effect in cell culture 
The effects of the addition of catechins at different time points, in cultures incubated for ten 
days under shaking conditions, were studied to identify proper feeding regimens of the 
compounds and to identify any differences amongst these compounds. 
5.2.2.1 Catechin 
5.2.2.1.1 Viable cell curve and growth rate 
The viable cell curve did not show any major changes compared to the control when adding 
catechin at 25 µM. The cell curve was preserved during the exponential phase for all adding 
treatments until day six. The main change in behaviour appeared after the sixth day. In more 
detail, the maximum viable cell density was observed at day seven under control conditions 
(12.34±0.20 106 viable cells/mL). On the other hand, this was shifted to day eight when adding 
the compound on the third day (11.08±1.66 106 viable cells/mL) or on the sixth day 
(11.45±0.68 106 viable cells/mL). There were no significant differences in the maximum 
density reached. Addition of 25 µM of catechin at time zero, did not cause a delay in time for 
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the maximum viable density, but significantly lowered it to 80% (9.80±0.91 106 viable 
cells/mL) (Figure 62A). 
On the other hand, the addition of catechin at a 50 µM concentration, caused significant 
changes in the overall behaviour of the viable cell density curve. Addition at the late stage of 
the growth phase (day six), caused minimal changes. The changes observed were a flattening 
of the growth that took place until day seven, and a reduction in the maximum viable cell 
density to 10.61±0.40 106 viable cells/mL. This treatment timing did not cause any further 
changes and the decay phase happened in identical terms to that of the control. When the 
chemical was added at day three, more severe growth repression was observed, similar to 
the one observed before; the sooner the inhibition of cell growth was induced, the lower the 
maximal viable cell density was (the lowest being 9.28±0.41 106 viable cells/mL). Regardless 
of the change in the exponential phase, the decay of the cell culture was maintained identical 
to that of the control from day eight onwards. Finally, the early addition of the chemical at 
time zero, caused the culture to grow slowly, reaching a prolonged stationary phase at day 
six. This was maintained until day nine at a very low viable cell density (5.55±0.57 106 viable 
cells/mL) (Figure 62B). 
The growth rate and period of growth under the presence of catechin did not change 
significantly from the control (0.87±0.09 day-1). This was observed in all treatments studied 
(Table 9). 
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Table 9 Growth rate of feed-batch cultures treated with catechin 
 
5.2.2.1.2 Viability 
Viability at 25 µM treatments was maintained at the control level and there were no 
significant differences depending on the addition time. The cell culture preserved its initial 
viability, with values close to 95% and above.  The decay phase of the cell culture and the 
drop in viability was evident between day seven and eight, as the values dropped to 
78.06±0.78% after 24 hours. By day ten values were as low as 26.66±0.78% (Figure 62C). 
On the other hand, treatments with 50 µM of catechin, showed differences in their effect in 
relation to the supplementation time. Treatments at days three and six did not cause any 
significant changes in behaviour. When catechin was added to the media at time zero, this 
resulted in high values similar to the ones observed with the control culture for the first 6 
days. After day six, viability started to drop sooner, but at a lower rate. Finally, by day ten, the 
viability of the culture was significantly higher (52.6±16.0%) (Figure 62D). 
 µ  (days⁻¹)  
 Growth phase 
(days) 
Treatment Mean     SD   Start Finish 
Control 0.87 ± 0.09  1 7 
Cat Day0 25 µM 0.81 ± 0.11  1 7 
Cat Day3 25 µM 0.81 ± 0.07  1 7 
Cat Day6 25 µM 0.82 ± 0.09  1 7 
Cat Day0 50 µM 0.78 ± 0.16  1 6 
Cat Day3 50 µM 0.79 ± 0.08  1 7 
Cat Day6 50 µM 0.82 ± 0.17   1 7 
(Cat) catechin, (SD) standard deviation 
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Figure 62 Effect of catechin over growth and IgG production in flask cultures 
Effect of catechin (Cat) treatments in viable cell density (A,B), viability (C,D) and IgG concentration (E,F) 
when added at days 0 (squares), 3 (diamonds) and 6 (circles) for 25 µM (green) and 50 µM (blue) 
concentrations. Cells were incubated in 125mL Erlenmeyer flasks with an initial 33 mL volume for 10 
days under shaking conditions  (section 2.1.3). The error bars represent the standard deviation of 
triplicates and the experiment was carried twice independently. 
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5.2.2.1.3 IgG final titre and specific productivity 
Control conditions indicated that the cell was able to produce recombinant IgG at a constant 
rate, reaching final titres of 158.6±11.2 µg/mL. The addition of catechin at 25 µM at time zero, 
did not cause any changes in the profile of the production curve and productivity reached 
values up to 179.2±20.7 µg/mL. Addition on day three had the same effect as the previously 
described treatment, with a final titre of 161.8±0.9 µg/mL. The addition of the chemical on 
day six, on the other hand, had a massive effect on IgG production. Cells under these 
conditions were able to maintain productivity at a higher rate during the last five days of the 
culture. This resulted in a final titre of 226.3±7.1 µg/mL (1.43-fold increase) by the end of the 
culture (Figure 62E).  
The addition of catechin at 50 µM, was more successful at improving titres under different 
feeding time regimes. Treatment at day zero had a very similar IgG production profile 
compared to control, but caused a significantly lower final IgG concentration, with a final titre 
of 138.4±8.3 µg/mL (0.87-fold change). On the other hand, treatments at day three and six 
behaved very similarly to the 25 µM treatments, having positive effects. Cells were able to 
maintain high levels of production beyond day six (unlike the control) and caused 
considerable increments in the final titre. Addition of the chemical after three days of 
incubation, resulted in a final titre of 243.6±12.3 µg/mL, while the respective value with 
supplementation at day six was 224.2±9.6 µg/mL (1.54 and 1.42-fold increase respectively) 
(Figure 62F).  
The specific protein production of the cells under control conditions was 2.21±0.17 
pg/cell·day. All treatments with catechin showed an improvement over the control value. 
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There was a mild increase at the specific productivity of the cells treated with 25 µM of 
catechin at day three, (2.53±0.12 pg/cell·day). This was the result of a small change in the 
viable cell curve towards a lower area, and no changes in the production of the recombinant 
protein. On the other hand, treatment with 50 µM at the same incubation time, resulted in a 
completely opposite effect, resulting in the most efficient production (4.21±0.25 pg/cell·day), 
almost doubling the level of the control. Treatments at days zero and six were not significantly 
different amongst each other. This indicates that cells were equally productive over the ten-
day culture for both situations, but the suppression of the cell growth when adding the 
chemical at time zero limited the final titre (Figure 63). 
 
Figure 63 Effect of Cat on relative protein production in flask cultures 
Relative protein production (qp) of 33 ml batch recombinant CHO cell cultures in 125 ml Erlenmeyer 
flasks after a period of 10 days (section 2.1.3) and treated with catechin (Cat) at 25 and 50 µM on days 
0, 3 or 6. qp was calculated by dividing final protein production by the integral of the VCD curve. Each 
data point represents the average from a triplicate, and the error bars correspond to ±SD. These 
experiments were repeated independently. One way ANOVA statistical test was perform for the 
treatment compared to the control for p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
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5.2.2.2 Epicatechin 
5.2.2.2.1 Viable cell curve and growth rate 
There was a steady increase in viable cell density during the first eight days under control 
conditions, reaching a maximum viable cell density of 10.87±0.14 106 viable cells/mL. After 
that, the viability decreased abruptly for the next 48 hours, finishing at 3.74±0.07 106 viable 
cells/mL by day ten. 
The addition of 25µM of epicatechin at time zero caused considerable changes in the viable 
cell density curve; cell growth was repressed and the maximum value observed was 7.63±0.99 
106 viable cells/mL. This only occurred after day four, indicating that the effect is linked to the 
deceleration section of the growth phase. This is similar to the behaviour observed in catechin 
treatments (Figure 64A). 
The addition of 25 µM of epicatechin at day six did not cause any main changes in the curve 
at any point in the culture. The maximum viable cell density remained very close to the one 
under control conditions (10.65±0.36 106 viable cells/mL). When epicatechin was added to 
the cultures at day three, the viable cell density did not change; it had an increase until day 
eight and then decreased over the last two days with very similar slopes to control. The 
maximum viable cell density was 9.43±0.17 106 viable cells/mL. 
The addition of epicatechin at a higher concentration (50 µM), caused a more severe 
difference, depending on the supplementation time. When epicatechin was added at time 
zero, the inhibition of the cell growth was persistent during the ten days of incubation; cells 
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were not able to divide under these conditions and the maximum viable cell density was 
1.32±0.38 106 viable cells/mL at day five. On the other hand, the addition of the chemical on 
day six, caused no main changes to the viable cell curve. The addition of the chemical at day 
three, caused an intermediate effect. The cells grew close to the control until day seven, but 
then the cell culture remained static until day eight and decayed similarly to the control 
afterward (Figure 64B).  
The growth phase of the culture lasted for the first eight days of incubation under control 
conditions, with an average growth rate of 0.74±0.14 days⁻¹. The addition of 25 µM of 
epicatechin at different time points did not cause any changes in the period of growth nor in 
the average growth rate. 50 µM treatments did not have any significant effects on the average 
growth rate either, regardless of the time of addition. Supplementation at days zero, three 
and six resulted in growth rates of 0.68±0.11, 0.79±0.10 and 0.72±0.14 days⁻¹ respectively. 
The addition of 50 µM at early stages, caused the growth phase to stop sooner. The addition 
of this concentration at time zero made the growth phase stop after the fourth day, while 
addition at day six caused it to stop on the sixth day (Table 10). 
Table 10 Growth rate of feed-batch cultures treated with epicatechin 
 
 µ  (days⁻¹)  
 Growth phase 
(days) 
Treatment Mean     SD   Start Finish 
Control 0.74 ± 0.14  1 8 
EC Day0 25 µM 0.81 ± 0.43  1 7 
EC Day3 25 µM 0.71 ± 0.14  1 8 
EC Day6 25 µM 0.72 ± 0.18  1 8 
EC Day0 50 µM 0.68 ± 0.11  1 4 
EC Day3 50 µM 0.79 ± 0.10  1 7 
EC Day6 50 µM 0.72 ± 0.14   1 8 
(EC) epicatechin, (SD) standard deviation 
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5.2.2.2.2 Viability 
Viability for the control was preserved until day eight; at that point the cell culture had an 
initial 8% drop in viability, to subsequently drop further at a rapid rate. At the end of the 
incubation period, viability reached values as low as 29.6±1.5%. Almost none of the conditions 
caused changes in the viability of the culture across time. The only treatment that caused 
viability changes was epicatechin at a 50 µM concentration when added at time zero. Under 
these conditions, viability started to drop slowly during the last six days of the culture, to 
reach values close to the control by the end of the ten-day incubation period (44.4±3.5%) 
(Figure 64C&D).   
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Figure 64 Effect of EC over growth and IgG production in flask cultures 
Effect of epicatechin (EC) treatments in viable cell density (A,B), viability (C,D) and IgG concentration 
(E,F) when added at days 0 (squares), 3 (diamonds) and 6 (circles) for 25 µM (green) and 50 µM (blue) 
concentrations. Cells were incubated in 125mL Erlenmeyer flasks with an initial 33 mL volume for 10 
days under shaking conditions (section 2.1.3). The error bars represent the standard deviation of 
triplicates and the experiment was carried twice independently. 
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5.2.2.2.3 IgG final titre and specific productivity 
IgG production in feed-batch cultures under control conditions delivered a constant increase 
in the monoclonal antibody production for the first eight incubation days. During the last two 
days, the production slowed down, yielding a final titre of 167.7±10.8 µg/ mL.  
Treatment with 25 µM of epicatechin at any given time point caused considerable increases 
in production compared to control. This was mainly seen after day eight. The highest yield 
was acquired when the treatment was administrated on day three. This resulted in 
226.0±13.7 µg/mL final product (1.35-fold increase) (Figure 64E). 
Treatments with 50 µM caused similar results. The addition of the chemical at either day three 
or six caused an improvement in the recombinant antibody final titre, up to 218.8±9.9 µg/mL 
(1.30-fold increase). On the other hand, addition at time zero caused consistent IgG 
production arrest, reducing the productivity of the culture to 32% of the control (53.9±2.2 
µg/mL) (Figure 64F). 
The specific productivity observed under these conditions, indicated that each cell was able 
to produce more protein under treatment conditions when compared to the control 
(2.65±0.22 pg/cell·day). In general, there seemed to be a trend in treatments; the earlier the 
chemical was added, the greater the increase in the specific productivity observed. The 
highest value was seen with the 25 µM concentration added at time zero (4.62±0.48 
pg/cell·day), almost doubling the one of the control (1.74-fold increase). On the other hand, 
adding 50 µM at day six caused the smallest improvement in qp (3.51±0.12 pg/cell·day), with 
a 1.32-fold increase. Finally, there were no main differences in qp improvement due to 
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concentration. Samples treated at the same incubation time, caused the same level of 
improvement in qp, regardless of the treatment concentration (Figure 65).  
 
Figure 65 Effect of EC on relative protein production in flask cultures 
Relative protein production (qp) of 33 ml batch recombinant CHO cell cultures in 125 ml Erlenmeyer 
flasks after a period of 10 days (section 2.1.3) and treated with epicatechin (EC) at 25 and 50 µM on 
days 0, 3 or 6. qp was calculated by dividing final protein production by the integral of the VCD curve. 
Each data point represents the average from a triplicate, and the error bars correspond to ±SD. These 
experiments were repeated independently. One way ANOVA statistical test was perform for the 
treatment compared to the control for p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
 
5.2.2.3 Gallocatechin-gallate 
5.2.2.3.1 Viable cell curve and growth rate 
There was a steady increase in viable cell density during the first eight days of the culture 
under control conditions, reaching a maximum viable cell density of 10.87±0.14 106 viable 
cells/mL. After that,  the viability decreased abruptly for the next 48 hours, finishing at 
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3.74±0.07 106 viable cells/mL by day ten. All the treatments caused changes in the growth, 
profile and behaviour of the viable cell curve. 
Treatment with the 25 µM concentration at day zero, caused complete repression of the cell 
growth for the first three days; the maximum concentration was 0.59±0.05 106 viable 
cells/mL. After that and for the rest of the incubation time, there was a slow decay. The same 
was observed when adding 50 µM at time zero, only that the peak of the viable cell density 
was at day two and at a lower concentration (0.41±0.04 106 viable cells/mL) (Figure 66A&B). 
The addition of 25 µM on day three caused the viable cell growth to decrease considerably 
after day four with respect to control. The growth was constant and slow, and there was no 
decay of the culture until day ten. The maximum viable cell density was 5.50±0.40 106 viable 
cells/mL; this was reached by the ninth day. The addition of 50 µM at day three, caused the 
cell culture to grow for the next 24 hours, close to the control rate. From day four onwards, 
the cell culture reached a stationary phase and the viable density stop increasing, remaining 
constant for the remaining of the culture at 2.57±0.15 106 viable cells/mL (Figure 66A&B). 
When cell cultures were treated with gallocatechin-gallate at the late stage of the growth 
phase (day six), the decay phase was not omitted as seen previously. Treatment with 25 µM 
caused the growth to slow down considerably, reaching a stationary phase that lasted until 
day nine with a concentration peak of 8.41±0.67 106 viable cells/mL.  When adding 50 µM, 
cell growth was maintained for 24 hours. At day seven, the cell population started to decay. 
As the culture did not grow between days seven and eight, the maximum viable cell density 
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was lower and equal to that of the control at day seven (8.84±0.19 106 viable cells/mL) (Figure 
66A&B). 
The average rate of growth of the different samples did not show significant differences when 
compared to control (0.74±0.14 days⁻¹). Nevertheless, the addition of the chemical had an 
effect on the length of the growth phase. Early additions of gallocatechin-gallate at 25 µM 
and 50 µM concentrations at day zero, caused an arrest of the growing phase at day three 
and day two respectively. Later addition of the chemical, at days three and six, caused a stop 
of the cell growth at approximately day six (Table 11). This probably indicates, that the 
chemical is more efficient in stopping cell growth before the growth phase starts (time zero) 
or when it is about to end (day six). On the other hand, if the cell culture is dividing rapidly, 
then the chemical needs more time to stop the growing population.  
   
Table 11 Growth rate of feed-batch cultures treated with gallocatechin-gallate 
 
 µ  (days⁻¹)  
 Growth phase 
(days) 
Treatment Mean     SD   Start Finish 
Control 0.74 ± 0.14  1 8 
GCG Day0 25 µM 0.54 ± 0.17  1 3 
GCG Day3 25 µM 0.75 ± 0.11  1 6 
GCG Day6 25 µM 1.07 ± 0.38  1 6 
GCG Day0 50 µM 0.57 ± 0.12  1 2 
GCG Day3 50 µM 0.72 ± 0.20  1 6 
GCG Day6 50 µM 0.92 ± 0.19   1 7 
(GCG) gallocatechin gallate, (SD) standard deviation 
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5.2.2.3.2 Viability 
The viability under control conditions was maintained at high levels for the first seven days of 
incubation with values above 90%. After that, it suddenly dropped to 29.6±1.5%. This aligned 
with the decay phase observed in the viable cell curve data, indicating that after day eight 
cells find inhospitable conditions in the culture and are not able to proliferate or maintain 
their population.  
Gallocatechin-gallate added at the beginning of the culture caused the most severe impact 
on the viability profile. Cultures treated with 25 µM, start to present a drop in viability after 
day three and this trend continued until the loss of viability remained stationary at 43.2±0.6% 
by day nine. Adding the 50 µM concentration, caused the same behaviour as explained 
previously, with a decrease of viability right after day three. In this case, the decay stabilized 
sooner, approximately at day six, at a higher viability level (67.0±1.5%) (Figure 66C&D). This 
probably indicates that there are fewer severe events at a higher concentration in the long 
run. The reasons for this phenomenon however are unclear; this could be a result of less 
media consumed or the chemical dropping out of solution when at high concentrations. A 
similar phenomenon was seen in the screening process, at which the lowest concentration 
treatment would often yield more viable cell growth arrest than the ones of 25 µM or 50 µM. 
It is possible that under these conditions something similar could have occurred. 
The viability of the cell culture was initially compromised under both time-zero treatments, 
but the viability values at day ten were never as low as the control (two to three folds higher). 
This may be a result of an incomplete consumption of the media and a lower concentration 
of toxic metabolites such as lactic acid.   
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The addition of 25 µM of gallocatechin-gallate at day three, did not inherently change the 
viability with respect to the control until day eight. After that, instead of a rapid decay in 
viability in the last 48 hours, there was a constant decay until 75.5±6.4% at day ten. The 
addition of 50 µM, also resulted in a constant slow decay of viability. The only difference, was 
that the drop started to occur at day five, reaching lower final viability (65.7±3.6%) than the 
one observed at 25 µM (Figure 66C&D). Nevertheless, the viability was always higher than 
the control, with an almost threefold increase. Again, the lack of a sudden drop in viability, 
could be a result of the slower consumption of the media and the accumulation of undesirable 
metabolites.  
Treatments on day six cause the less dramatic changes in viability. Addition of 25 µM caused 
a delay in the viability drop after day seven and mildly slowed the drop. On the other hand, 
treatment at 50 µM did not cause any significant changes (Figure 66C&D). Overall, the 
behaviour of viability in the culture did not change under these conditions, and the abrupt 
decay of the culture during the last 40 hours was preserved.  
The addition of gallocatechin-gallate, heavily affected the viability profile of the culture over 
the ten days of incubation. The time of addition of the chemical was the most important 
parameter; the earlier the supplementation, the more predominant the effect on viability. 
This is expected as gallocatechin-gallate is a cell growth inhibitor and its effect should be more 
predominant the sooner it is implemented in the growing phase. 
 Chapter 5 242 
 
Figure 66 Effect of GCG over growth and IgG production in flask cultures 
Effect of gallocatechin-gallate (GCG) treatments in viable cell density (A,B), viability (C,D) and IgG 
concentration (E,F) when added at days 0 (squares), 3 (diamonds) and 6 (circles) for 25 µM (green) and 
50 µM (blue) concentrations. Cells were incubated in 125mL Erlenmeyer flasks with an initial 33 mL 
volume for 10 days under shaking conditions (section 2.1.3). The error bars represent the standard 
deviation of triplicates and the experiment was carried twice independently. 
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5.2.2.3.3 IgG final titre and specific productivity 
Control conditions in feed-batch cultures delivered a constant increase in monoclonal 
antibody production for the first eight incubation days. During the last two days, the 
production slowed down yielding a final titre of 167.7±10.8 µg/ mL.  
Adding gallocatechin-gallate at time zero and three, resulted in complete repression of the 
production of IgG. There is no actual growth with treatments at time zero and a lack of 
production was to be expected. On the other hand, treatment at day three, resulted in some 
cell growth; however, the antibody production was close to zero by the end of the ten days 
of incubation. 
The addition of 25mM at the latest stage of the growth phase (day six) caused a delay in the 
IgG produced, but it did not cause a reduction of the final titre; the values were identical to 
the control. This is thanks to the slowing down of IgG production by the control in the last 48 
hours.  The addition of a higher concentration (50 µM) caused the cells to produce less over 
the next 4 days and a considerable decrease (23.8%) was observed by the end of incubation  
(128.1±11.8 µg/mL) (Figure 66E&F). 
Specific protein production was also heavily influenced. Control had a final qp of 2.68±0.13 
pg/cell·day. Treatment at day three, regardless of the concentration, caused an almost 
complete arrest in specific productivity with values as low as 0.14±0.02 pg/cell·day. This was 
the result of the complete arrest of the antibody production, while retaining a discrete viable 
cell concentration through the incubation time. This indicated that cells under these 
conditions are not able to produce IgG, regardless of successfully surviving to some degree. 
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The addition of 25 µM of gallocatechin-gallate at time zero did not result in any differences 
with respect to control. On the other hand, the 50 µM treatment resulted in a considerable 
1.34 fold increase in qp (3.60±0.015 pg/cell·day). Either way, small changes in the final IgG 
production, could lead to big changes in specific productivity due to its low values. The 
addition of 25 µM at day six, caused a 1.20-fold increase of qp  (3.21±0.09 pg/cell·day). This 
was due to slower growth of the cell culture after day six whilst the final titre being constant. 
The addition of 50 µM, did not cause any main changes in specific productivity, as the viable 
cell concentration and final titre were reduced proportionally (Figure 67).  
 
Figure 67 Effect of GCG on relative protein production in flask cultures 
Relative protein production (qp) of 33 ml batch recombinant CHO cell cultures in 125 ml Erlenmeyer 
flasks after a period of 10 days (section 2.1.3) and treated with gallocatechin gallate (GCG) at 25 and 
50 µM on days 0, 3 or 6. qp was calculated by dividing final protein production by the integral of the 
VCD curve. Each data point represents the average from a triplicate, and the error bars correspond to 
±SD. These experiments were repeated independently. One way ANOVA statistical test was perform 
for the treatment compared to the control for p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
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5.2.2.4 Epigallocatechin-gallate 
5.2.2.4.1 Viable cell curve and growth rate 
There was a steady increase in viable cell density during the first eight days of the culture, 
reaching a maximum of 10.87±0.14 106 viable cells/mL. After that, the viability decreased 
abruptly for the next 48 hours, finishing at 3.74±0.07 106 viable cells/mL by day ten. All the 
treatments caused changes in the growth, profile or behaviour of the viable cell curve. 
The addition of epigallocatechin-gallate at time zero caused complete inhibition of the cell 
growth for the entire period of incubation, regardless of the concentration of the treatment. 
Treatment with 25 µM reached maximum viable cell concentration at day three, with 
0.58±0.07 106 viable cells/mL, to then slowly decay to 0.24±0.02 106 viable cells/mL by day 
ten. Although the behaviour of the culture was the same, higher treatment concentrations 
caused even more severe inhibition. At 50 µM, the peak of viable cell density was reached 
sooner, at day two (0.41±0.02 106 viable cells/mL). Once again, there was a decay until day 
ten (0.10±0.02 106 viable cells/mL) (Figure 68A&B). 
The addition of epigallocatechin-gallate on day three caused partial inhibition of viable cell 
growth. When added at 25 µM, cells were partially inhibited and growth was maintained at a 
lower rate until day nine, with a peak at day eight (7.02±0.57 106 viable cells/mL). After day 
nine, there was a normal decay that correlated with the one observed at control. When 
adding 50 µM, the inhibitory effect on cell growth was more relevant; cells grew at a much 
slower rate from supplementation until day six. After that, the culture reached a stationary 
phase and the viable cell concentration was maintained for the rest of the culture at 
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3.87±0.73 106 viable cells/mL (Figure 68A&B). This means that by the end of incubation the 
viable cell density was close to that of the control. 
Adding 25 µM epigallocatechin-gallate at day six, did not cause any main changes in the viable 
cell concentration curve. There was only some small repression of cell growth, which led to a 
maximum viable cell density of 9.16±0.80 106 viable cells/mL by day eight. Finally, the decay 
phase was identical over the last 24 hours. Higher concentration treatments (50µM), caused 
a more immediate response to the adverse conditions. As a result, after 24 hours from 
supplementation, the culture reached a maximum concentration at day seven (9.36±0.05 106 
viable cells/mL). Immediately after, the viable cell density started to decay and continued to 
do so for the remaining three days (Figure 68A&B).  
The average rate of growth of the different samples did not show significant differences when 
compared to the control (0.74±0.14 days⁻¹). Nevertheless, the chemical addition had an effect 
on the length of the growth phase. Early addition of epigallocatechin-gallate at day zero, 
caused a stop of the growing phase at day two, for both concentration treatments (25 and 50 
µM). Later addition of the chemical at days three and six, caused a stop of the cell growth 
approximately at day six-seven (Table 12). This seems to indicate that the chemical is more 
efficient in stopping cell growth before the growth phase starts (time zero) or when it is about 
to end (day six). On the other hand, if the cell culture is dividing rapidly, the chemical needs 
more time to stop the growing population. This behaviour is identical to the one observed in 
GCG.  
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Table 12 Growth rate of feed-batch cultures treated with epigallocatechin-gallate 
 
5.2.2.4.2 Viability 
Under control conditions, viability was maintained at high levels for the first seven days of 
incubation, with values above 90%. After that, it suddenly dropped to 29.6±1.5%. This aligned 
with the decay phase observed in the viable cell curve data, indicating that after day eight 
cells find inhospitable conditions in the culture and are not able to proliferate or maintain 
their population.  
When epigallocatechin-gallate was added at day zero, the viability profile of the culture over 
the ten days of incubation changed drastically.  The addition of 25 µM caused the cell viability 
to start dropping at a constant rate since day three, to reach the final viability of 37.2±4.2%. 
When adding 50 µM of epigallocatechin-gallate, viability dropped even earlier on day two. 
After that, the viability lost was contained during the last part of incubation reaching an 
evident stationary viability level after day six (62.6±7.2%). Similar to gallocatechin-gallate, this 
seemed to indicate that higher concentrations on the long run had less drastic effects. The 
reasons for this phenomenon however were unclear. This could be a result of less media 
consumed or the chemical dropping out of solution when at high concentration. A similar 
 µ  (days⁻¹)  
 Growth phase 
(days) 
Treatment Mean     SD   Start Finish 
Control 0.74 ± 0.14  1 8 
EGCG Day0 25 µM 0.81 ± 0.11  1 2 
EGCG Day3 25 µM 0.71 ± 0.10  1 7 
EGCG Day6 25 µM 0.80 ± 0.23  1 7 
EGCG Day0 50 µM 0.61 ± 0.08  1 2 
EGCG Day3 50 µM 0.72 ± 0.20  1 6 
EGCG Day6 50 µM 0.83 ± 0.27   1 7 
(EGCG) epigallocatechin gallate, (SD) standard deviation 
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phenomenon was seen in the screening process; the lowest concentration treatment would 
yield a more viable cell growth arrest than 25 µM or 50 µM. It is possible that the culture has 
the same behaviour, regardless of the different conditions in the screening and the flask study 
(Figure 68C&D). 
The addition of EGCG on day three caused a different effect, depending on the concentration. 
Lower concentrations of 25 µM did not cause any changes in viability during the first eight 
days. The decay phase, on the other hand, was slightly delayed. 50 µM of the treatment 
caused more severe effects; viability started to decay after day six, slowly avoiding the abrupt 
decay seen at control and reaching the lowest viability at day ten (69.0±3.9%) (Figure 68C&D). 
Treatments at day six did not cause any main changes in the viability profile at any point 
during the incubation process. This indicates that at this point in the culture, the addition of 
the chemical compound (EGCG) does not have a significant toxic effect. The differences 
observed in the viable cell density curves were therefore a result of cell growth inhibition, 
which makes epigallocatechin-gallate mainly cytostatic under these conditions (Figure 
68C&D).   
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Figure 68 Effect of EGCG over growth and IgG production in flask cultures 
Effect of epigallocatechin-gallate (EGCG) treatments in viable cell density (A,B), viability (C,D) and IgG 
concentration (E,F) when added at days 0 (squares), 3 (diamonds) and 6 (circles) for 25 µM (green) and 
50 µM (blue) concentrations (section 2.1.3). Cells were incubated in 125mL Erlenmeyer flasks with an 
initial 33 mL volume for 10 days under shaking conditions. The error bars represent the standard 
deviation of triplicates and the experiment was carried twice independently. 
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5.2.2.4.3 IgG final titre and specific productivity 
Under control conditions, feed-batch culture delivered a constant increase in monoclonal 
antibody production for the first eight incubation days. During the last two days, the 
production slowed down, yielding a final titre of 167.7±10.8 µg/ mL. Protein titre was 
compromised at some point under all conditions, and most of them caused a decrease in the 
final titre. 
A complete arrest of production regardless of the concentration treatment was observed 
when adding the chemical at time zero. At 25 µM, the antibody concentration increased to 
14.60±0.33 µg/mL and stayed constant. The 50 µM concentration caused even more IgG 
repression, allowing it to increase only up to day five (7.25±0.65 µg/mL) to then remain 
constant. Intermediate supplementation of 25 µM of epigallocatechin-gallate (day three) 
caused a delay in antibody production. Nevertheless, the production continued during the 
ten days of incubation, reaching final IgG concentration equal to control (166.1±10.5 µg/mL). 
When the concentration was increased to 50 µM, the inhibition of IgG production was 
irreversible, and the culture produced at a considerably lower rate during the last five days. 
The final titre was 88.4±7.9 µg/mL, corresponding to a 48% decrease. Once more, when EGCG 
was added on day six, there was a decrease in the final titre observed. The parameter of the 
concentration did not make significant changes in the production profile of the antibody. As 
a result, after supplementation, the production of antibody was heavily reduced, showing a 
slower increase in production with a final titre of 132.7±9.8 µg/mL and 116.6±10.0 for 25 and 
50 µM respectively (Figure 68E&F).   
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The capacity of the cells to produce IgG was affected by the treatment of EGCG. Addition of 
the compound at day six, led to lower average specific productivity for 25 µM (2.42±0.18 
pg/cell·day) and 50 µM (2.27±0.20 pg/cell·day) when compared to the control (2.68±0.13 
pg/cell·day). Treatment with 25 µM at day three, caused a considerable increase in specific 
productivity (3.76±0.26 pg/cell·day). This was a result of the culture’s capacity to maintain 
productivity until the end of the incubation time. Adding 50 µM at time zero also resulted in 
a significant increase in qp (3.22±0.20 pg/cell·day), but in this case the reason for that was the 
lack of cells along the incubation time. The qp for the rest of the treatments remained at levels 
close to control (Figure 69). 
 
Figure 69 Effect of EGCG on relative protein production in flask cultures 
Relative protein production (qp) of 33 ml batch recombinant CHO cell cultures in 125 ml Erlenmeyer 
flasks after a period of 10 days (section 2.1.3) and treated with epigallocatechin gallate (EGCG) at 25 
and 50 µM on days 0, 3 or 6. qp was calculated by dividing final protein production by the integral of 
the VCD curve. Each data point represents the average from a triplicate, and the error bars correspond 
to ±SD. These experiments were repeated independently. One way ANOVA statistical test was perform 
for the treatment compared to the control for p-values: (*)< 0.05, (**) < 0.01 and  (***) < 0.001. 
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5.2.2.5 Discussion 
There were two main reasons for cell death and viability decay under these conditions. The 
first one was the addition of the chemicals; catechin seems to be only a cytostatic compound; 
the others caused severe toxicity depending on the concentration and the time of addition. 
This caused a slow drop in viability along the incubation time. On the other hand, cultures 
that are not heavily inhibited, grow to their maximum potential and deplete the media while 
increasing toxic metabolites (Kumar, Gammell and Clynes, 2007). This situation causes a stipe 
drop in viability during the last two-three days of the culture.  
Toxicity was not immediate and it required at least two days to have an effect on the viability 
of the culture. The more drastic the effect of the treatment over the culture, the sooner the 
viability drop starts to appear. There is no sign of toxicity until day five when adding 
epicatechin at time zero. EGCG at 50 µM, added at time zero, affected viability after two days 
of incubation.  
In general, addition at time zero caused more severe effects; these related to cell inhibition, 
increase in toxicity and in many occasions decrease of the antibody production. The later the 
chemical was added, the less effective it was at lowering the viability of the culture. This is 
because the toxicity effect is a slow process that needs time. If the chemical is added later, 
the cells have less time in contact with it and thus suffer less from its toxic effects. 
Furthermore, the toxicity of these chemicals could be linked to dividing cells and more 
importantly to topoisomerase inhibition, as discussed in Chapter 2. The present results 
indicate that this could be the case, as the cultures treated at the end of the growth phase 
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(day six) did not show any additional loss of viability compared to a normal decay phase. This 
was true for all chemicals at all concentrations. 
The present studies indicate that the effect of the chemicals on the cell culture departs from 
each other in a very similar trend to the results from viable cell cycle. Catechin seems to be 
very different to the rest, followed close by epicatechin which is an intermediate into 
catechins with galloyl group and being GCG and EGCG the closes match.  
Results showed that the effect of epigallocatechin-gallate and gallocatechin-gallate are very 
close to each other with similar viable cell growth inhibition and viability profiles. Interestingly 
enough, independently of this similarity, gallocatechin-gallate was able to arrest specific 
productivity more efficiently than epigallocatechin-gallate. The reason for this difference is 
not clear.  
All the chemicals were used under the same conditions in order to better compare the 
different effects of the molecules. The results indicate that catechins without the galloyl 
group have a positive effect on the optimization of IgG production. The negative effects of 
GCG and EGCG however, do not imply that these chemicals do not have the possibility to be 
used as additives. Lower concentrations of epigallocatechin-gallate or gallocatechin-gallate 
could cause similar results to the ones observed with catechin and epicatechin. The presence 
of the galloyl group seems to increase the toxicity of the chemical and lower concentration 
treatments may palliate the severity of the effect and increase the chance of positive results. 
Parallel studies in recombinant protein production in CHO cells, showed that EGCG can be 
implemented in growth cell media composition from 44 µM to 1.1 mM concentrations. The 
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chemical had the potential to enhance protein production by 20% (Hossler et al., 2015). The 
discrepancy with the current study could be due to a different cell line, recombinant protein 
or culture conditions. The study by Hossler et al. showed that the half-life of EGCG in the 
media was of about six hours (Hossler et al., 2015). This, in relation to the results presented 
here, seems to indicate that the chemical is able to penetrate the cells and accumulate inside. 
The less cell density there is, the more the accumulation of EGCG there would be in each cell 
increasing the toxicity of the chemical the sooner it is added. 
Furthermore, the compounds without the galloyl group were able to increase the IgG 
production when added along the growth phase (day three and six). Adding these chemicals 
at time zero rarely caused any improvement in production.  This validates the hypothesis that 
if chemicals were to be used at a later stage of the culture, it would be more likely that they 
would help the productivity by modulating growth and increasing specific protein production; 
this would lead to a higher antibody titre. Nevertheless, the addition of catechins to the media 
can result in changes in the quality of the recombinant antibody produced. Previous studies 
on the effect of EGCG in recombinant antibody characteristics by media supplementation, 
indicated that there is a reduction of the acidic and basic species of the protein of interest, 
reducing the product’s relative charge heterogeneity consistently across the time of the 
culture (Hossler et al., 2015). 
In order to further consider catechins as possible tools for the production of recombinant 
proteins in CHO cells, the quality of the product needs to be assessed in order to ensure that 
it is not compromised. Catechin was selected to further study the quality of the product as it 
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is the compound that had the fewest adverse effects and resulted in a considerable increase 
in the final IgG production.  
5.3 Conclusions 
The sooner the chemicals were added, the more intense the negative traits observed (lower 
viable cell density, lower viability and lower IgG produced). Resveratrol, catechin and 
epicatechin caused an improvement in the final antibody titre. On the other hand,  GCG and 
EGCG were too toxic under these conditions and they did not cause any improvements in the 
final IgG production. Since catechin and epicatechin are quite similar, catechin and resveratrol 
were selected to be studied further, in order to test their effect on the quality of the 
recombinant antibody. 
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6.1 Initial remarks 
It has already been described in previous chapters, that catechin and resveratrol were able to 
enhance the specific productivity of the recombinant IgG product in a CHO cell line (Chapter 
3). When scaled up and optimized feeding, these chemicals also succeeded in increasing the 
final titre (Chapter 5) through the use of biphasic strategies. However, in order for these 
chemicals to be considered as appropriate additives, their effect on the quantity should not 
affect negatively the quality. The aim of this chapter was to study whether the addition of 
these chemicals to the media would change the characteristics of the product. The structural 
integrity of the heterologous protein was assessed by size exclusion chromatography, while 
charge heterogeneity was assessed by cation exchange chromatography (CEX). Mass 
spectrometry was used to study the specific modifications.   
Flask cultures were performed under similar conditions specified in chapter 5 following 
section 2.1.3 of the matherials and methods, with the exception of being treated at day 3 with 
catechin at 10, 25 and 50 µM concentrations and resveratrol at 10, 25, 50, 100, 250 µM and 
500 µM concentrations (Appendix 2). Final IgG production was assessed on day ten (section 
2.1.5). Cultures were purified (section 2.3.1) and purity was assessed by SDS-PAGE (section 
2.3.2) (Appendix 3). The purified IgG was studied by size exclusion chromatography (section 
2.4.1) and cation exchange chromatography (section 2.4.2). The IgG was digested (section 
2.5.1), the fragments were run through LC-MS/MS (section 2.5.2) and later analyzed (section 
2.5.3). The experiment was run in four independent replicates. 
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6.2 Results 
6.2.1 Size exclusion chromatography 
6.2.1.1 Peak identification 
The samples were run in a high-performance liquid chromatography (HPLC) system, using the 
size exclusion chromatography technique, in order to quantify the relative abundance of the 
different components of the IgG in the purified product.  
Firstly, the peaks for the different possible fragments of the recombinant product were 
identified. Spectra from bovine serum albumin (BSA) were used to correlate the time of 
retention with the molecular weight. The spectra were characterized by four main peaks 
evenly separated, ranging from lower to maximum levels of absorbance (Figure 70A). This 
spectrum indicated that the sample was composed of a single protein that interacts with 
itself. This resulted in the monomer peak which was the highest and latest, but it also resulted 
in peaks corresponding to the dimer, trimer and tetramer. This theory explains the consistent 
increase of the peaks observed with increased elution time. The monomer was the most 
relevant form of the protein in the solution, followed by the dimer and so on. This has been 
previously described in previous studies done in bovine serum albumin (Ombelli et al., 2011). 
The logarithmic molecular weight of each peak was linearly associated with their specific 
elution time (Figure 70B). The equation (Equation 5) of the linear fit was used to estimate the 
molecular weight of the different fragments of the IgG spectrum. The data was 
underestimating the size of the molecules (Table 13). The main peak of the IgG chromatogram 
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(Figure 70C), appeared at 13.68 min of elution time.  The elution time calculated with 
Equation 1 was 95.5 KDa, instead of the 144 KDa expected.  
#'3Y0(R'#"?E#9&	("=3ℎ)) = −0.2115("#E)='<	)=R") + 4.8729 
Equation 5 
 
The differences in the molecular weight, could be a result of the differences in structure 
between the proteins. Bovine serum albumin is a compact globular protein, while IgG or its 
chains are less globular and have a different relative size. We hypothesized that the capacity 
of the column to separate different fragments of the IgG is maintained and therefore, the 
slope should be very similar independently of the molecule. However, the elution times could 
vary due to the different structure of the antibody.  
The main peak of the size exclusion chromatogram (144 KDa after 13.68 minutes), was used 
to determine the intersection of the new equation (Equation 6). 
#'3Y0(R'#"?E#9&	("=3ℎ)) = −0.2115("#E)='<	)=R") + 5.0517 
Equation 6  
 
 The molecular weight values were then calculated with the adapted IgG linear equation. 
Values seemed to be aligning consistently with the expected ones (Figure 70B). The most 
deviated values were the ones coming from molecules that had a single heave chain in their 
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structure. Structures associated with a single heavy chain or a heavy chain associated with a 
light chain, gave lower calculated values than expected (7.9 and 5.6 KDa respectively) (Table 
13). It seems that single heavy chains have a different conformation that causes them to 
collapse on themselves, thus reducing their hydrodynamic radius with respect to a completely 
assembled heavy chain. This causes the underestimation of the molecular weight when a 
monomer is used as a point of reference.  
Table 13 Calculation of molecular weight of IgG peaks from size exclusion chromatograms  
 
 
 
Elution time Expected Calc BSA Calc IgG Diff
Peak struture (minutes) (KDa) (KDa) (KDa) (KDa)
2 mAb 12.23 288 191.5 290.8 -2.8
1 mAb 13.68 144 94.8 144.0 0.0
2 HC 14.45 98.2 65.3 99.1 -0.9
1HC 1LC 15.26 72.3 43.9 66.7 5.6
1HC 16.24 49.2 27.2 41.3 7.9
1LC 17.33 23.1 16.0 24.3 -1.2
Monoclonal antobody (mAb), heavy chain (HC), light chain (LC), bovine serum albumin (BSA)
(‡)Calcuations of the peak molecular weight based on the BSA linear equation  (Calc BSA),
(†)Calcuations of the peak molecular weight based on the IgG linear equation  (Calc IgG),
(*) difference between the expected and calculated values from IgG linear equation (Diff)
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Figure 70 Peak identification of purified IgG proteins in a size exclusion chromatogram 
( A) Identification of the peaks of a known component; bovine serum albumin (BSA) in its monomer, 
dimer, trimer and tetramer form in a size exclusion chromatogram spectrum. (B) Correlation between 
the elution time and the logarithm of the molecular weight (MW) for BSA (red). Extrapolation of the 
linear relationship to an IgG molecule (green line). The expected values of the IgG chromatogram for 
each peak (blue circles). (C) Identification of the molecular structures of the IgG in a size exclusion 
chromatogram based on their elution time. 
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6.2.1.2 Peak quantification 
Some peaks identified by SEC were often lost in the noise of the spectrum or other more 
intense signals, due to the overlap between them and due to the lower concentrations of 
these species (Figure 70C). The only signals that were consistent across the spectra were the 
ones corresponding to the monomeric form (retention time 13.68 minutes), the one 
corresponding to the heavy chain (16.24 minutes) and the one of the light chain (17.33 
minutes). This indicates that rituximab, produced under these conditions was not prone to 
aggregation, with or without the chemical addition. These findings are very similar to those 
previously recorded (Beck et al., 2013). 
The fragmentation of the molecule was not massive, with values of the monomer always 
being at 96% or above. The addition of resveratrol in the media feed increased the relative 
concentration of the purified monomer, in a concentration-dependent manner (from 96.2 ± 
0.04 % at level control to 97.6 ± 0.9 % at 100 µM treatment) (Figure 71A). As the monomer 
increased in a relative quantity, there was a trend of a decrease in the relative quantity of the 
light chain (Figure 71E). However, the heavy chain did not follow this trend and remained 
static with quantities below 1% at all times. Resveratrol at 100 µM caused the peak to 
disappear. This could be a result of the signal not being intense enough, as the concentration 
of the antibody is considerably lower than in the previous cases. 
Catechin did not cause any main changes in the relative quantity, however, there was a 
consistent trend of decrease (1% reduction) (Figure 71B). Overall, none of the light or the 
heavy chains showed any significant changes in quantity (Figure 71D&F). 
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Figure 71 Relative quantification of the SEC peaks for purified IgG 
The monomeric (A, B), heavy chain (LC) (C, D) and light chain (LC) (E&F) peaks were assessed (section 
2.4.1) under resveratrol and catechin culture addition. Recombinant CHO cells were grown for 10 days 
in flask cultures and treated on day 3 (section 2.1.3). The IgG was then collected and purified (section 
2.3). The error bars displayed here correlate to ± SD. The experiment was run 4 times independently. 
 
There were no changes in the product quality, based on the size exclusion chromatography 
analysis and there were no main changes in the profile. Furthermore, the absence of 
aggregates and fragments confirmed that there were no changes in the behaviour of the 
production process or the protein. As a result, based on the current findings, the addition of 
these chemicals under these conditions is not contraindicated. 
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6.2.2 Cation exchange chromatography 
The distribution of the charge species for the purified antibody was studied by ion-exchange 
chromatography. Spectra results were in line with previous studies (Andrasi, Gyemant and 
Gaspar, 2014).  The current study showed that resveratrol treatments up to 50 µM did not 
cause any main changes in the charge heterogeneity of the product. High concentrations of 
resveratrol (100 µM) on the other hand, caused changes in the relative amount of charge 
species of IgG, as the acidic species dropped by 6.75 ± 3.91 % and the acidic species increased 
by 15.91 ± 5.71%. At the same time, the main peak also had an average decrease of 9.16 ± 
9.46 % (Figure 73 A). These big deviations were the result of the low-intensity signals of the 
spectra; small deviations have bigger changes in the overall relative abundance of the charge 
groups. Further correction of the spectra was performed in order to diminish the variability 
due to variations at baseline. Although the variability across the replicates could not be 
completely eliminated, it seemed clear that resveratrol treatment at high concentrations 
changes the charge heterogeneity of the IgG and result in a more basic product (Figure 72). 
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Figure 72 Normalized spectra of purified IgG for samples treated at 100 µM Resv 
The graph shows the normalized four replicates results of the cation exchange chromatography of 
recombinant monoclonal purified IgG for treatment at 100 µM of resveratrol. Recombinant CHO cells 
were grown for 10 days in flask cultures and treated on day 3 (section 2.1.3). 
 
Catechin treatment caused changes in the charge heterogeneity of the recombinant product, 
in a concentration-dependent manner. The addition of catechin caused an increase in the 
main peak while reducing the acidic species. Treatments with 25 µM resulted in a 1.80 ± 1.10 
%, decrease in acidic species, while causing a 2.04 ± 0.77 % increase of the main peak. 
Treatments with 50 µM, caused more severe changes, with a 3.58 ± 0.28% decrease observed 
in acidic species and a 3.64 ± 0.23% increase of the main peak (Figure 73B). Net changes in 
the basic species of the IgG seemed to result in proportional increases in the main peak. As a 
result, the basic species of the protein remained constant under these treatment conditions.  
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Figure 73 Relative quantification (%) of charge species for purified IgG  
Data from cation exchange chromatography (section 2.4.2). The acidic (left), main (center) and basic 
(right) species were assessed under resveratrol (A) and catechin (B) culture additions at different 
concentrations. Recombinant CHO cells were grown for 10 days in flask cultures (section 2.1.3)  and 
treated at day 3 The IgG was then collected and purified (section 2.3). The error bars displayed here 
correlate to ± SD. The experiment was run 4 times independently. One-way ANOVA statistical test was 
perform for the treatment compared to the control for p-values: (*)< 0.05, (**) < 0.01 and  (***) < 
0.001. 
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6.2.2.1 Discussion    
Catechins were able to cause a relative reduction of the acidic species in the purified IgG 
product and an increase in the amount of protein with main charge. This was a significant 
change (although it was only 4%), as approximately 20% of the IgG fell in this category. As a 
result, the fold change was 16.5 ± 1.2 % when compared to control. The same can be stated 
for the main species, although most of the molecules belong to this category; a more 
moderate change was observed, as a 3.64 ± 0.23% change relates to a 6.59 ± 0.4 % fold 
increase. In the same manner, treatment with 100 µM of resveratrol had a drastic change in 
charge species, causing a 24.4 ± 13.1 % decrease of the acidic species and, more importantly, 
a 73.3 ± 25.5 % increase of the basic species that almost doubled the relative amount found 
in the control. 
Epigallocatechin-gallate was studied as an additive for recombinant protein expression by 
Hossler and colleagues in 2015. It was found to have very similar effects to the ones observed 
using catechin in our study. When the chemical was added to the CHO culture media, it caused 
changes in the charge heterogeneity of the purified product (decrease of the acidic species of 
up to 4%, a decrease of the basic species of 2% and a consequent increase of the main peak 
charge of 6%) (Hossler et al., 2015). Although the changes described in the paper are very 
similar to ours, the range of concentrations that resulted in significant changes, varied 
between 100-450 µM. Treatments with 10 or 50 µM on the other hand, did not have any 
impact. The studies conducted, also showed that the mechanism by which epigallocatechin 
gallate reduces the acidic species was transferable; similar effects were observed on other 
proteins, cell line expression level or scale-up conditions. The decrease in the acidic species, 
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was not linked to any phase of the culture; as the culture fermented, the acidic species 
become more abundant. The addition of epigallocatechin gallate caused a decrease of the 
acidic species during the first stages of the culture, but after 48 hours, the relative increase of 
the acidic species was the same as observed using control. This explains why the reduction of 
acidic species in the current experiment, is still effective regardless of addition on day three.  
Cation exchange chromatograms can be indicative of the distribution of the general charge 
of the population of recombinant proteins. However, this view is a bit simplistic. Cation 
exchange chromatography is more related to localized surface charges. As a result, studies 
have found different shifts in chromatograms, although the same modifications were located 
in a different residue (Perkins et al., 2000). Furthermore, modifications that do not cause any 
change in the overall charge or do not involve charge residues, could cause shifts in the 
chromatogram, because they can change the structural conformation of the IgG and expose 
charge areas (Saphire et al., 2002).  
While the above is true, most of the changes in the heterogeneity of the IgG cation exchange 
chromatogram, are associated with a well-known group of modifications. Basic species can 
be explained by modifications such as N-terminal glutamine cyclization, C-terminal lysine 
clipping and oxidation. Acidic species shifts are more difficult to interpret and can be 
explained by deamidation and glycan profiles with sialic acid or high mannose content 
although more modifications can cause it. Acidification of the product, although very 
common, is more difficult to interpret because it is the result of aging and degradatory 
pathways (Gandhi et al., 2012; Leblanc et al., 2017) on top of the post-translational 
modification.  
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Both chemicals showed the capacity to reduce acidic species when compared to the control 
indicating that they could add important characteristics to the product such as increase if 
shelf-life against depredatory pathways of degradation.  
In order to identify the specific modifications, the mass spectrometry technique was used. 
6.2.3 Mass spectrometry 
6.2.3.1 Sequence coverage 
The raw data was used to study the sequence coverage of the molecule, previous to analyzing 
the data obtained from mass spectrometry. The light chain was covered almost in its entirety, 
with only amino acids 207 to 213 missing. This was consistent for all the samples as lysine in 
position 206 and arginine in position 210 were actively cleaved by trypsin. This fragmentation 
is possibly efficient due to the exposure of the end of the peptide chain (Figure 74A).   
This leaves two fragments of 523 and 307 Da within the range of molecular mass studied (up 
to 6.6 KDa) but the length is 4 and 3 respectively which is below the limit of minimum peptide 
length studied (seven amino acids). 
The heavy chain missed a considerable fragment of its sequence (from 152 to 221 amino acid). 
This fragment possesses no arginine or lysine. This resulted in a peptide of 69 amino acids, 
with a molecular weight of 7555 Da when treated with trypsin. The molecular weight 
exceeded the range stated for the experimentation and was not analyzed. To study this region 
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an alternative protease could be used, which would cleave the sequence at a different amino 
acid.  
Furthermore, regions 323-330 and 338-344 of the amino acid sequence were often missing. 
This is because the region is rich in lysine residues, resulting in small peptides bellow seven 
residues. Although reducing the peptide length of study would result in bigger sequence 
coverage, this would also imply the need for higher computational power. More importantly, 
it would create a staggering number of short peptide spectra, for which the assignment of the 
sequence might be dubious. In conclusion, although an expansion of the sequence coverage 
would be desirable, the reliability of the spectra sequence matching is the most important 
feature and should not be compromised. 
Another section missing from the mass spectrometry spectra sequence identification was 
293-305. There was no apparent reason for this 13-amino acid peptide (molecular weight 1.67 
KDa) to be missing from the mass spectrometry analysis. This region is characteristic in 
rituximab, as it contains a glycosylation site in the asparagine in position 301. The presence 
of glycosylation in the area complicates the identification of the spectrum, and sequence 
could not be found for these spectra. Control treatment only resulted in one sample out of 
four to which there was coverage of the sequence. This was due to a peptide (amino acids 
293-324, molecular weight 3.88 KDa), which avoided the cleavage at arginine 305. The 
elongated peptide sequence resulting from the miscleavage, allowed for a better 
interpretation of the spectrum, despite the glycosylation pattern (Figure 74B). 
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Figure 74 Heatmap of sequence coverage from the mass spectrometry study of Rituximab 
The heatmaps show the accumulative intensity across the amino acid sequence for the light chain (A) 
and the heavy chain (B). Red colour indicates a complete absence of the region when mass 
spectrometry was performed, blue colour shows the presence of the region; darker blue indicates more 
signal intensity. Rituximab was produced in recombinant CHO cells grown cultures incubated for 10 
days in flasks (section 2.1.3) and treated at day 3 with resveratrol and catechin at different 
concentrations. The IgG was purified by protein A affinity chromatography (section 2.3) and digested 
with trypsin (section 2.5.1) for mass spectrometry analysis (section 2.5.3). The intensities shown here 
are the additives of 4 independent replicates. 
 
Finally, the C-terminal fragment (444-451) was also often missing. The last eight amino acid 
sequence (SLSLSPGK) has an ionizable amino acid and a molecular weight of 788 Da. The 
peptide was only observed consistently across the four independent replicates of the control 
conditions, although this happened in relatively low intensities (106). It was also present in 
two out of four samples during the treatments with resveratrol at 25 µM and catechin at 10 
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µM. While all these samples represented the unmodified peptides, a specific search for C-
terminal truncated peptides (SLSLSPG_) was performed, but with no result. It is possible that 
the absence of the sequence coverage in most of the treated samples had to do with this 
fragment not being identifiable, although the reason for this is unknown.  Cation exchange 
chromatography, with and without carboxypeptidase treatment, was also used to investigate 
further and verify whether there was any main change in the peak profile.  There were not 
main changes observed in the profile. This result was similar to previous experiments studying 
the C-terminal lysine heterogeneity (Laurence 2008). This seems to indicate, that this cell line 
is very consistent in cleaving C-terminal lysine residues efficiently, but that does not give an 
answer for the absence of this fragment in the sequence coverage analysis. It is likely that a 
modification of the region could be responsible for the absence.  
These results showed that the addition of resveratrol and catechin to the media causes 
modifications of the C-terminal region.  Modifications that include changes in the C-terminal 
region of the heavy chain do not affect the antibody’s function in general; this is due to the 
fact that its antigen recognition site and the recruitment site for the immune response are far 
away from the C-terminal. It has been shown that modifications such as lysine clipping to 
those regions, do not cause structural changes (Tang et al., 2013). However, a recent study 
showed that terminal lysine residues, lower the complement-dependent cytotoxicity (CDC) 
response, by inhibiting the formation of hexametric rings (van den Bremer et al., 2015).  
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The addition of resveratrol and catechin to the product caused changes to the C-terminal 
region of the heavy chain and maybe of the light chain, but the nature of these modifications 
is unknown and it is unlikely that it would have a meaningful impact on the potency of the 
product.    
Finally, 97% of the sequence of the light chain was studied by mass spectrometry. However,  
only 77% of the heavy chain was studied in the worst-case scenario. This was consistent 
amongst the different treatment conditions. This indicates that the sequence coverage was 
robust across samples (although not complete) and further investigations could take place. 
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Table 14 General information on amino acids 
 
6.2.3.2 Dependent peptide search and unspecific search for IgG modifications by overall mass 
shift differences 
A dependent peptide search, with a follow-up search for significant differences in the 
presence of mass shifts, was performed in order to try and identify the causes of the changes 
in charge variants in the IgG.  The study showed that most mass shifts were exceptional when 
compared to the control, and only three modifications were consistent across most 
treatments (Table 15).  
Name 3-Letter Symbol
1-Letter 
Symbol
MW 
(Da)
Isoelectric 
Point Type
Alanine ALA A 89.09 6 Non-polar
Isoleucine ILE I 131.17 5.94 Non-polar
Leucine LEU L 131.17 5.98 Non-polar
Valine VAL V 117.15 5.96 Non-polar
Phenylalanine PHE F 165.19 5.48 Non-polar aromatic
Tryptophan TRP W 204.23 5.89 Non-polar aromatic
Tyrosine TYR Y 181.19 5.66 Non-polar aromatic
Asparagine ASN N 132.12 5.41 Polar uncharge
Glutamine GLN Q 146.15 5.65 Polar uncharge
Methionine MET M 149.21 5.74 Polar uncharge
Serine SER S 105.09 5.68 Polar uncharge
Threonine THR T 119.12 5.64 Polar uncharge
Arginine ARG R 174.2 11.15 Positive charge
Histidine HIS H 155.16 7.47 Positive charge
Lysine LYS K 146.19 9.59 Positive charge
Aspartic Acid ASP D 133.1 2.77 Negative charge
Glutamic Acid GLU E 147.13 3.22 Negative charge
Glycine GLY G 75.07 5.97 Special
Proline PRO P 115.13 6.3 Special
Cysteine CYS C 121.16 5.02 Special
Molecular weight (MW)
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Table 15 Mass shift differences for recombinant IgG samples treated with resveratrol and 
catechin compared to control 
 
All consistent modifications seem to be the result of artifacts during the preparation of the 
samples. A 27.99 mass shift could be the result of formylation, which is a modification that 
can occur under a high concentration of formic acid present in the suspension. As the protocol 
stopped the trypsin reaction with 100% formic acid added to the sample, it is likely that this 
could have caused formylation. It seems treatment with resveratrol and catechin causes an 
increase in this phenomenon, as it was more present under these conditions than in the 
control. 
The 21.98 Da mass shift could not be easily linked to any specific modification. It could be 
related either to the incorporation of magnesium or to sodium adduction. Both mass shifts 
described seem to be linked to each other, as they were always missing or appearing together 
(Table 15).  
Finally, the -57.02 Da mass shift is a modification that could be associated with several 
changes. Firstly, it could be the result of asparagine to glycine or glutamine to alanine 
Resveratrol Catechin
10 µM 25 µM 50 µM 100 µM 10 µM 25 µM 50 µM
-57.02 -57.02 -57.02 --- --- -57.02 -57.02
--- --- --- --- -9.04* --- ---
--- 21.98 21.98 21.98 --- 21.98 ---
--- 27.99 27.99 27.99 --- 27.99 ---
--- --- 52.92* --- --- --- ---
--- 57.99* --- --- --- --- ---
--- --- 190.08* --- --- --- ---
*Non-consistent mass shift  differences across samples. These values only 
appear in one treatment and only for one chain
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substitution. What was apparent from the experiment, is that under treatment conditions the 
IgG seems to be suffering more of these substitutions than under control conditions.   
On the other hand, the difference could be an artifact from sample processing. Alkylation of 
samples with iodoacetamide, causes peptides with cysteine residues to be carboxy-
methylated and thus increasing the mass of the peptide by 57.02 Da. If a sample is not 
modified at cysteine, then a molecular shift of -57.02 can be observed. If this was the case, 
then samples under treatment conditions, would be less likely to suffer 
carboxyamidomethylation. In order to further check which process took place, substitutions 
associated with this mass shift were studied by a specific modification search. However, the 
shift from polar neutral amino acids to polar amino acids did not explain the shifts in acidic 
and basic species.  
Overall, the present results do not seem to explain the changes observed during the cation 
exchange experimentation. 
6.2.3.3 Modification search by LFQ 
Specific modification search showed that most modifications were not affected when treated 
with either resveratrol or catechin. Only a few modifications showed differences with respect 
to the control.  
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6.2.3.3.1 Oxidation 
Oxidation was studied in methionine, histidine and proline residues. Proline oxidation was 
not detected in this experiment, unlike histidine and methionine. Oxidation of methionine 
was found in 10% of the peptides (Figure 75). Histidine was a less prone modification and 
appeared at a much lower rate (0.025-0.075%).   
Methionine was the most predominant modification, with four consistent residues at sites 
34, 81, 256 and 432 of the heavy chain. Most of the modifications were commonly shared for 
all treatments. One exception was position 432; this was only found in catechin treated 
samples and at samples treated with 10 µM and 100 µM of resveratrol (Table 16).  Another 
exception was histamine modification at site 433; most conditions did not cause a 
modification, however high concentrations of catechin and resveratrol caused oxidation of 
the amino acid. We think that resveratrol at high concentrations is likely to interact directly 
with this region and induces oxidation of both sites. This can also be true for catechin 
treatments, but it is less clear. 
The residues in positions 256 and 432, have been identified as the most susceptible ones 
when exposed to stress incubating conditions such as high temperature and addition of 
chemicals (Shen et al., 1996). This is thought to be a result of exposure, as these residues are 
not imbedded inside the chain domains; Met256 is located between the CH2-CH3 and Met432 is 
situated in the final part of the heavy chain. Residues 34 and 81 of the heavy chain were also 
consistently oxidized. This was probably a result of their exposure, as they are part of the 
variable region. This effect on Met34 has been previously described (Wei et al., 2007). On the 
other hand, the effect on Met81 has not been previously reported. The increase of molecules 
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with oxidized residues, resulted in an increase of the basic species in the ion exchange 
chromatogram.  
Table 16 Oxidation modification sites for rituximab   
 
Catechin Resveratrol
Position
Control Cat 10 µM
Cat 25 
µM
Cat 50 
µM
Rsv 10 
µM
Rsv 25 
µM
Rsv 50 
µM
Rsv 100 
µM
HC-34-OxiM Yes Yes Yes Yes Yes Yes Yes Yes
HC-81-OxiM Yes Yes Yes Yes Yes Yes Yes Yes
HC-256-OxiM Yes Yes Yes Yes Yes Yes Yes Yes
HC-432-OxiM --- Yes --- --- --- --- --- Yes
HC-433-OxiH --- --- --- Yes --- --- --- Yes
Presence (Yes) or absence (---) of oxidation modification in methionine(M) and histidine (H) residues of the 
light (LC) and heavy (HC) chain of rituximab
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Figure 75 Oxidation ratio in the recombinant IgG 
Modified peptide (oxidation) to non-modified peptide ratio in methionine residues 34(A), 81(B) 256(C) 
and 432 (D) of the heavy chain (HC) of rituximab.  Data are shown for treatments under control 
conditions (red) and treatments with catechin (green) and resveratrol (blue). Samples were purified 
(section 2.3), and trypsin-digested (section 2.5.1) previous to LC-MS/MS (section 2.5.2). Modifications 
were looked for with the targeted approach and the label-free quantification method with MaxQuant 
software (section 2.5.3) 
 
B 
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6.2.3.3.2 Tri-oxidation 
Rituximab was found to have four sites that suffered tri-oxidation consistently; One in the 
light chain at Cys193, and the other three located at the heavy chain at Cys positions 148, 265 
and 371. This pattern of tri-oxidation is not very clear. Control had three modifications out of 
four presented consistently (Table 17). Catechin treatment at 10 µM also resulted in three 
out of four modifications, however, these were different than the ones observed at control. 
Treatments with higher concentrations of the chemical (50 or 100 µM) led to only one tri-
oxidation site.  Resveratrol treatments were also very inconsistent, with 50 µM being the 
treatment with more modification sites (four), while the others had lower counts.  
Table 17 Tri-oxidation modification sites for rituximab 
 
When looking into the abundance of the modification, tri-oxidation was found only in small 
proportions, with 2% rates observed in the best-case scenario.  This was to be expected, as 
tri-oxidation is a rare event. There was a tri-oxidation at site 371 of the heavy chain with most 
catechin treatments, but not with control (Figure 76D); the rate of oxidation of the amino acid 
was close to 0.3%. It is quite possible that the absence of tri-oxidation when treating with 
control, was due to chance, since the event itself is rare. Resveratrol treatment had similar 
Catechin Resveratrol
Position
Control Cat 10 µM
Cat 25 
µM
Cat 50 
µM
Rsv 10 
µM
Rsv 25 
µM
Rsv 50 
µM
Rsv 100 
µM
LC-193-TrOx Yes Yes --- --- Yes Yes Yes ---
HC-148-TrOx Yes --- --- --- --- --- Yes ---
HC-265-TrOx Yes Yes --- Yes --- --- Yes ---
HC-371-TrOx --- Yes Yes --- Yes --- Yes Yes
Presence (Yes) or absence (---) of tri-oxidation modification in rituximab  light chain (LC) and heavy chain 
(HC)
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results for site 371 (Figure 76 D). On the other hand, an opposite effect was observed in the 
other sites, with control having the modifications and resveratrol and catechin showing no 
significant increase in them (Figure 76 A, B & C). This modification is rare as most cysteines 
are forming disulphide bonds and later are modified by carboxy-methylation the preparation 
of the samples.  
 
 
Figure 76 Tri-oxidation ratio of the recombinant IgG 
Modified peptide (tri-oxidation) to non-modified peptide ratio in residue Cys193(A) of the light 
chain(LC) of rituximab and residues Cys148(B) Cys265 (B) and Cys371(C) of the heavy chain (HC). Data 
are shown for treatments under control conditions (red) and treatments with catechin (green) and 
resveratrol (blue). Samples were purified (section 2.3), and trypsin-digested (section 2.5.1) previous to 
LC-MS/MS (section 2.5.2). Modifications were looked for with the targeted approach and the label-
free quantification method with MaxQuant software (section 2.5.3) 
 
A B 
C D 
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6.2.3.3.3 Carboxy-methylation 
Carboxy-methylation, was the most relevant modification, as expected, with a total of 
thirteen modified sites on a consistent basis (Table 18). The light chain was found to possess 
four main cysteine residues susceptible to alkylation (23, 87, 133 and 193). The four sites were 
associated with the disulphide bonds in the two domains of the light chains; the variable 
region (Cys23 and Cys87) and the constant region (Cys133 and Cys193). Another region with a 
disulphide bond is the Cys214 residue, which connects the light chain to the heavy chain. 
However, the last section of the peptide could not be properly assessed, as mentioned in the 
sequence coverage section.  
There were nine carboxymethylated sites at the studied section of the heavy chain; these 
were found in positions 96, 148, 224, 230, 233, 265, 371 and 429. Only three sites were 
consistently carboxymethylated across all treatments (224 230 and 233). These areas in the 
peptide chain are located in the hinge of the heavy chain and correspond to the three main 
sulphide bonds that link the four peptide chains together.  Cys224 links the heavy chain to the 
light chain and Cys230 and Cys233 link the heavy chains between them. Internal peptide 
disulphide bonds of the heavy chain are also present in the variable domain of the heavy 
chain, between Cys22 and Cys96. However, only the latter was found modified in the present 
experimentation. Furthermore, it is known that cysteine at position 148 bounds to cysteine 
at position 204, but we could not screen this position, as it was not found in the sequence 
coverage. Cysteines in charge of stabilizing the second constant domain of the constant region 
of the antibody, are located at positions 265 and 325; the latter was missing as the area is rich 
in lysine and prone to excessive digestion cleavage. Finally, the third constant domain of the 
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heavy chain is held by cysteines 371 and 429, both of which were identified and modified 
during the alkylation process.  
Table 18 Carboxy-methylation modification sites for rituximab 
 
Interestingly, resveratrol treatment at 50 µM, caused complete inhibition of the carboxy-
methylation, but only for cysteines in the hinge area, suggesting that the effect must be 
localized in this region and is related to sulphide bonds between different chains.   This was 
the only exception as all the other treatments including control had different results, as 
mentioned above.  It is possible that this is due to resveratrol being able to bond with the 
region and interact. It is highly possible that traces of resveratrol were still present in the 
media after purification. More interesting is the fact that this treatment also caused tri-
oxidation of the adjacent cysteine residues consistently at HC 96, 148, 265 and 371. This is 
Catechin Resveratrol
Position
Control Cat 10 µM
Cat 25 
µM
Cat 50 
µM
Rsv 10 
µM
Rsv 25 
µM
Rsv 50 
µM
Rsv 100 
µM
LC-23-Ctyl Yes *Yes Yes Yes Yes Yes Yes *Yes
LC-87-Ctyl Yes Yes Yes Yes Yes --- Yes *Yes
LC-133-Ctyl Yes Yes Yes Yes Yes Yes Yes *Yes
LC-193-Ctyl Yes Yes Yes Yes Yes Yes Yes *Yes
HC-96-Ctyl Yes Yes Yes Yes Yes Yes Yes Yes
HC-148-Ctyl Yes --- Yes Yes Yes Yes Yes Yes
*HC-224-Ctyl Yes Yes Yes Yes Yes Yes --- Yes
*HC-230-Ctyl Yes Yes Yes Yes Yes Yes --- Yes
*HC-233-Ctyl Yes Yes Yes Yes Yes Yes --- Yes
HC-265-Ctyl Yes Yes Yes Yes Yes Yes Yes *Yes
HC-371-Ctyl Yes *Yes Yes *Yes Yes Yes Yes *Yes
HC-429-Ctyl Yes Yes Yes Yes Yes Yes Yes Yes
Presence (Yes) or absence (---) of carboxy-methylation modification in rituximab  light chain (LC) and heavy 
chain (HC)
*Sites that had 100% of their peptides modified 
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paradoxical, as treatment with 100 µM of resveratrol caused the opposite effect and almost 
all the studied sites become permanently modified (Figure 77). 
 
 
 
Figure 77 Carboxy-methylation ratio of the recombinant IgG 
The ratio of carboxy-methylation modification in cysteine residues 23(A), 87(B) 133(C) and 193 (D) of 
the light chain (LC) of rituximab. Data are shown for treatments under control conditions (red) and 
treatments with catechin (green) and resveratrol (blue). Samples were purified (section 2.3), and 
trypsin-digested (section 2.5.1) previous to LC-MS/MS (section 2.5.2). Modifications were looked for 
with the targeted approach and the label-free quantification method with MaxQuant software (section 
2.5.3) 
B 
C D 
A 
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Furthermore, and in line with the dependent peptide search, there was a clear dichotomy 
between the treated samples. One group included catechin treatments at 25 and 50 µM as 
well as resveratrol at 10, 25 and 50 µM. These treatments had little effect on the changes of 
carboxy-methylation. The second group included resveratrol at 100 µM and catechin at 10 
µM, which caused a considerable increase in the ratio of carboxy-methylations (Figure 77). 
These results further ratify the previously identified modifications of the samples found by 
the dependent peptide search. 
Furthermore, other possible modifications with the same mass shift, like the substitution of 
glutamine by alanine and asparagine by glycine, were examined but were not found. 
Therefore, it is apparent that the changes observed are due to carboxy-methylation. 
6.2.3.3.4 Reduction 
Only one reduction site was found during the current experimentations (Ser84 at the heavy 
chain). This modification was common during the control treatments; 10% of the peptides 
were substituting Ser, an amino acid with a polar neutral side chain to Ala, a smaller amino 
acid with a hydrophobic side chain. Growth of the culture under catechin concentrations 
repressed the modification completely. Resveratrol treatments, on the other hand, were less 
efficient, but still caused some repression (Figure 78). This modification did not cause any 
direct changes in the overall charge of the IgG. However, alanine is highly hydrophobic, while 
serine possesses a polar chain. This substitution could cause some structural changes that 
could induce local charges on the molecule and cause shifts in the cation exchange 
chromatogram. Residue 84 appertains to the variable region of the heavy chain, as such 
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changes in this region could cause changes in the affinity of the biologic for the target 
molecule, in this case CD20. The repression of this modification could render the product 
more efficient as potentially 15% of the product will not carry this modification under some 
of the treatment conditions, but further research needs to be undertaken about the effect of 
this modification in the monoclonal antibody to clarify this.  
 
 
Figure 78 Reduction ratio of the recombinant IgG 
Modified peptide to non-modified peptide ratio in residue Ser84 of the heavy chain (HC) of rituximab. 
Data are shown for treatments under control conditions (red) and treatments with catechin (green) 
and resveratrol (blue). Samples were purified (section 2.3), and trypsin-digested (section 2.5.1) 
previous to LC-MS/MS (section 2.5.2). Modifications were looked for with the targeted approach and 
the label-free quantification method with MaxQuant software (section 2.5.3) 
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6.2.3.3.5 Deamidation 
Deamidation of asparagine to aspartate was found only in one residue, at position 136 of the 
light chain. However, this modification only occurred during treatment with high 
concentrations of resveratrol (100 µM) and accounted only for 0.3% of the peptides in the 
sample. This modification has been previously described (Chelius, Rehder and Bondarenko, 
2005). Deamidation causes the relative number of acidic species to increase and it is a process 
that occurs at a very low rate. This phenomenon is often observed in late cultures and is 
symptomatic of the degradation and age of the product. Non- enzymatic deamidation is 
among the most common modifications that cause charge heterogeneity (Ponniah et al., 
2017). It can result in a considerable effect in the ion exchange chromatograms, leading to 
distinguishable peaks in some cases (Perkins et al., 2000; Vlasak et al., 2009). Although 
deamidation contributes to the charge heterogeneity, the shift in charge species observed by 
cation exchange chromatography, is unlikely to be mainly due to this. 
 
 
Figure 79 Deamidation ratio of the 
recombinant IgG 
Modified peptide to non-modified 
peptide ratio in residue Asn136 of the 
light chain (HC) of rituximab. Data 
are shown for treatments under 
control conditions (red) and 
treatments with catechin (green) 
and resveratrol (blue). Samples 
were purified (section 2.3), and 
trypsin-digested (section 2.5.1) 
previous to LC-MS/MS (section 
2.5.2). Modifications were looked 
for with the targeted approach and 
the label-free quantification 
method with MaxQuant software 
(section 2.5.3) 
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6.2.3.3.6 Loss of ammonia 
The loss of an ammonia group from asparagine, was found in four different locations (Table 
19). One was found in the light chain at position 157, although this modification was only 
present when the sample was treated with 10 µM of resveratrol (affected 0.15% of the 
peptides). On the other hand, modified sites at positions 55, 319 and 388 of the heavy chain, 
were consistent for all samples and affected double or more peptides than the previously 
described one. The modifications were constant across all samples and differences were not 
apparent (Figure 80). 
 
 
 
Figure 80 Ammonia loss ratio of the recombinant IgG  
The ratio of loss of ammonia in asparagine residues 55(A), 319(B) and 388(C) of the heavy chain (HC) 
of rituximab. Data are shown for treatments under control conditions (red) and treatments with 
catechin (green) and resveratrol (blue). Samples were purified (section 2.3), and trypsin-digested 
(section 2.5.1) previous to LC-MS/MS (section 2.5.2). Modifications were looked for with the targeted 
approach and the label-free quantification method with MaxQuant software (section 2.5.3) 
 
 
A B C 
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Table 19 Loss of ammonia sites for rituximab 
  
6.3 Conclusions 
The addition of catechin or resveratrol to the media did not cause any changes in IgG 
aggregation or fragmentation, at any of the studied concentrations. Treatment with catechin 
caused a decrease of the acidic species and an increase of the main species in a concentration-
dependent manner. Treatment with resveratrol caused a decrease of the acidic species and 
an increase of the basic species in a concentration-dependent manner. This deacidification of 
the product caused by both chemicals could be a positive trait towards the stability of the 
product and the shelf-life. The addition of flavonoids was able to stop changes in the 
hydrophobicity of the variable region, by avoiding reduction in specific residues (Ser24); this 
could enhance the IgG binding to the antigen. Furthermore, modification patterns suggest 
that resveratrol compounds can target specific regions of the IgG, such as the hinge section. 
Overall, resveratrol and catechin did not cause any modifications that could negatively affect 
the quality of the product.  
 
 
Catechin Resveratrol
Position
Control Cat 10 µM
Cat 25 
µM
Cat 50 
µM
Rsv 10 
µM
Rsv 25 
µM
Rsv 50 
µM
Rsv 100 
µM
LC-157-AmLs --- --- --- --- Yes --- --- ---
HC-55-AmLs Yes Yes Yes Yes Yes Yes Yes Yes
HC-319-AmLs Yes Yes Yes Yes Yes Yes Yes Yes
HC-388-AmLs Yes Yes Yes Yes Yes Yes Yes Yes
Presence (Yes) or absence (---) of ammonia loss in rituximab  light chain (LC) and heavy chain (HC)
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Out of fifteen chemicals studied,  this research has shown that resveratrol and catechins are 
plausible chemicals to use for the improvement of recombinant IgG production as they do 
not compromise the quality of the product (Figure 81). The key results are summarized below 
and compared with the available literature. 
 
Figure 81 Flow chart of chemicals studied across the project.   
Flow chart of chemicals studied across the project; green represents positive results while red 
represents undesirable traits found during experimentation across the four stages of research of this 
project. Of the initial 15 chemicals screened, only two were taken to the final experimentation chapter. 
Chemical acronyms stand for: 4-PBA (sodium 4-phenylbutyrate), CAPE (caffeic acid phenethyl ester), 
ECG (epicatechin gallate), EGCG (epigallocatechin gallate), GCG (gallocatechin gallate). 
 
 
 Chapter 7 296 
7.1 Key results 
7.1.1 Initial toxicological and recombinant production screening 
• The screening method using 24-well plates, was very efficient at identifying chemicals 
able to shift cell growth into specific protein production, but it is uncertain whether it 
has the capacity to assess other mechanisms of improvement of recombinant IgG 
production 
• Among the chemicals screened, 4-PBA, betaine, caffeine and piceid caused no 
improvements in the production process. Curcumin, kaempferol and CAPE showed 
drastic toxic effects and the increase of qp was only present at low levels of viability. 
Catechin, epicatechin, resveratrol, EGC, tocopherol, EGCG and GCG all showed 
positive effects on recombinant IgG production 
• Most of the chemicals with positive features were able to improve the specific protein 
production by inhibiting cell growth without lowering viability 
7.1.2 The effect of flavonoids over time on culture behaviour and cell cycle 
• Resveratrol stopped cell cycle in an aphasic way and elongated the stationary stage. 
Resveratrol caused cell growth arrest during the S phase in the first cell divisions of 
the culture; this phenomenon is linked to its toxic effect in CHO cells 
• Catechin compounds caused an increase of the cells in the G2/M and S phases of the 
cell cycle, while reducing the number of cells in G1/G0. The galloyl group was identified 
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as a fundamental part of the catechins structure resulting in an increase of the cell 
growth arrest  
7.1.3 Scale-up and optimization of the recombinant IgG production 
• Flask culture early feeding strategies caused an increase of the negative traits 
observed (lower viable cell density, lower viability and lower IgG produced) for all the 
chemicals studied 
• Feeding the culture at later stages with resveratrol, catechin and epicatechin caused 
an improvement of the final antibody titre 
• GCG and EGCG were too toxic under these conditions and they did not cause any 
positive improvements in the final IgG production 
7.1.4 Recombinant IgG product characterization and quality assessment  
• Treatment with catechin and resveratrol did not cause any changes in the IgG 
aggregation or fragmentation at any of the studied concentrations 
• Treatment with catechin caused a decrease of the acidic species and an increase of 
the main species in a concentration-dependent manner 
• Treatment with resveratrol caused a decrease of the acidic species and an increase of 
the basic species in a concentration-dependent manner 
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• Overall, resveratrol and catechin did not cause any modifications that could negatively 
affect the quality of the product  
From the results displayed, it is apparent that the principal goals stated at the beginning of 
this project have been achieved (section 1.8). In addition to the aims, a list of questions was 
established which is considered during the overall discussion.  
 
7.2 Overall discussion 
7.2.1 How does resveratrol help with the production of recombinant IgG in CHO cell 
cultures? 
Present results from experimentation with resveratrol showed that this chemical was able to 
increase qp with different setups (section 3.3.1.2.14) and when added to the culture at the 
late stages of the exponential phase it was able to enhance recombinant production (section 
5.2.1.3). Resveratrol was able to cause cytostatic conditions that enhanced the capacity to 
increase the recombinant product.  
As these experiments were taking place, resveratrol was included in a patent in order to be 
used as an additive for recombinant protein production in CHO cells. This study found 
resveratrol able to cause up to a 1.44-fold increase in production when added at 1mM 
concentration with no negative effects (Tian 2016). Our study showed that resveratrol, in 
concentrations as low as 50 µM, caused a considerable delay of the cell curve when added at 
the beginning of the culture. It also caused a drastic drop in viability and a decay in the final 
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titre in low concentrations. Concentrations above 100 µM caused complete repression of the 
cell growth and IgG production with a complete loss of cell viability (Appendix 2). These 
differences in the effects of resveratrol are difficult to reconcile. Other studies performed 
with CHO cells (Basso et al., 2013; Mallebrera et al., 2015) and different mammalian host 
systems (Lu, Ou and Lu, 2013; Quoc Trung et al., 2013), identified a much lower tolerance of 
the compounds than what claimed by Tian and colleagues. This indicates that probably the 
results claimed in this patent are an exception to the rule and that most likely, the range of 
sensitivity of most mammalian cells, and more specifically CHO cells, is lower than what was 
claimed.   
Regardless of the differences in the results in the use of resveratrol to improve recombinant 
protein production in CHO cells,  it seems that this chemical can be used in different cell lines 
and for the production of different recombinant proteins with successful outcomes, although 
the specific feeding regime may need to be adjusted for each specific case.  
7.2.2 What would be a plausible cellular mechanism to explain the improvement in 
recombinant IgG production by resveratrol? 
Cell cycle results showed that there was a drop in viability at the end of the cell growth 
adaptation phase. This was then followed by the accumulation peak of cells passing through 
S phase. This phenomenon could be associated to the capacity of resveratrol to interfere with 
DNA duplication, repair and segregation (Basso et al., 2013; Traversi et al., 2016), thus 
accumulating cells in the S phase through direct (N’soukpoé-Kossi et al., 2015) and indirect 
(Leone et al., 2010)  mechanisms late in the culture (Subramanian, Soundar and Mangoli, 
2016). Previous studies report that DNA damage occurs at high concentrations with a 
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subsequent possibility of apoptotic events (Basso et al., 2013; Uchiumi et al., 2016). However, 
not all studies reported the same results (Sainz et al., 2003). One of the mechanisms of 
resveratrol’s toxicity on CHO cell dividing cultures, could be its interaction with 
topoisomerases during the S phase (Leone et al., 2012; Basso et al., 2013). Recent enzymatic 
studies identified the capacity of resveratrol to inhibit topoisomerase II by preventing the 
attachment of ATP to the protein complex in human models (Lee, Wendorff and Berger, 
2017). 
The toxic behaviour of resveratrol seen along the different chapters of this project seems to 
be linked to the capacity of cell cultures to grow. This relates to resveratrol’s capacity to 
interference with DNA replication, repair and segregation. This hypothesis also correlates 
with cancer studies where resveratrol was identified to have anti-tumour effects due to its 
capacity to selectively cause higher toxic effects in highly dividing tissues (Zhou et al., 2011; 
Trung et al., 2015).  
The connection between the arrest at S phase and the growth inhibition should not be 
assumed. There is a strong correlation between the peak of cells in S phase, the drop in 
viability and the start of the exponential phase (section 4.2.2). However, growth arrest 
previous to the exponential phases is difficult to be explained by S phase interference with 
replication as cells in the cell cycle phase do not increase consistently during this period. This 
means that another mechanism could be at play, an idea that was also speculated in previous 
studies  (Della Ragione et al., 1998). Furthermore, resveratrol has been found to stop cell cycle 
in other phases (Rubiolo et al., 2012; Gokbulut et al., 2013) or to stop it in a non-specific way 
(Pozo-Guisado et al., 2002). 
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It is likely that the results observed by resveratrol are due to complex effects. Due to its 
bioactive characteristics, it is likely that resveratrol is causing a pleiotropic effect on CHO cells 
by interfering with signaling and metabolic pathways in different ways (Hahnvajanawong et 
al., 2011; Rubiolo et al., 2012; Bosutti and Degens, 2015).  
7.2.3 How do catechins help the production of recombinant IgG in CHO cell cultures? 
Present results from experimentation with catechins showed that these chemicals were able 
to increase qp within different setups (section 3.3.1.2) and enhance recombinant production 
(section 5.2.2). It was also apparent that the chemicals with a galloyl group (ECG, EGCG, GCG) 
had a more severe effect over the different parameters studied in comparison to those 
without this group (catechin and epicatechin). Out of these compounds studied, only catechin 
and EGCG had a previous tracking record as chemical additives in recombinant protein 
production.  
Catechin was studied recently and was patented to improve recombinant protein production. 
When using catechin at high concentrations (1 mM), titre was improved by 17% in 20 L 
reactors. The reason behind these was the elongation of the culture time due to catechin 
decreasing ammonia and lactate levels (Tian, 2016). In general, our results seem to correlate 
with the data by Tian et al, although we achieved higher increases of the final titre by the 
addition of lower concentrations. Scale down studies in this area tend to show big 
improvements in recombinant protein production, but when scaled-up, the gain observed is 
often reduced. On the other hand, viable cell growth was clearly inhibited in our study at low 
concentrations. The addition of high concentrations of catechin did not seem to cause any 
inhibition in the Tian et al study. This could be the result of the use of different cell lines 
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(aCD137 vs DG44) or different growth conditions. The resilience of cells to suffer toxic effects 
seems to be consistent when comparing our research and respective patent for resveratrol 
and catechin (Tian, 2016). 
The catechin family seems to be capable of improving recombinant protein production in CHO 
cells.  Both previous studies and the results of this study, indicate that catechins can be used 
successfully in different cell lines and for the production of different recombinant proteins. 
Furthermore, the effect seems to be transferable among all the chemicals studied, although 
each of them has different optimization conditions.  
7.2.4 What is a plausible cellular mechanism to explain the fact that catechins improve 
recombinant IgG production? 
Catechins caused an inhibitory effect on cell cultures in a concentration-dependent manner. 
The degree of cell arrest seems to be linked to the structure. Catechin was the less effective 
in reducing cell growth, while EGCG and ECG and GCG had very similar trends. EC was found 
between both extremes. The structure of the compounds seems to be key in the different 
effects over cell growth inhibition, as the chemicals with the galloyl group (EGCG, GCG and 
ECG) had a more severe effect. Viability had a direct relation to growth inhibition. EGCG and 
GCG caused considerable effects while catechin and epicatechin were less impactful. The 
addition of any of the catechins at the end of exponential did not cause an effect on viability 
(section 5.2.2).  
All catechins affected cell cycle in similar ways with an increase of G2/M and S phases while 
and a decrease of the G1/G0 phase (section 5.2.2). EGCG is the most studied compound of the 
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catechin family. Previous studies indicate that this compound is able to inhibit cell cycle in the 
S phase (Shabana et al., 2014; Shen et al., 2014). Huang et al looked into the effect of catechin 
in murine microglial cells.  Catechin caused cell cycle arrest in S phase (Q. Huang et al., 2005). 
Comparative studies of the effect of different catechin compounds on the cell cycle were 
consistent in identifying different behaviours depending on the presence of the galloyl group 
(Tan et al., 2000). A further comparative study of compounds with galloyl groups indicated 
that ECG, gallocatechin (GC) and EGCG cause very similar responses on the cell cycle arrest. 
All the chemicals inhibit cell growth in a concentration-dependent manner and cause 
inhibition of Nf-κB, an increase in S phase and a decrease in G1/G0 (Kürbitz et al., 2011).  
The mechanism by which catechins are acting on the cell cycle could include their inhibitory 
effect on the topoisomerase enzymes. EGCG was found to inhibit topoisomerase I and II 
(Bandele 2008) by sequestrating the enzyme in a complex that seems to be mediated by 
hydrogen peroxide (Lopez-Lazaro 2011). This inhibition of topoisomerases leads to a G2/M 
and S phase arrest (Cliby 2002). A comparative enzymatic study describes the inhibition 
capacity according to catechin structure, with EGCG being the most effective in inhibiting 
topoisomerases followed by ECG; EC had a very low inhibitory capacity (Suzuki 2001). This 
trend of enzyme inhibition correlates with the studies of cell growth arrest presented here 
(section 4.2.3.1).  
Regardless of the proven capacity of these compounds to interfere with topoisomerases, 
these chemicals also tend to affect the regulation of many different cell cycle proteins such 
as p21, p27 and Nf-κB (Shabana et al., 2014; Shen et al., 2014). It is likely that the effect of 
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catechins over cell cycle arrest occurs at many levels; there might be pleiotropic mechanisms 
linked to the high bioactive capability of the compound (Ye et al., 2017) 
7.2.5 How can the catechin feeding regime help the quality of the product of recombinant 
IgG production? 
Catechin was able to cause a relative reduction of the acidic species in the purified IgG product 
and an increase in the amount of protein with main charge. Epigallocatechin-gallate was 
found to have very similar effects (Hossler et al., 2015). The study also showed that the 
mechanism by which epigallocatechin gallate reduces the acidic species was transferable to 
other proteins, cell line expression level or scale up conditions. The addition of 
epigallocatechin gallate caused a decrease of the acidic species during the first stages of the 
culture, but after 48 hours, the relative increase of the acidic species was the same as 
observed using control (Hossler et al., 2015). 
The charge heterogeneity shift caused by catechin could be used for adjusting the biosimilar 
charge variant profile of antibodies. The deacidification profile seen could also have a positive 
impact on the shelf-life and stability of the product, as acidification of the product is often the 
result of aging and depredatory pathways (Gandhi et al., 2012; Leblanc et al., 2017). 
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7.2.6 How do these newly defined molecules fit the current state of the art for chemical 
addition on recombinant CHO cell culture feeding strategies?  
Previous studies have used mild hypothermia, hyperosmotic pressure and the addition of 
small molecules with no direct nutritional value to improve qp or reduce recombinant protein 
production problems such as aggregation (Johari et al., 2015b).  
Temperature shift is the most common strategy used in mammalian cell cultures. Mild 
hypothermia has been used to slow cellular growth while allowing protein synthesis to 
continue, improving the qp values and reducing aggregation (Chen, Wu and Liu, 2004; 
Trummer et al., 2006; Kou et al., 2011; Gomez et al., 2012; Johari et al., 2015a). Osmolyte 
chemicals such as glycine betaine have also been used. This chemical achieves slower cellular 
growth and in some circumstances, it can improve the qp value (Ryu et al., 2000; Tae Kyung 
et al., 2000; Kim and Lee, 2002).  
Other low-molecular weight additives have also been used. Butyric acid, valeric acid, valproic 
acid, 4-phenylbutyric acid and zinc have been added to recombinant CHO cell culture media 
(Yam et al., 2007; Jiang and Sharfstein, 2008; Yang, Lu and Nguyen, 2014; Coronel et al., 2016; 
Avello et al., 2017; Paul et al., 2018; Prabhu, Gadre and Gadgil, 2018). Valeric acid (pentanoic 
acid) produced higher product titres and increased qp for an unnamed recombinant protein 
in CHO cells (Liu, Chu and Hwang, 2001; Coronel et al., 2016). Valproic acid (2-propylpentanoic 
acid) addition to cell culture media has also been reported to improve antibody expression 
(Yang, Lu and Nguyen, 2014; Paul et al., 2018). 4-phenylbutyrate has also been used to 
minimize aggregation in proteins expressed in CHO cells (Yam et al., 2007). The number of 
chemical additives developed, and the understanding of their mechanism is limited.  
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The capacity of these chemicals to shift cell growth into productivity is not exclusive, as other 
strategies involving low temperature and osmolytes (eg. glycine betaine) have already been 
developed. However, the mechanism by which they induce cell arrest and protein 
improvement is not the same as the ones previously described. Catechins and resveratrol 
compounds caused a significant decrease in the relative quantity of cells in the G1/G0 phase. 
This is contrasting the common trend of chemical cell cycle arrest strategies which focus on 
specific cell cycle arrest in G1/G0 and on increasing cell size (Hendrick et al., 1999; Carvalhal, 
Marcelino and Carrondo, 2003; Bi, Shuttleworth and Al-Rubeai, 2004; Dutton, Scharer and 
Moo-Young, 2006). Furthermore, not all cell lines are susceptible to these strategies, as the 
added chemicals are often very specific in the way they interact with the production process 
and cannot always be used across different cell lines or recombinant molecules reliably.  
Conclusively, the chemicals studied in the present study could be used as an alternative or 
combining tools to improve recombinant protein production in CHO cell lines. 
7.2.7 What future work needs to be done to further assess these chemicals and make them 
reliable for industry purposes? 
The initial screening process was very efficient in identifying chemicals able to shift cell 
growth into specific protein production. This was done conservatively, to ensure reliable 
candidates for future steps of the project. As a result, other candidates cannot be discarded 
as non suitable. The change of parametres, such as using different concentrations, altering 
the shaking conditions and adding times could make a drastic difference as illustrated in the 
present report. A better screening system would have involved different cell lines, each one 
with a well-defined bottleneck for the production of biologics. 
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While a lot of work has been done on catechins and resveratrol during the present project, 
further studies are needed in order to have a better understanding of the mechanisms of the 
chemicals on the cell and their feasibility as additives in industry.  
In the present report, it was presumed that a main mechanism of action of resveratrol and 
catechins could be the inhibition capacity on the topoisomerases as well as their effect on the 
regulation of gene expression. A study of chemical localization inside the cell as well as the 
study of the gene expression through q-PCR could give more information about the effect 
over different metabolic pathways.  
In order to assess if the results displayed here are adaptable to an industry set-up, issues like 
the size of the reactor need to be considered. Scale down studies in this area tend to show 
big improvements in recombinant protein production, but when scaled-up, the gain observed 
is often reduced. Industry reactors can reach volumes of up to 2000 L. Shear stress, pH and 
dissociation of relevant gases such as CO2 or O2 are some of the principal variables that could 
affect the cell population conditions, the results of adding these chemicals to the media and 
the quality of the product when changing the cell culture size (Brunner et al., 2017).  
Finally, a further study of the glycosylation pattern of the recombinant IgG is essential. This is 
a very important parameter that can determine the quality of the product. On the same line, 
a study of the shelf-life of the product when formulated, could also bring interesting 
information about the long-term effects of the chemicals.  
Overall, these future experiments could help understand the adaptability of the chemicals to 
industry standards. This would also empower the capacity to use them in an engineering 
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context. Lastly, the study of other chemical candidates such as tocopherol or luteolin which 
showed positive results during the screening stage could be of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 7 309 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 7 310 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 References 311 
 
 
 
 
References 
 
 
 
 
 References 312 
 
 
 
 
 
 
 
 
 
 
 
 
 
 References 313 
8 References 
 
Abcam (2012) ‘Propidium iodide staining of cells to assess DNA cell cycle Flow’, Abcam, pp. 1–3. 
Acosta-martin, A. E. et al. (2016) ‘Detection of busulfan adducts on proteins’, Rapid communications 
in mass spectrometry, 30, pp. 2517–2528. doi: 10.1002/rcm.7730. 
Ahn, Y.-H. et al. (1999) ‘Effect of glycine betaine as osmoprotectant on the production of 
erythropoietin by cho cells in hyperosmotic serum free media culture’, Animal Cell Technology, 10(3), 
pp. 247–250. 
Alessandri, L. et al. (2012) ‘Increased serum clearance of oligomannose species present on a human 
IgG1 molecule Leslie’, mAbs, 4(4), pp. 509–520. doi: 10.4161/mabs.20450. 
Allen, M. J. et al. (2008) ‘Identification of novel small molecule enhancers of protein production by 
cultured mammalian cells’, Biotechnology and Bioengineering, 100(6), pp. 1193–1204. doi: 
10.1002/bit.21839. 
De Almeida, S. F. et al. (2007) ‘Chemical chaperones reduce endoplasmic reticulum stress and prevent 
mutant HFE aggregate formation’, Journal of Biological Chemistry, 282(38), pp. 27905–27912. doi: 
10.1074/jbc.M702672200. 
Almo, S. C. and Love, J. D. (2014) ‘Better and faster: Improvements and optimization for mammalian 
recombinant protein production’, Current Opinion in Structural Biology. Elsevier Ltd, 26(1), pp. 39–43. 
doi: 10.1016/j.sbi.2014.03.006. 
Altman, D. G. and Bland, J. M. (2005) ‘Standard deviations and standard errors.’, Methods in medical 
research, 331, p. 903. 
Andrasi, M., Gyemant, G. and Gaspar, A. (2014) ‘Analysis of Rituximab, A Therapeutic Monoclonal 
Antibody by Capillary Zone Electrophoresis’, Journal of chromatography separation techniques, 6, pp. 
1–8. doi: 10.4172/2157-7064.1000259. 
 References 314 
Anfinsen, C. B. (1973) ‘Principles that Govern the Folding of Protein Chains’, Science, 181(4096), pp. 
223–230. doi: 10.1126/science.181.4096.223. 
Antunes, L. M. G. et al. (2005) ‘Effects of H2O2, Fe2+and Fe3+on curcumin-induced chromosomal 
aberrations in CHO cells’, Genetics and Molecular Biology, 28(1), pp. 161–164. doi: 10.1590/S1415-
47572005000100028. 
Armagan, A. et al. (2008) ‘Caffeic acid phenethyl ester modulates methotrexate-induced oxidative 
stress in testes of rat’, Human and Experimental Toxicology, 27(7), pp. 547–552. doi: 
10.1177/0960327108092293. 
Auger, C. et al. (2005) ‘Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect 
hypercholesterolemic hamsters against aortic fatty streak accumulation’, Journal of Agricultural and 
Food Chemistry, 53(6), pp. 2015–2021. doi: 10.1021/jf048177q. 
Avello, V. et al. (2017) ‘Impact of sodium butyrate and mild hypothermia on metabolic and 
physiological behaviour of CHO TF 70R cells’, Electronic Journal of Biotechnology. Elsevier España, 
S.L.U., 27, pp. 55–62. doi: 10.1016/j.ejbt.2017.03.008. 
Baek, E. et al. (2016) ‘Chemical inhibition of autophagy: Examining its potential to increase the specific 
productivity of recombinant CHO cell lines’, Biotechnology and Bioengineering, 113(9), pp. 1953–
1961. doi: 10.1002/bit.25962. 
Baeshen, M. N. et al. (2015) ‘Production of Biopharmaceuticals in E. coli: Current scenario and future 
perspectives.’, Journal of microbiology and biotechnology, 25(7), pp. 953–962. doi: 
10.4014/jmb.1405.05052. 
Basso, E. et al. (2013) ‘Effects of resveratrol on topoisomerase II-?? activity: Induction of micronuclei 
and inhibition of chromosome segregation in CHO-K1 cells’, Mutagenesis, 28(3), pp. 243–248. doi: 
10.1093/mutage/ges067. 
Bastianetto, S. et al. (2006) ‘Neuroprotective effects of green and black teas and their catechin gallate 
esters against β-amyloid-induced toxicity’, European Journal of Neuroscience, 23(1), pp. 55–64. doi: 
 References 315 
10.1111/j.1460-9568.2005.04532.x. 
Beck, A. et al. (2013) ‘Characterization of therapeutic antibodies and related products’, Analytical 
Chemistry, Jan. 
Bertolotti,  a et al. (2000) ‘Dynamic interaction of BiP and ER stress transducers in the unfolded-protein 
response.’, Nature cell biology, 2(6), pp. 326–332. doi: 10.1038/35014014. 
Bi, J. X., Shuttleworth, J. and Al-Rubeai, M. (2004) ‘Uncoupling of Cell Growth and Proliferation Results 
in Enhancement of Productivity in p21CIP1-Arrested CHO Cells’, Biotechnology and Bioengineering, 
85(7), pp. 741–749. doi: 10.1002/bit.20025. 
Bieschke, J. et al. (2010) ‘EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces 
cellular toxicity.’, Proceedings of the National Academy of Sciences of the United States of America, 
107(17), pp. 7710–7715. doi: 10.1073/pnas.0910723107. 
Bleiholder, C. et al. (2013) ‘Ion mobility spectrometry reveals the mechanism of amyloid formation of 
Aβ(25-35) and its modulation by inhibitors at the molecular level: Epigallocatechin gallate and scyllo-
inositol’, Journal of the American Chemical Society, 135(45), pp. 16926–16937. doi: 
10.1021/ja406197f. 
Borana, M. S. et al. (2014) ‘Curcumin and kaempferol prevent lysozyme fibril formation by modulating 
aggregation kinetic parameters’, Biochimica et Biophysica Acta - Proteins and Proteomics. Elsevier 
B.V., 1844(3), pp. 670–680. doi: 10.1016/j.bbapap.2014.01.009. 
Bosutti, A. and Degens, H. (2015) ‘The impact of resveratrol and hydrogen peroxide on muscle cell 
plasticity shows a dose-dependent interaction.’, Scientific reports, 5, p. 8093. doi: 10.1038/srep08093. 
Braakman, I. and Bulleid, N. J. (2011) ‘Protein Folding and Modification in the Mammalian Endoplasmic 
Reticulum’, Annual Review of Biochemistry, 80(1), pp. 71–99. doi: 10.1146/annurev-biochem-062209-
093836. 
van den Bremer, E. T. J. Van Den et al. (2015) ‘Human IgG is produced in a pro-form that requires 
 References 316 
clipping of C-terminal lysines for maximal complement activation’, mAbs, 7(4), pp. 672–680. 
Brunner, M. et al. (2017) ‘Investigation of the interactions of critical scale-up parameters (pH, pO2and 
pCO2) on CHO batch performance and critical quality attributes’, Bioprocess and Biosystems 
Engineering. Springer Berlin Heidelberg, 40(2), pp. 251–263. doi: 10.1007/s00449-016-1693-7. 
Buchberger, A., Bukau, B. and Sommer, T. (2010) ‘Protein quality control in the cytosol and the 
endoplasmic reticulum: brothers in arms.’, Molecular cell. Elsevier Inc., 40(2), pp. 238–52. doi: 
10.1016/j.molcel.2010.10.001. 
Buren, N. V. A. N. et al. (2009) ‘Elucidation of Two Major Aggregation Pathways in an IgG2 Antibody’, 
Journal of Pharmaceutical Sciences, 98(9), pp. 3013–3030. doi: 10.1002/jps. 
Byoun, S. and Park, H. (2006) ‘Short-term Hypothermic Preservation of CHO Cells Using Serum-Free 
Media’, Korean Society for Biotechnology and Bioengineering, 21(4), pp. 306–311. 
Carvalhal, A. V., Marcelino, I. and Carrondo, M. J. T. (2003) ‘Metabolic changes during cell growth 
inhibition by p27 overexpression’, Applied Microbiology and Biotechnology, 63(2), pp. 164–173. doi: 
10.1007/s00253-003-1385-5. 
Carver, J. H., Carrano, A. V and Macgregor, J. T. (1983) ‘galangin on Chinese hamster ovary cells in 
vitro’, Mutation research, 113, pp. 45–60. 
Chelius, D., Rehder, D. S. and Bondarenko, P. V (2005) ‘Identification and Characterization of 
Deamidation Sites in the Conserved Regions of Human Immunoglobulin Gamma Antibodies’, 
Analytical Chemistry, 77(18), pp. 6004–6011. 
Chen, Z., Wu, B. and Liu, H. (2004) ‘Temperature shift as a process optimization step for the production 
of pro-urokinase by a reCHO cell line in high-density perfusion culture’, Journal of Bioscience and 
Bioengineering, 97(4), pp. 239–243. 
Cho, J. a. et al. (2014) ‘4-Phenylbutyrate Attenuates the ER Stress Response and Cyclic AMP 
Accumulation in DYT1 Dystonia Cell Models’, PLoS ONE, 9(11), p. e110086. doi: 
 References 317 
10.1371/journal.pone.0110086. 
Choi, A. Y. et al. (2011) ‘Luteolin induces apoptosis through endoplasmic reticulum stress and 
mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells’, European Journal of 
Pharmacology. Elsevier B.V., 668(1–2), pp. 115–126. doi: 10.1016/j.ejphar.2011.06.047. 
Chollet, M. E. et al. (2015) ‘The chemical chaperone sodium 4-phenylbutyrate improves the secretion 
of the protein CA267T mutant in CHO-K1 cells trough the GRASP55 pathway.’, Cell & bioscience. 
BioMed Central, 5, p. 57. doi: 10.1186/s13578-015-0048-4. 
Chung, S. et al. (2019) ‘An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive 
assessment of nonspecific clearance of antibody therapeutics in humans’, mAbs. Taylor & Francis, 
11(5), pp. 942–955. doi: 10.1080/19420862.2019.1605270. 
Churches, Q. I. et al. (2014) ‘Naturally occurring polyphenolic inhibitors of amyloid beta aggregation’, 
Bioorganic & Medicinal Chemistry Letters. Elsevier Ltd, 24(14), pp. 3108–3112. doi: 
10.1016/j.bmcl.2014.05.008. 
Conte, A., Pellegrini, S. and Tagliazucchi, D. (2003) ‘Synergistic protection of PC12 cells from β-amyloid 
toxicity by resveratrol and catechin’, Brain Research Bulletin, 62(1), pp. 29–38. doi: 
10.1016/j.brainresbull.2003.08.001. 
Coronel, J. et al. (2016) ‘Valeric acid supplementation combined to mild hypothermia increases 
productivity in CHO cell cultivations’, Biochemical Engineering Journal. Elsevier B.V., 114, pp. 101–109. 
doi: 10.1016/j.bej.2016.06.031. 
DeZengotita, V. M. et al. (2002) ‘Selected amino acids protect hybridoma and CHO cells from elevated 
carbon dioxide and osmolality’, Biotechnology and Bioengineering, 78(7), pp. 741–752. doi: 
10.1002/bit.10255. 
Dick, L. W. J. et al. (2007) ‘Determination of the Origin of the N-Terminal Pyro-Glutamate Variation in 
Monoclonal Antibodies Using Model Peptides’, Biotechnology and Bioengineering, 97(3), pp. 544–553. 
doi: 10.1002/bit. 
 References 318 
Dick, L. W. J. et al. (2008) ‘C-Terminal Lysine Variants in Fully Human Monoclonal Antibodies : 
Investigation of Test Methods and Possible Causes’, Biotechnology and Bioengineering, 100(6), pp. 
1132–1143. doi: 10.1002/bit.21855. 
Dobson, C. M. (2003) ‘Protein Folding and Misfolding’, Nature, 426, pp. 884–890. doi: 10.1007/978-3-
642-22230-6. 
Du, Z. et al. (2015) ‘Use of a small molecule cell cycle inhibitor to control cell growth and improve 
specific productivity and product quality of recombinant proteins in CHO cell cultures’, Biotechnology 
and Bioengineering, 112(1), pp. 141–155. doi: 10.1002/bit.25332. 
Dutton, R. L., Scharer, J. and Moo-Young, M. (2006) ‘Cell cycle phase dependent productivity of a 
recombinant Chinese hamster ovary cell line’, Cytotechnology, 52(1), pp. 55–69. doi: 10.1007/s10616-
006-9041-4. 
Ehrnhoefer, D. E. et al. (2008) ‘EGCG redirects amyloidogenic polypeptides into unstructured, off-
pathway oligomers.’, Nature structural & molecular biology, 15(6), pp. 558–566. doi: 
10.1038/nsmb.1437. 
Eisele, Y. S. et al. (2015) ‘Targeting protein aggregation for the treatment of degenerative diseases’, 
Nature Reviews Drug Discovery. Nature Publishing Group, pp. 759–780. doi: 10.1038/nrd4593. 
El-Khattouti, A. et al. (2015) ‘CD133+melanoma subpopulation acquired resistance to caffeic acid 
phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: Significance for 
melanoma treatment’, Cancer Letters. Elsevier Ireland Ltd, 357(1), pp. 83–104. doi: 
10.1016/j.canlet.2014.10.043. 
Eletto, D. et al. (2014) ‘Redox controls UPR to control redox.’, Journal of cell science, 127, pp. 3649–
3658. doi: 10.1242/jcs.153643. 
Endo, H. et al. (2014) ‘Structure activity relationship study of curcumin analogues toward the amyloid-
beta aggregation inhibitor’, Bioorganic & Medicinal Chemistry Letters. Elsevier Ltd, 24(24), pp. 5621–
5626. doi: 10.1016/j.bmcl.2014.10.076. 
 References 319 
Esser, P and Weitzmann, L. (2011) ‘Evaporation From Cell Culture Plates’, Thermo Scientific Bolletin, 
(2). 
Fabris, S. et al. (2008) ‘Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles 
and monolamellar liposomes’, Biophysical Chemistry, 135(1–3), pp. 76–83. doi: 
10.1016/j.bpc.2008.03.005. 
Fazzio, A., Marilley, D. and Azzi, A. (1997) ‘The effect of alfa-Tocopherol and beta-tocopherol on 
proliferation, protein kinase C activity and gene expression in different cell lines.’, Biochemistry and 
molecular biology international, 41(1), pp. 93–101. 
Fekete, S. et al. (2013) ‘Analytical strategies for the characterization of therapeutic monoclonal 
antibodies’, TrAC - Trends in Analytical Chemistry. Elsevier Ltd, 42, pp. 74–83. doi: 
10.1016/j.trac.2012.09.012. 
Ferreira, N., Saraiva, M. J. and Almeida, M. R. (2012) ‘Epigallocatechin-3-gallate as a potential 
therapeutic drug for TTR-related amyloidosis: “In vivo” evidence from FAP mice models’, PLoS ONE, 
7(1), pp. 5–14. doi: 10.1371/journal.pone.0029933. 
Fliedl, L., Grillari, J. and Grillari-Voglauer, R. (2014) ‘Human cell lines for the production of recombinant 
proteins: on the horizon’, New Biotechnology. Elsevier B.V., 32(6), pp. 673–679. doi: 
10.1016/j.nbt.2014.11.005. 
Flintoff, W. F., Davidson, S. V and Siminovitch, L. (1976) ‘Isolation and partial characterization of three 
methotrexate-resistant phenotypes from Chinese hamster ovary cells.’, Somatic cell genetics, 2, pp. 
245–261. 
Flores-Ortiz, L. F. et al. (2014) ‘Physicochemical properties of Rituximab’, Journal of Liquid 
Chromatography and Related Technologies, 37(10), pp. 1438–1452. doi: 
10.1080/10826076.2013.794738. 
Fomina-Yadlin, D. et al. (2015) ‘Transcriptome analysis of a CHO cell line expressing a recombinant 
therapeutic protein treated with inducers of protein expression’, Journal of Biotechnology. Elsevier 
 References 320 
B.V., 212, pp. 106–115. doi: 10.1016/j.jbiotec.2015.08.025. 
Food and Drug Administration (2015) ‘Novel New Drugs 2014’. 
Le Fourn, V. et al. (2014) ‘CHO cell engineering to prevent polypeptide aggregation and improve 
therapeutic protein secretion’, Metabolic Engineering, 21, pp. 91–102. doi: 
10.1016/j.ymben.2012.12.003. 
Freund, N. W. and Croughan, M. S. (2018) ‘A simple method to reduce both lactic acid and ammonium 
production in industrial animal cell culture’, International Journal of Molecular Sciences, 19(2). doi: 
10.3390/ijms19020385. 
Fried, J., Perez, A. G. and Clarkson, B. D. (1976) ‘Flow Cytofluorometric Analysis of Cell Cycle 
Distributions Using Propidium Iodide’, The Journal of Cell Biology, 71(1), pp. 172–181. 
Gandhi, S. et al. (2012) ‘Elucidation of Degradants in Acidic Peak of Cation Exchange Chromatography 
in an IgG1 Monoclonal Antibody Formed on Long-Term Storage in a Liquid Formulation’, 
Pharmacological Research, 29, pp. 209–224. doi: 10.1007/s11095-011-0536-0. 
Garnier,  a et al. (1994) ‘Scale-up of the adenovirus expression system for the production of 
recombinant protein in human 293S cells.’, Cytotechnology, 15(1–3), pp. 145–155. doi: doi: 
10.1007/bf00762389. 
Gemelli, T. F. et al. (2015) ‘Evaluation of Safety of Arrabidaea chica Verlot (Bignoniaceae), a Plant with 
Healing Properties’, Journal of Toxicology and Environmental Health - Part A: Current Issues. Taylor & 
Francis, 78(18), pp. 1170–1180. doi: 10.1080/15287394.2015.1072070. 
Ginsberg, J. (2008) ‘Development of Deep-tank Fermentation’, Pfizer Inc. 
Goetze, A. M. et al. (2011) ‘High-mannose glycans on the Fc region of therapeutic IgG antibodies 
increase serum clearance in humans’, Glycobiology, 21(7), pp. 949–959. doi: 10.1093/glycob/cwr027. 
Gokbulut, A. A. et al. (2013) ‘Resveratrol and quercetin-induced apoptosis of human 232B4 chronic 
 References 321 
lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest.’, Hematology, 18(3), pp. 
144–150. doi: 10.1179/1607845412Y.0000000042. 
Gomez, N. et al. (2012) ‘Culture temperature modulates aggregation of recombinant antibody in cho 
cells’, Biotechnology and Bioengineering, 109(1), pp. 125–136. doi: 10.1002/bit.23288. 
Gonçalves,  a. M. et al. (2013) ‘Pichia pastoris: A recombinant microfactory for antibodies and human 
membrane proteins’, Journal of Microbiology and Biotechnology, 23(5), pp. 587–601. doi: 
10.4014/jmb.1210.10063. 
Gramer, M. J. et al. (1995) ‘Removal of Sialic Acid from a Glycoprotein in CHO Cell Culture Supernatant 
by Action of an Extracellular CHO Cell Sialidase’, Biotechnology, 13(July), pp. 692–698. 
Gramer, M. J. and Goochee, C. F. (1993) ‘Glycosidase Activities in Chinese Hamster Ovary Cell Lysate 
and Cell Culture Supernatant’, Biotechnology Progress, 9, pp. 366–373. 
Gusnard, D. and Kirschner, R. H. (1977) ‘Cell and organelle shrinkage during preparation for scanning 
electron microscopy: effects of fixation, dehydration and critical point drying’, Journal of Microscopy, 
110(1), pp. 51–57. doi: 10.1111/j.1365-2818.1977.tb00012.x. 
Hadavand, N., Valadkhani, M. and Zarbakhsh, A. (2011) ‘Biologicals Current regulatory and scienti fi c 
considerations for approving biosimilars in Iran’, Biologicals. Elsevier Ltd, 39(5), pp. 325–327. doi: 
10.1016/j.biologicals.2011.06.019. 
Hahnvajanawong, C. et al. (2011) ‘Inhibition of cell cycle progression and apoptotic activity of 
resveratrol in human intrahepatic cholangiocarcinoma cell lines’, Asian Biomedicine, 5(6), pp. 775–
785. doi: 10.5372/1905-7415.0506.116. 
Hartl, F. U., Bracher, A. and Hayer-Hartl, M. (2011) ‘Molecular chaperones in protein folding and 
proteostasis.’, Nature, 475(7356), pp. 324–332. doi: 10.1038/nature10317. 
Hartl, F. U. and Hayer-Hartl, M. (2009) ‘Converging concepts of protein folding in vitro and in vivo’, 
Nature structural & Molecular Biology, 16(6), pp. 574–581. doi: 10.1038/nsmb.1591. 
 References 322 
Hayashi, T. and Su, T.-P. (2007) ‘Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface 
Regulate Ca2+ Signaling and Cell Survival’, Cell, 131(3), pp. 596–610. doi: 10.1016/j.cell.2007.08.036. 
Hendrick, V. et al. (1999) ‘MODULATION OF CELL CYCLE FOR OPTIMAL RECOMBINANT 
PROTEINPRODUCTION’, Animal Cell Technology: Products from Cells, Cells as Products, pp. 179–181. 
Ho, S. C. L. et al. (2013) ‘Control of IgG LC: HC ratio in stably transfected CHO cells and study of the 
impact on expression, aggregation, glycosylation and conformational stability’, Journal of 
Biotechnology. Elsevier B.V., 165(3–4), pp. 157–166. doi: 10.1016/j.jbiotec.2013.03.019. 
Hobro, A. J. and Smith, N. I. (2017) ‘An evaluation of fixation methods: Spatial and compositional 
cellular changes observed by Raman imaging’, Vibrational Spectroscopy. Elsevier B.V., 91, pp. 31–45. 
doi: 10.1016/j.vibspec.2016.10.012. 
Hosoi, T. et al. (2014) ‘Caffeine attenuated ER stress-induced leptin resistance in neurons.’, 
Neuroscience letters. Elsevier Ireland Ltd, 569, pp. 23–6. doi: 10.1016/j.neulet.2014.03.053. 
Hossler, P. et al. (2015) ‘Cell culture media supplementation of bioflavonoids for the targeted 
reduction of acidic species charge variants on recombinant therapeutic proteins’, Biotechnology 
Progress, 31(4), pp. 1039–1052. doi: 10.1002/btpr.2095. 
Hsiao, G. et al. (2007) ‘Characterization of a novel and potent collagen antagonist, caffeic acid 
phenethyl ester, in human platelets: In vitro and in vivo studies’, Cardiovascular Research, 75(4), pp. 
782–792. doi: 10.1016/j.cardiores.2007.05.005. 
Huang, L. et al. (2005) ‘In Vivo Deamidation Characterization of Monoclonal Antibody by LC / MS / 
MS’, Analytical Chemistry, 77(5), pp. 1432–1439. doi: 10.1021/ac0494174. 
Huang, Q. et al. (2005) ‘(+)-Catechin, an ingredient of green tea, protects murine microglia from 
oxidative stress-induced DNA damage and cell cycle arrest.’, Journal of Pharmacological Sciences, 
98(1), pp. 16–24. doi: 10.1254/jphs.FPJ04053X. 
Huh, J. H. et al. (2013) ‘Pharmaceutical Biotechnology The Identification of Free Cysteine Residues 
 References 323 
Within Antibodies and a Potential Role for Free Cysteine Residues in Covalent’, Journal of 
Pharmaceutical Sciences. Elsevier Masson SAS, 102(6), pp. 1701–1711. doi: 10.1002/jps.23505. 
Hussain, H., Maldonado-Agurto, R. and Dickson, A. J. (2014) ‘The endoplasmic reticulum and unfolded 
protein response in the control of mammalian recombinant protein production’, Biotechnology 
Letters, 36(8), pp. 1581–1593. doi: 10.1007/s10529-014-1537-y. 
Hwang, S. J. et al. (2011) ‘Effect of chemical chaperone addition on production and aggregation of 
recombinant flag-tagged COMP-angiopoietin 1 in chinese hamster ovary cells’, Biotechnology 
Progress, 27(2), pp. 587–591. doi: 10.1002/btpr.579. 
IFPMA, I. F. of P. M. A. (2012) ‘The Pharmaceutical Industry and Global Health : Facts and Figures 2012’. 
IFPMA, I. F. of P. M. A. (2014) ‘The Pharmaceutical Industry and Global Health : Facts and Figures 2014’. 
Jaramillo-García, V. et al. (2018) ‘Chemical characterization and cytotoxic, genotoxic, and mutagenic 
properties of Baccharis trinervis (Lam, Persoon) from Colombia and Brazil’, Journal of 
Ethnopharmacology. Elsevier Ireland Ltd, 213(July 2017), pp. 210–220. doi: 
10.1016/j.jep.2017.10.027. 
Jayapal, K. et al. (2007) ‘Recombinant protein therapeutics from CHO cells-20 years and counting’, 
Chemical Engineering Progress, 103(10), pp. 40–47. Available at: 
http://www.aiche.org/sites/default/files/docs/pages/CHO.pdf. 
De Jesus, M. and Wurm, F. M. (2011) ‘Manufacturing recombinant proteins in kg-ton quantities using 
animal cells in bioreactors’, European Journal of Pharmaceutics and Biopharmaceutics. Elsevier B.V., 
78(2), pp. 184–188. doi: 10.1016/j.ejpb.2011.01.005. 
Jiang, Z. and Sharfstein, S. T. (2008) ‘Sodium butyrate stimulates monoclonal antibody over-expression 
in CHO cells by improving gene accessibility’, Biotechnology and Bioengineering, 100(1), pp. 189–194. 
doi: 10.1002/bit.21726. 
Jin, U. H. et al. (2008) ‘Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in 
 References 324 
human myeloid leukemia U937 cells’, Molecular and Cellular Biochemistry, 310(1–2), pp. 43–48. doi: 
10.1007/s11010-007-9663-7. 
Johari, Y. B. et al. (2015a) ‘Integrated cell and process engineering for improved transient production 
of a “difficult-to-express” fusion protein by CHO cells’, Biotechnology and Bioengineering, 112(12), pp. 
2527–2542. doi: 10.1002/bit.25687. 
Johari, Y. B. et al. (2015b) ‘Integrated cell and process engineering for improved transient production 
of a “difficult-to-express” fusion protein by CHO cells’, Biotechnology and Bioengineering, 112(12), pp. 
2527–2542. doi: 10.1002/bit.25687. 
Jones, D. et al. (2003) ‘High-level expression of recombinant IgG in the human cell line per.c6.’, 
Biotechnol Prog, 19(1), pp. 163–168. doi: 10.1021/bp025574h. 
Jovanovic, S. V et al. (1994) ‘Flavonoids as Antioxidants’, Journal of the American Chemical Society, 
116(11), pp. 4846–4851. doi: 10.1021/ja00090a032. 
Kaas, C. et al. (2015) ‘Sequencing the CHO DXB11 genome reveals regional variations in genomic 
stability and haploidy’, BMC Genomics, 16(1), p. 160. doi: 10.1186/s12864-015-1391-x. 
Kaisermayer, C. et al. (2016) ‘Biphasic cultivation strategy to avoid Epo-Fc aggregation and optimize 
protein expression’, Journal of Biotechnology. Elsevier B.V., 227, pp. 3–9. doi: 
10.1016/j.jbiotec.2016.03.054. 
Kanda, Y. et al. (2006) ‘Comparison of biological activity among nonfucosylated therapeutic IgG1 
antibodies with three different N -linked Fc oligosaccharides : the high-mannose , hybrid , and complex 
types’, Glycobiology, 17(1), pp. 104–118. 
Kavakli, H. S. et al. (2010) ‘Caffeic acid phenethyl ester decreases oxidative stress index in blunt spinal 
cord injury in rats’, Hong Kong Journal of Emergency Medicine, 17(3), pp. 250–255. doi: 
10.1177/102490791001700308. 
Kim, J. K. et al. (2010) ‘Protective Effects of Kaempferol (3,4ʹ,5,7-tetrahydroxyflavone) against Amyloid 
 References 325 
Beta Peptide (Aβ)-Induced Neurotoxicity in ICR Mice’, Bioscience, Biotechnology, and Biochemistry, 
74(2), pp. 397–401. doi: 10.1271/bbb.90585. 
Kim, J. Y., Kim, Y. G. and Lee, G. M. (2012) ‘CHO cells in biotechnology for production of recombinant 
proteins: Current state and further potential’, Applied Microbiology and Biotechnology, 93(3), pp. 
917–930. doi: 10.1007/s00253-011-3758-5. 
Kim, N. S. and Lee, G. M. (2002) ‘Response of recombinant Chinese hamster ovary cells to 
hyperosmotic pressure: Effect of Bcl-2 overexpression’, Journal of Biotechnology, 95(3), pp. 237–248. 
doi: 10.1016/S0168-1656(02)00011-1. 
Kishishita, S. et al. (2015) ‘Optimization of chemically defined feed media for monoclonal antibody 
production in Chinese hamster ovary cells’, Journal of Bioscience and Bioengineering. Elsevier Ltd, 
120(1), pp. 78–84. doi: 10.1016/j.jbiosc.2014.11.022. 
Kmetič, I. et al. (2009) ‘Lindane-induced cytotoxicity and the role of vitamin e in Chinese hamster ovary 
(CHO-K1) cells’, Toxicology Mechanisms and Methods, 19(8), pp. 518–523. doi: 
10.1080/15376510903280107. 
Kou, T. C. et al. (2011) ‘Detailed understanding of enhanced specific productivity in Chinese hamster 
ovary cells at low culture temperature’, Journal of Bioscience and Bioengineering. The Society for 
Biotechnology, Japan, 111(3), pp. 365–369. doi: 10.1016/j.jbiosc.2010.11.016. 
Krishan, A. (1975) ‘RAPID FLOW CYTOFLUOROMETRIC MAMMALIAN ANALYSIS OF IODIDE STAINING’, 
The Journal of Cell Biology, 66, pp. 188–193. 
Krishnan, R., Rendeiro, D. and San-Dadi, S. (2010) ‘WO 2010/036767 Al’. 
Kubota, K. et al. (2006) ‘Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors 
and endoplasmic reticulum stress’, Journal of Neurochemistry, 97(5), pp. 1259–1268. doi: 
10.1111/j.1471-4159.2006.03782.x. 
Kumar, N. et al. (2014) ‘Synthesis, structural elucidation, and in vitro antiproliferative activities of 
 References 326 
mixed-ligand titanium complexes’, Medicinal Chemistry Research, 23(8), pp. 3897–3906. doi: 
10.1007/s00044-014-0963-7. 
Kumar, N., Gammell, P. and Clynes, M. (2007) ‘Proliferation control strategies to improve productivity 
and survival during CHO based production culture: A summary of recent methods employed and the 
effects of proliferation control in product secreting CHO cell lines’, Cytotechnology, 53(1–3), pp. 33–
46. doi: 10.1007/s10616-007-9047-6. 
Kürbitz, C. et al. (2011) ‘Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate 
in growth suppression and anti-inflammatory activities in pancreatic tumor cells’, Cancer Science, 
102(4), pp. 728–734. doi: 10.1111/j.1349-7006.2011.01870.x. 
Kuryatov, A., Mukherjee, J. and Lindstrom, J. (2013) ‘Chemical Chaperones Exceed the Chaperone 
Effects of RIC-3 in Promoting Assembly of Functional ??7 AChRs’, PLoS ONE, 8(4), pp. 1–11. doi: 
10.1371/journal.pone.0062246. 
Lacy, E. R., Baker, M. and Brigham-burke, M. (2008) ‘Free sulfhydryl measurement as an indicator of 
antibody stability’, Analytical Chemistry, 382, pp. 66–68. doi: 10.1016/j.ab.2008.07.016. 
Ladiwala, A. R. a et al. (2010) ‘Resveratrol selectively remodels soluble oligomers and fibrils of amyloid 
A?? into off-pathway conformers’, Journal of Biological Chemistry, 285(31), pp. 24228–24237. doi: 
10.1074/jbc.M110.133108. 
Lao, M. S. and Toth, D. (1997) ‘Effects of ammonium and lactate on growth and metabolism of a 
recombinant Chinese hamster ovary cell culture’, Biotechnology Progress, 13(5), pp. 688–691. doi: 
10.1021/bp9602360. 
Leblanc, Y. et al. (2017) ‘Charge variants characterization of a monoclonal antibody by ion exchange 
chromatography coupled on-line to native mass spectrometry : Case study after a long-term storage 
at + 5 ◦C’, Journal of Chromatography B. Elsevier B.V., 1048, pp. 130–139. doi: 
10.1016/j.jchromb.2017.02.017. 
Lee, C. L. et al. (2010) ‘Ixorapeptide i and ixorapeptide II, bioactive peptides isolated from Ixora 
 References 327 
coccinea’, Bioorganic and Medicinal Chemistry Letters. Elsevier Ltd, 20(24), pp. 7354–7357. doi: 
10.1016/j.bmcl.2010.10.058. 
Lee Ching, H. et al. (1996) ‘Mutual interactions among ingredients of betel quid in inducing 
genotoxicity on Chinese hamster ovary cells’, Mutation Research - Genetic Toxicology, 367(2), pp. 99–
104. doi: 10.1016/0165-1218(95)00081-X. 
Lee, J. H., Wendorff, T. J. and Berger, J. M. (2017) ‘Resveratrol: A novel type of topoisomerase II 
inhibitor’, The Journal of Biological Chemistry. Applied Microbiology and Biotechnology, 292(51), pp. 
21011–21022. doi: 10.1021/cb500798y. 
Lee, Y. J., Kim, S. J. and Heo, T. H. (2011) ‘Protective effect of catechin in type I Gaucher disease cells 
by reducing endoplasmic reticulum stress’, Biochemical and Biophysical Research Communications. 
Elsevier Inc., 413(2), pp. 254–258. doi: 10.1016/j.bbrc.2011.08.080. 
Lehmann, A. R. and Kirk-Bell, S. (1972) ‘{Post-Replication} Repair of {DNA} in {Ultraviolet-Irradiated} 
Mammalian Cells’, European Journal of Biochemistry, 31(3), pp. 438–445. doi: 10.1111/j.1432-
1033.1972.tb02550.x. 
Lenin, R. et al. (2012) ‘Amelioration of glucolipotoxicity-induced endoplasmic reticulum stress by a 
chemical chaperone in human THP-1 monocytes’, Experimental Diabetes Research, 2012(c). doi: 
10.1155/2012/356487. 
Leone, S. et al. (2010) ‘Resveratrol induces DNA double-strand breaks through human topoisomerase 
II interaction’, Cancer Letters. Elsevier Ireland Ltd, 295(2), pp. 167–172. doi: 
10.1016/j.canlet.2010.02.022. 
Leone, S. et al. (2012) ‘Resveratrol acts as a topoisomerase II poison in human glioma cells’, 
International Journal of Cancer, 131(3). doi: 10.1002/ijc.27358. 
Lewis, N. E. et al. (2013) ‘Genomic landscapes of Chinese hamster ovary cell lines as revealed by the 
Cricetulus griseus draft genome.’, Nature biotechnology. Nature Publishing Group, 31(8), pp. 759–65. 
doi: 10.1038/nbt.2624. 
 References 328 
Li, Y.-C. et al. (2008) ‘Protective Effects of Antioxidants on Micronuclei Induced by Irradiated 9-
Fluorenone/N,N-Dimethyl-p-toluidine in CHO Cells’, Journal of Biomedical Materials Research, 84B(1), 
pp. 58–63. doi: 10.1002/jbmb. 
Liu, C., Chu, I. and Hwang, S. (2001) ‘Pentanoic acid, a novel protein synthesis stimulant for Chinese 
Hamster Ovary (CHO) cells.’, Journal of bioscience and bioengineering, 91(1), pp. 71–5. doi: 
http://dx.doi.org/10.1016/S1389-1723(01)80114-6. 
Liu, H. et al. (2008) ‘Heterogeneity of monoclonal antibodies’, Journal of Pharmaceutical Sciences. 
Elsevier Masson SAS, 97(7), pp. 2426–2447. doi: 10.1002/jps.21180. 
Liu, H. et al. (2016) ‘Impact of Cell Culture on Recombinant Monoclonal Antibody Product 
Heterogeneity’, Biotechnology Progress, 32(5), pp. 1103–1013. doi: 10.1002/btpr.2327. 
Liu, H. F. et al. (2010) ‘Recovery and purification process development for monoclonal antibody 
production’, mAbs, 2(5), pp. 480–499. doi: 10.4161/mabs.2.5.12645. 
Liu, Y. et al. (2001) ‘A domain-sw apped RNase A dimer w ith implications for amyloid formation’, 
Nature, 8(3), pp. 211–214. 
Lloyd, D. R. et al. (1999) ‘The role of the cell cycle in determining gene expression and productivity in 
CHO cells.’, Cytotechnology, 30(1–3), pp. 49–57. doi: 10.1023/A:1008093404237. 
Lloyd, D. R. et al. (2000) ‘Relationship between cell size, cell cycle and specific recombinant protein 
productivity.’, Cytotechnology, 34(1–2), pp. 59–70. doi: 10.1023/A:1008103730027. 
Long, L. H. et al. (2007) ‘Different cytotoxic and clastogenic effects of epigallocatechin gallate in 
various cell-culture media due to variable rates of its oxidation in the culture medium’, Mutation 
Research - Genetic Toxicology and Environmental Mutagenesis, 634(1–2), pp. 177–183. doi: 
10.1016/j.mrgentox.2007.07.009. 
Lu, L. Y., Ou, N. and Lu, Q. Bin (2013) ‘Antioxidant Induces DNA damage, cell death and mutagenicity 
in human lung and skin normal cells’, Scientific Reports, 3, pp. 1–11. doi: 10.1038/srep03169. 
 References 329 
Lyubarskaya, Y. et al. (2006) ‘Analysis of recombinant monoclonal antibody isoforms by electrospray 
ionization mass spectrometry as a strategy for streamlining characterization of recombinant 
monoclonal antibody charge heterogeneity’, Analytical Biochemistry, 348(1), pp. 24–39. doi: 
10.1016/j.ab.2005.10.003. 
Ma, W., Goldberg, E. and Goldberg, J. (2017) ‘ER retention is imposed by COPII protein sorting and 
attenuated by 4-phenylbutyrate’, eLife, 6, pp. 1–22. doi: 10.7554/eLife.26624. 
Maeda, E. et al. (2012) ‘Analysis of Nonhuman N -Glycans as the Minor Constituents in Recombinant 
Monoclonal Antibody Pharmaceuticals’, Analytical Chemistry, 84, p. 2373−2379. 
Mallebrera, B. et al. (2015) ‘Cytoprotective effect of resveratrol diastereomers in CHO-K1 cells 
exposed to beauvericin’, Food and Chemical Toxicology. Elsevier Ltd, 80, pp. 319–327. doi: 
10.1016/j.fct.2015.03.028. 
Marambaud, P., Zhao, H. and Davies, P. (2005) ‘Resveratrol promotes clearance of Alzheimer’s disease 
amyloid-?? peptides’, Journal of Biological Chemistry, 280(45), pp. 37377–37382. doi: 
10.1074/jbc.M508246200. 
Mendoza-Espinosa, P. et al. (2009) ‘Disorder-to-order conformational transitions in protein structure 
and its relationship to disease’, Molecular and Cellular Biochemistry, 330(1–2), pp. 105–120. doi: 
10.1007/s11010-009-0105-6. 
Mo, J. et al. (2016) ‘Understanding the Impact of Methionine Oxidation on the Biological Functions of 
IgG1 Antibodies Using Hydrogen/Deuterium Exchange Mass Spectrometry’, Analytical Chemistry, 
88(19), pp. 9495–9502. doi: 10.1021/acs.analchem.6b01958. 
Molecular Probes, I. (1999) ‘Propidium iodide nucleic acid stain’, Molecular Probes, pp. 1–3. doi: 
10.1101/pdb.caut676. 
Mortazavi, M. et al. (2018) ‘Coordinate effects of betaine in reducing intra and extracellular 
erythropoietin aggregation’, Research Journal of Biotechnology, 13, pp. 79–84. 
 References 330 
Murugesan, M. and Manju, V. (2013) ‘Luteolin promotes mitochondrial protection during acute and 
chronic periods of isoproterenol induced myocardial infarction in rats’, Egyptian Heart Journal. The 
Egyptian Heart Journal, 65(4), pp. 319–327. doi: 10.1016/j.ehj.2013.02.005. 
N’soukpoé-Kossi, C. N. et al. (2015) ‘Structural modeling for DNA binding to antioxidants resveratrol, 
genistein and curcumin.’, Journal of Photochemistry and Photobiology B: Biology, 151, pp. 69–75. doi: 
10.1016/j.jphotobiol.2015.07.007. 
Van Ness, K. P. et al. (2005) ‘US 6872549 B2’. doi: 10.1038/incomms1464. 
Nisha, V. M. et al. (2014) ‘Apigenin and Quercetin Ameliorate Mitochondrial Alterations by 
Tunicamycin-Induced ER Stress in 3T3-L1 Adipocytes’, Applied Biochemistry and Biotechnology, 
174(4), pp. 1365–1375. doi: 10.1007/s12010-014-1129-2. 
Noh, S. M., Shin, S. and Lee, G. M. (2018) ‘Comprehensive characterization of glutamine synthetase-
mediated selection for the establishment of recombinant CHO cells producing monoclonal 
antibodies’, Scientific Reports. Springer US, 8(1), pp. 1–11. doi: 10.1038/s41598-018-23720-9. 
Ombelli, M. et al. (2011) ‘Competitive protein adsorption on polysaccharide and hyaluronate modified 
surfaces.’, Biofouling, 27(5), pp. 505–518. doi: 10.1080/08927014.2011.585711. 
Ono, K. et al. (2004) ‘Curcumin Has Potent Anti-Amyloidogenic Effects for Alzheimer’s ??-Amyloid 
Fibrils In Vitro’, Journal of Neuroscience Research, 75(6), pp. 742–750. doi: 10.1002/jnr.20025. 
Onuchic, J. N. and Wolynes, P. G. (2004) ‘Theory of protein folding’, Current Opinion in Structural 
Biology, 14(1), pp. 70–75. doi: 10.1016/j.sbi.2004.01.009. 
Ozdal, T., Capanoglu, E. and Altay, F. (2013) ‘A review on protein-phenolic interactions and associated 
changes’, Food Research International. Elsevier Ltd, 51(2), pp. 954–970. doi: 
10.1016/j.foodres.2013.02.009. 
Ozturk, G. et al. (2012) ‘The anticancer mechanism of caffeic acid phenethyl ester (CAPE): review of 
melanomas, lung’, European Review for Medical and Pharmacological Sciences, 16, pp. 2064–2068. 
 References 331 
doi: 10.1016/j.egypro.2017.09.655. 
Pace, A. L. et al. (2013) ‘Asparagine Deamidation Dependence on Buffer Type , pH , and Temperature’, 
Journal of Pharmaceutical Sciences. Elsevier Masson SAS, 102(6), pp. 1712–1723. doi: 
10.1002/jps.23529. 
Painter, R. B. (1980) ‘Effect of caffeine on DNA synthesis in irradiated and unirradiated mammalian 
cells’, Journal of Molecular Biology, 143(3), pp. 289–301. doi: 10.1016/0022-2836(80)90191-6. 
Pany, S., You, Y. and Das, J. (2016) ‘Curcumin Inhibits Protein Kinase Cα Activity by Binding to Its C1 
Domain’, Biochemistry, 55(45), pp. 6327–6336. doi: 10.1021/acs.biochem.6b00932. 
Park, J. H. et al. (2016) ‘Valeric acid induces cell cycle arrest at G1 phase in CHO cell cultures and 
improves recombinant antibody productivity’, Biotechnology Journal, 11(4), pp. 487–496. doi: 
10.1002/biot.201500327. 
Park, S. H. et al. (2013) ‘Induction of endoplasmic reticulum stress-mediated apoptosis and non-
canonical autophagy by luteolin in NCI-H460 lung carcinoma cells’, Food and Chemical Toxicology. 
Elsevier Ltd, 56, pp. 100–109. doi: 10.1016/j.fct.2013.02.022. 
Paul, A. J. et al. (2018) ‘Identification of process conditions influencing protein aggregation in Chinese 
hamster ovary cell culture’, Biotechnology and Bioengineering, 115(5), pp. 1173–1185. doi: 
10.1002/bit.26534. 
Percell Biologyca AB (2000) ‘Growth of Recombinant and Non- recombinant CHO-cells’, Application 
Notes, 113. 
Pereira, A. et al. (2018) ‘13 C Flux Analysis Reveals that Rebalancing Medium Amino Acid Composition 
can Reduce Ammonia Production while Preserving Central Carbon Metabolism of CHO Cell Cultures’, 
Biotechnology Journal, 13, p. 1700518. doi: 10.1002/biot.201700518. 
Pereira, S., Kildegaard, H. F. and Andersen, M. R. (2018) ‘Impact of CHO Metabolism on Cell Growth 
and Protein Production: An Overview of Toxic and Inhibiting Metabolites and Nutrients’, 
 References 332 
Biotechnology Journal, 13(3), pp. 1–13. doi: 10.1002/biot.201700499. 
Perkins, M. et al. (2000) ‘Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal 
Antibody’, Pharmacological Research, 17(9), pp. 1110–1117. 
Pietta, P. G. (2000) ‘Flavonoids as antioxidants’, Journal of Natural Products, 63(7), pp. 1035–1042. 
doi: 10.1021/np9904509. 
Pilbrough, W., Munro, T. P. and Gray, P. (2009) ‘Intraclonal protein expression heterogeneity in 
recombinant CHO cells’, PLoS ONE, 4(12). doi: 10.1371/journal.pone.0008432. 
Ponniah, G. et al. (2017) ‘Characterization of charge variants of a monoclonal antibody using weak 
anion exchange chromatography at subunit levels’, Analytical Biochemistry. Elsevier Inc, 520, pp. 49–
57. doi: 10.1016/j.ab.2016.12.017. 
Pozarowski, P. and Darzynkiewicz, Z. (2004) ‘Analysis of cell cycle by flow cytometry.’, Methods Mol 
Biol, 281, pp. 301–311. doi: 10.1385/1-59259-811-0:301. 
Pozo-Guisado, E. et al. (2002) ‘The antiproliferative activity of resveratrol results in apoptosis in MCF-
7 but not in MDA-MB-231 human breast cancer cells: Cell-specific alteration of the cell cycle’, 
Biochemical Pharmacology, 64(9), pp. 1375–1386. doi: 10.1016/S0006-2952(02)01296-0. 
Prabhu, A., Gadre, R. and Gadgil, M. (2018) ‘Zinc supplementation decreases galactosylation of 
recombinant IgG in CHO cells’, Applied Microbiology and Biotechnology. Applied Microbiology and 
Biotechnology, 102(14), pp. 5989–5999. doi: 10.1007/s00253-018-9064-8. 
Prasad, S., Khadatare, P. B. and Roy, I. (2011) ‘Effect of Chemical Chaperones in Improving the 
Solubility of Recombinant Proteins in Escherichia coli’, Applied and Environmental Microbiology, 
77(13), pp. 4603–4609. doi: 10.1128/AEM.05259-11. 
Puck, T. T., Cieciura, S. J. and Robinson, A. (1958) Long-Term Cultivation of Euploid Cells From Human 
and Animal Subjects, Genetics of somatic mammalian cells. 
 References 333 
Quoc Trung, L. et al. (2013) ‘Resveratrol Induces Cell Cycle Arrest and Apoptosis in Malignant NK Cells 
via JAK2/STAT3 Pathway Inhibition’, PLoS ONE, 8(1). doi: 10.1371/journal.pone.0055183. 
Della Ragione, F. et al. (1998) ‘Resveratrol arrests the cell division cycle at S/G2 phase transition.’, 
Biochemical and biophysical research communications, 250(1), pp. 53–58. doi: 
10.1006/bbrc.1998.9263. 
Reinhart, D. et al. (2014) ‘In search of expression bottlenecks in recombinant CHO cell lines - A case 
study’, Applied Microbiology and Biotechnology, 98(13), pp. 5959–5965. doi: 10.1007/s00253-014-
5584-z. 
Ren, D. et al. (2009) ‘An improved trypsin digestion method minimizes digestion-induced 
modifications on proteins’, Analytical Biochemistry. Elsevier Inc., 392(1), pp. 12–21. doi: 
10.1016/j.ab.2009.05.018. 
Renard, J. M. et al. (1988) ‘Evidence that monoclonal antibody production kinetics is related to the 
integral of the viable cells curve in batch systems’, Biotechnology Letters, 10(2), pp. 91–96. 
Robb, E. L. and Stuart, J. A. (2014) ‘The stilbenes resveratrol, pterostilbene and piceid affect growth 
and stress resistance in mammalian cells via a mechanism requiring estrogen receptor beta and the 
induction of Mn-superoxide dismutase’, Phytochemistry. Elsevier Ltd, 98, pp. 164–173. doi: 
10.1016/j.phytochem.2013.11.019. 
Robben, J. H. et al. (2006) ‘Rescue of Vasopressin V2 Receptor Mutants by Chemical Chaperones: 
Specificity and Mechanism’, Molecular biology of the cell, 17(January), pp. 379–386. doi: 
10.1091/mbc.E05. 
Roth, A., Schaffner, W. and Hertel, C. (1999) ‘Phytoestrogen kaempferol (3,4’,5,7-
tetrahydroxyflavone) protects PC12 and T47D cells from ??-amyloid-induced toxicity’, Journal of 
Neuroscience Research, 57(3), pp. 399–404. doi: 10.1002/(SICI)1097-4547(19990801)57:3<399::AID-
JNR12>3.0.CO;2-W. 
Roth, S. D. et al. (2012) ‘Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor 
 References 334 
VIII in Mice with Hemophilia A’, PLoS ONE, 7(9). doi: 10.1371/journal.pone.0044505. 
Rubiolo, J. A. et al. (2012) ‘Resveratrol Inhibits Proliferation of Primary Rat Hepatocytes in G0/G1 by 
Inhibiting DNA Synthesis’, Folia Biologica, 58(4), pp. 166–172. 
Ryu, J. S. et al. (2000) ‘Osmoprotective effect of glycine betaine on foreign protein production in 
hyperosmotic recombinant Chinese hamster ovary cell cultures differs among cell lines’, 
Biotechnology and Bioengineering, 70(2), pp. 167–175. doi: 10.1002/1097-
0290(20001020)70:2<167::AID-BIT6>3.0.CO;2-P. 
Sainz, R. M. et al. (2003) ‘Antioxidant activity of melatonin in Chinese hamster ovarian cells: Changes 
in cellular proliferation and differentiation’, Biochemical and Biophysical Research Communications, 
302(3), pp. 625–634. doi: 10.1016/S0006-291X(03)00230-4. 
Sakakibara, D. et al. (2009) ‘Protein structure determination in living cells by in-cell NMR 
spectroscopy’, Nature, 458(7234), pp. 102–105. doi: 10.1038/nature07814. 
Sambrook, J. F. (1990) ‘The involvement of calcium in transport of secretory proteins from the 
endoplasmic reticulum’, Cell, 61(2), pp. 197–199. doi: 10.1016/0092-8674(90)90798-J. 
Saphire, E. O. et al. (2002) ‘Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility’, 
Journal of Molecular Biology, 319, pp. 9–18. doi: 10.1016/S0022-2836(02)00244-9. 
Sato, N. et al. (2004) ‘Fluctuation of chromatin unfolding associated with variation in the level of gene 
expression’, PLoS ONE, 4(7), pp. 619–630. doi: 10.1371/journal.pone.0008432. 
Schlatter, S. et al. (2005) ‘On the optimal ratio of heavy to light chain genes for efficient recombinant 
antibody production by CHO cells.’, Biotechnology progress, 21(1), pp. 122–33. doi: 
10.1021/bp049780w. 
Schuler, M. et al. (2010) ‘Evaluation of phenolphthalein, diazepam and quinacrine dihydrochloride in 
the in vitro mammalian cell micronucleus test in Chinese hamster ovary (CHO) and TK6 cells’, Mutation 
Research - Genetic Toxicology and Environmental Mutagenesis. Elsevier B.V., 702(2), pp. 219–229. doi: 
 References 335 
10.1016/j.mrgentox.2010.04.004. 
Shabana, S. M. et al. (2014) ‘Anti-Proliferative and Pro-Apoptotic Effects of (-)-Epigallocatechin-3- 
Gallate Encapsulated in Chitosan Nanoparticles on Human Prostate Carcinoma Cells’, Journal of 
Pharmaceutics & Pharmacology, 2(1), pp. 1–8. doi: 10.13188/2327-204X.1000007. 
Sheikholeslami, Z., Jolicoeur, M. and Henry, O. (2013) ‘The impact of the timing of induction on the 
metabolism and productivity of CHO cells in culture’, Biochemical Engineering Journal. Elsevier B.V., 
79, pp. 162–171. doi: 10.1016/j.bej.2013.07.015. 
Shen, F. J. et al. (1996) ‘The Application of tert-Butylhydroperoxide Oxidation to Study Sites of 
Potential Methionine Oxidation in a Recombinant Antibody’, Analytical Chemistry Dept. Genentech, 
Inc, pp. 275–284. 
Shen, X. et al. (2014) ‘Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S 
phase arrest in hepatocellular carcinoma by suppressing the AKT pathway’, International Journal of 
Oncology, 44(3), pp. 791–796. doi: 10.3892/ijo.2014.2251. 
Soloneski, S., Reigosa, M. A. and Larramendy, M. L. (2003) ‘Vitamin E prevents ethylene 
bis(dithiocarbamate) pesticide zineb-induced sister chromatid exchange in Chinese hamster ovary 
cells’, Mutagenesis, 18(6), pp. 505–510. doi: 10.1093/mutage/geg026. 
Song, Y. S. et al. (2002) ‘Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and 
enzyme activity’, Cancer Letters, 175(1), pp. 53–61. doi: 10.1016/S0304-3835(01)00787-X. 
Storniolo, C. E. et al. (2014) ‘Classification of Chemical Chaperones Based on Their Effect on Protein 
Folding Landscapes’, Journal of Biological Chemistry. Elsevier Inc., 6(1), pp. 1–12. doi: 
10.1371/journal.pone.0054505. 
Su, D. et al. (2013) ‘Comparision of Piceid and Resveratrol in Antioxidation and Antiproliferation 
Activities In Vitro’, PLoS ONE, 8(1). doi: 10.1371/journal.pone.0054505. 
Subramanian, M., Soundar, S. and Mangoli, S. (2016) ‘DNA damage is a late event in resveratrol-
 References 336 
mediated inhibition of Escherichia coli’, Free Radical Research, 50(7), pp. 708–719. doi: 
10.3109/10715762.2016.1169404. 
Sunley, K. and Butler, M. (2010) ‘Strategies for the enhancement of recombinant protein production 
from mammalian cells by growth arrest’, Biotechnology Advances. Elsevier Inc., 28(3), pp. 385–394. 
doi: 10.1016/j.biotechadv.2010.02.003. 
Tae Kyung, K. et al. (2000) ‘Osmoprotective effect of glycine betaine on thrombopoietin production in 
hyperosmotic Chinese hamster ovary cell culture: Clonal variations’, Biotechnology Progress, 16(5), 
pp. 775–781. doi: 10.1021/bp000106y. 
Tai, M. et al. (2015) ‘Protective effects of luteolin against acetaminophen-induced acute liver failure 
in mouse’, International Immunopharmacology. Elsevier B.V., 27(1), pp. 164–170. doi: 
10.1016/j.intimp.2015.05.009. 
Tan, X. et al. (2000) ‘Differences of four catechins in cell cycle arrest and induction of apoptosis in LoVo 
cells’, Cancer Letters, 158(1), pp. 1–6. doi: 10.1016/S0304-3835(00)00445-6. 
Tang, L. et al. (2013) ‘Conformational characterization of the charge variants of a human IgG1 
monoclonal antibody using H/D exchange mass spectrometry’, mAbs, 5(1), pp. 114–125. doi: 
10.4161/mabs.22695. 
Tatsumi, K. and Strauss, B. S. (1979) ‘Accumulation of DNA growing points in caffeine-treated human 
lymphoblastoid cells’, Journal of Molecular Biology, 135(2), pp. 435–449. doi: 10.1016/0022-
2836(79)90445-5. 
Thompson, L. H. and Baker, R. M. (1973) ‘Isolation of Mutants of Cultured Mammalian Cells’, Methods 
in Cell Biology, 6, pp. 209–281. 
Thorpe, A. S. et al. (2009) ‘Root exudate is allelopathic in invaded community but not in native 
community: Field evidence for the novel weapons hypothesis’, Journal of Ecology, 97(4), pp. 641–645. 
doi: 10.1111/j.1365-2745.2009.01520.x. 
 References 337 
Tian, J. (2016) ‘WO 2016/130734 Al’. 
Torkashvand, F. and Vaziri, B. (2017) ‘Main Quality Attributes of Monoclonal Antibodies and Effect of 
Cell Culture Components’, Iranian biomedical journal, 21(3), pp. 131–141. doi: 
10.18869/acadpub.ibj.21.3.131. 
Traganos, F., Kaminska-Eddy, B. and Darzynkiewicz, Z. (1991) ‘Caffeine reverses the cytotoxic and cell 
kinetic effects of Novantrone (mitoxantrone)’, Cell Proliferation, 24(3), pp. 305–319. doi: 
10.1111/j.1365-2184.1991.tb01159.x. 
Traversi, G. et al. (2016) ‘Resveratrol and its methoxy-derivatives as modulators of DNA damage 
induced by ionising radiation’, Mutagenesis, 31(4), pp. 433–441. doi: 10.1093/mutage/gew002. 
Trummer, E. et al. (2006) ‘Process Parameter Shifting: Part I. Effect of DOT, pH, and Temperature on 
the Performance of Epo-Fc Expressing CHO Cells Cultivated in Controlled Batch Bioreactors’, 
Bioresource and Bioengineering, 94(6), pp. 1033–1044. doi: 10.1002/bit. 
Trung, L. Q. et al. (2015) ‘Resveratrol selectively induces apoptosis in malignant cells with the 
JAK2V617F mutation by inhibiting the JAK2 pathway’, Molecular Nutrition and Food Research, 59(11), 
pp. 2143–2154. doi: 10.1002/mnfr.201500166. 
Tsao, Y. S. et al. (2005) ‘Monitoring Chinese hamster ovary cell culture by the analysis of glucose and 
lactate metabolism’, Journal of Biotechnology, 118, pp. 316–327. doi: 10.1016/j.jbiotec.2005.05.016. 
Uchiumi, F. et al. (2016) ‘The effect of trans-resveratrol on the expression of the human DNA-repair 
associated genes’, Integrative Molecular Medicine, 3(5), pp. 783–792. doi: 10.15761/IMM.1000246. 
Urlaub, G. et al. (1983) ‘Deletion of the Diploid Dihydrofolate reductase Locus from Cultured 
MAmmalian Cells’, Cell, 33, pp. 405–412. 
Urlaub, G. and Chasin, L. a (1980) ‘Isolation of Chinese hamster cell mutants deficient in dihydrofolate 
reductase activity.’, Proceedings of the National Academy of Sciences of the United States of America, 
77(7), pp. 4216–4220. doi: VL  - 77. 
 References 338 
Vergara, M. et al. (2014) ‘Differential effect of culture temperature and specific growth rate on CHO 
cell behavior in chemostat culture’, PLoS ONE, 9(4), pp. 1–6. doi: 10.1371/journal.pone.0093865. 
Vlasak, J. et al. (2009) ‘Identification and characterization of asparagine deamidation in the light chain 
CDR1 of a humanized IgG1 antibody’, Analytical Biochemistry. Elsevier Inc., 392(2), pp. 145–154. doi: 
10.1016/j.ab.2009.05.043. 
Walsh, G. (2010) ‘Biopharmaceutical benchmarks 2010’, Nature, 28(9), pp. 917–924. 
Walsh, G. (2014) ‘Biopharmaceutical benchmarks 2014’, Nature, 32(10), pp. 992–1000. doi: 
http://dx.doi.org/10.1038/nbt.3040. 
Walsh, G. and Jefferis, R. (2006) ‘Post-translational modifications in the context of therapeutic 
proteins’, Nature Biotechnology, 24(10), pp. 1241–1252. doi: 10.1038/nbt1252. 
Wang, K. et al. (2016) ‘Effects of Chinese Propolis in Protecting Bovine Mammary Epithelial Cells 
against Mastitis Pathogens-Induced Cell Damage’, Mediators of Inflammation. Hindawi Publishing 
Corporation, 2016. doi: 10.1155/2016/8028291. 
Wang, Q., Groenendyk, J. and Michalak, M. (2015) ‘Glycoprotein Quality Control and Endoplasmic 
Reticulum Stress’, Molecules, 20(8), pp. 13689–13704. doi: 10.3390/molecules200813689. 
Wei, Z. et al. (2007) ‘Identification of a Single Tryptophan Residue as Critical for Binding Activity in a 
Humanized Monoclonal Antibody against Respiratory Syncytial Virus’, Analytical Chemistry, 79(7), pp. 
2797–2805. 
Wiebe, M. E. et al. (1989) ‘A multifaced approach to assure that recombinant T-Pa is free of 
adventittious virus’, Developments in Biological Standardization, pp. 147–148. 
Wright, H. T. and Urry, D. W. (2008) ‘Nonenzymatic Deamidation of Asparaginyl and Glutaminyl 
Residues in Protein’, Critical Reviews in Biotechnology and Molecular Biology, 26(1), pp. 1–52. doi: 
10.3109/10409239109081719. 
 References 339 
Wu, J. et al. (2015) ‘Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-
mediated inflammation and apoptosis with regulation of AMPK in endothelial cells’, European Journal 
of Pharmacology, 745, pp. 59–68. doi: 10.1016/j.ejphar.2014.09.046. 
Wurm, F. (2013) ‘CHO Quasispecies—Implications for Manufacturing Processes’, Processes, 1(3), pp. 
296–311. doi: 10.3390/pr1030296. 
Wurm, F. M. (2004) ‘Production of recombinant protein therapeutics in cultivated mammalian cells.’, 
Nature biotechnology, 22(11), pp. 1393–1398. doi: 10.1038/nbt1026. 
Wurm, F. M. and Hacker, D. (2011) ‘First CHO genome’, Nature Biotechnology. Nature Publishing 
Group, 29(8), pp. 718–720. doi: 10.1038/nbt.1943. 
Xu, X. et al. (2011) ‘The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line’, Nature 
Biotechnology. Nature Publishing Group, 29(8), pp. 735–741. doi: 10.1038/nbt.1932. 
Xue, Y., Dong, J. and Liang, J. (2016) ‘Chinese hamster ovary-sphingomyelin synthase2 biospecific 
extraction and liquid chromatography with tandem mass spectrometry analysis for the prediction of 
bioactive components of Rhizoma Polygoni Cuspidati’, Journal of Separation Science, 39(6), pp. 1067–
1072. doi: 10.1002/jssc.201501075. 
Yam, G. H. F. et al. (2007) ‘Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded 
myocilin to rescue cells from endoplasmic reticulum stress and apoptosis’, Investigative 
Ophthalmology and Visual Science, 48(4), pp. 1683–1690. doi: 10.1167/iovs.06-0943. 
Yan, D., Geusz, M. E. and Jamasbi, R. J. (2012) ‘Properties of Lewis Lung Carcinoma Cells Surviving 
Curcumin Toxicity’, Journal of Cancer, 3, pp. 32–41. doi: 10.7150/jca.3659. 
Yang, W. C., Lu, J. and Nguyen, N. B. (2014) ‘Addition of Valproic Acid to CHO Cell Fed-Batch Cultures 
Improves Monoclonal Antibody Titers’, Molecular Biotechnology, 56, pp. 421–428. doi: 
10.1007/s12033-013-9725-x. 
Ye, F. et al. (2017) ‘Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by 
 References 340 
altering the embedding of transmembrane domains’, Journal of Biological Chemistry, 292(24), pp. 
9858–9864. doi: 10.1074/jbc.C117.787309. 
Yeh, H. W. et al. (2009) ‘Comparative cytotoxicity of five current dentin bonding agents: Role of cell 
cycle deregulation’, Acta Biomaterialia. Acta Materialia Inc., 5(9), pp. 3404–3410. doi: 
10.1016/j.actbio.2009.05.036. 
Yoon, S. K. and Ahn, Y. (2007) ‘Effect of Glycine Betaine on Follicle-Stimulating Hormone Production 
by Chinese Hamster Ovary Cells at Low Culture Temperature’, Korean Society for Biotechnology and 
Bioengineering Journal, 22(2), pp. 109–113. 
Zhang, J. et al. (2010) ‘Discovery and synthesis of novel luteolin derivatives as DAT agonists’, 
Bioorganic and Medicinal Chemistry. Elsevier Ltd, 18(22), pp. 7842–7848. doi: 
10.1016/j.bmc.2010.09.049. 
Zhang, J. J. et al. (2010) ‘Discovery and synthesis of novel luteolin derivatives as DAT agonists Jiange’, 
Bioorganic & Medicinal Chemistry. Elsevier Ltd, 18, pp. 7842–7848. doi: 10.1016/j.fct.2013.02.022. 
Zhang, W. and Czupryn, M. J. (2002) ‘Free Sulfhydryl in Recombinant Monoclonal Antibodies’, 
Biotechnology Progress, 18, pp. 509–513. 
Zhang, Y. et al. (2013) ‘Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of 
epigallocatechin 3-O-gallate and several quercetin derivatives’, Journal of Natural Products, 76(3), pp. 
368–373. doi: 10.1021/np3007292. 
Zhao, G. et al. (2010) ‘Neurochemistry International Functional activation of monoamine transporters 
by luteolin and apigenin isolated from the fruit of Perilla frutescens ( L .) Britt’, 56, pp. 168–176. doi: 
10.1016/j.neuint.2009.09.015. 
Zhou, J.-H. et al. (2011) ‘Resveratrol induces apoptosis in pancreatic cancer cells.’, Chinese medical 
journal, 124(11), pp. 1695–9. doi: 10.3760/cma.j.issn.0366-6999.2011.11.017. 
Zhu, H. (2012) ‘Cell Cycle Analysis Using Propidium Iodide Staining with GFP Detection’, bio-protocol, 
 References 341 
2(7), pp. 1–3. 
Zhu, J. (2012) ‘Mammalian cell protein expression for biopharmaceutical production’, Biotechnology 
Advances. Elsevier Inc., 30(5), pp. 1158–1170. doi: 10.1016/j.biotechadv.2011.08.022. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 References 342 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendices 343 
 
 
Appendices 
 
 
 
 
 
 
 Appendices 344 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendices 345 
9 Appendices 
 
9.1 Appendix 1: Calculation of LC50 and GI50 
Luis	Toronjo	Urquiza	23/12/2018	
#######################	
# Calculation of LC50 #	
#######################		
calcula.lc <- function(status, conc, lc=0.5, alfa=0.05, func='probit', arr
ed=2)	
{	
  #Testing if status is a matrix with 2 columns	
  if(!is.matrix(status)) 	
    stop('The status matrix must be a matrix with 2 columns')	
  else{	
    if(dim(status)[2]!=2)stop('The status matrix must have 2 column')	
  }	
  #A function to invert the linear function from a model object, eg. x=(y-
a)/b	
  invlin<-function(x,y){	
    return((y-x$coef[1])/x$coef[2])	
  }	
  #The model itself with the matrix as the outcome and the concentration v
ector as the independent	
  modelo<-glm(status~conc, family = binomial(func))	
  #Getting the significance for the model	
  signif<-as.numeric(anova(modelo, test='Chisq')[2,c(1,4:5)])	
  #Getting the point estimate from the model for the desired LC(default=50
%-0.5)	
  fit<-as.numeric(invlin(modelo, family(modelo)$linkfun(lc)))	
  #Getting the standard error of the estimate, in the link function scale	
  erro<-predict(modelo, se.fit=T, type='response', newdata=data.frame(conc
=fit))$se.fit	
  #Calculating the lower and upper CI based on the error and the chosen al
pha (defaults to 95%CI)	
  lwr<-invlin(modelo, family(modelo)$linkfun(lc+qnorm(alfa/2)*erro))	
  upr<-invlin(modelo, family(modelo)$linkfun(lc-qnorm(alfa/2)*erro))	
  #Packaging everything in an object to be returned	
  lc_resp<-round(data.frame(lc,fit,lwr,upr), arred)	
  #For the Anova, special rounding is required	
  lc_resp<-cbind(lc_resp, df=round(signif[1]), chisq=round(signif[2],2), p
val=signif[3])	
  #Returning the object	
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  return(lc_resp)	
}			
LC50<-read.csv('LC50.csv',na.strings=c(""," ","NA"))			
Treatment<-c(unique(as.character(LC50$Treatment)))		
LCAll1<-matrix(NA,nrow=length(Treatment),ncol =8 )		
colnames(LCAll1)<- c('Treatment','Measurement', '[LC50]','Lower','Upper','
df','ChiSq','p-val')		
for (dx in 1:length(Treatment)){	
  	
  Treat<-Treatment[dx]	
  	
  LC50loop<-subset(LC50[,c(2:length(LC50))],LC50$Treatment==Treatment[[dx]
])	
  	
  LC50loop<-LC50loop[1:24,]	
  	
  if (nrow(subset(LC50loop, is.na(LC50loop$live.cells)))<length(LC50loop$l
ive.cells)){	
    	
    LC50loop<-as.matrix(LC50loop)	
    	
    rslt<-calcula.lc(LC50loop[,c("live.cells","dead.cells")],LC50loop[,c("
Concentration")])	
    	
    	
    LCAll1[dx,2]<-rslt[1,1]	
    LCAll1[dx,3]<-rslt[1,2]	
    LCAll1[dx,4]<-rslt[1,3]	
    LCAll1[dx,5]<-rslt[1,4]	
    LCAll1[dx,6]<-rslt[1,5]	
    LCAll1[dx,7]<-rslt[1,6]	
    LCAll1[dx,8]<-rslt[1,7]	
  }	
  LCAll1[dx,1]<-Treatment[dx]	
}				
LCAll2<-matrix(NA,nrow=length(Treatment),ncol =8 )		
colnames(LCAll2)<- c('Treatment','Measurement', '[LC50]','Lower','Upper','
df','ChiSq','p-val')		
for (dx in 1:length(Treatment)){	
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  Treat<-Treatment[dx]	
  	
  LC50loop<-subset(LC50[,c(2:length(LC50))],LC50$Treatment==Treatment[[dx]
])	
  	
  LC50loop<-LC50loop[25:length(LC50loop[,1]),]	
  	
  	
  if (nrow(subset(LC50loop, is.na(LC50loop$live.cells)))<length(LC50loop$l
ive.cells)){	
    	
    LC50loop<-as.matrix(LC50loop)	
    	
    rslt<-calcula.lc(LC50loop[,c("live.cells","dead.cells")],LC50loop[,c("
Concentration")])	
    	
    	
    LCAll2[dx,2]<-rslt[1,1]	
    LCAll2[dx,3]<-rslt[1,2]	
    LCAll2[dx,4]<-rslt[1,3]	
    LCAll2[dx,5]<-rslt[1,4]	
    LCAll2[dx,6]<-rslt[1,5]	
    LCAll2[dx,7]<-rslt[1,6]	
    LCAll2[dx,8]<-rslt[1,7]	
  }	
  LCAll2[dx,1]<-Treatment[dx]	
}		
LCAll<-matrix(NA,nrow=length(Treatment),ncol =8 )		
colnames(LCAll)<- c('Treatment','Measurement', '[LC50]','Lower','Upper','d
f','ChiSq','p-val')		
for (dx in 1:length(Treatment)){	
  	
  Treat<-Treatment[dx]	
  	
  LC50loop<-(subset(LC50[,c(2:length(LC50))],LC50$Treatment==Treatment[[dx
]]))	
  	
  	
  if (nrow(subset(LC50loop, is.na(LC50loop$live.cells)))<length(LC50loop$l
ive.cells)){	
    	
    LC50loop<-as.matrix(LC50loop)	
    	
    rslt<-calcula.lc(LC50loop[,c("live.cells","dead.cells")],LC50loop[,c("
Concentration")])	
    	
    LCAll[dx,2]<-rslt[1,1]	
    LCAll[dx,3]<-rslt[1,2]	
    LCAll[dx,4]<-rslt[1,3]	
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    LCAll[dx,5]<-rslt[1,4]	
    LCAll[dx,6]<-rslt[1,5]	
    LCAll[dx,7]<-rslt[1,6]	
    LCAll[dx,8]<-rslt[1,7]	
  }	
  LCAll[dx,1]<-Treatment[dx]	
}			
write.csv(LCAll,file='LC50Results.csv')      			
##########################################################################	
##########################################################################		
##########################################################################	
##########################################################################				
#######################	
# Calculation of GI50 #	
#######################		
calcula.lc <- function(status, conc, lc=0.5, alfa=0.05, func='probit', arr
ed=2)	
{	
  #Testing if status is a matrix with 2 columns	
  if(!is.matrix(status)) 	
    stop('The status matrix must be a matrix with 2 columns')	
  else{	
    if(dim(status)[2]!=2)stop('The status matrix must have 2 column')	
  }	
  #A function to invert the linear function from a model object, eg. x=(y-
a)/b	
  invlin<-function(x,y){	
    return((y-x$coef[1])/x$coef[2])	
  }	
  #The model itself with the matrix as the outcome and the concentration v
ector as the independent	
  modelo<-glm(status~conc, family = binomial(func))	
  #Getting the significance for the model	
  signif<-as.numeric(anova(modelo, test='Chisq')[2,c(1,4:5)])	
  #Getting the point estimate from the model for the desired LC(default=50
%-0.5)	
  fit<-as.numeric(invlin(modelo, family(modelo)$linkfun(lc)))	
  #Getting the standard error of the estimate, in the link function scale	
  erro<-predict(modelo, se.fit=T, type='response', newdata=data.frame(conc
=fit))$se.fit	
  #Calculating the lower and upper CI based on the error and the chosen al
pha (defaults to 95%CI)	
  lwr<-invlin(modelo, family(modelo)$linkfun(lc+qnorm(alfa/2)*erro))	
  upr<-invlin(modelo, family(modelo)$linkfun(lc-qnorm(alfa/2)*erro))	
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  #Packaging everything in an object to be returned	
  lc_resp<-round(data.frame(lc,fit,lwr,upr), arred)	
  #For the Anova, special rounding is required	
  lc_resp<-cbind(lc_resp, df=round(signif[1]), chisq=round(signif[2],2), p
val=signif[3])	
  #Returning the object	
  return(lc_resp)	
}		
GI50<-read.csv('GI50.csv',na.strings=c(""," ","NA"))		
GI50$Rlt.Growth<-round(GI50$Rlt.Growth)		
GI50$Rlt.Inhibit<-round(GI50$Rlt.Inhibit)		
Treatment<-c(unique(as.character(GI50$Treatment)))		
GIAll1<-matrix(NA,nrow=length(Treatment),ncol =8 )		
colnames(GIAll1)<- c('Treatment','Measurement', '[GI50]','Lower','Upper','
df','ChiSq','p-val')		
for (dx in 1:length(Treatment)){	
  	
  Treat<-Treatment[dx]	
  	
  GI50loop<-subset(GI50[,c(2:length(GI50))],GI50$Treatment==Treatment[[dx]
])	
  	
  GI50loop<-GI50loop[1:24,]	
  	
  if (nrow(subset(GI50loop, is.na(GI50loop$Rlt.Growth)))<length(GI50loop$R
lt.Growth)){	
    	
    GI50loop<-as.matrix(GI50loop)	
    	
    rslt<-calcula.lc(GI50loop[,c("Rlt.Growth","Rlt.Inhibit")],GI50loop[,c(
"Concentration")])	
    	
    	
    GIAll1[dx,2]<-rslt[1,1]	
    GIAll1[dx,3]<-rslt[1,2]	
    GIAll1[dx,4]<-rslt[1,3]	
    GIAll1[dx,5]<-rslt[1,4]	
    GIAll1[dx,6]<-rslt[1,5]	
    GIAll1[dx,7]<-rslt[1,6]	
    GIAll1[dx,8]<-rslt[1,7]	
  }	
  GIAll1[dx,1]<-Treatment[dx]	
}			
 Appendices 350 
	
GIAll2<-matrix(NA,nrow=length(Treatment),ncol =8 )		
colnames(GIAll2)<- c('Treatment','Measurement', '[GI50]','Lower','Upper','
df','ChiSq','p-val')		
for (dx in 1:length(Treatment)){	
  	
  Treat<-Treatment[dx]	
  	
  GI50loop<-subset(GI50[,c(2:length(GI50))],GI50$Treatment==Treatment[[dx]
])	
  	
  GI50loop<-GI50loop[25:length(GI50loop[,1]),]	
  	
  	
  if (nrow(subset(GI50loop, is.na(GI50loop$Rlt.Growth)))<length(GI50loop$R
lt.Growth)){	
    	
    GI50loop<-as.matrix(GI50loop)	
    	
    rslt<-calcula.lc(GI50loop[,c("Rlt.Growth","Rlt.Inhibit")],GI50loop[,c(
"Concentration")])	
    	
    	
    GIAll2[dx,2]<-rslt[1,1]	
    GIAll2[dx,3]<-rslt[1,2]	
    GIAll2[dx,4]<-rslt[1,3]	
    GIAll2[dx,5]<-rslt[1,4]	
    GIAll2[dx,6]<-rslt[1,5]	
    GIAll2[dx,7]<-rslt[1,6]	
    GIAll2[dx,8]<-rslt[1,7]	
  }	
  GIAll2[dx,1]<-Treatment[dx]	
}		
GIAll<-matrix(NA,nrow=length(Treatment),ncol =8 )		
colnames(GIAll)<- c('Treatment','Measurement', '[GI50]','Lower','Upper','d
f','ChiSq','p-val')		
for (dx in 1:length(Treatment)){	
  	
  Treat<-Treatment[dx]	
  	
  GI50loop<-(subset(GI50[,c(2:length(GI50))],GI50$Treatment==Treatment[[dx
]]))	
  	
  	
  if (nrow(subset(GI50loop, is.na(GI50loop$Rlt.Growth)))<length(GI50loop$R
lt.Growth)){	
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    GI50loop<-as.matrix(GI50loop)	
    	
    rslt<-calcula.lc(GI50loop[,c("Rlt.Growth","Rlt.Inhibit")],GI50loop[,c(
"Concentration")])	
    	
    GIAll[dx,2]<-rslt[1,1]	
    GIAll[dx,3]<-rslt[1,2]	
    GIAll[dx,4]<-rslt[1,3]	
    GIAll[dx,5]<-rslt[1,4]	
    GIAll[dx,6]<-rslt[1,5]	
    GIAll[dx,7]<-rslt[1,6]	
    GIAll[dx,8]<-rslt[1,7]	
  }	
  GIAll[dx,1]<-Treatment[dx]	
}			
write.csv(GIAll,file='GI50Results.csv')      	
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9.2 Appendix 1: Cell growth curves for IgG characterization experiments 
Effect of catechin (Cat) (green) and resveratrol (Resv)(blue) treatments in viable cell density (A), 
viability (B) and total cell density (C) when added at days 3 for different concentrations. Cells were 
incubated in 125mL Erlenmeyer flasks with initial 33 mL volume for 10 days under shaking conditions. 
The error bars represent the standard deviation of triplicates and the experiment was carried twice 
independently. 
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9.3 Appendix 3: SDS-PAGE of purified IgG 
 
SDS-PAGE gels of initial and final sample purified for each batch.  Preliminary (A) and final gel (B) done 
with control (Cnt), resveratrol (Resv) at 500 µM treatment and final wash  (NaOH peak) samples from 
purified IgG recombinant proteins produced in CHO cell line. 
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9.4 Appendix 2: Alignment of CEX spectra and quantification of basic and acidic 
species 
Luis	Toronjo	Urquiza	23/12/2018	
###################################################	
# alignment of cation exchange chromatograms and  # 	
# quantification of acidic and basic species for  #	
#                   Resveratrol                  #	
###################################################		
library(sp)	
library(raster)	
library(ncdf4)	
#library(NoiseFiltersR)	
library(readxl)		
#First we collect the files from chromeleon and extract the data from them 
and save then in csv files to be later processed		
#insert a table with the number of files from chromeleon that need to be a
nalysed(.CDF)	
# and the corresponding names of the sample types (Control Resv Cat etc)	
flnams<-read_excel('filenames.xlsx',col_names=F) #we want this file to be 
excel because that way it can be differentiated 	
# the created files are .csv and the software for alignment mistaken it fo
r reading file	
colnames(flnams)<-c('file','name')		
#pre-determine parameters of time of measurement	
mintime<-NULL	
maxtime<-NULL	
maxreading<-NULL			
#create a loop that will go through the filenames extracting the files one 
by one 	
for (xxd in 1:length(flnams$file)){	
  	
  #select the file we want to work on	
  tempfl<-as.character(flnams$file[[xxd]])	
  	
  #opens the file	
  test<-nc_open(tempfl)	
  	
  #this command shows all the variables in the spectrum file	
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  #attributes(test$var)	
  	
  ### get the desired variables out of the file ###	
  	
  # outputs the intensity of the signal (y-axis) dependent variable	
  intensity<-ncvar_get(test,'ordinate_values')	
  	
  ##outputs the length (time) of the chromatogram	
  #actual_run_time_length<-ncvar_get(test,'actual_run_time_length')	
  	
  #length of time between data points (in seconds)	
  timeinterval<-ncvar_get(test,'actual_sampling_interval')	
  	
  #creates a vector that matches the time of acquisition of the intensity 
values	
  time<-seq_along(intensity)*timeinterval	
  	
  #creates the table joining both time and intensity variables	
  chrom<-as.data.frame(cbind(time,intensity))	
  	
  #we need to select the right range of the spectra to study (from minute 
2.5 to 17.75 MINUTES is the entire time of chromatography)	
  #this time was selected based on a high intensity chromatogram obtained 
from high concentrated Fujifilm IgG samples.	
  chrom<-chrom[17000:156000,]	
  	
  	
  #create a csv document in the directory to later analyse	
  write.table(chrom,paste(as.character(flnams$name[[xxd]]), ".csv", sep = 
""),sep=' ', row.names=FALSE,col.names=FALSE)	
  	
  #this actualizes the extreme values for time and intensity, if a value i
s more extreme it refreshes it	
  mintime<-min(c(mintime,min(chrom$time)))	
  maxtime<-max(c(maxtime,max(chrom$time)))	
  maxreading<-max(c(maxreading,max(chrom$intensity)))	
  	
  	
}						
### COMPILE ALL SPECTRA ###		
library(ChemoSpec) #used for the alignment and correction for the spectra	
#library(R.utils)	
library(baseline)			
#creates a file that combines all the spectra csv files together, make sur
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e is empty of other csv files as the program will pick them	
#all the same and will cause errors	
ssp <- files2SpectraObject(	
  gr.crit = c('Control','Resv010','Resv025','Resv050','Resv100'),	
  freq.unit = "time(seconds)",	
  int.unit = "mAU(280nm)",	
  descrip = "Control",	
  #,out.file = "mydata"	
  debug=T	
)		
#command that shows the general info of the spectra 	
sumSpectra(ssp)		
# command that works for ploting the graphs	
plotSpectra(ssp,	
            which = c(4,8,12,16,20),	
            yrange = c(0, (maxreading+(maxreading/10)*4)),	
            offset = maxreading/10,	
            lab.pos = mintime*1.5,	
            xlim = c(mintime, maxtime)	
)						
### ALIGN SPECTRA ###		
#library('BiocManager') #pakcages for alignment	
#library('MassSpecWavelet')	
#library('impute')	
#library(speaq) 	
# Does alignment, but since the main point of alignment is the maximum pea
k this method is not efficient	
#ssp2<-clupaSpectra(ssp, bT=0.005)			
library(Rfast)	
# find the max values for all the chromatograms and output the time	
allmax<-rowMaxs(ssp$data)			
unmatch<-(-allmax+max(allmax))			
ssp2<-ssp		
# extend the matrix	
ssp2$data<-matrix(data=NA,nrow =20,ncol = (length(ssp$data[1,])+ (max(allm
ax)-min(allmax))))		
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#reinsert the values to the matrix	
for (xxf in 1:length(ssp2$data[,1])){	
  ssp2$data[xxf,]<-c(seq(0,0,length.out=unmatch[xxf]),ssp$data[xxf,], seq(
0,0,length.out=(max(allmax)-min(allmax)-unmatch[xxf])))	
}		
#extend the x axis time	
ssp2$freq<-seq(from=ssp$freq[1],by=(ssp$freq[2]-ssp$freq[1]),length.out=le
ngth(ssp2$data[1,]))			
# command that works for ploting the graphs for alingment	
plotSpectra(ssp2,	
            which = c(4,8,12,16,20),	
            yrange = c(0, (max(ssp2$data[1,])+(max(ssp2$data[1,]/10)*6))),	
            offset = max(ssp2$data[1,]/8),	
            lab.pos = min(ssp2$freq)*1.5,	
            xlim = c(min(ssp2$freq), max(ssp2$freq))	
)				
### CUT THE EXCESS ###		
#cut the excess of chromatogram. This will leave the same distance to the 
maximum peak for all samples	
#ensures that if there are any differences in acidic or basic species, the
se are not due to a shift in the retention	
#time of the main peak.		
#it was decided to cut between 250 and 1400 seconds	
#first extract the position of the time values for the ssp2	
lowcrop<-which(round(ssp2$freq,digits = 2)==250.00)	
highcrop<-which(round(ssp2$freq,digits = 2)==1400.00)		
#cut the sides of the time series	
ssp2$freq<-ssp2$freq[lowcrop:highcrop]	
#cut the sides of the data series	
ssp2$data<-ssp2$data[,lowcrop:highcrop]			
# command that works for plotting the graphs for alignment	
plotSpectra(ssp2,	
            which = c(4,8,12,16,20),	
            yrange = c(0, (max(ssp2$data[1,])+(max(ssp2$data[1,]/10)*6))),	
            offset = max(ssp2$data[1,]/8),	
            lab.pos = min(ssp2$freq)*1.5,	
            xlim = c(min(ssp2$freq), max(ssp2$freq))	
)			
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### CREATE BASELINE ###	
# creates a baseline for all chromatograms and corrects by it	
ssp2<-baselineSpectra(ssp2,	
                      int = FALSE,	
                      method = "modpolyfit",	
                      deg=1, #the higher the degree the further from the d
esired baseline. Linear is the best adjustment for the data in this case	
                      retC = TRUE)			
### CORRECT NEGATIVE VALUES ###		
# we shift all values up to make the minimum value of each spectra 0, this 
will help when normalizing all the values 	
# as negative values subtract the positive ones and the final area of the 
curve 	
# adjusting for baseline could give different cumulative areas other than 
one.	
for (dxx in 1:length(ssp2$data[,1])){	
  ssp2$data[dxx,]<-ssp2$data[dxx,]+abs(min(ssp2$data[dxx,]))	
}		
# command that works for plotting the graphs for alignment	
plotSpectra(ssp2,	
            which = c(4,8,12,16,20),	
            yrange = c(0, (max(ssp2$data[1,])+(max(ssp2$data[1,]/10)*6))),	
            offset = max(ssp2$data[1,]/8),	
            lab.pos = min(ssp2$freq)*1.5,	
            xlim = c(min(ssp2$freq), max(ssp2$freq))	
)			
### NORMALIZE ###	
#normalization of the data to a total area under the curve of 1	
ssp2<-normSpectra(ssp2, method = "TotInt", RangeExpress = NULL)		
plotSpectra(ssp2,	
            which = c(4,8,12,16,20),	
            yrange = c(0, (max(ssp2$data[1,])+(max(ssp2$data[1,]/10)*6))),	
            offset = max(ssp2$data[1,]/8),	
            lab.pos = min(ssp2$freq)*1.5,	
            xlim = c(min(ssp2$freq), max(ssp2$freq))	
)				
#export the data for  the different spectra but does it in a trasposed for
m	
# this leaves rows for time points and columns for spectra	
#outputs it as  a data frame and joins the time period		
ftr<-NULL	
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ftr<-matrix(NA, nrow =length(ssp2$freq), ncol = 2)		
ftr[,1]<-ssp2$freq	
ftr[,2]<-ssp2$data[1,]	
ftr<-as.data.frame(ftr)				
# next we need to make the graph smooth so that it is easier to find local 
minima and maxima	
loessMod10 <- loess(V2~V1, data=ftr, span=0.05)				
#this is the formula that fill detect local minima and maxima	
findpeaks2 <- function(vec,bw=1,x.coo=c(1:length(vec)))	
{	
  pos.x.max <- NULL	
  pos.y.max <- NULL	
  pos.x.min <- NULL	
  pos.y.min <- NULL     	
  for(i in 1:(length(vec)-1))   {       if((i+1+bw)>length(vec)){	
    sup.stop <- length(vec)}else{sup.stop <- i+1+bw	
    }	
    if((i-bw)<1){inf.stop <- 1}else{inf.stop <- i-bw}	
    subset.sup <- vec[(i+1):sup.stop]	
    subset.inf <- vec[inf.stop:(i-1)]	
    	
    is.max   <- sum(subset.inf > vec[i]) == 0	
    is.nomin <- sum(subset.sup > vec[i]) == 0	
    	
    no.max   <- sum(subset.inf > vec[i]) == length(subset.inf)	
    no.nomin <- sum(subset.sup > vec[i]) == length(subset.sup)	
    	
    if(is.max & is.nomin){	
      pos.x.max <- c(pos.x.max,x.coo[i])	
      pos.y.max <- c(pos.y.max,vec[i])	
    }	
    if(no.max & no.nomin){	
      pos.x.min <- c(pos.x.min,x.coo[i])	
      pos.y.min <- c(pos.y.min,vec[i])	
    }	
  }	
  return(list(pos.x.max,pos.y.max,pos.x.min,pos.y.min))	
}			
#run the code to find local minima and maxima and save it as lists	
minmax<-findpeaks2(loessMod10$fitted)		
# format it into a data frame with two columns (time, intensity)	
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tblt<-as.data.frame(rbind(t(rbind(minmax[[1]],minmax[[2]])),t(rbind(minmax
[[3]],minmax[[4]]))))		
#organize the maxima and minima chronologically in the data frame	
library(dplyr)	
tblt<-arrange(tblt,tblt$V1)			
#find highest max in the table and output the row position	
highestpeak<-which.max(tblt[,2])			
# Identify the local minima of the graph before and after the mean peak	
lowbond<-tblt$V1[highestpeak-1]	
highbond<-tblt$V1[highestpeak+1]			
#find the relative areas of the three regions for all the samples		
# calculate complete area under the curve, this is important as the proces
s does not lead to equal values 	
totalarea<-rowSums(ssp2$data) 		
acid<-rowSums(ssp2$data[,0:lowbond])/totalarea		
meanpeak<-rowSums(ssp2$data[,lowbond:highbond])/totalarea		
base<-rowSums(ssp2$data[,highbond:length(ssp2$data[1,])])/totalarea				
names<-ssp2$names		
grps<-ssp2$alt.sym		
finaldata<-cbind(names,grps,acid,meanpeak,base)		
write.table(finaldata,'finaldata resv.csv', sep=',', row.names=FALSE)			
########################################################################	
########################################################################		
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9.5 Appendix 3: Sequence coverage of LC and HC 
Luis	Toronjo	Urquiza	23/12/2018	
  ##############################################################	
  #Code to process de sequence coverage of the Mass Spec results#	
  ##############################################################		
library(readxl) # to read and import excel files	
library(magicfor)  # to extract data from for loop	
library(seqinr) # to import sequences from fasta files 	
library(tibble) # to add columns to data frames 	
library(plyr) #to help binding tables of different sizes  	
##########################################################################
###	
 	
  #Imports the fasta file to r with the sequence to analyze	
  fasta<-read.fasta(file = 'AntiCD20.fasta.txt', seqtype = 'AA')	
  	
  #conver each chain into a vector with the aas	
  HC<-unlist(fasta[1])	
  LC<-unlist(fasta[2])	
  	
  seqchoice<-'HC'	
  	
  if (seqchoice=='LC') {	
    	
    aachain<-LC # Decide what chain will be assest  	
    	
    Sequence<-read.csv('Seq.csv') #Select the file name for the analysis	
    	
    Sequence<-Sequence[,c(1:9)]	
    	
    colnames(Sequence)<-c('Chem','Conc','Length','Chain','StartPos','EndPo
s','Sample','Intensity','Treatment')	
    	
    Subsequence<-subset(Sequence, Chain=='Anti_CD20_LC')	
  }	
  	
  if (seqchoice=='HC') {	
    	
    aachain<-HC # Decide what chain will be assess  	
    	
    Sequence<-read.csv('Seq.csv') #Select the file name for the analysis	
    	
    Sequence<-Sequence[,c(1:9)]	
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    colnames(Sequence)<-c('Chem','Conc','Length','Chain','StartPos','EndPo
s','Sample','Intensity','Treatment')	
    	
    Subsequence<-subset(Sequence, Chain=='Anti-CD20_HC')	
  }	
  	
  SumTable<-matrix(NA,nrow =length(unique(Subsequence$Treatment)) ,ncol = 
length(aachain))	
  	
  tretm<-matrix(NA,ncol=1,nrow = length(unique(Subsequence$Treatment)))	
  	
  tretm<-as.data.frame(tretm)	
  	
  for (pdx in 1:length(unique(Subsequence$Treatment))){	
    	
    treatments<-unique(Subsequence$Treatment)	
    	
    tretm[pdx,1]<-as.character(treatments[pdx])	
    	
    Subsequence2<-subset(Subsequence,Treatment==as.character(treatments[pd
x]))	
    	
    Table<-matrix(NA,nrow =length(Subsequence2$Intensity) ,ncol = length(a
achain))	
    	
    Table<-as.data.frame(Table)	
    	
    for (dz in 1:length(Subsequence2$Intensity)) {	
    	
      Table[dz,seq(by=1, from=Subsequence2$StartPos[dz],to=Subsequence2$En
dPos[dz])]<-Subsequence2$Intensity[dz]	
    	
    }	
    	
    SumTable[pdx,]<-colSums(Table, na.rm = T)	
    	
  }		
colnames(SumTable)<-paste(c(1:length(aachain)),aachain)		
rownames(SumTable)<-unique(Subsequence$Treatment)		
SumTable<-t(SumTable)			
  	
#create pallate of colours for the heat map	
library('circlize')	
color.palette  <- c("red",'white', (colorRampPalette(c("aliceblue","steelb
lue"))(n=100000)))			
 Appendices 366 
#create rowlabels	
Rowss<-matrix(' ',ncol=1,nrow=(length(SumTable[,1])))		
Rowss<-as.data.frame(Rowss,stringsAsFactors = FALSE)		
RowsNum<-seq(by=10, from = 10, to = (floor(length(SumTable[,1])/10)*10) )		
RowsNum<-as.data.frame(RowsNum,stringsAsFactors = FALSE)		
for (ptx in 1:length(RowsNum[,1])){	
  	
  Rowss[RowsNum[ptx,1],1]<-RowsNum[ptx,1]	
  	
}	
SumTable2<-SumTable		
rownames(SumTable2)<-Rowss[,1]		
SumTable2<-SumTable2[,c(1,2,3,4,6,7,8,5)]		
library('ComplexHeatmap')	
Heatmap(SumTable2, 	
        name = 'Intensity',	
        cluster_rows = F, 	
        cluster_columns = F, 	
        row_names_side = 'left', 	
        column_names_side = 'bottom',	
        column_title = 'Treatment',	
        column_title_side = 'bottom',	
        row_names_gp = gpar(cex=0.8),	
        column_names_gp = gpar(cex=1),	
        row_title = 'peptide sequence',	
        col = color.palette	
        )	
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9.6 Appendix 4: Identification of mass shift differences between sample treatments 
Luis	Toronjo	Urquiza	23/12/2018	
######################################################	
# Comparison of mass shift differences across        #	
# sample treatments for Light chain mass spect data  #	
######################################################			
##################################	
# COMPARISON OF LIGHT CHAIN DATA #	
##################################			
## Supplementary material for the book chapter:	
## "Detection of unknown chemical adduct modifications on proteins: from w
et to dry laboratory"	
## Paola Antinori, Theo Michelot, Pierre Lescuyer, Markus Muller and Adeli
na E. Acosta-Martin	
## in Mass Spectrometry of Proteins: Methods and Protocols - Quantitative 
Proteomics and associated Bioinformatics	
##	
## This script has been modified, adapted and improved for MaxQuant-type d
ata,from:	
## Acosta-Martin AE, Antinori P, Uppugunduri CR, Daali Y, Ansari M, Scherl 
A, M?ller M, Lescuyer P. (2016) 	
## Detection of busulfan adducts on proteins. Rapid Commun Mass Spectrom 3
0: 2517-2528		
##This code was redesigned to check mass difference shifts differences bet
ween two samples, in a one to one	
##comparison and identify outliers for both samples compared		
##  system.Exporting:	
   	
   #1) a final pdf file with all the plots comparing the the samples one t
o one and a label that is considered 	
   #   an outlier base on the z-threshold desired by the user.		
   #2)a final pdf file with histograms relating to each of the peaks that 
were considered outliers before.		
   #3)a final csv table of the possible peaks in each histogram (as there 
is maybe more than one in each histogram)	
   #  showing the specific mass shift, and to which sample apartains with 
respect to which compared partner. 		
##This program is currently designed to run a maximum of 28 comparisons, b
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ut if the user need to add more	
 #increase the vector 'nonzeroZ' to de desired number. 			
############################################	
##Libraries needed during for the analysis##	
############################################	
library(ggplot2)	
library(FSA)	
library(data.table)	
library(quantmod)	
library(ggrepel)			
set.seed(123) # for reproducibility of bootstrap			
#############################	
## Parameters of the study ##	
#############################		
by<-0.05            # General bin: Da distance in which the entire range o
f massshifts will split to be compared		
range<-c(-750,750) # Part of the spectrum of Da mass shifts that will be s
tudy		
zthresh<-3.5         # The minimum z-score value of each 'by' bin to be co
nsidered an outlier for further analysis		
brks<-50           # Approximated number of bins for each histogram(how ma
ny times the by bin is broken into)		
mbpk<-0.01        # Minimum distance in Da to consider different local max
imum peaks 	
                   # of mass shift difference for a histogram		
pksmin<-3          # Threshold to consider a peak a possible maximum (elim
inates noise in the histograms)	
                   # This is for frequency so the use integrers is ideal. 
The value given is consider as well.			
##################	
## Files Outcome##	
##################		
Plotname<-'ZscoreplotLC.pdf'  #Name of the pdf file compilating all the pl
ot Z-score comparisons		
Histname<-'HistLC.pdf'        #Name of the pdf file compilating all the hi
stograms	
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FullTablname<-'PeaksLC.csv'   #Name of the csv file compilating all the re
levant peaks		
Comparison<-'CompareLC.pdf'   #Name of the pdf file compilating groups in 
scatter plot		
###########################	
## Load and prepare data ##	
###########################		
# all files to compare one to one.	
 #Naming the samples	
 allCond1 <- c("Rsv10LC","Rsv25LC","Rsv50LC",	
              "Rsv100LC","Rsv10LC","Rsv10LC",	
              "Rsv10LC","Rsv25LC","Rsv25LC",	
              "Rsv50LC","Cat10LC","Cat25LC",	
              "Cat50LC","Cat10LC","Cat10LC",	
              "Cat25LC","Rsv10LC","Rsv10LC",	
              "Rsv10LC","Rsv25LC","Rsv25LC",	
              "Rsv25LC","Rsv50LC","Rsv50LC",	
              "Rsv50LC","Rsv100LC","Rsv100LC",	
              "Rsv100LC")	
 	
 #Referencing the files	
 allFile1Prot <- c("allPeptides_Rsv10.txt","allPeptides_Rsv25.txt","allPep
tides_Rsv50.txt",	
                  "allPeptides_Rsv100.txt","allPeptides_Rsv10.txt","allPep
tides_Rsv10.txt",	
                  "allPeptides_Rsv10.txt","allPeptides_Rsv25.txt","allPept
ides_Rsv25.txt",	
                  "allPeptides_Rsv50.txt","allPeptides_Cat10.txt","allPept
ides_Cat25.txt",	
                  "allPeptides_Cat50.txt","allPeptides_Cat10.txt","allPept
ides_Cat10.txt",	
                  "allPeptides_Cat25.txt","allPeptides_Rsv10.txt","allPept
ides_Rsv10.txt",	
                  "allPeptides_Rsv10.txt","allPeptides_Rsv25.txt","allPept
ides_Rsv25.txt",	
                  "allPeptides_Rsv25.txt","allPeptides_Rsv50.txt","allPept
ides_Rsv50.txt",	
                  "allPeptides_Rsv50.txt","allPeptides_Rsv100.txt","allPep
tides_Rsv100.txt",	
                  "allPeptides_Rsv100.txt")		
 #Naming the samples	
 allCond2 <- c("Control","Control","Control",	
              "Control","Rsv25LC","Rsv50LC",	
              "Rsv100LC","Rsv50LC","Rsv100LC",	
              "Rsv100LC","Control","Control",	
              "Control","Cat25LC","Cat50LC",	
              "Cat50LC","Cat10LC","Cat25LC",	
              "Cat50LC","Cat10LC","Cat25LC",	
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              "Cat50LC","Cat10LC","Cat25LC",	
              "Cat50LC","Cat10LC","Cat25LC",	
              "Cat50LC")	
 	
 #Referencing the files	
 allFile2Prot <- c("allPeptides_Control.txt","allPeptides_Control.txt","al
lPeptides_Control.txt",	
                  "allPeptides_Control.txt","allPeptides_Rsv25.txt","allPe
ptides_Rsv50.txt",	
                  "allPeptides_Rsv100.txt","allPeptides_Rsv50.txt","allPep
tides_Rsv100.txt",	
                  "allPeptides_Rsv100.txt","allPeptides_Control.txt","allP
eptides_Control.txt",	
                  "allPeptides_Control.txt","allPeptides_Cat25.txt","allPe
ptides_Cat50.txt",	
                  "allPeptides_Cat50.txt","allPeptides_Cat10.txt","allPept
ides_Cat25.txt",	
                  "allPeptides_Cat50.txt","allPeptides_Cat10.txt","allPept
ides_Cat25.txt",	
                  "allPeptides_Cat50.txt","allPeptides_Cat10.txt","allPept
ides_Cat25.txt",	
                  "allPeptides_Cat50.txt","allPeptides_Cat10.txt","allPept
ides_Cat25.txt",	
                  "allPeptides_Cat50.txt")				
####################################################	
##Actual coding no more variables need to be added##	
####################################################		
# number of comparisons	
nbComp <- length(allCond1)		
allZscore <- list()	
allData1 <- list()	
allData2 <- list()		
# define bins for general mass shifts comparisons	
by <-by	
range <-range	
breaks <- seq(range[1]-by/2,range[2]+by/2,by=by)	
mids <- seq(range[1],range[2],by=by)		
for(i in 1:nbComp) {	
    # iterate over conditions and files	
    cond1 <- allCond1[i]	
    file1Prot <- allFile1Prot[i]		
    cond2 <- allCond2[i]	
    file2Prot <- allFile2Prot[i]		
    cat("Comparison",i,'in',nbComp,cond1,"vs.",cond2,"...\n")	
 Appendices 372 
    	
    # load files	
    cat("Reading files... ")	
    allData1Prot <- read.csv(file1Prot,header=TRUE,sep="\t")		
    allData2Prot <- read.csv(file2Prot,header=TRUE,sep="\t")		
    cat("Done.\n")	
  		
      	
    # Keep columns: ######################################################
##################	
    #  - Raw.file	
    #  - DP.Mass.Difference	
    #  - DP.PEP	
    #  - DP.Proteins	
    data1Prot <- allData1Prot[,c(1,34,37,45)]	
    data2Prot <- allData2Prot[,c(1,34,37,45)]	
    	
    # Select Light Chain IgG only ("Anti_CD20_LC") #######################
##################	
    data1Prot <- subset(data1Prot, DP.Proteins=="Anti_CD20_LC")	
    data2Prot <- subset(data2Prot, DP.Proteins=="Anti_CD20_LC")	
    	
    	
    # # if only one protein (also, comment out all HSA-related lines above
)#################	
    data1 <- data1Prot	
    data2 <- data2Prot	
    	
    # remove DP PEP > 0.01  ##############################################
##################	
    data1 <- subset(data1, DP.PEP<0.01)	
    data2 <- subset(data2, DP.PEP<0.01)	
    	
    # remove empty rows ("NA") ###########################################
##################	
    data1 <- subset(data1, !is.na(DP.Mass.Difference))	
    data2 <- subset(data2, !is.na(DP.Mass.Difference))	
    	
    # remove out-of-bound mass differences ###############################
##################	
    data1 <- subset(data1, DP.Mass.Difference>range[1] & DP.Mass.Differenc
e<range[2])	
    data2 <- subset(data2, DP.Mass.Difference>range[1] & DP.Mass.Differenc
e<range[2])	
    	
    # lists of raw files #################################################
##################	
    listfiles1 <- unique(data1$Raw.file)	
    listfiles2 <- unique(data2$Raw.file)	
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    ############################	
    ## Calculate the Z scores ##	
    ############################	
    # resample nbRep times over the "raw file" column	
    nbRep <- 100	
    h1mat <- matrix(NA,nrow=nbRep,ncol=length(breaks)-1)	
    h2mat <- matrix(NA,nrow=nbRep,ncol=length(breaks)-1)	
    pb <- txtProgressBar(min = 1, max = nbRep, style = 3)	
    for(rep in 1:nbRep) {	
        dmass1 <- NULL	
        dmass2 <- NULL	
        	
        # sample over runs (indicated by "raw file" column)	
        samp1 <- sample(listfiles1,replace=TRUE)	
        for(file in samp1)	
            dmass1 <- c(dmass1,data1$DP.Mass.Difference[which(data1$Raw.fi
le==file)])	
        samp2 <- sample(listfiles2,replace=TRUE)	
        for(file in samp2)	
            dmass2 <- c(dmass2,data2$DP.Mass.Difference[which(data2$Raw.fi
le==file)])	
        	
        h1mat[rep,] <- hist(dmass1,breaks=breaks,plot=FALSE)$counts	
        h2mat[rep,] <- hist(dmass2,breaks=breaks,plot=FALSE)$counts	
        	
        setTxtProgressBar(pb, rep)	
    }	
    cat("\n\n")	
    	
    # MSH(condition 1) - MSH(condition 2)	
    dh <- hist(data1$DP.Mass.Difference,breaks=breaks,plot=FALSE)$counts - 	
        hist(data2$DP.Mass.Difference,breaks=breaks,plot=FALSE)$counts 		
    # variances on counts for each condition	
    var1 <- apply(h1mat,2,var)	
    var2 <- apply(h2mat,2,var)	
    	
    # Z-scores	
    Zscore <- rep(0,length(dh))	
    ind <- which(var1+var2>0) # var1+var2=0 -> Zscore=0	
    Zscore[ind] <- dh[ind]/(sqrt(var1[ind]+var2[ind]))	
    	
    allZscore[[i]] <- Zscore	
    allData1[[i]] <- data1	
    allData2[[i]] <- data2	
}		
# non-zero Z scores	
                          #for (i in 1:nbComp) {          	
                          #  nonzeroZ <- c(allZscore[[(i)]])     	
                          #}		
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# non-zero Z scores	
nonzeroZ <- c(allZscore[[1]],allZscore[[2]],allZscore[[3]],allZscore[[4]],
allZscore[[5]],	
              allZscore[[6]],allZscore[[7]],allZscore[[8]],allZscore[[9]],
allZscore[[10]],	
              allZscore[[11]],allZscore[[12]],allZscore[[13]],allZscore[[1
4]],allZscore[[15]],	
              allZscore[[16]],allZscore[[17]],allZscore[[18]],allZscore[[1
9]],allZscore[[20]],	
              allZscore[[21]],allZscore[[22]],allZscore[[23]],allZscore[[2
4]],allZscore[[25]],	
              allZscore[[26]],allZscore[[27]],allZscore[[28]])		
              	
#              allZscore[[29]],allZscore[[30]],	
#              allZscore[[31]],allZscore[[32]],allZscore[[33]],allZscore[[
34]],allZscore[[35]],	
#              allZscore[[36]],allZscore[[37]],allZscore[[38]],allZscore[[
39]],allZscore[[40]],	
#              allZscore[[41]],allZscore[[42]],allZscore[[43]],allZscore[[
44]],allZscore[[45]],	
#              allZscore[[46]],allZscore[[47]],allZscore[[48]],allZscore[[
49]],allZscore[[50]],	
#              allZscore[[51]],allZscore[[52]],allZscore[[53]],allZscore[[
54]],allZscore[[55]],	
#              allZscore[[56]],allZscore[[57]],allZscore[[58]],allZscore[[
59]],allZscore[[60]],	
#              allZscore[[61]],allZscore[[62]],allZscore[[63]],allZscore[[
64]],allZscore[[65]],	
#              allZscore[[66]],allZscore[[67]],allZscore[[68]],allZscore[[
69]],allZscore[[70]],	
#              allZscore[[71]],allZscore[[72]],allZscore[[73]],allZscore[[
74]],allZscore[[75]],	
#              allZscore[[76]],allZscore[[77]],allZscore[[78]],allZscore[[
79]],allZscore[[80]],	
#              allZscore[[81]],allZscore[[82]],allZscore[[83]],allZscore[[
84]],allZscore[[85]],	
#              allZscore[[86]],allZscore[[87]],allZscore[[88]],allZscore[[
89]],allZscore[[90]],	
#              allZscore[[91]],allZscore[[92]],allZscore[[93]],allZscore[[
94]],allZscore[[95]],	
#              allZscore[[96]],allZscore[[97]],allZscore[[98]],allZscore[[
99]],allZscore[[100]])		
#Reduces the vector to only comparisons which give 	
nonzeroZ <- nonzeroZ[nonzeroZ!=0]		
# significance threshold		
thresh <-zthresh		
# y-axis range		
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   #general range for all z-score plots	
ylim <- 1.1*c(min(nonzeroZ),max(nonzeroZ))		
   #Specific range for individual z-score plots	
#ylim <-1.1*c(min(allZscore[[i]]),max(allZscore[[i]]))		
##########################################################################	
###################	
## Plot Z-scores ##	
###################	
##########################################################################	
pdf(Plotname) #To safe the plots in a pdf file at the working directory		
par(mfrow=c(1,1))	
for(i in 1:nbComp) {	
  # plot Z-scores against mass shift	
  plot(mids,allZscore[[i]],type="h",lwd=2,ylim=ylim,xlab="Mass Shift (Da)"
, ylab="Z score",	
       main=paste(allCond1[i],"vs.",allCond2[i]))	
  abline(h=0,lwd=2)	
  	
  # plot significance threshold	
  abline(h=c(-thresh,thresh),lty=2,col="darkgrey")	
  	
  # label significant peaks	
  offset <- max(nonzeroZ)/20;	
  idxp1 <- which(allZscore[[i]]>thresh)	
  idxp2 <- which(allZscore[[i]]< (-thresh))	
  	
  if(length(idxp1)>0) {	
    for(idp1 in idxp1) {	
      mass1 <- allData1[[i]]$DP.Mass.Difference	
      label1 <- median(mass1[abs(mass1-mids[idp1])<by])	
      text(x=mids[idp1],y=allZscore[[i]][idp1]+offset,labels=round(label1,
3))	
    }	
  }	
  	
  if(length(idxp2)>0) {	
    for(idp2 in idxp2) {	
      mass2 <- allData2[[i]]$DP.Mass.Difference	
      label2 <- median(mass2[abs(mass2-mids[idp2])<by])	
      text(x=mids[idp2],y=allZscore[[i]][idp2]-offset,labels=round(label2,
3))	
    }	
  }	
}	
par(mfrow=c(1,1))		
dev.off()		
##########################################################################	
####################################################	
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## Plot histogram of mass shifts around each peak ##	
####################################################	
##########################################################################		
pdf(Histname) #To safe the plots in a pdf pdf file at the working director
y		
idntpk<-NULL #vector to compile all the relevant mass shift peaks		
for(i in 1:nbComp) {	
  # label significant peaks	
  idxh1 <- which(allZscore[[i]]>thresh)	
  idxh2 <- which(allZscore[[i]]< (-thresh))	
  	
  	
  ##################################################    	
  ## creates the histograms of (+) z-scores peaks ##	
  ##################################################	
  	
  idntpk1<-NULL  	
  if(length(idxh1)>0) {	
    	
    for(idh1 in idxh1) {	
      massA <- allData1[[i]]$DP.Mass.Difference	
      mass1<-massA[abs(massA-mids[idh1])<by]	
      res1<-hist(mass1,breaks=brks,xlab="Mass Shift (Da)",	
                 main=paste(allCond1[i],"vs.",allCond2[i],", mass shift ="
,round(median(mass1[abs(mass1-mids[idh1])<by]),3)))	
      abline(v=median(mass1[abs(mass1-mids[idh1])<by]),col=2)	
      	
      ##extracting information from the histgram##	
      midshist1<-res1$mids	
      countshist1<-res1$counts	
      relpos1<-seq(1,length(midshist1),1)	
      tabl1=data.frame(relpos=relpos1, sample=allCond1[i],compare=allCond2
[i],Zscore=(allZscore[[i]])[idh1],massf=midshist1,counts=countshist1)	
      	
      ##Normalizing distance between relevant peaks##	
      	
      by<-by                       #Initial bin to compare among samples	
      brkbin<-length(countshist1)  #Actual break of the by bin (not always 
equal to the breaks asked for)	
      mbpk1<-mbpk                   # Distance in Da to consider diferent 
maximum peaks	
                                   #Find decimal places of the mbpk	
      dcpl<-if ((mbpk1 %% 1) != 0) {  	
        nchar(strsplit(sub('0+$', '', as.character(mbpk1)), ".", fixed=TRU
E)[[1]][[2]])	
      } else {	
        return(0)	
      }                            	
      distance<-by/brkbin          #distance of each bar in the histgram i
n Da	
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                                   #Vector of Da distances with equal numb
er of decimal places to the mbpk	
      m<-signif(seq(1,1000,1)*distance,digits=dcpl) 	
      pksdis1<-which.max(m>=mbpk1)    #Looks for the lower number of bins 
that will satisfy the mbpk	
      	
      	
      ##Find reliable maximum peaks in Histgrams##	
      pks1<-NULL	
      pksmin1<-pksmin #minimum threshold to consider a maximum peak	
      shape1 <- diff(sign(diff(countshist1, na.pad = FALSE)))	
      pks1 <-unlist(sapply(which(shape1 < 0), FUN = function(pksi1){	
        pksz1 <- pksi1 - pksdis1 + 1	
        pksz1 <- ifelse(pksz1 > 0, pksz1, 1)	
        pksw1 <- pksi1 + pksdis1 + 1	
        pksw1 <- ifelse(pksw1 < length(countshist1), pksw1, length(countsh
ist1))	
        if(countshist1[pksi1+1]>=pksmin1) {	
          if(all(countshist1[c(pksz1 : pksi1, (pksi1 + 2) : pksw1)] <= cou
ntshist1[pksi1 + 1])){	
              return(pksi1 + 1)}	
            else {return(NULL)}} else {return(NULL)}	
      })) 	
      	
      ##When there are relevant peaks adds them to the vector##	
      if(length(pks1)) {	
        tmp1    <- setDT(tabl1, key = 'relpos')[J(pks1)]	
        idntpk1 <- rbind(idntpk1, tmp1)	
      }	
    }	
  }		
  ##################################################    	
  ## creates the histograms of (-) z-scores peaks ##	
  ##################################################	
   idntpk2<-NULL	
  if(length(idxh2)>0) {	
    for(idh2 in idxh2) {	
      massB <- allData2[[i]]$DP.Mass.Difference	
      mass2<-massB[abs(massB-mids[idh2])<by]	
      res2<-hist(mass2,breaks=brks,xlab="Mass Shift (Da)",	
                 main=paste(allCond2[i],"vs.",allCond1[i],", mass shift ="
,round(median(mass2[abs(mass2-mids[idh2])<by]),3)))	
      abline(v=median(mass2[abs(mass2-mids[idh2])<by]),col=2)	
      	
      ##extracting information from the histgram########################## 	
      midshist2<-res2$mids	
      countshist2<-res2$counts	
      relpos2<-seq(1,length(midshist2),1)	
      tabl2=data.frame(relpos=relpos2,sample=allCond2[i],compare=allCond1[
i],counts=countshist2,Zscore=(allZscore[[i]])[idh2],massf=midshist2)	
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      ##Normalizing distance between relevant peaks####################### 	
      	
      by<-by                       #Initial bin to compare among samples	
      brkbin<-length(countshist2)  #Actual break of the by bin (not always 
equal to the breaks asked for)	
      mbpk2<-mbpk                  # Distance in Da to consider diferent m
aximum peaks	
                                   #Find decimal places of the mbpk	
      dcpl<-if ((mbpk2 %% 1) != 0) {  	
        nchar(strsplit(sub('0+$', '', as.character(mbpk2)), ".", fixed=TRU
E)[[1]][[2]])	
      } else {	
        return(0)	
      }                            	
      distance<-by/brkbin          #distance of each bar in the histgram i
n Da	
                                   #Vector of Da distances with equal numb
er of decimal places to the mbpk	
      m<-signif(seq(1,1000,1)*distance,digits=dcpl) 	
      pksdis2<-which.max(m>=mbpk2)    #Looks for the lower number of bins 
that will satisfy the mbpk	
      	
      ##Find peaks in Histgrams########################################### 	
      pks2<-NULL	
      pksmin2<-pksmin #minimum threshold to consider a maximum peak	
      shape2 <- diff(sign(diff(countshist2, na.pad = FALSE)))	
      pks2 <-unlist(sapply(which(shape2 < 0), FUN = function(pksi2){	
        pksz2 <- pksi2 - pksdis2 + 1	
        pksz2 <- ifelse(pksz2 > 0, pksz2, 1)	
        pksw2 <- pksi2 + pksdis2 + 1	
        pksw2 <- ifelse(pksw2 < length(countshist2), pksw2, length(countsh
ist2))	
        if(countshist2[pksi2+1]>=pksmin2) {	
          if(all(countshist2[c(pksz2 : pksi2, (pksi2 + 2) : pksw2)] <= cou
ntshist2[pksi2 + 1])){	
            return(pksi2 + 1)}	
          else {return(NULL)}} else {return(NULL)}	
        })) 	
      	
      	
      ##When there are relevant peaks adds them to the vector##	
      if(length(pks2)) {	
        tmp2    <- setDT(tabl2, key = 'relpos')[J(pks2)]	
        idntpk2 <- rbind(idntpk2, tmp2)	
      }	
    }	
  }	
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  ##When there are relevant peaks adds them to the final vector##	
  if(length(idntpk1)) {	
    idntpk <- rbind(idntpk,idntpk1)}	
  if(length(idntpk2)){	
    idntpk <- rbind(idntpk,idntpk2) 	
  }	
}		
dev.off()		
##Remove duplicatres	
idntpk<-unique(idntpk)		
##Remove relative position column	
idntpk$relpos <- NULL		
#Rearrange columns in the desired order	
idntpk[,c(idntpk$sample,idntpk$compare,idntpk$Sam,idntpk$Com,idntpk$massf,
idntpk$Zscore,idntpk$counts)];		
##Export the complete table with all information from relevant peaks to an 
cvs (Excel) file	
write.csv(idntpk,FullTablname)				
##Creating columns to greate groups Resveratrol,Catechin and Control	
idntpk$Sam <- substr(idntpk$sample, 0, 3)		
idntpk$Com<- substr(idntpk$compare, 0, 3)			
## round frequency of the histgram and mass shift	
idntpk$massf<-round(idntpk$massf, digits=2)	
idntpk$Zscore<-round(idntpk$Zscore, digits=2)				
pdf(Comparison)			
#Create subset of datatables for later analysis and export as a csv file		
#Frist comparison group		
Comp1<-subset(idntpk,Sam=='Rsv' & Com=='Rsv')		
Zscr<-tapply(Comp1$Zscore,Comp1$massf, FUN=mean)		
Frq<-tapply(Comp1$counts,Comp1$massf, FUN=sum)		
Comp1=rbind(Zscr,Frq)	
 Appendices 380 
	
Comp1<-t(Comp1)		
masshift<-rownames(Comp1)			
Comp1<- cbind(masshift, data.frame(Comp1, row.names=NULL))		
Comp1$masshift<- as.numeric(as.character(Comp1$masshift))		
Comp1<-Comp1[order(Comp1$masshift),]		
Comp1=data.frame(masshift=Comp1$masshift,AvgZscore=Comp1$Zscr,TotFrequency
=Comp1$Frq)		
if (length(Comp1)){write.csv(Comp1,'Comp1')}	
if (length(Comp1)){	
ggplot(Comp1, aes(x=masshift, y=AvgZscore, size=TotFrequency))+	
  geom_point(colour= "blue4", alpha= 0.5)+scale_size(range = c(1,15))+	
  theme_bw()+	
  xlab("Mass Shift (Da)")+ ylab("Average Z-score")+	
  geom_abline(intercept = 0, slope = 0)+	
  geom_abline(intercept = 0, slope = 90)+	
  geom_label_repel(label=Comp1$masshift, size=2.5, label.padding = 0.15)+	
  scale_x_continuous(limits = 1.2*c(min(Comp1$masshift),max(Comp1$masshift
)))+	
  scale_y_continuous(limits = 1.2*c(min(Comp1$AvgZscore),max(Comp1$AvgZsco
re)))+	
  annotate("text", x=c(min(Comp1$masshift-5)), y=c(0), label=c("Peak\n Los
s"))+	
  annotate("text", x=c(1.2*max(Comp1$masshift-5)), y=c(0), label=c("Peak\n 
Gain"))+	
  annotate("text", y=c(1.2*max(Comp1$AvgZscore)), x=c(37), label=c("Condit
ion 1"))+	
  annotate("text", y=c(1.2*min(Comp1$AvgZscore)), x=c(37), label=c("Condit
ion 2"))+	
  ggtitle('Rsv vs Rsv LC')+labs(size='Frequency')	
}  				
#Second comparison group		
Comp2<-subset(idntpk,Sam=='Cat' & Com=='Cat')		
Zscr<-tapply(Comp2$Zscore,Comp2$massf, FUN=mean)		
Frq<-tapply(Comp2$counts,Comp2$massf, FUN=sum)		
Comp2=rbind(Zscr,Frq)		
Comp2<-t(Comp2)	
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masshift<-rownames(Comp2)			
Comp2<- cbind(masshift, data.frame(Comp2, row.names=NULL))		
Comp2$masshift<- as.numeric(as.character(Comp2$masshift))		
Comp2<-Comp2[order(Comp2$masshift),]		
Comp2=data.frame(masshift=Comp2$masshift,AvgZscore=Comp2$Zscr,TotFrequency
=Comp2$Frq)		
if (length(Comp2)){write.csv(Comp2,'Comp2')}		
if (length(Comp2)){	
ggplot(Comp2, aes(x=masshift, y=AvgZscore, size=TotFrequency))+	
  geom_point(colour= "blue4", alpha= 0.5)+scale_size(range = c(1,15))+	
  theme_bw()+	
  xlab("Mass Shift (Da)")+ ylab("Average Z-score")+	
  geom_abline(intercept = 0, slope = 0)+	
  geom_abline(intercept = 0, slope = 90)+	
  geom_label_repel(label=Comp2$masshift, size=2.5, label.padding = 0.15)+	
  #scale_x_continuous(limits = 1.2*c(min(Comp2$masshift),max(Comp2$masshif
t)))+	
  #scale_y_continuous(limits = 1.2*c(min(Comp2$AvgZscore),max(Comp2$AvgZsc
ore)))+	
  #annotate("text", x=c(min(Comp2$masshift-5)), y=c(0), label=c("Peak\n Lo
ss"))+	
  #annotate("text", x=c(1.2*max(Comp2$masshift-5)), y=c(0), label=c("Peak\
n Gain"))+	
  #annotate("text", y=c(1.2*max(Comp2$AvgZscore)), x=c(37), label=c("Condi
tion 1"))+	
  #annotate("text", y=c(1.2*min(Comp2$AvgZscore)), x=c(37), label=c("Condi
tion 2"))+	
  ggtitle('Cat vs Cat LC')+labs(size='Frequency')	
}			
#Third comparison group		
RsvvsCon1<-subset(idntpk,Sam=='Rsv' & Com=='Con')	
RsvvsCon2<-subset(idntpk,Com=='Rsv' & Sam=='Con')	
Comp3<-rbind(RsvvsCon1,RsvvsCon2)		
Zscr<-tapply(Comp3$Zscore,Comp3$massf, FUN=mean)		
Frq<-tapply(Comp3$counts,Comp3$massf, FUN=sum)		
Comp3=rbind(Zscr,Frq)		
Comp3<-t(Comp3)	
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masshift<-rownames(Comp3)			
Comp3<- cbind(masshift, data.frame(Comp3, row.names=NULL))		
Comp3$masshift<- as.numeric(as.character(Comp3$masshift))		
Comp3<-Comp3[order(Comp3$masshift),]		
Comp3=data.frame(masshift=Comp3$masshift,AvgZscore=Comp3$Zscr,TotFrequency
=Comp3$Frq)		
if (length(Comp3)){write.csv(Comp3,'Comp3')}		
if (length(Comp3)){	
  ggplot(Comp3, aes(x=masshift, y=AvgZscore, size=TotFrequency))+	
    geom_point(colour= "blue4", alpha= 0.5)+scale_size(range = c(1,15))+	
    theme_bw()+	
    xlab("Mass Shift (Da)")+ ylab("Average Z-score")+	
    geom_abline(intercept = 0, slope = 0)+	
    geom_abline(intercept = 0, slope = 90)+	
    geom_label_repel(label=Comp3$masshift, size=2.5, label.padding = 0.15)
+	
    #scale_x_continuous(limits = 1.2*c(min(Comp3$masshift),max(Comp3$massh
ift)))+	
    #scale_y_continuous(limits = 1.2*c(min(Comp3$AvgZscore),max(Comp3$AvgZ
score)))+	
    #annotate("text", x=c(min(Comp3$masshift-5)), y=c(0), label=c("Peak\n 
Loss"))+	
    #annotate("text", x=c(1.2*max(Comp3$masshift-5)), y=c(0), label=c("Pea
k\n Gain"))+	
    #annotate("text", y=c(1.2*max(Comp3$AvgZscore)), x=c(37), label=c("Con
dition 1"))+	
    #annotate("text", y=c(1.2*min(Comp3$AvgZscore)), x=c(37), label=c("Con
dition 2"))+	
    ggtitle('Rsv vs Con LC')+labs(size='Frequency')	
}			
#Forth comparison		
CatvsCon1<-subset(idntpk,Sam=='Cat' & Com=='Con')	
CatvsCon2<-subset(idntpk,Com=='Cat' & Sam=='Con')	
Comp4<-rbind(CatvsCon1,CatvsCon2)			
Zscr<-tapply(Comp4$Zscore,Comp4$massf, FUN=mean)		
Frq<-tapply(Comp4$counts,Comp4$massf, FUN=sum)		
Comp4=rbind(Zscr,Frq)	
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Comp4<-t(Comp4)		
masshift<-rownames(Comp4)			
Comp4<- cbind(masshift, data.frame(Comp4, row.names=NULL))		
Comp4$masshift<- as.numeric(as.character(Comp4$masshift))		
Comp4<-Comp4[order(Comp4$masshift),]		
Comp4=data.frame(masshift=Comp4$masshift,AvgZscore=Comp4$Zscr,TotFrequency
=Comp4$Frq)		
if (length(Comp4)){write.csv(Comp4,'Comp4')}		
if (length(Comp4)){	
  ggplot(Comp4, aes(x=Comp4$masshift, y=Comp4$AvgZscore, size=Comp4$TotFre
quency))+	
    geom_point(colour= "blue4", alpha= 0.5)+scale_size(range = c(1,15))+	
    theme_bw()+	
    xlab("Mass Shift (Da)")+ ylab("Average Z-score")+	
    geom_abline(intercept = 0, slope = 0)+	
    geom_abline(intercept = 0, slope = 90)+	
    geom_label_repel(label=Comp4$masshift, size=2.5, label.padding = 0.15)
+	
    #scale_x_continuous(limits = 1.2*c(min(Comp4$masshift),max(Comp4$massh
ift)))+	
    #scale_y_continuous(limits = 1.2*c(min(Comp4$AvgZscore),max(Comp4$AvgZ
score)))+	
    #annotate("text", x=c(min(Comp4$masshift-5)), y=c(0), label=c("Peak\n 
Loss"))+	
    #annotate("text", x=c(1.2*max(Comp4$masshift-5)), y=c(0), label=c("Pea
k\n Gain"))+	
    #annotate("text", y=c(1.2*max(Comp4$AvgZscore)), x=c(37), label=c("Con
dition 1"))+	
    #annotate("text", y=c(1.2*min(Comp4$AvgZscore)), x=c(37), label=c("Con
dition 2"))+	
    ggtitle('Cat vs Con LC')+labs(size='Frequency')	
}			
#Fith Comparison		
RsvvsCat1<-subset(idntpk,Sam=='Rsv' & Com=='Cat')	
RsvvsCat2<-subset(idntpk,Com=='Rsv' & Sam=='Cat')	
Comp5<-rbind(RsvvsCat1,RsvvsCat2)			
Zscr<-tapply(Comp5$Zscore,Comp5$massf, FUN=mean)		
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Frq<-tapply(Comp5$counts,Comp5$massf, FUN=sum)		
Comp5=rbind(Zscr,Frq)		
Comp5<-t(Comp5)		
masshift<-rownames(Comp5)			
Comp5<- cbind(masshift, data.frame(Comp5, row.names=NULL))		
Comp5$masshift<- as.numeric(as.character(Comp5$masshift))		
Comp5<-Comp5[order(Comp5$masshift),]		
Comp5=data.frame(masshift=Comp5$masshift,AvgZscore=Comp5$Zscr,TotFrequency
=Comp5$Frq)		
if (length(Comp5)){write.csv(Comp5,'Comp5')}		
if (length(Comp5)){	
  ggplot(Comp5, aes(x=Comp5$masshift, y=Comp5$AvgZscore, size=Comp5$TotFre
quency))+	
    geom_point(colour= "blue4", alpha= 0.5)+scale_size(range = c(1,15))+	
    theme_bw()+	
    xlab("Mass Shift (Da)")+ ylab("Average Z-score")+	
    geom_abline(intercept = 0, slope = 0)+	
    geom_abline(intercept = 0, slope = 90)+	
    geom_label_repel(label=Comp5$masshift, size=2.5, label.padding = 0.15)
+	
    #scale_x_continuous(limits = 1.2*c(min(Comp5$masshift),max(Comp5$massh
ift)))+	
    #scale_y_continuous(limits = 1.2*c(min(Comp5$AvgZscore),max(Comp5$AvgZ
score)))+	
    #annotate("text", x=c(min(Comp5$masshift-5)), y=c(0), label=c("Peak\n 
Loss"))+	
    #annotate("text", x=c(1.2*max(Comp5$masshift-5)), y=c(0), label=c("Pea
k\n Gain"))+	
    #annotate("text", y=c(1.2*max(Comp5$AvgZscore)), x=c(37), label=c("Con
dition 1"))+	
    #annotate("text", y=c(1.2*min(Comp5$AvgZscore)), x=c(37), label=c("Con
dition 2"))+	
    ggtitle('Rsv vs Cat LC')+labs(size='Frequency')	
}		
dev.off()	
 
 Appendices 385 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendices 386 
9.7 Appendix 5: Z-plots from mass shift comparison 
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9.8 Appendix 6: Mass spectrometry modifications results analysis 
Luis	Toronjo	Urquiza	23/12/2018	
         #####################################################	
         # Search and Export consistent modifications from  #	
         # specific search mass spectrometry data            #	
         ##################################################### 		
library(readxl) #for the use of read_excel	
library(bazar) # for the use of is.empty			
#Parameter that defines the minimum number of samples that can be missing  
to consider it for further study	
 # or it will be ignored and counted as NA	
#Example: if i put 1 only measurements of a modification of a specific tre
atment that appear in 3 out of the 4	
#replicates will be considered, the rest will not be consider consistent a
nd will not be counted	
xdd<-1	
#Set working directory before using this code(desktop)		
# First import the file with the file names	
filename<-read_excel('Names.xlsx',col_names=F)		
#command to save all the plots created by the code	
pdf("MSplotsAllFinal.pdf")		
#create a matrix previous to import all the data so that the information c
an be collected	
allresult<-matrix(NA,nrow=8,ncol = 1)		
colnames(filename)<-'names'		
#creates a for loop that goes through the file names import them 		
# format the data and add it the already created file	
for (d in 1:length(filename$names)){	
#Import Csv file	
MyData<-NULL	
Modif<-NULL	
#imports the file of the working directory, specify that has headers and t
hat is comma separated	
 MyData<-read.csv(as.character(filename[d,1]),header = T, sep = ',')	
#Name the modification the code is corrently extrancting for future refere
nces 	
 Modif<-sub("-.*", "", as.character(filename[d,1]))		
 Appendices 391 
	
 	
#select Columns of interest (information, intensity and ration mod/base)	
MyData<- MyData[ ,c(2,4,6,8,146,424,425,428,429,156:219)]		
#Select Rows asociated with Anti_CD20_LC/HC	
MyData<-subset(MyData, Protein=='Anti_CD20_LC' | Protein=='Anti-CD20_HC')		
#Select only the files that have some modifications, of the rows are 2,whi
ch is the original dimension,	
# no modifications were found and further analysis is not need meaning. It 
will jump to the next file	
if (nrow(MyData)>2){	
#Change values that are 0 to Na	
MyData[MyData==0]<-NA		
#create a column variable where the modification is stated for each row, a
s the data will be merge	
# and it might be difficult to identify to what modification the signal co
rresponds	
MyData$Modification<-(Modif)		
#creates variable name were the peptide chain, the position and the modifi
cation is determine	
MyData$ModID<-paste(MyData$Protein,formatC(as.character(MyData$Positions.w
ithin.proteins), width=3, flag="0"),Modif, sep="-")		
#create a matrix to insert all the data for the z value for loop	
results<-NULL	
results<-matrix(NA, nrow =16, ncol = 1)		
#create a iteration loop in order to obtain all the means and SD of each s
ample for each modification.=	
for (z in 1:nrow(MyData)){	
  	
  rowresult<-NULL	
  rowresult<-matrix(, nrow =16, ncol = 2) 	
  x<-NULL	
 for (x in 1:16){	
   mean<-NULL	
   stnd<-NULL	
   NAnum<-NULL	
   	
   mean<-rowMeans(MyData[z,(x*4+6):(x*4+9)], na.rm = T)	
   stnd<-sd(MyData[z,(x*4+6):(x*4+9)], na.rm = T)	
   NAnum<-rowSums(is.na(MyData[z,(x*4+6):(x*4+9)]))	
   	
   	
   rowresult[x,1]<-mean	
   rowresult[x,2]<-stnd	
   	
   #if more than half the values are missing we want to omit this value	
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   if(NAnum>xdd){rowresult[x, ]<-NA}	
 }	
  results<-cbind(results,rowresult)	
}		
#eliminate the first empty column	
results<-results[,c(2:ncol(results))]		
#Change name of rows	
rownm<-NULL	
rownm<-colnames(MyData)	
rownm<-rownm[c(10,14,18,22,26,30,34,38,42,46,50,54,58,62,66,70)]	
rownames(results)<-rownm		
#Change name of columns	
colnm<-NULL	
p<-NULL	
for (p in 1:nrow(MyData)){	
  p1<-NULL	
  p2<-NULL	
  p1<-paste(MyData$ModID[p],'Avrg',sep = ' ')	
  p2<-paste(MyData$ModID[p],'StDv',sep = ' ')	
  	
  colnm<-c(colnm,p1,p2)	
}		
colnames(results)<-colnm	
results<-as.data.frame.matrix(results) 		
results2<-results[1:8,]		
#select only ratio values and order them	
ratioresults<-NULL	
ratioresults<-results[9:16,]	
#this exposes the modifications that occurs 100% of the times and instead 
of ratio puts the intensity of the signal	
ratioresults[is.na(ratioresults)]<-results2[is.na(ratioresults)]		
#lowers all the numbers to 20 if they are above, vales above 20 2000% of t
he times are modified. also helps to graph it	
ratioresults[ratioresults>20]<-20		
#previous step we made all the standard devations 20 as well, we get them 
back to zero	
for (lx in 1:(length(ratioresults)/2)){	
  lxcol<-lx*2	
  temprat<-NULL	
  temprat<-ratioresults[,lxcol]	
  temprat[temprat==20]<-0	
  ratioresults[,lxcol]<-temprat	
  	
}		
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ratioresults<-ratioresults[c(4,1,2,3,6,7,8,5),]	
ratioresults<-as.data.frame.matrix(ratioresults)		
library(ggplot2)	
n<-NULL	
 for (n in 1:nrow(MyData) ) {	
 grtbl<-NULL 	
 grtbl<-ratioresults[,c((n*2)-1,(n*2))] 	
 rownames(grtbl)<-c(' Ctrl','Cat10','Cat25','Cat50', 'Rsv010','Rsv025','Rs
v050','Rsv100')	
 grtbl<-cbind(rownames(grtbl), data.frame(grtbl))	
 colnames(grtbl)<-c('Treatment','Mean','SD')		
  grtbl[is.na(grtbl)]<-0	
#if the data in the tabe is all 0 then we dont need to graph it	
 if(max(grtbl[,2:3])>0){	
 #graph	
  	
   g<-ggplot(grtbl, aes(x=Treatment, y= Mean, fill=Treatment))+ 	
     geom_col(color=c('#990000',"#006633", "#006633", "#006633",'#000033',
'#000033','#000033','#000033'),	
              fill=c('#990000',"#00CC33", "#009900", "#006633",'#0099FF','
#0000FF','#000066','#000033'))+ 	
     geom_errorbar(aes(ymin =Mean - SD, ymax =Mean + SD), width=0.4, colou
r="black", alpha=0.9, size=1.3)+	
     labs(title = MyData$ModID[n], y= "Ratio (Mod/Base)", x = "Treatment")
+	
     theme(panel.background = element_rect(fill = "white", colour = "grey5
0"))+	
     theme(axis.text = element_text(size = 12,face = 'bold'))+	
     theme( axis.line = element_line(colour = "black",size = 0.75, linetyp
e = "solid"))+	
     theme(axis.title.x = element_text(size=14,face = 'bold',colour = 'bla
ck'))+	
     theme(axis.title.y = element_text(size=14,face = 'bold',colour = 'bla
ck'))+	
     theme(title = element_text(size=16,face = 'bold'))	
  print(g)	
  }	
 }	
allresult<-cbind(allresult,ratioresults)	
}	
}	
#comand to stop the addtion of plots to the pdf file and export the file	
dev.off()		
write.csv(allresult,'allresult.csv')	
 
 
